Note: Descriptions are shown in the official language in which they were submitted.
CA 02942883 2016-09-15
- 1 -
Description
Title of Invention: 1,3-BENZODIOXOLE DERIVATIVE
Technical Field
[0001]
The present invention relates to a compound having a
particular chemical structure or a pharmacologically
acceptable salt thereof which has an excellent inhibitory
effect on EZH1 and/or EZH2 activity.
Background Art
[0002]
Chromosomes dynamically control gene replication or
transcription by changing their higher-order structures
through methylation modification of their constituent DNA
and various modifications (acetylation, methylation,
phosphorylation, ubiquitination, etc.) of histones
(histones H2A, H2B, H3, and H4).
In general, trimethylation of lysine at the fourth
position counted from the N-terminus of histone H3
(H3K4me3) functions to activate transcription, whereas
trimethylation of lysine at the 27th position (H3K27me3)
functions to suppress transcription. The former and
latter modifications are performed by a trithorax complex
and Polycomb repressive complex 2 (PRC2), respectively
(Non Patent Literature 1 and 2).
CA 02942883 2016-09-15
- 2 -
[0003]
The Polycomb gene group was identified as a gene
controlling the embryogenesis of Drosophila and is also
conserved in vertebrates (Non Patent Literature 3). In
Drosophila, the enhancer of zeste protein is a catalytic
subunit responsible for the H3K27 methylation
modification of PRC2. Both EZH1 (enhancer of zeste
homolog 1 (Drosophila)) and EZH2 (enhancer of zeste
homolog 2 (Drosophila)) are mammalian homologs of the
Drosophila enhancer of zeste (Non Patent Literature 4 and
5). The enzyme activity domains (SET domains) of EZH1
and EZH2 have high homology. In humans or mice, two
types of PRC2 exist (PRC2-EZH1 and PRC2-EZH2) which
contain EZH1 or EZH2 as a catalytic unit (Non Patent
Literature 6 and 7).
[0004]
In ES cells, EZH1 and EZH2 function cooperatively to
participate in maintenance of ES cells (Non Patent
Literature 6). EZH1 and EZH2 also act cooperatively on
the formation and maintenance of hair follicles and the
differentiation of Merkel cells, and both have been
reported to also play an important role in maintaining
hematopoietic stem cells (Non Patent Literature 8 to 12).
Overexpression of EZH2 has to date been reported in
many cancers including prostate cancer, breast cancer,
stomach cancer, lung cancer, ovarian cancer, pancreatic
cancer, kidney cancer, and head and neck cancer, and the
CA 02942883 2016-09-15
- 3 -
poor prognosis in some of these cancers reportedly
correlates with overexpression of EZH2 (Non Patent
Literature 13 to 21). There are reports stating that
EZH2 knockdown of a cell line derived from such a cancer
inhibits cell growth (Non Patent Literature 13 and 22).
When EZH2 is overexpressed in an epithelial non-cancer
cell line, phenotypes characteristic of cancers appear,
such as invasiveness and increased cell growth in a soft
agar medium (Non Patent Literature 14).
[0005]
In follicular lymphoma or follicular center B cell-
type diffuse large B-cell lymphoma, somatic mutations
have been found in tyrosine 641, alanine 677, and alanine
687 (Y641F, Y641N, Y641S, Y641H, Y6410, A677G, and A687V)
of EZH2, and these mutations have been reported to render
EZH2 hyperactive to significantly increase intracellular
H3K27me3 modification levels (Non Patent Literature 23 to
26). Compounds specifically inhibiting the enzyme
activity of EZH2 inhibit, both in vitro and in vivo
(xenograft models), the growth of a cancer cell line
having such a somatic mutation in EZH2 (Non Patent
Literature 27 and 28).
These facts suggest that knockdown of EZH2 or
inhibition of its enzyme activity is useful in the
treatment of cancers involving overexpression of EZH2 or
a somatic mutation in EZH2.
CA 02942883 2016-09-15
- 4 -
Although much is known about the malignant
transformation of cells containing EZH2, much remains to
be analyzed on the relation of EZH1 to the malignant
transformation of cells. However, it has recently been
found that general inhibition of PRC2 suppresses the
progression of acute myeloid leukemia caused by MLL-AF9
fusion gene, whereas inhibition of EZH2 alone is not
sufficient for this suppression (Non Patent Literature
29). This means that inhibition of PRC2-EZH2 alone is
insufficient for suppressing acute myeloid leukemia
caused by MLL-AF9 fusion gene, and that simultaneous
inhibition of PRC2-EZH1 and PRC2-EZH2 is necessary for
this purpose.
Citation List
Non Patent Literature
[0006]
Non Patent Literature 1: Cell, 128, 735-745 (2007)
Non Patent Literature 2: Nat. Rev. Cancer, 10, 669-682
(2010)
Non Patent Literature 3: Nat. Rev. Genet., 8, 9-22 (2007)
Non Patent Literature 4: EMBO J., 16, 3219-3232 (1997)
Non Patent Literature 5: Mamm. Genome., 10, 311-314
(1999)
Non Patent Literature 6: Mol. Cell, 32, 491-502 (2008)
Non Patent Literature 7: Mol. Cell, 32, 503-518 (2008)
Non Patent Literature 8: Genes Dev., 25, 485-498 (2011)
CA 02942883 2016-09-15
- 5 -
Non Patent Literature 9: EMBO J., 32, 1990-2000 (2013)
Non Patent Literature 10: Blood, 118, 6553-6561 (2011)
Non Patent Literature 11: Cell Stem Cell, 11, 649-662
(2012)
Non Patent Literature 12: Cell Stem Cell, 14, 68-80
(2014)
Non Patent Literature 13: Nature, 419, 624-629 (2002)
Non Patent Literature 14: Proc. Natl. Acad. Sci. USA, 100,
11606-11611 (2003)
Non Patent Literature 15: Asian Pac. J. Cancer Prev., 13,
3173-3178 (2012)
Non Patent Literature 16: Clin. Cancer Res., 19, 6556-
6565 (2013)
Non Patent Literature 17: Cancer Cell, 18, 185-197 (2010)
Non Patent Literature 18: Hum. Pathol., 41, 1205-1209
(2010)
Non Patent Literature 19: BMC Cancer, 10, 524 (2010)
Non Patent Literature 20: Cancer, 118, 2858-2871 (2012)
Non Patent Literature 21: Mutat Res., 647, 21-29 (2008)
Non Patent Literature 22: Oncogene, 28, 843-853 (2009)
Non Patent Literature 23: Nat. Genet., 42, 181-185 (2010)
Non Patent Literature 24: FEBS Lett., 585, 3011-3014
(2011)
Non Patent Literature 25: Proc. Natl. Acad. Sci. USA, 109,
2989-2994 (2012)
Non Patent Literature 26: FEBS Lett., 586, 3448-3451
(2012)
CA 02942883 2016-09-15
- 6 -
Non Patent Literature 27: Nature, 492, 108-112 (2012)
Non Patent Literature 28: Nat. Chem. Biol., 8, 890-896
(2012)
Non Patent Literature 29: Proc. Natl. Acad. Sci. USA, 109,
5028-5033 (2012)
Summary of Invention
Technical Problem
[0007]
An object of the present invention is to provide a
novel low-molecular weight compound that has excellent
EZH1 and/or EZH2 activity and exhibits an antitumor
effect.
Solution to Problem
[0008]
The compound of the present invention has the effect
of inhibiting both EZH1 and EZH2 methyltransferase
activity. This compound has an anticancer effect on
cancers dependent on EZH1 alone, cancers dependent on
EZH2 alone, and cancers dependent on both EZH1 and EZH2,
and offers treatment of these cancers.
The present invention relates to the following (1)
to (16):
[0009]
(1) A compound represented by the general formula
(I) or a pharmacologically acceptable salt thereof:
CA 02942883 2016-09-15
- 7 -
[Formula 11
R R6
rThrNH
0 NH 0
R4
Ri Si 0 2
0 ---/-___v R
R3
(1)
wherein
R1 represents a hydrogen atom, a halogen atom, a C1-C6
alkyl group optionally having 1 to 3 halogen atoms, a Cl-
C6 alkoxy group optionally having 1 to 3 halogen atoms, a
C3-C6 cycloalkyl group, a 01-06 alkylcarbonyl group, a C2-
C6 alkenyl group, a C2-C6 alkynyl group, a 03-06
cycloalkenyl group, a phenyl group, a 5- or 6-membered
aromatic heterocyclic group optionally having, in the
ring, 1 to 3 heteroatoms independently selected from the
group consisting of a nitrogen atom, an oxygen atom, and
a sulfur atom, or a 5- or 6-membered aliphatic
heterocyclic group optionally having an unsaturated bond
in a portion of the ring and optionally having, in the
ring, 1 or 2 heteroatoms independently selected from the
group consisting of a nitrogen atom, an oxygen atom, and
a sulfur atom, wherein
the phenyl group, the 5- or 6-membered aromatic
heterocyclic group, and the 5- or 6-membered aliphatic
heterocyclic group optionally having an unsaturated bond
_
CA 02942883 2016-09-15
- 8 -
in a portion of the ring each optionally have 1 to 3
substituents independently selected from group A
described below,
V represents a single bond, a C1-C6 alkylene group, or an
oxy-C1-C6 alkylene group,
R2 represents a hydrogen atom, a C1-C6 alkyl group, a C3-
C6 cycloalkyl group, a bicyclo-05-C8 cycloalkyl group, a
5- or 6-membered aliphatic heterocyclic group optionally
having, in the ring, 1 or 2 heteroatoms independently
selected from the group consisting of a nitrogen atom, an
oxygen atom, and a sulfur atom, or a spiro ring group
containing two spiro-fused rings independently selected
from the group consisting of a 4- to 6-membered aliphatic
heterocyclic ring optionally having, in the ring, 1 or 2
heteroatoms independently selected from the group
consisting of a nitrogen atom, an oxygen atom, and a
sulfur atom and a C3-C6 cycloalkyl ring, wherein
the C1-C6 alkyl group, the C3-C6 cycloalkyl group, the
bicyclo-05-C8 cycloalkyl group, the 5- or 6-membered
aliphatic heterocyclic group, and the spiro ring group
each optionally have 1 to 3 substituents independently
selected from group C described below,
R3 represents a C1-C6 alkyl group,
R4 represents a halogen atom or a C1-C6 alkyl group
optionally having 1 to 3 halogen atoms,
R5 represents a Cl-C6 alkyl group or a C1-C6 alkoxy group,
R6 represents a C1-C6 alkyl group,
CA 02942883 2016-09-15
- 9 -
group A consists of a halogen atom, a 01-06 alkyl group,
a 01-06 alkoxy group, and a 5- or 6-membered aliphatic
heterocyclic group optionally having, in the ring, 1 or 2
heteroatoms independently selected from the group
consisting of a nitrogen atom, an oxygen atom, and a
sulfur atom
(wherein the 01-06 alkyl group, the 01-06 alkoxy group,
and the 5- or 6-membered aliphatic heterocyclic group
each optionally have 1 to 3 substituents independently
selected from group B described below),
group B consists of a halogen atom, a 01-06 alkyl group,
and a 5- or 6-membered aliphatic heterocyclic group
optionally having, in the ring, 1 or 2 heteroatoms
independently selected from the group consisting of a
nitrogen atom, an oxygen atom, and a sulfur atom, and
group C consists of a hydroxy group, a formyl group, a
01-06 alkyl group, a C1-C6 alkylcarbonyl group, a 01-06
alkoxy group, a 01-06 alkylsulfonyl group, -NR20R21, a Cl-
06 alkoxy-01-06 alkyl group, a di-Cl-C6 alkylamino-C1-C6
alkyl group, and a 4- to 6-membered aliphatic
heterocyclic group optionally having, in the ring, 1 or 2
heteroatoms independently selected from the group
consisting of a nitrogen atom, an oxygen atom, and a
sulfur atom
(wherein R2 and R21 each independently represent a
hydrogen atom, a formyl group, or a 01-06 alkyl group).
[0010]
CA 02942883 2016-09-15
- 10 -
(2) The compound according to (1) or a
pharmacologically acceptable salt thereof, wherein in the
formula (I),
R1 represents a hydrogen atom, a halogen atom, a 01-06
alkyl group, a C1-C6 alkoxy group, a C3-C6 cycloalkyl
group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a
phenyl group, a C3-C6 cycloalkenyl group, a 5- or 6-
membered aromatic heterocyclic group optionally having,
in the ring, 1 to 3 heteroatoms independently selected
from the group consisting of a nitrogen atom, an oxygen
atom, and a sulfur atom, or a 5- or 6-membered aliphatic
heterocyclic group optionally having an unsaturated bond
in a portion of the ring and optionally having, in the
ring, 1 or 2 heteroatoms independently selected from the
group consisting of a nitrogen atom, an oxygen atom, and
a sulfur atom.
[0011]
(3) The compound according to (1) or (2) or a
pharmacologically acceptable salt thereof, wherein R1
represents a hydrogen atom, a halogen atom, a methyl
group, an ethyl group, a methoxy group, an ethoxy group,
a cyclopropyl group, a vinyl group, an acetylene group, a
phenyl group, a cyclohexenyl group, a dihydropyranyl
group, or a thiazolyl group.
[0012]
(4) The compound according to any one of (1) to (3)
or a pharmacologically acceptable salt thereof, wherein
,
CA 02942883 2016-09-15
- 11 -
R2 represents a C1-06 alkyl group, a 03-C6 cycloalkyl
group, or a 5- or 6-membered aliphatic heterocyclic group
optionally having, in the ring, 1 or 2 heteroatoms
independently selected from the group consisting of a
nitrogen atom, an oxygen atom, and a sulfur atom, wherein
the Cl-C6 alkyl group, the C3-C6 cycloalkyl group, and the
5- or 6-membered aliphatic heterocyclic group each
optionally have 1 to 3 substituents independently
selected from the group consisting of a Ci-C6 alkyl group,
a Cl-C6 alkylsulfonyl group, a Cl-C6 alkylamino group, and
a di-Ci-C6 alkylamino group.
[0013]
(5) The compound according to any one of (1) to (4)
or a pharmacologically acceptable salt thereof, wherein
V represents a single bond or a methylene group,
R2 represents a methyl group, a cyclohexyl group, a
tetrahydropyranyl group, or a piperidyl group, and
R3 represents a methyl group, wherein
the cyclohexyl group, the tetrahydropyranyl group, and
the piperidyl group each have one substituent
independently selected from the group consisting of a
methyl group, an ethyl group, an ethylsulfonyl group, a
methylamino group, a dimethylamino group, and an
ethylmethylamino group.
[0014]
(6) A compound represented by the general formula
(II) or a pharmacologically acceptable salt thereof:
CA 02942883 2016-09-15
- 12 -
[Formula 2]
R 7zC H3
I NH
0 NH 0
CH3
R7 11 o
,R9
H3C-9'8
R 00
wherein
R7 represents a hydrogen atom, a halogen atom, a methyl
group, an ethyl group, or a cyclopropyl group;
R8 and R9 each independently represent a hydrogen atom, a
methyl group, or an ethyl group;
Rlo represents a methyl group, an ethyl group, or a
methoxy group; and
U represents an oxygen atom or CH2.
[0015]
(7) Any one compound selected from the following
group or a pharmacologically acceptable salt thereof:
7-bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2-(1-ethy1-4-piperidy1)-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide,
7-bromo-2-Etrans-4-(dimethylamino)cyclohexyll-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide,
CA 02942883 2016-09-15
- 13 -
(2R)-7-bromo-2-[trans-4-(dimethylamino)cyclohexyl]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide,
7-bromo-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4-
methoxy-6-methy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide,
7-bromo-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4-
ethy1-6-methy1-2-oxo-1,2-dihydropyridin-3-y1)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide,
7-bromo-2-[trans-4-(dimethylamino)cyclohexyl]-2,4-
dimethyl-N-[(6-methy1-2-oxo-4-propy1-1,2-dihydropyridin-
3-yl)methy1]-1,3-benzodioxole-5-carboxamide,
7-bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2-[trans-4-[N-ethyl(N-
methyl)amino]cyclohexyl]-2,4-dimethy1-1,3-benzodioxole-5-
carboxamide,
7-bromo-2-[[cis-4-(dimethylamino)cyclohexyl]methy1]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide,
7-chloro-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-2-[trans-4-
(methylamino)cyclohexy1]-1,3-benzodioxole-5-carboxamide,
7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide,
CA 02942883 2016-09-15
- 14 -
(2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide,
7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4-
methoxy-6-methy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide,
7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4-
ethy1-6-methy1-2-oxo-1,2-dihydropyridin-3-y1)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide,
2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methy1]-7-fluoro-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide,
2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methy1]-2,4,7-trimethyl-1,3-
benzodioxole-5-carboxamide,
(2S)-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4,7-
trimethy1-1,3-benzodioxole-5-carboxamide,
4,7-dichloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methy1]-2-
methy1-1,3-benzodioxole-5-carboxamide,
7-(cyclopenten-1-y1)-2-[trans-4-
(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methy1]-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide,
CA 02942883 2016-09-15
- 15 -
2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methy1]-2,4-dimethyl-7-
pheny1-1,3-benzodioxole-5-carboxamide,
7-(cyclohexen-1-y1)-2-[trans-4-
(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methy1]-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide,
7-(3,6-dihydro-2H-pyran-4-y1)-2-[trans-4-
(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methy1]-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide,
2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methy1]-2,4-dimethyl-7-vinyl-
1,3-benzodioxole-5-carboxamide,
2-(trans-4-(dimethylamino)cyclohexyl)-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-y1)methy1]-7-ethynyl-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide,
7-cyclopropy1-2-[trans-4-(dimethylamino)cyclohexyl]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide,
2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-y1)methy1]-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide, and
2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-y1)methy1]-7-ethy1-2,4-dimethyl-
1,3-benzodioxole-5-carboxamide.
[0016]
CA 02942883 2016-09-15
- 16 -
(8) Any one compound selected from the following
group or a pharmacologically acceptable salt thereof:
7-bromo-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide,
(2R)-7-bromo-2-[trans-4-(dimethylamino)cyclohexyl]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide,
7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide,
(2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide,
2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methy1]-2,4,7-trimethyl-1,3-
benzodioxole-5-carboxamide,
(2S)-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4,7-
trimethy1-1,3-benzodioxole-5-carboxamide,
4,7-dichloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2-
methy1-1,3-benzodioxole-5-carboxamide,
2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methy1]-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide, and
CA 02942883 2016-09-15
- 17 -
2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methy1]-7-ethyl-2,4-dimethyl-
1,3-benzodioxole-5-carboxamide.
[0017]
(9) A pharmaceutical composition comprising a
compound according to any one of (1) to (8) or a
pharmacologically acceptable salt thereof as an active
ingredient.
[0018]
(10) An EZH1 and/or EZH2 enzyme activity inhibitor
comprising a compound according to any one of (1) to (8)
or a pharmacologically acceptable salt thereof as an
active ingredient.
[0019]
(11) A therapeutic agent for tumors that is capable
of treating the tumor by inhibiting EZH1 and/or EZH2
enzyme activity, the therapeutic agent comprising a
compound according to any one of (1) to (8) or a
pharmacologically acceptable salt thereof as an active
ingredient.
[0020]
(12) An antitumor agent comprising a compound
according to any one of (1) to (8) or a pharmacologically
acceptable salt thereof as an active ingredient.
[0021]
(13) The antitumor agent according to (12), wherein
the tumor is lymphoma, a rhabdoid tumor, leukemia, lung
CA 02942883 2016-09-15
- 18 -
cancer, stomach cancer, prostate cancer, colorectal
cancer, ovarian cancer, or liver cancer.
[0022]
(14) A therapeutic agent for tumors that exhibit
overexpression of EZH1 and/or EZH2, the therapeutic agent
comprising a compound according to any one of (1) to (8)
or a pharmacologically acceptable salt thereof as an
active ingredient.
[0023]
(15) A therapeutic agent for tumors having a
mutation in EZH1 and/or EZH2, the therapeutic agent
comprising a compound according to any one of (1) to (8)
or a pharmacologically acceptable salt thereof as an
active ingredient.
[0024]
(16) A therapeutic agent for tumors having a SWI/SNF
complex mutation, the therapeutic agent comprising a
compound according to any one Of (1) to (8) or a
pharmacologically acceptable salt thereof as an active
ingredient.
Advantageous Effects of Invention
[0025]
The compound of the present invention or the
pharmacologically acceptable salt thereof has excellent
EZH1 and/or EZH2 inhibitory activity and inhibits cell
growth. Thus, the compound of the present invention or
CA 02942883 2016-09-15
- 19 -
the pharmacologically acceptable salt thereof is useful
as an antitumor agent, particularly, a therapeutic agent
for tumors such as lymphoma, rhabdoid tumors, leukemia,
lung cancer, stomach cancer, prostate cancer, colorectal
cancer, ovarian cancer, or/and liver cancer. The
compound of the present invention or the
pharmacologically acceptable salt thereof is effective as
a therapeutic drug for tumors that can be treated by
inhibiting EZH1 and EZH2 enzyme activity, including the
tumors described above.
Description of Embodiments
[0026]
In the present invention, the "halogen atom" is a
fluorine atom, a chlorine atom, a bromine atom, or an
iodine atom.
[0027]
In the present invention, the "Cl-C6 alkyl group"
refers to a linear or branched alkyl group having 1 to 6
carbon atoms. Examples thereof include a methyl group,
an ethyl group, a propyl group, an isopropyl group, a
butyl group, an isobutyl group, a sec-butyl group, a
tert-butyl group, a pentyl group, an isopentyl group, a
2-methylbutyl group, a neopentyl group, a 1-ethylpropyl
group, a hexyl group, an isohexyl group, and a 4-
methylpentyl group.
[0028]
CA 02942883 2016-09-15
- 20 -
In the present invention, the "03-06 cycloalkyl
group" is a cyclopropyl group, a cyclobutyl group, a
cyclopentyl group, or a cyclohexyl group.
In the present invention, the "01-06 alkoxy group"
refers to a 01-06 alkoxy group formed from the Ci-C6 alkyl
group mentioned above. Examples thereof include a
methoxy group, an ethoxy group, a n-propoxy group, an
isopropoxy group, a butoxy group, an isobutoxy group, a
sec-butoxy group, a tert-butoxy group, a pentoxy group,
an isopentoxy group, a 2-methylbutoxy group, a hexyloxy,
and an isohexyloxy group.
[0029]
In the present invention, the "01-06 alkylcarbonyl
group" refers to a group in which a carbonyl group is
substituted by one 01-06 alkyl group mentioned above.
Examples thereof include an acetyl group, an
ethylcarbonyl group, a propylcarbonyl group, and an
isopropylcarbonyl group.
[0030]
In the present invention, the "01-06 alkylene group"
refers to a group in which one 01-06 alkyl group
mentioned above forms a divalent substituent. Examples
thereof include a methylene group, an ethylene group, a
propylene group, and a butylene group.
[0031]
In the present invention, the "oxy-C1-06 alkylene
group" refers to a group in which one 01-06 alkylene
CA 02942883 2016-09-15
- 21 -
group mentioned above is substituted by one oxy group.
Examples thereof include an oxymethylene group and an
oxyethylene group. The oxy group binds to R2.
[0032]
In the present invention, the "C2-C6 alkenyl group"
refers to a linear or branched alkenyl group having 2 to
6 carbon atoms. Examples thereof include a vinyl group,
an allyl group, a 1-propenyl group, an isopropenyl group,
a 2-methyl-1-propenyl group, a 2-methyl-2-propenyl group,
a 1-butenyl group, a 2-butenyl group, a 3-butenyl group,
a 1-pentenyl group, a 1-hexenyl group, a 1,3-hexadienyl
group, and a 1,5-hexadienyl group.
[0033]
In the present invention, the "C2-C6 alkynyl group"
refers to a linear or branched alkynyl group having 2 to
6 carbon atoms. Examples thereof include an ethynyl
group, a 1-propynyl group, a 2-propynyl group, a 1-
butynyl group, a 2-butynyl group, a 3-butynyl group, a 1-
ethyny1-2-propynyl group, a 1-methyl-2-propynyl group, a
1-pentynyl group, a 1-hexynyl group, a 1,3-hexadiynyl
group, and a 1,5-hexadiynyl group.
[0034]
In the present invention, the "C1-C6 alkoxy-Cl-C6
alkyl group" refers to a group in which the Ci-C6 alkyl
group mentioned above is substituted by one C1-C6 alkoxy
group mentioned above. Examples thereof include a
methoxymethyl group, an ethoxymethyl group, a
CA 02942883 2016-09-15
- 22 -
propoxymethyl group, an isopropoxymethyl group, a
methoxyethyl group, an ethoxyethyl group, a propoxyethyl
group, and an isopropoxyethyl group.
[0035]
In the present invention, the "C1-C6 alkylsulfonyl
group" refers to a group in which a sulfonyl group is
substituted by one Ci-C6 alkyl group mentioned above.
Examples thereof include a methylsulfonyl group, an
ethylsulfonyl group, a propylsulfonyl group, and an
isopropylsulfonyl group.
[0036]
In the present invention, the "di-Ci-C6 alkylamino-
Ci-C6 alkyl group" refers to a group in which the C1-C6
alkyl group mentioned above is substituted by an amino
group substituted by two C1-C6 alkyl groups mentioned
above. Examples thereof include a dimethylaminomethyl
group, a dimethylaminoethyl group, and a
dimethylaminopropyl group.
[0037]
In the present invention, the "C3-C6 cycloalkenyl
group" is a cyclopropenyl group, a cyclobutenyl group, a
cyclopentenyl group, or a cyclohexenyl group.
[0038]
In the present invention, the "aromatic heterocyclic
group" refers to a group derived from a 5- or 6-membered .
monocyclic aromatic compound containing 1 to 3 atoms each
independently selected from the group consisting of a
CA 02942883 2016-09-15
- 23 -
nitrogen atom, an oxygen atom, and a sulfur atom in
addition to carbon as atoms constituting the ring.
Examples thereof include a furyl group, a thienyl group,
a pyrrolyl group, an oxazolyl group, an isoxazolyl group,
a thiazolyl group, an isothiazolyl group, an imidazolyl
group, an oxadiazolyl group, a thiadiazolyl group, a
triazinyl group, a pyrazolyl group, a pyridyl group, a
pyrazyl group, a pyrimidinyl group, and a pyridazinyl
group.
[0039]
In the present invention, the "aliphatic
heterocyclic group" refers to a group derived from a 3-
to 6-membered monocyclic aliphatic cyclic compound having
a saturated ring and containing 1 or 2 atoms each
independently selected from the group consisting of a
nitrogen atom, an oxygen atom, and a sulfur atom in
addition to carbon as atoms constituting the ring.
Examples thereof include an oxiranyl group, an aziridinyl
group, a thiiranyl group, an oxetanyl group, an
azetidinyl group, a thietanyl group, a tetrahydrofuranyl
group, a pyrrolidinyl group, a tetrahydrothiophenyl group,
a tetrahydropyranyl group, a piperazinyl group, a
tetrahydrothiopyranyl group, a morpholino group, a
morpholinyl group, and a piperidinyl group.
[0040]
In the present invention, the "aliphatic
heterocyclic group optionally having an unsaturated bond
CA 02942883 2016-09-15
- 24 -
in a portion of the ring" refers to a group derived from
a 3- to 6-membered monocyclic aliphatic cyclic compound
optionally containing a double bond in the ring and
containing 1 or 2 atoms each independently selected from
the group consisting of a nitrogen atom, an oxygen atom,
and a sulfur atom in addition to carbon as atoms
constituting the ring. Examples thereof include the
aliphatic heterocyclic group mentioned above, an azirinyl
group, an oxirenyl group, a thiirenyl group, a
dihydropyrrolyl group, a dihydrofuranyl group, a
dihydrothiophenyl group, a dihydropyranyl group, a
tetrahydropyridinyl group, and a dihydrothiopyranyl group.
[0041]
In the present invention, the "bicyclo-05-C8
cycloalkyl group" refers to a group derived from an
aliphatic hydrocarbon compound in which two cycloalkyl
rings share two atoms. Examples thereof include a
bicyclo[1.1.1]pentyl group, a bicyclo[2.1.0]pentyl group,
a bicyclo[2.1.1]hexyl group, a norbornanyl group, and a
bicyclo[2.2.2]octanyl group.
[0042]
In the present invention, the "spiro ring group"
refers to a group derived from a cyclic compound in which
the aliphatic heterocyclic group mentioned above and the
C3-C6 cycloalkyl ring mentioned above are bonded by
sharing one atom and have no linkage through any other
CA 02942883 2016-09-15
- 25 -
bridge. Examples thereof include a spiro[3.3]heptanyl
group and an azaspiro[3.3]heptanyl group.
[0043]
In the present invention, the term "tumor" is not
limited to malignant tumors and includes every type of
tumor, for example, carcinoma, sarcoma, and benign tumors.
Particularly, malignant tumors are also referred to as
"cancer".
[0044]
In the present invention, "EZH1 and/or EZH2 enzyme
activity" means enzyme activity that is possessed by EZH1
and/or EZH2 and introduces methyl groups to lysine 27 of
histone H3.
[0045]
In the present invention, "overexpression of EZH1
and/or EZH2" means that the expression level of the EZH1
protein and/or the EZH2 protein is increased by enhanced
gene transcription activity, promoted translation,
suppressed proteolysis, improved protein stabilization,
etc.
[0046]
In the present invention, the phrase "having a
mutation in EZH1 and/or EZH2" means that a mutation
exists in the nucleotide sequence and/or the amino acid
sequence of EZH1 and/or EZH2. For example, somatic
mutations in tyrosine 641, alanine 677, and alanine 687
CA 02942883 2016-09-15
- 26 -
(Y641F, Y641N, Y641S, Y641H, Y6410, A677G, and A687V) of
EZH2 are found.
[0047]
In the present invention, the "SWI/SNF complex"
means a chromatin structure conversion factor complex
that acts antagonistically on PRC2. The SWI/SNF complex
controls activities essential for cell survival, such as
DNA transcription, replication, and repair by changing a
nucleosome structure in an ATP dependent manner.
[0048]
In the present invention, the phrase "having a
SWI/SNF complex mutation" means that a mutation exists in
the nucleotide sequence and/or the amino acid sequence of
a subunit constituting the SWI/SNF complex. SWI/SNF
complex mutations are known as inactivating mutations in
cancers. For example, rhabdoid tumors having a deletion
mutation in subunit SNF5 are known.
[0049]
Next, each preferred substituent in the general
formula (I) will be described.
[0050]
Rl is preferably a hydrogen atom, a halogen atom, a
methyl group, an ethyl group, a cyclopropyl group, a
vinyl group, an acetylene group, a phenyl group, a
cyclohexenyl group, a dihydropyranyl group, or a
thiazolyl group, more preferably a bromine atom, a
chlorine atom, or a methyl group.
CA 02942883 2016-09-15
- 27 -
[0051]
V is preferably a single bond or a methylene group,
more preferably a single bond.
[0052]
R2 is preferably, each independently, a methyl group,
a N-ethyl-piperidinyl group, a N-ethylsulfonyl-
piperidinyl group, a dimethylamino-tetrahydropyranyl
group, a methylamino-cyclohexyl group, a dimethylamino-
cyclohexyl group, or an ethyl(methyl)amino-cyclohexyl
group.
[0053]
R3 is preferably a methyl group.
[0054]
According to a preferred combination of V, R2, and R3,
V is a single bond, R2 is a dimethylamino-cyclohexyl
group, and R3 is a methyl group.
[0055]
R4 is preferably a chlorine atom, a bromine atom, or
a methyl group.
[0056]
R5 is preferably a methyl group, an ethyl group, or
a methoxy group.
[0057]
R6 is preferably a methyl group.
[0058]
The compound represented by the general formula (I)
of the present invention can form a pharmaceutically
CA 02942883 2016-09-15
- 28 -
acceptable salt, if desired. The pharmaceutically
acceptable salt refers to a salt that has no significant
toxicity and can be used as a drug. The compound
represented by the general formula (I) of the present
invention can form a salt through reaction with an acid
when having a basic group.
[0059]
Examples of the salt based on a basic group include:
hydrohalides such as hydrofluoride, hydrochloride,
hydrobromide, and hydroiodide; inorganic acid salts such
as nitrate, perchlorate, sulfate, and phosphate; C1-C6
alkylsulfonates such as methanesulfonate,
trifluoromethanesulfonate, and ethanesulfonate;
arylsulfonates such as benzenesulfonate and p-
toluenesulfonate; organic acid salts such as acetate,
malate, fumarate, succinate, citrate, ascorbate, tartrate,
oxalate, adipate, and maleate; and amino acid salts such
as glycine salt, lysine salt, arginine salt, ornithine
salt, glutamate, and aspartate.
[0060]
The compound represented by the general formula (I)
of the present invention or the salt thereof, when left
in air or recrystallized, may incorporate water
molecule(s) to form a hydrate. Such a hydrate is also
included in the salt of the present invention.
[0061]
CA 02942883 2016-09-15
- 29 -
The compound represented by the general formula (I)
of the present invention or the salt thereof, when left
in a solvent or recrystallized, may absorb a certain kind
of solvent to form a solvate. Such a solvate is also
included in the salt of the present invention.
[0062]
The present invention also encompasses a compound
that serves as an active ingredient in the pharmaceutical
composition of the present invention and that is
converted to compound (1) through reaction with an enzyme,
gastric acid, or the like under physiological conditions
in vivo, i.e., a "pharmaceutically acceptable prodrug
compound" that is converted to compound (1) by enzymatic
oxidation, reduction, hydrolysis, etc., or is converted
to compound (1) by hydrolysis, etc., by gastric acid or
the like.
[0063]
Examples of the prodrug of compound (1) containing
an amino group can include compounds in which the amino
group is acylated, alkylated, or phosphorylated (e.g.,
compounds in which the amino group is eicosanoylated,
alanylated, pentylaminocarbonylated, (5-methy1-2-oxo-1,3-
dioxolen-4-yl)methoxycarbonylated, tetrahydrofuranylated,
pyrrolidylmethylated, pivaloyloxymethylated, or tert-
butylated). Examples of the prodrug of compound (1)
containing a hydroxy group include compounds in which the
hydroxy group is acylated, alkylated, phosphorylated, or
CA 02942883 2016-09-15
- 30 -
borated (e.g., compounds in which the hydroxy group is
acetylated, palmitoylated, propanoylated, pivaloylated,
succinylated, fumarylated, alanylated, or
dimethylaminomethylcarbonylated). Examples of the
prodrug of compound (1) containing a carboxy group
include compounds in which the carboxy group is
esterified or amidated (e.g., compounds in which the
carboxy group is ethyl esterified, phenyl esterified,
carboxymethyl esterified, dimethylaminomethyl esterified,
pivaloyloxymethyl esterified, ethoxycarbonyloxyethyl
esterified, amidated, or methylamidated).
[0064]
The prodrug of the compound of the present invention
can be produced from compound (1) by a method known in
the art. The prodrug of the compound of the present
invention also includes a compound that is converted to
compound (1) under physiological conditions as described
in "Iyakuhin No Kaihatsu (Development of Pharmaceuticals
in English)", Vol. 7, Bunshi Sekkei (Molecular Design in
English), Hirokawa-Shoten Ltd., 1990, pp. 163-198.
[0065]
The compound represented by the general formula (I)
of the present invention or the pharmacologically
acceptable salt thereof encompasses all stereoisomers.
[0066]
For the compound of the present invention, its
isomers and mixtures of these isomers are all represented
CA 02942883 2016-09-15
- 31 -
by a single formula, i.e., the general formula (I). Thus,
the present invention includes all of these isomers and
even mixtures of these isomers at arbitrary ratios.
[0067]
The compound of the present invention may also
contain unnatural proportions of atomic isotopes at one
or more of the atoms constituting such a compound.
Examples of the atomic isotopes include deuterium (2H),
tritium (3H), iodine-125 (125I), and carbon-14 (140) The
compound may be radiolabeled with a radioisotope such as
tritium (3H), iodine-125 (1251), or carbon-14 (140) . The
radiolabeled compound is useful as a therapeutic or
prophylactic agent, a research reagent (e.g., an assay
reagent), and a diagnostic agent (e.g., an in vivo
diagnostic imaging agent). All isotopic variants of the
compound of the present invention are included in the
scope of the present invention, regardless of being
radioactive or not.
[0068]
The inhibitory effect on EZH1 and/or EZH2 enzyme
activity according to the present invention can be
measured by, for example, the methods of Test Examples 1
to 3.
The cell growth inhibitory activity of the compound
of the present invention can be examined by use of a
growth inhibition test method usually employed by those
skilled in the art. For example, the cell growth
CA 02942883 2016-09-15
- 32 -
inhibitory activity can be measured by the method of Test
Example 4.
In vivo antitumor activity can be examined by use of
a growth inhibition test method usually employed by those
skilled in the art. For example, the in vivo antitumor
activity can be measured by the methods of Test Examples
to 8.
[0069]
The compound of the present invention can be used in
the treatment of tumors. The compound of the present
invention can be used in the treatment of, for example,
lymphoma, rhabdoid tumors, leukemia, lung cancer, stomach
cancer, prostate cancer, colorectal cancer, ovarian
cancer, or liver cancer.
It has been suggested that EZH1 and/or EZH2 are
involved in cancer growth, survival, etc. Therefore, the
compound of the present invention is preferably used for
tumors that exhibit an increased expression level of EZH1
and/or EZH2, and/or tumors having a mutation in EZH1
and/or EZH2.
Tumors in the prostate, the breast, the stomach, the
lung, the ovary, the pancreas, the kidney, or the head
and neck are known as tumors that exhibit an increased
expression level of EZH1 and/or EZH2.
[0070]
An increase in the expression level of EZH1 and/or
EZH2 can be confirmed by examining the expression level
CA 02942883 2016-09-15
- 33 -
or the like of EZH1 and/or EZH2 in a test tissue (e.g.,
collected by blood collection or biopsy) of a patient by
use of a method known in the art such as Western blotting,
ELISA, Northern blotting, quantitative PCR, analysis
using DNA chip immunohistochemical staining, etc., or a
pathological approach.
[0071]
The presence of a mutation in EZH1 and/or EZH2 can
be confirmed by examining the nucleotide sequence of the
genomic DNA.
[0072]
The SWI/SNF complex acts antagonistically on PRC2.
Therefore, PRC2 is presumed to be hyperactive in cancers
involving a deletion mutation in its subunit. The
compound of the present invention can be used in the
treatment of such cancers.
[0073]
The presence of a mutation in the SWI/SNF complex
can be confirmed by examining the nucleotide sequence of
the genomic DNA.
[0074]
Rhabdoid tumors involving a deletion mutation in the
subunit SNF5 are known as tumors having a SWI/SNF complex
mutation.
[0075]
The compound of the present invention may be used in
combination with an additional antitumor agent. Examples
CA 02942883 2016-09-15
- 34 -
thereof include antitumor antibiotics, antitumor plant
components, BRM (biological response modifiers), hormones,
vitamins, antitumor antibodies, molecular target drugs,
and other antitumor agents.
[0076]
More specifically, examples of alkylating agents
include: alkylating agents such as nitrogen mustard,
nitrogen mustard N-oxide, and chlorambucil; aziridine
alkylating agents such as carboquone and thiotepa;
epoxide alkylating agents such as dibromomannitol and
dibromodulcitol; nitrosourea alkylating agents such as
carmustine, lomustine, semustine, nimustine hydrochloride,
streptozocin, chlorozotocin, and ranimustine; and others
such as busulfan, improsulfan tosylate, and dacarbazine.
[0077]
Examples of various antimetabolites include: purine
antimetabolites such as 6-mercaptopurine, 6-thioguanine,
and thioinosine; pyrimidine antimetabolites such as
fluorouracil, tegafur, tegafur uracil, carmofur,
doxifluridine, broxuridine, cytarabine, and enocitabine;
and antifolates such as methotrexate and trimetrexate.
[0078]
Examples of the antitumor antibiotics include:
anthracycline antibiotic antitumor agents such as
mitomycin C, bleomycin, peplomycin, daunorubicin,
aclarubicin, doxorubicin, pirarubicin, THP-adriamycin,
CA 02942883 2016-09-15
- 35 -
4'-epidoxorubicin, and epirubicin; and others such as
chromomycin A3 and actinomycin D.
[0079]
Examples of the antitumor plant components include:
vinca alkaloids such as vindesine, vincristine, and
vinblastine; taxanes such as paclitaxel and docetaxel;
and epipodophyllotoxins such as etoposide and teniposide.
[0080]
Examples of the BRM include tumor necrosis factors
and indomethacin.
Examples of the hormones include hydrocortisone,
dexamethasone, methylprednisolone, prednisolone,
prasterone, betamethasone, triamcinolone, oxymetholone,
nandrolone, metenolone, fosfestrol, ethynyl estradiol,
chlormadinone, and medroxyprogesterone.
[0081]
Examples of the vitamins include vitamin C and
vitamin A.
[0082]
Examples of the antitumor antibodies and the
molecular target drugs include trastuzumab, rituximab,
cetuximab, nimotuzumab, denosumab, bevacizumab,
infliximab, imatinib mesylate, gefitinib, erlotinib,
sunitinib, lapatinib, and sorafenib.
[0083]
Examples of other antitumor agents include cisplatin,
carboplatin, oxaliplatin, tamoxifen, camptothecin,
CA 02942883 2016-09-15
- 36 -
ifosfamide, cyclophosphamide, melphalan, L-asparaginase,
aceglatone, sizofiran, picibanil, procarbazine,
pipobroman, neocarzinostatin, hydroxyurea, ubenimex, and
krestin.
[0084]
The compound of the present invention or the
pharmacologically acceptable salt thereof can be
administered in various forms. Examples of the dosage
form include tablets, capsules, granules, emulsions,
pills, powders, and syrups (solutions) for oral
administration and injections (intravenous, intramuscular,
subcutaneous, or intraperitoneal administration), drip
infusions, and suppositories (rectal administration) for
parenteral administration. These various preparations
can be formulated according to routine methods using aids
that may be usually used in the field of pharmaceutical
formulation techniques such as excipients, binders,
disintegrants, lubricants, corrigents, solubilizers,
suspending agents, and coating agents, in addition to the
active ingredient.
[0085]
For use as a tablet, examples of carriers that can
be used include: excipients such as lactose, saccharose,
sodium chloride, glucose, urea, starch, calcium carbonate,
kaolin, crystalline cellulose, and silicic acid; binders
such as water, ethanol, propanol, simple syrup, glucose
solutions, starch solutions, gelatin solutions,
CA 02942883 2016-09-15
- 37 -
carboxymethylcellulose, shellac, methylcellulose,
potassium phosphate, and polyvinylpyrrolidone;
disintegrants such as dry starch, sodium alginate, agar
powder, laminaran powder, sodium bicarbonate, calcium
carbonate, polyoxyethylene sorbitan fatty acid esters,
sodium lauryl sulfate, monoglyceride stearate, starch,
and lactose; disintegration inhibitors such as saccharose,
stearin, cocoa butter, and hydrogenated oil; absorption
promoters such as quaternary ammonium salts and sodium
lauryl sulfate; moisturizing agents such as glycerin and
starch; adsorbents such as starch, lactose, kaolin,
bentonite, and colloidal silicic acid; and lubricants
such as purified talc, stearate, boric acid powder, and
polyethylene glycol. Alternatively, tablets coated in a
usual manner, for example, sugar coated tablets, gelatin
coated tablets, enteric coated tablets, film coated
tablets, double layer tablets, and multilayered tablets
may be prepared, if necessary.
[0086]
For use as a pill, examples of carriers that can be
used include: excipients such as glucose, lactose, cocoa
butter, starch, hydrogenated plant oil, kaolin, and talc;
binders such as gum arabic powder, powdered tragacanth,
gelatin, and ethanol; and disintegrants such as laminaran
and agar.
[0087]
CA 02942883 2016-09-15
- 38 -
For use as a suppository, conventional carriers
known in the art can be widely used. Examples thereof
include polyethylene glycol, cocoa butter, higher
alcohols, esters of higher alcohols, gelatin, and
semisynthetic glyceride.
[0088]
For use as an injection, solutions, emulsions, or
suspensions can be used. These solutions, emulsions, or
suspensions are preferably sterilized and adjusted to be
isotonic to blood. Any solvent that can be used as a
medical diluent can be used without limitations in the
production of these solutions, emulsions, or suspensions.
Examples thereof include water, ethanol, propylene glycol,
ethoxylated isostearyl alcohol, polyoxylated isostearyl
alcohol, and polyoxyethylene sorbitan fatty acid esters.
In this case, each preparation may contain common salt,
glucose, or glycerin in an amount sufficient for
preparing an isotonic solution. Also, each preparation
may contain a usual solubilizer, buffer, soothing agent,
and the like.
[0089]
These preparations may also contain a colorant, a
preservative, a fragrance, a flavor, a sweetener, and the
like, if necessary, and may further contain an additional
pharmaceutical product.
The amount of the active ingredient compound
contained in each of these preparations is not
CA 02942883 2016-09-15
- 39 -
particularly limited and is appropriately selected in a
wide range. The composition usually contains 0.5 to 70%
by weight, preferably 1 to 30% by weight of the compound
with respect to the total weight.
[0090]
The amount of the compound used differs depending on
the symptoms, age, etc. of a patient (warm-blooded animal,
particularly a human). The daily dose for oral
administration to an adult human is 2000 mg (preferably
100 mg) as the upper limit and 0.1 mg (preferably 1 mg,
more preferably 10 mg) as the lower limit and is
desirably administered once to 6 times a day according to
the symptoms.
[0091]
[Production method]
Next, a typical method for producing the compound
represented by the general formula (I) will be described.
The compound of the present invention can be produced by
various production methods. The production method shown
below is given for illustrative purposes. It should be
understood that the present invention is not limited by
this example.
[0092]
The compound represented by the general formula (I)
and intermediates for production thereof can be produced
through the use of various reactions known in the art as
described below.
CA 02942883 2016-09-15
- 40 -
[0093]
The compound of the present invention or the
pharmacologically acceptable salt thereof can be produced
by use of various production methods known in the art
taking into account the chemical properties of the
backbone and its substituents. The methods known in the
art are methods described in, for example, "Organic
Functional Group Preparations", 2nd ed., Academic Press,
Inc., 1989 and "Comprehensive Organic Transformations",
VCH Publishers Inc., 1989.
[0094]
Depending on the type of functional group(s) present
in the compound, functional group(s) in a starting
material or an intermediate may be protected with an
appropriate protective group, or may be replaced with a
group that can be readily converted to the functional
group. Such an approach may be effective for the
production technique.
[0095]
Examples of such a functional group include an amino
group, a hydroxy group, and a carboxy group. Examples of
their protective groups include protective groups
described in T.W. Greene and P.G. Wuts, "Protective
Groups in Organic Synthesis (4th ed., 2006)."
[0096]
The protective group or the group that can be
readily converted to the functional group can be
CA 02942883 2016-09-15
- 41 -
appropriately selected for use according to the reaction
conditions of each production method for compound
production.
[0097]
According to such a method, reaction can be carried
out after introduction of the group, followed by the
removal of the protective group or the conversion to the
desired group according to the need to obtain the desired
compound.
[0098]
A prodrug of the compound can be produced by, as in
the case of the protective group mentioned above,
introducing a particular group into a starting material
or an intermediate, or by carrying out a reaction using
the obtained compound. The reaction for producing the
prodrug can be carried out by use of a method generally
known to those skilled in the art such as conventional
esterification, amidation, dehydration, or hydrogenation.
[0099]
Hereinafter, methods for producing compounds will be
described. However, the production method of the present
invention is not limited to the methods described below
by any means.
[0100]
Method A-(a) is a method which involves:
halogenating compound (AO) by step A-1; then ketalizing
the resulting compound Al to produce compound (A2) (step
CA 02942883 2016-09-15
- 42 -
A-2); further hydrolyzing the compound (A2) by step A-3;
and then amidating the resulting compound (A3) by step A-
4 using a condensing agent to produce compound (A4).
[Formula 3]
Method A-(a)
C H3
C H3 0 a ÇH3
6 o 0 OLO H
R4
R4 R4 R4
halogenation XOH ketalization hydrolysis
CrcH OH 0 2 r4j0
0 H A-1 A-2 iR A-3
R3 R3
AO A1 A2 A3
Rxtr5R6
6
R=4õ4trR N H
I N H 0 NH 0
NH20 R4
coupling reagent x 0 2
04v5
A-4 R3
A4
wherein R2, R3, R4, Rs, R6, and V are as defined above,
and X represents a chlorine atom or a bromine atom.
[0101]
Step A-1 (halogenation reaction):
[0102]
(1) Chlorination:
This step involves stirring compound (AO) for 0.5 to
24 hours under cooling or under heating in the presence
of an equal amount or an excess amount of a chlorinating
agent in a solvent inert to the reaction to obtain
compound (Al) (X = 01). This compound is preferably
obtained by stirring at 0 to 60 C for 0.5 to 12 hours.
CA 02942883 2016-09-15
- 43 -
The solvent used in this reaction is not particularly
limited as long as the solvent is inert to the reaction.
Examples thereof include water, acetonitrile,
tetrahydrofuran, ethyl acetate, acetic acid,
dichloromethane, and mixtures thereof. Examples of the
chlorinating agent include sulfuryl chloride, N-
chlorosuccinimide (NCS), and chlorine. 1 to 2
equivalents of an additive such as p-anisole can be used
for preventing by-products and improving yields.
[0103]
(2) Bromination:
This step involves stirring compound (AO) for 0.5 to
24 hours under cooling or under heating in the presence
of an equal amount or an excess amount of a brominating
agent in a solvent inert to the reaction to obtain
compound Al (X = Br). This compound is preferably
obtained by stirring at 0 to 60 C for 0.5 to 12 hours.
The solvent used in this reaction is not particularly
limited as long as the solvent is inert to the reaction.
Examples thereof include tetrahydrofuran, ethyl acetate,
acetic acid, dichloromethane, and mixtures thereof.
Examples of the brominating agent include N-
bromosuccinimide (NBS) and bromine. An equal amount or
an excess amount of an additive such as p-anisole can be
used for preventing by-products and improving yields.
[0104]
Step A-2 (ketalization reaction):
CA 02942883 2016-09-15
- 44 -
[0105]
(1) In the case of using ketone:
This step involves heating compound (A1) to reflux
for 1 to 72 hours under reflux conditions using 0.01 to
0.5 equivalents of an acid catalyst in a solvent inert to
the reaction, while dehydrating the compound using a
Dean-Stark apparatus or the like to obtain compound (A2).
This compound is preferably obtained by heating compound
(A1) to reflux at 80 to 120 C for 3 to 24 hours using 0.1
to 0.3 equivalents of an acid catalyst, while dehydrating
the compound using a Dean-Stark apparatus or the like.
The solvent used in this reaction is not particularly
limited as long as the solvent is inert to the reaction.
Examples thereof include benzene, toluene, and xylene.
Examples of the acid catalyst include hydrochloric acid,
sulfuric acid, phosphoric acid, p-toluenesulfonic acid,
and montmorillonite K10.
[0106]
(2) In the case of using acetylene derivative:
The reaction can be carried out under conditions
shown in the following literature (Ming Li et al., J. Org.
Chem., 73, 8658-8660 (2008)). This step involves
stirring compound (A1) for 1 to 24 hours under heating
conditions using an equal amount or an excess amount of
an acetylene derivative and 0.01 to 0.3 equivalents of a
Ru catalyst in a solvent inert to the reaction to obtain
compound (A2). This compound is preferably obtained by
CA 02942883 2016-09-15
- 45 -
stirring at 60 to 150 C for 1 to 6 hours using 0.01 to
0.1 equivalents of a Ru catalyst. The solvent used in
this reaction is not particularly limited as long as the
solvent is inert to the reaction. Examples thereof
include benzene, toluene, and xylene. Examples of the Ru
catalyst include, but are not limited to, triruthenium(0)
dodecacarbonyl. The product can be obtained in good
yield even from a low reactive acetylene derivative by
use of 0.01 to 0.5 equivalents of a phosphine ligand.
Examples of the phosphine ligand used in this reaction
include triphenylphosphine, (2-biphenyl)di-tert-
butylphosphine (JohnPhos), 2-dicyclohexylphosphino-2',6'-
diisopropoxybiphenyl (RuPhos), and 5-(di-tert-
butylphosphino)-11,3',5'-tripheny1-1'H-[1,4']bipyrazole
(BippyPhos). The Ru catalyst and each ligand can be
purchased from Sigma-Aldrich Co., Strem Chemicals Inc.,
etc.
[0107]
Step A-3 (hydrolysis):
This step involves stirring compound (A2) for 3 to
96 hours under cooling or under heating using an equal
amount or an excess amount of an aqueous alkali solution
in a solvent to obtain compound (A3). This compound is
preferably obtained by stirring at room temperature to
60 C for 3 to 48 hours. The solvent used in this
reaction is not particularly limited as long as the
solvent does not inhibit the reaction. Examples thereof
CA 02942883 2016-09-15
- 46 -
include methanol, ethanol, tetrahydrofuran,
dimethoxyethane, acetonitrile, and mixtures thereof.
Examples of the alkali include inorganic bases such as
lithium hydroxide, sodium hydroxide, and potassium
hydroxide.
[0108]
Step A-4 (amidation reaction):
This step involves stirring compound (A3) for 1 to
24 hours, under cooling or under heating using an equal
amount or an excess amount of a corresponding amine and a
condensing agent in a solvent inert to the reaction to
obtain compound (A4). This compound is preferably
obtained by stirring at room temperature to 120 C for 1
to 8 hours. The solvent used in this reaction is not
particularly limited as long as the solvent is inert to
the reaction. Examples thereof include N,N-
dimethylformamide, dimethylacetamide, dichloromethane,
1,2-dichloroethane, chloroform, tetrahydrofuran, 1,2-
dimethoxyethane, acetonitrile, and mixtures thereof.
Examples of the condensing agent include
dicyclocarbodiimide (DCC), 1-ethy1-3-(3-
dimethylaminopropyl)carbodiimide (EDCI), and 1,1'-
carbonyldiimidazole. Use of an additive may be preferred
for the reaction. Examples of the additive include N-
hydroxysuccinimide (HOSu), 1-hydroxybenzotriazole (HOBt),
and 1-hydroxy-7-azabenzotriazole (HOAt). In addition, an
organic base such as triethylamine or
CA 02942883 2016-09-15
- 47 -
diisopropylethylamine, or an inorganic base such as
potassium carbonate, sodium carbonate, potassium
hydroxide, or sodium hydroxide may be advantageous for
the smooth progression of the reaction.
[0109]
Method A-(b) is a method which involves deprotecting
a protective group for the amino group contained in R2 or
R3 in compound (A4a) in which the amino group contained
in R2 or R3 of the compound (A4) synthesized in method A-
(a) has the protective group, and then carrying out
alkylation, acylation, sulfonylation, or the like to
produce compound (A5) (step A-5). Depending on the
properties of the compound, the steps may be carried out
in a different order such that compound (A2) is first
subjected to step A-5, followed by step A-3 (hydrolysis)
and step A-4 (amidation reaction).
[Formula 4]
Method A-(b) 5
RR
I N H
0 NHO
1) deprotection R4
A4a _______________________________________ =
2) alkylation, acylation, X 0 R2
orsuffonylabon 0¨A
V'
R3
A-5 A5
wherein R2, R3, R4, R5, R6, and V are as defined above,
and X represents a chlorine atom or a bromine atom.
[0110]
CA 02942883 2016-09-15
- 48 -
Step A-5
[0111]
(1) Deprotection of amino group:
[0112]
(In the case of Boc group)
This step involves stirring compound (A4a)
containing a Boc group for 0.5 to 24 hours under cooling
or under heating in the presence of an acid in a solvent
inert to the reaction to obtain an amine. This compound
is preferably obtained by stirring at 0 C to room
temperature for 0.5 to 12 hours. The solvent used in
this reaction is not particularly limited as long as the
solvent is inert to the reaction. Examples thereof
include methanol, ethanol, tetrahydrofuran, 1,2-
dimethoxyethane, 1,4-dioxane, ethyl acetate,
dichloromethane, 1,2-dichloroethane, chloroform, and
mixtures thereof. Examples of the acid include
hydrochloric acid-methanol, hydrochloric acid-1,4-dioxane,
hydrochloric acid-ethyl acetate, and trifluoroacetic acid.
[0113]
(In the case of Cbz group)
This step involves stirring compound (A4a)
containing a Cbz group for 0.5 to 12 hours under a
hydrogen atmosphere under cooling or under heating in the
presence of a reducing catalyst in a solvent inert to the
reaction to obtain an amine. This compound is preferably
obtained by stirring at room temperature to 40 C for 0.5
CA 02942883 2016-09-15
- 49 -
to 6 hours under a hydrogen atmosphere. The solvent used
in this reaction is not particularly limited as long as
the solvent is inert to the reaction. Examples thereof
can include methanol, ethanol, tetrahydrofuran, water,
and mixtures thereof. Examples of the reducing catalyst
include palladium-carbon, Raney nickel, platinum-carbon,
and platinum oxide.
[0114]
(2) Alkylation, acylation, or sulfonylation:
[0115]
(Alkylation)
This step involves stirring the amine obtained by
deprotection for 0.5 to 24 hours under cooling or under
heating using an equal amount or an excess amount of a
corresponding alkyl halide or dialkylsulfuric acid in the
presence of a base in a solvent inert to the reaction to
obtain compound (A5). This compound is preferably
obtained by stirring at 0 C to 60 C for 0.5 to 12 hours.
The solvent used in this reaction is not particularly
limited as long as the solvent is inert to the reaction.
Examples thereof can include tetrahydrofuran, 1,2-
dimethoxyethane, acetonitrile, dichloromethane, 1,2-
dichloroethane, chloroform, N,N-dimethylformamide, and
mixtures thereof. Examples of the base include organic
bases such as triethylamine and diisopropylethylamine,
and inorganic bases such as potassium carbonate, sodium
carbonate, potassium hydroxide, and sodium hydroxide.
CA 02942883 2016-09-15
- 50 -
Alternatively, an equal amount or an excess amount
of a corresponding aldehyde and ketone may be added to
the amine obtained by deprotection in a solvent inert to
the reaction, and the mixture can be stirred for 0.5 to
24 hours under cooling or under heating in the presence
of a reducing agent to obtain compound A5. This compound
is preferably obtained by stirring at 0 to 60 C for 0.5
to 12 hours. The solvent used in this reaction is not
particularly limited as long as the solvent is inert to
the reaction. Examples thereof can include methanol,
ethanol, tetrahydrofuran, 1,2-dimethoxyethane,
dichloromethane, 1,2-dichloroethane, chloroform, and
mixtures thereof. Examples of the reducing agent include
sodium cyanoborohydride, sodium triacetoxyborohydride,
and sodium borohydride. Alternatively, a reducing
catalyst such as palladium-carbon, Raney nickel,
platinum-carbon, or platinum oxide may be used instead of
the reducing agent under a hydrogen atmosphere.
[0116]
(Acylation)
This step involves stirring the amine obtained by
deprotection for 0.5 to 24 hours under cooling or under
heating using an equal amount or an excess amount of a
corresponding acyl chloride or carboxylic anhydride in
the presence of a base in a solvent inert to the reaction
to obtain compound (A5). This compound is preferably
obtained by stirring at 0 to 60 C for 0.5 to 6 hours.
CA 02942883 2016-09-15
- 51 -
The solvent used in this reaction is not particularly
limited as long as the solvent is inert to the reaction.
Examples thereof can include tetrahydrofuran, 1,2-
dimethoxyethane, acetonitrile, dichloromethane, 1,2-
dichloroethane, chloroform, and mixtures thereof.
Examples of the base include organic bases such as
triethylamine and diisopropylethylamine, and inorganic
bases such as potassium carbonate, sodium carbonate,
potassium hydroxide, and sodium hydroxide.
[0117]
(Sulfonylation)
This step involves stirring the amine obtained by
deprotection for 0.5 to 24 hours under cooling or under
heating using an equal amount or an excess amount of a
corresponding sulfonyl chloride or sulfonic anhydride in
the presence of a base in a solvent inert to the reaction
to obtain compound A5. This compound is preferably
obtained by stirring at 0 to 60 C for 0.5 to 6 hours.
The solvent used in this reaction is not particularly
limited as long as the solvent is inert to the reaction.
Examples thereof can include tetrahydrofuran, 1,2-
dimethoxyethane, acetonitrile, dichloromethane, 1,2-
dichloroethane, chloroform, and mixtures thereof.
Examples of the base include organic bases such as
triethylamine and diisopropylethylamine, and inorganic
bases such as potassium carbonate, sodium carbonate,
potassium hydroxide, and sodium hydroxide.
CA 02942883 2016-09-15
- 52 -
[0118]
Method A-(c) is a method which involves deprotecting
a protective group (ketal group) for the carbonyl group
contained in R2 or R3 in compound (A4b) in which the
carbonyl group contained in R2 or R3 of the compound (A4)
synthesized in method A-(a) has the protective group
(ketal group), and subsequently carrying out reductive
amination or the like using an amine to produce compound
(A6). Depending on the properties of the compound, the
steps may be carried out in a different order such that
compound (A2) is first subjected to step A-6, followed by
step A-3 (hydrolysis) and step A-4 (amidation reaction).
[Formula 5]
Method A-(c) Rz5 R6
I N H
0 N H 0
1) deprotection R4
A4b _________________________________
=
2) amination for X W r, R-
2
aldehydes or ketones
R3
A-6 A6
wherein R2, R3, R4, R5, R6, and V are as defined above,
and X represents a chlorine atom or a bromine atom.
[0119]
Step A-6
[0120]
(1) This step involves stirring compound (A4b)
containing a carbonyl group protected with ketal for 0.5
CA 02942883 2016-09-15
- 53 -
to 48 hours under cooling or under heating in the
presence of a catalytic amount to an excess amount of an
acid in an aqueous solvent inert to the reaction to
obtain a carbonyl compound. This compound is preferably
obtained by stirring at 0 to 60 C for 0.5 to 24 hours.
The aqueous solvent used in this reaction is not
particularly limited as long as the solvent does not
inhibit the reaction. Examples thereof can include
aqueous solvents such as methanol, ethanol,
tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane,
acetonitrile, and mixtures thereof. Examples of the acid
include hydrochloric acid, sulfuric acid, hydrochloric
acid-methanol, hydrochloric acid-1,4-dioxane,
hydrochloric acid-ethyl acetate, acetic acid, p-
toluenesulfonic acid, and pyridinium p-toluenesulfonate.
[0121]
(2) This step involves adding an equal amount or an
excess amount of a corresponding primary or secondary
amine to the carbonyl compound obtained in the preceding
step in a solvent inert to the reaction, and stirring the
mixture for 0.5 to 24 hours under cooling or under
heating in the presence of a reducing agent to also
obtain compound (A6). This compound is preferably
obtained by stirring at 0 to 60 C for 0.5 to 12 hours.
The solvent used in this reaction is not particularly
limited as long as the solvent is inert to the reaction.
Examples thereof can include methanol, ethanol,
CA 02942883 2016-09-15
- 54 -
tetrahydrofuran, 1,2-dimethoxyethane, dichloromethane,
1,2-dichloroethane, chloroform, and mixtures thereof.
Examples of the reducing agent include sodium
cyanoborohydride, sodium triacetoxyborohydride, and
sodium borohydride. Alternatively, a reducing catalyst
such as palladium-carbon, Raney nickel, platinum-carbon,
or platinum oxide may be used instead of the reducing
agent under a hydrogen atmosphere.
[0122]
Method A-(d) is a method which involves deprotecting
a protective group for the hydroxy group in R2 in
compound (A2a') in which the hydroxy group in R2 of the
compound (A2) synthesized in method A-(a) has the
protective group, and trifluoromethanesulfonylating the
hydroxy group, followed by the introduction of a
substituent through a subsequent substitution reaction.
After the introduction of a substituent, step A-8 (ester
hydrolysis) and step A-9 (amidation) can be carried out
to produce compound (A9). When R2 contains a protected
amino group, the deprotection of the amino group and
subsequent reaction such as alkylation, acylation, or
sulfonylation can be carried out in the same way as in
method A- (b).
[Formula 6]
CA 02942883 2016-09-15
- 55 -
Method A-(d)
9113
0 0 0 OH
1 ) deprotection4 ___________________________ hydrolysis
A2a' R R4
2) trifluoromethanesulfonylation
of hydroxy groups X 0 R2 A-8 X 0 02
3) substistution of -0Tf groups V 0-4. =
R3 R3
V
A-7 A7 A8
R,s
crri6 5
RrR6
5
R IIõRs
r
I NH I NH NH
0 NH 0 0 NH 0
NH20 1) deprotection
coupling reagent R4
R4
011
2) alkylation, acylation, 011 2
X 0 V
A-9 0-1R2 4. = or sulfonylation X R
04, =
V
R3 A-10 R3
A9 A10
wherein R2, R3, R4, R5, R6, and V are as defined above,
and X represents a chlorine atom or a bromine atom.
[0123]
Step A-7
[0124]
(1) Deprotection of hydroxy group
(In the case of tetrahydropyranyl (THP) group, 1-
ethoxyethyl group, methoxymethyl group,
methoxyethoxymethyl group, or the like)
This step involves stirring compound (A2a')
containing a hydroxy group protected with the protective
group mentioned above for 0.5 to 48 hours under cooling
or under heating in the presence of a catalytic amount to
an excess amount of an acid in a solvent to obtain an
alcohol compound. This compound is preferably obtained
CA 02942883 2016-09-15
- 56 -
by stirring at 0 to 60 C for 0.5 to 24 hours. The
solvent used in this reaction is not particularly limited
as long as the solvent does not inhibit the reaction.
Examples thereof can include methanol, ethanol,
tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane,
acetonitrile, water, and mixtures thereof. Examples of
the acid include hydrochloric acid, sulfuric acid,
hydrochloric acid-methanol, hydrochloric acid-1,4-dioxane,
hydrochloric acid-ethyl acetate, acetic acid, p-
toluenesulfonic acid, and pyridinium p-toluenesulfonate.
[0125]
(In the case of silyl group)
This step involves stirring compound (A2a')
containing a hydroxy group protected with a silyl group
for 0.5 to 48 hours under cooling or under heating using
an equal amount or an excess amount of a desilylation
reagent in a solvent to obtain an alcohol compound. This
compound is preferably obtained by stirring at 0 to 60 C
for 0.5 to 24 hours. The solvent used in this reaction
is not particularly limited as long as the solvent does
not inhibit the reaction. Examples thereof can include
methanol, ethanol, tetrahydrofuran, 1,2-dimethoxyethane,
1,4-dioxane, acetonitrile, water, and mixtures thereof.
Examples of the desilylation reagent include acids,
tetrabutyl ammonium fluoride (TBAF), hydrogen fluoride,
and pyridine hydrofluoride. Examples of the acid can
include hydrochloric acid, sulfuric acid, hydrochloric
CA 02942883 2016-09-15
- 57 -
acid-methanol, hydrochloric acid-1,4-dioxane,
hydrochloric acid-ethyl acetate, acetic acid, p-
toluenesulfonic acid, and trifluoroacetic acid. The
reaction may be carried out using a catalytic amount of
the acid.
[0126]
(2) This step involves stirring the alcohol compound
obtained by the preceding step for 0.5 to 48 hours under
cooling or under heating using an equal amount or an
excess amount of a trifluoromethanesulfonylation reagent
in the presence of a base in a solvent inert to the
reaction to obtain a trifluoromethanesulfonyloxy compound.
This compound is preferably obtained by stirring at -20 C
to room temperature for 0.5 to 24 hours. The solvent
used in this reaction is not particularly limited as long
as the solvent is inert to the reaction. Examples
thereof can include tetrahydrofuran, 1,2-dimethoxyethane,
1,4-dioxane, acetonitrile, dichloromethane, 1,2-
dichloroethane, chloroform, and mixtures thereof.
Examples of the trifluoromethanesulfonylation reagent
include trifluoromethanesulfonic anhydride,
trifluoromethanesulfonic acid chloride, and N-phenyl
bis(trifluoromethanesulfonimide). Examples of the base
include organic bases such as triethylamine and
diisopropylethylamine, and inorganic bases such as
potassium carbonate, sodium carbonate, potassium
hydroxide, and sodium hydroxide.
CA 02942883 2016-09-15
- 58 -
[0127]
(3) This step involves stirring the
trifluoromethanesulfonyloxy compound obtained by the
preceding step for 0.5 to 48 hours under cooling or under
heating using an equal amount or an excess amount of a
nucleophilic reagent in the presence or absence of a base
in a solvent inert to the reaction to obtain compound
(A7). This compound is preferably obtained by stirring
at -78 to 80 C for 0.5 to 24 hours. The solvent used in
this reaction is not particularly limited as long as the
solvent is inert to the reaction. Examples thereof can
include tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane,
acetonitrile, dichloromethane, 1,2-dichloroethane,
chloroform, N,N-dimethylformamide, dimethylacetamide,
dimethyl sulfoxide, and mixtures thereof. Examples of
the nucleophilic reagent include primary and secondary
amines, and ate complexes such as Gilman reagents.
Examples of the base include organic bases such as
triethylamine and diisopropylethylamine, inorganic bases
such as potassium carbonate, sodium carbonate, potassium
hydroxide, and sodium hydroxide.
[0128]
Step A-8: This step can be carried out in the same
way as in step A-3.
[0129]
Step A-9: This step can be carried out in the same
way as in step A-4.
CA 02942883 2016-09-15
- 59 -
[0130]
Step A-10: This step can be carried out in the same
way as in step A-5.
[0131]
Method B is a method which employs the compound (Al)
(X = Br) synthesized by method A as a starting material
and involves converting the bromine atom to F by use of
lithiation and subsequent use of an electrophilic
fluorinating agent to produce fluorine intermediate (B6),
and further carrying out ketalization (B-7), hydrolysis
(B-8), amidation (B-9), and conversion of an amino group
(B-10) in the same way as in method A to produce compound
(59) or compound (B10). Depending on the properties of
the compound, the steps may be carried out in a different
order such that compound (B7) is first subjected to step
B-10, followed by step B-8 (hydrolysis) and step B-9
(amidation reaction).
[Formula 7]
CA 02942883 2016-09-15
- 60 -
Method 13
CH3 CH3
o 6 o 6 pc PG
BuLi, THF
0 d
arat R4 methylation am Ra 1) reduction 4 (PhS02)2NE 4
deprotection
Br OH
R
C H3 2) Protection of 0
*
WI
13-1 Br W 0' 'CH3 6-3 F 0'CH3 I:"
OH O.CH2 hydroxy group Br
6-2 0'CH3 0'CH3
A1 (X=Br) 61 62 133
9 113
CH3 0 0
OH 1) S03-Py, 0 OD . o 6 R4
DMSO -4' 3 deprotection Ra ketalization =
Op hydrolysis
R4 R
C H3 2)12, KOH, Ill C H 40 - ' F o
F4(0' F 0- 3 F OH 0---i_vR2 -----.8-8 -
/ Me0H B-6
0'C H3 0'C H3 OH B-7 R3
13-5
B4 B5 B6 B7
Rr5 R6
R.r,R6
5
R, 1...,,R6 Jt.1rNH (If R2 and/or R3 contain(s) I NH
0 OH t. NH 0 NH 0 protected amino groups)
l 11
0 NH 0
R4 NH20 R4 1 ) deprotection R4
F 011,, 2
...= R coupling reagent
______.
F OP 0 W ____________________________________ _
2) alkylation, acylation F VI
el 2
0-4.._v= 61-9 04...v or sulfonylation 0-4
R3 W W
1340
68 69 B10
wherein R2, R3, R4, R5, R6, and V are as defined above,
and PG represents a silyl protective group.
[0132]
Step B-1 (methylation reaction):
This step involves stirring compound (Al) for 0.5 to
48 hours under cooling or under heating using an excess
amount of a methylation reagent in the presence of a base
in a solvent inert to the reaction to obtain compound
(B1). This compound is preferably obtained by stirring
at 0 to 60 C for 0.5 to 24 hours. The solvent used in
this reaction is not particularly limited as long as the
solvent is inert to the reaction. Examples thereof can
include tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane,
acetonitrile, dichloromethane, 1,2-dichloroethane,
chloroform, N,N-dimethylformamide, dimethyl sulfoxide,
CA 02942883 2016-09-15
- 61 -
and mixtures thereof. Examples of the methylation
reagent include methyl iodide and methyl sulfate.
Examples of the base include organic bases such as
triethylamine and diisopropylethylamine, and inorganic
bases such as potassium carbonate, sodium carbonate,
potassium hydroxide, and sodium hydroxide.
[0133]
Step B-2
[0134]
(1) Reduction of ester:
This step involves stirring compound (B1) for 0.5 to
48 hours under cooling or under heating using an equal
amount or an excess amount of a reducing agent in a
solvent inert to the reaction to obtain an alcohol
compound. This compound is preferably obtained by
stirring at -78 C to room temperature for 0.5 to 24 hours.
The solvent used in this reaction is not particularly
limited as long as the solvent is inert to the reaction.
Examples thereof can include tetrahydrofuran, 1,2-
dimethoxyethane, 1,4-dioxane, and mixtures thereof.
Examples of the reducing agent include lithium aluminum
hydride, diisobutyl aluminum hydride, and sodium bis(2-
methoxyethoxy)aluminum hydride.
[0135]
(2) Protection of hydroxy group with silyl group:
This step involves stirring the alcohol obtained by
the preceding step for 0.5 to 48 hours under cooling or
CA 02942883 2016-09-15
- 62 -
under heating using an equal amount or an excess amount
of a silylating agent in the presence of a base in a
solvent inert to the reaction to obtain compound (B3).
This compound is preferably obtained by stirring at 0 to
60 C for 0.5 to 24 hours. The solvent used in this
reaction is not particularly limited as long as the
solvent is inert to the reaction. Examples thereof can
include tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane,
acetonitrile, dichloromethane, 1,2-dichloroethane,
chloroform, N,N-dimethylformamide, dimethyl sulfoxide,
and mixtures thereof. Examples of the silylating agent
include trimethylchlorosilane, trimethylsilyl
trifluoromethanesulfonate, triethylchlorosilane,
triethylsilyl trifluoromethanesulfonate,
triisopropylchlorosilane, triisopropylsilyl
trifluoromethanesulfonate, tert-butyldimethylchlorosilane,
tert-butyldimethylsilyl trifluoromethanesulfonate, tert-
butyldiphenylchlorosilane, and tert-butyldiphenylsilyl
trifluoromethanesulfonate. Examples of the base include
organic bases such as triethylamine,
diisopropylethylamine, imidazole, and 4-
dimethylaminopyridine, and inorganic bases such as
potassium carbonate, sodium carbonate, potassium
hydroxide, and sodium hydroxide.
[0136]
Step 3-3 (fluorination):
CA 02942883 2016-09-15
- 63 -
This step involves lithiating the compound (B2)
obtained by the preceding step with an organic lithium
reagent or the like under cooling in a solvent inert to
the reaction, and stirring the resulting compound for 0.5
to 48 hours under cooling or under heating using an equal
amount or an excess amount of a fluorinating agent to
obtain compound (B3). This compound is preferably
obtained by stirring at -78 C to room temperature for 0.5
to 24 hours. The solvent used in this reaction is not
particularly limited as long as the solvent is inert to
the reaction. Examples thereof can include
tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane, and
mixtures thereof. Examples of the organic lithium
reagent include n-butyllithium, sec-butyllithium, and
tert-butyllithium. Examples of the fluorinating agent
include N-fluorobenzenesulfonimide and N-fluoropyridinium
triflate.
[0137]
Step B-4 (deprotection):
This step involves stirring compound (B3) for 0.5 to
48 hours under cooling or under heating using an equal
amount or an excess amount of a desilylation reagent in a
solvent to obtain compound (B4). This compound is
preferably obtained by stirring at 0 to 60 C for 0.5 to
24 hours. The solvent used in this reaction is not
particularly limited as long as the solvent does not
inhibit the reaction. Examples thereof can include
CA 02942883 2016-09-15
- 64 -
methanol, ethanol, tetrahydrofuran, 1,2-dimethoxyethane,
1,4-dioxane, acetonitrile, water, and mixtures thereof.
Examples of the desilylation reagent include acids,
tetrabutyl ammonium fluoride (TBAF), hydrogen fluoride,
and pyridine hydrofluoride. Examples of the acid can
include hydrochloric acid, sulfuric acid, hydrochloric
acid-methanol, hydrochloric acid-1,4-dioxane,
hydrochloric acid-ethyl acetate, acetic acid, p-
toluenesulfonic acid, and trifluoroacetic acid. The
reaction may be carried out using a catalytic amount of
the acid.
[0138]
Step B-5 (oxidation into aldehyde and methyl ester
synthesis)
[0139]
(1) Oxidation into aldehyde:
This step involves stirring compound (B4) for 0.5 to
48 hours under cooling or under heating using an equal
amount or an excess amount of an oxidizing agent in a
solvent inert to the reaction to obtain an aldehyde
compound. This compound is preferably obtained by
stirring at -78 to 60 C for 0.5 to 24 hours. The solvent
used in this reaction is not particularly limited as long
as the solvent is inert to the reaction. Examples
thereof can include dimethyl sulfoxide, dichloromethane,
1,2-dichloroethane, chloroform, and mixtures thereof.
Examples of the oxidizing agent include dimethyl
CA 02942883 2016-09-15
- 65 -
sulfoxide and acetic anhydride (Albright-Goldman
oxidation), dimethyl sulfoxide, S03-pyridine, and
triethylamine (Parikh-Doering oxidation), dimethyl
sulfoxide, N,N'-dicyclohexylcarbodiimide, and
trifluoroacetic acid (Pfitzner-Moffatt oxidation),
dimethyl sulfoxide, manganese dioxide, or oxalyl chloride
and triethylamine (Swern oxidation).
[0140]
(2) Methyl ester synthesis:
This step involves stirring the aldehyde obtained by
the preceding step for 0.5 to 48 hours under cooling or
under heating using an equal amount or an excess amount
of iodine in the presence of a base in a solvent to
obtain compound (B5). This compound is preferably
obtained by stirring at 000 to room temperature for 0.5
to 24 hours. The solvent used in this reaction is not
particularly limited as long as the solvent does not
inhibit the reaction. Examples thereof can include
methanol. Examples of the base include potassium
carbonate, sodium carbonate, potassium hydroxide, and
sodium hydroxide.
[0141]
Step B-6 (deprotection of catechol):
This step involves stirring compound (B5) for 0.5 to
48 hours under cooling or under heating using an equal
amount or an excess amount of a deprotection reagent in a
solvent inert to the reaction to obtain compound (B6).
CA 02942883 2016-09-15
- 66 -
This compound is preferably obtained by stirring at -78
to 60 C for 0.5 to 24 hours. The solvent used in this
reaction is not particularly limited as long as the
solvent is inert to the reaction. Examples thereof can
include dichloromethane, 1,2-dichloroethane, chloroform,
and mixtures thereof. Examples of the deprotection
reagent include boron tribromide, boron trichloride,
aluminum chloride, aluminum bromide, and magnesium iodide.
[0142]
Step B-7 can be carried out in the same way as in
step A-2.
[0143]
Step B-8 can be carried out in the same way as in
step A-3.
[0144]
Step B-9 can be carried out in the same way as in
step A-4.
[0145]
Step B-10 can be carried out in the same way as in
step A-5.
[0146]
Method C employs the compound (A1) (X = Cl or Br)
synthesized by method A as a starting material. Halogen
is replaced with an alkyl group (Rc) to produce an
intermediate (C1), and ketalization (0-2), hydrolysis (C-
3), amidation (C-4), and conversion of an amino group (C-
5) can be further carried out in the same way as in
CA 02942883 2016-09-15
- 67 -
method A to produce compound (C4) or compound (C5).
Depending on the properties of the compound, the steps
may be carried out in a different order such that
compound (C2) is first subjected to step C-5, followed by
step C-3 (hydrolysis) and step C-4 (amidation reaction).
[Formula 8]
MeModC
OH2 CH,
0 6 0 6 o a
c H3 0 OH
R4
R4 .. R4 ilk R4
alkylation ketalization hydrolysis 14,P
---.. Re 411
---- - Rc 111111111 Rc 0 R2
X . OH OH 0 R2 -----... 0-4.,v=
C-1 0 H C-2
0 H C-3
o-3/...v,
Fe
A1 (X = Cl, Br) C1 RC2 C3
R5eR6 R3r.....r,R6
I N H
R5rkieR6 I N H (If R2 and/or R3 contain(s)
I N H 0 N H 0 protected amino groups) 0 N H 0
4 R4
NH20 R 1 ) deprotection
0
coupling reagent 1
4
.x Rc ,.,
r 0 R2 2) alkylation, acylation ._. R2
C-4 0-1...v or sulfonylation 0-7(v=
R3 R3
C4
C-5 C5
wherein R2, R3, R4, R5, R6, and V are as defined above, Rc
represents a C1-C6 alkyl group, and X represents a
chlorine atom or a bromine atom.
[0147]
The reaction of step C-1 (alkylation reaction) can
be carried out under the conditions shown in the
following literature (Adv. Synth. Catal., 348, 686-690
(2006)). This step involves stirring compound (Al) for
0.5 to 48 hours under cooling or under heating using an
equal amount or an excess amount of an alkylation reagent,
a palladium catalyst, and a ligand in a solvent inert to
the reaction to obtain compound (01). This compound is
CA 02942883 2016-09-15
- 68 -
preferably obtained by stirring at room temperature to
80 C for 0.5 to 24 hours. The solvent used in this
reaction is not particularly limited as long as the
solvent is inert to the reaction. Examples thereof can
include tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane,
benzene, toluene, xylene, hexane, and mixtures thereof.
Examples of the alkylation reagent include trialkyl
aluminum-tertiary amine adducts such as trimethyl
aluminum-1,4-diazabicyclo[2.2.2]octane adducts and
triethyl aluminum-1,4-diazabicyclo[2.2.2]octane adducts.
Examples of the palladium catalyst can include
tris(dibenzylideneacetone)dipalladium and
tetrakis(triphenylphosphine)palladium. Examples of the
ligand include 2-(dicyclohexylphosphino)-2'-
(dimethylamino)biphenyl (DavePhos), 2-
dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl
(Xphos), and 2-di-tert-butylphosphino-2',4',6'-
triisopropylbiphenyl (t-BuXPhos).
[0148]
Step C-2 can be carried out in the same way as in
step A-2.
[0149]
Step C-3 can be carried out in the same way as in
step A-3.
[0150]
Step C-4 can be carried out in the same way as in
step A-4.
CA 02942883 2016-09-15
- 69 -
[0151]
Step C-5 can be carried out in the same way as in
step A-5.
[0152]
Method D is a method which employs the compound (A1)
(X = Br) synthesized by method A as a starting material
and involves converting the bromine atom to a hydroxy
group to produce an alkoxy intermediate (D4), and further
carrying out ketalization (D-5), hydrolysis (D-6),
amidation (D-7), and conversion of an amino group (D-8)
in the same way as in method A to produce compound (D7)
or compound (D8). Depending on the properties of the
compound, the steps may be carried out in a different
order such that compound (D5) is first subjected to step
D-8, followed by step D-6 (hydrolysis) and step D-7
(amidation reaction).
[Formula 9]
CA 02942883 2016-09-15
- 70 -
Method _ _
CH,
o 6 o OH 9113
c" R4R4 0 0
0 0 KOH, Pcylba,
tBuXPhos, HO este
Br OR4H
4( BnBr, K2CO3
H0
D-1 Br 0
06 -A0
I3-2a 0"--)0
01 nfication ft4
0 H
() 1:141:1 0,
A1 (X=Br)
D1 ¨ D2' ¨ D2 0%
c H, c H3
0 0
c H3 0 0
R4
alkylation
.1 Pd-C, li, 0 0
R4 ketalization R4
hydrolysis
0 13')0 --- ..2
Ad Oi 0-5
0-3 D-4 ittl 04,-- D-6
0 4:(0 H
Ad 0 H le -
D3 0 04
135
K
0 R 6 5 R6
N r
W R5crN f 76 Rcr.
(If 111 anclior R2 contain(s) I NH
protected amino groups)
0 OH NH2 Ize 0 NH 0 0 NH 0
WI
6,R4 R2 coupling reagent
41 ) deprotection le
_________________ ...
... RP
0 0 2) alkylatMn, acylation 0 0 R,
rid 04_ = D-7 9ZCo R2
or suffonylation
R V Rd 03/....v = Rd 03/...v =
R D-8 R
138 D7 D8
wherein R2, R3, R4, R5, R5, and V are as defined above,
and Rd represents a Ci-C6 alkyl group.
[0153]
Step D-1 (protection with benzyl ether):
Compound (D1) can be obtained in the same way as in
step B-1 using compound (Al) and an equal amount or an
excess amount of a benzyl halide.
[0154]
Step D-2a (substitution reaction):
This step involves stirring compound (D1) for 0.5 to
48 hours under cooling or under heating using an equal
amount or an excess amount of an alkali metal hydroxide,
a palladium catalyst, and a ligand in a solvent inert to
the reaction to obtain compound (D2). This compound is
preferably obtained by stirring at room temperature to
CA 02942883 2016-09-15
- 71 -
80 C for 0.5 to 24 hours. The solvent used in this
reaction is not particularly limited as long as the
solvent is inert to the reaction. Examples thereof can
include tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane,
water, and mixtures thereof. Examples of the alkali
metal hydroxide include potassium hydroxide, sodium
hydroxide, and lithium hydroxide. Examples of the
palladium catalyst can include
tris(dibenzylideneacetone)dipalladium and
tetrakis(triphenylphosphine)palladium. Examples of the
ligand include 2-(dicyclohexylphosphino)-2'-
(dimethylamino)biphenyl (DavePhos), 2-
dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl
(Xphos), and 2-di-tert-butylphosphino-2',4',6'-
triisopropylbiphenyl (t-BuXPhos).
If compound (D21) is obtained by the hydrolysis of
an ester in step D-2a, the methyl ester can be
synthesized again in step -2b.
[0155]
Step D-2b (methyl esterification):
This step involves stirring compound (D2') for 0.5
to 48 hours under cooling or under heating in the
presence of an acid in a methanol solvent to obtain
compound (D2). This compound is preferably obtained by
stirring at room temperature to reflux temperature for
0.5 to 24 hours. Examples of the acid used in this
reaction include hydrochloric acid, sulfuric acid,
CA 02942883 2016-09-15
- 72 -
hydrochloric acid-methanol, hydrochloric acid-1,4-dioxane,
and p-toluenesulfonic acid.
[0156]
Step D-3 (alkylation reaction):
This step involves obtaining compound (D3) in the
same way as in step B-1 using compound (D2) and an equal
amount or an excess amount of an alkyl halide or
dialkylsulfuric acid, etc.
When Rd represents a methyl group, compound (D3) can
be synthesized by the methylation of compound (D2') in
one step in the same way as in step B-1.
[0157]
Step D-4 (deprotection reaction):
This step involves stirring compound (D3) for 0.5 to
24 hours under a hydrogen atmosphere under cooling or
under heating using a reducing catalyst in a solvent
inert to the reaction to obtain compound (D4). This
compound is preferably obtained by stirring at room
temperature to 40 C for 0.5 to 6 hours. The solvent used
in this reaction is not particularly limited as long as
the solvent is inert to the reaction. Examples thereof
can include methanol, ethanol, tetrahydrofuran, 1,2-
dimethoxyethane, water, and mixtures thereof. Examples
of the reducing catalyst include palladium-carbon, Raney
nickel, platinum-carbon, and platinum oxide.
[0158]
CA 02942883 2016-09-15
- 73 -
Step D-5 can be carried out in the same way as in
step A-2.
[0159]
Step D-6 can be carried out in the same way as in
step A-3.
[0160]
Step D-7 can be carried out in the same way as in
step A-4.
[0161]
Step D-8 can be carried out in the same way as in
step A-5.
[0162]
Method E is a method which involves subjecting
compound (E0) to dichlorination (E-1) and esterification
(E-2) to produce compound (E2), and further carrying out
ketalization (E-3), hydrolysis (E-4), amidation (E-5),
and conversion of an amino group (E-6) in the same way as
in method A to produce compound (E6). Depending on the
properties of the compound, the steps may be carried out
in a different order such that compound (E3) is first
subjected to step E-6, followed by step E-4 (hydrolysis)
and step E-5 (amidation reaction).
[Formula 10]
CA 02942883 2016-09-15
- 74 -
Method E
CH3
CH3 o 6
O OH 0 OH o 6
4
M
_.,. esterificafion
di .,.
0 H r6 Cl
ketalization ci W n
chlorination 2
.., R-
CI .--... 0 H E-2 OH
E-3
OH E-1 OH OH RV3
Ed El E2
R:=.õ1....R6
R5i......70R6
R5rR6 I N H I
0 OH r.I r
NH N H
01N .. H 0
01 _N H 0
hydrolysis ci
CI R2 NH20 CI 1 ) deprotection
coupling reagent CI
1111W
0 ------.. Aiso R2 2) alkylation, acylation
0-4, = E-5 or sulfonylation AX0 w
E-4 R3 V (3
R71-V CI-i-11
E4 E5 E-6 R
E6
wherein R2, R2, R5, R5, and V are as defined above.
[0163]
Step E-1 (chlorination reaction):
This step involves stirring compound (E0) for 0.5 to
24 hours under cooling or under heating using an equal
amount or an excess amount of a chlorinating agent in a
solvent inert to the reaction to obtain compound E2.
This compound is preferably obtained by stirring at 0 to
80 C for 0.5 to 12 hours. The solvent used in this
reaction is not particularly limited as long as the
solvent is inert to the reaction. Examples thereof can
include tetrahydrofuran, dichloromethane, acetic acid,
ethyl acetate, and mixtures thereof. Examples of the
chlorination reagent include sulfuryl chloride and
chlorine.
[0164]
Step E-2 can be carried out in the same way as in
step D-2b'.
[0165]
CA 02942883 2016-09-15
- 75 -
Step E-3 can be carried out in the same way as in
step A-2.
[0166]
Step E-4 can be carried out in the same way as in
step A-3.
[0167]
Step E-5 can be carried out in the same way as in
step A-4.
[0168]
Step E-6 can be carried out in the same way as in
step A-5.
[0169]
Method F-(a) is a method which involves subjecting
the compound (A4), the compound (A5), the compound (A6),
or the compound (A10) obtained by the method mentioned
above to a cross-coupling reaction using a transition
metal catalyst or the like to produce compound (F1).
When Rl contains a protected amino group, hydroxy group,
or carbonyl group, corresponding compound (F2) can be
produced by deprotection.
[Formula 11]
Method F-(a)
H 6 H 6
0 N R 0 N R 0 N R6
(I( RI contains protected
amino, hydroxy,
0 NH R50 N H R5 or calbonyl groups) 5
cross-coupling 0 NH R
R4 reaction R4 deprotection R4
X !0
R1 =
R1 -41
ci R2 0 IR2 F4 Fe
F-1
0--/,,v =
R3 R3 R3
A4, A5, A6, or A10 F1 F2
CA 02942883 2016-09-15
- 76 -
wherein R2, R2, R4, R5, R6, and V are as defined above,
and X represents a chlorine atom or a bromine atom.
[0170]
Step F-1 (cross-coupling reaction):
This step involves stirring compound (A4), compound
(A5), compound (A6), or compound (A10) for 0.5 to 24
hours under heating conditions using a palladium catalyst
or a nickel catalyst and an equal amount or an excess
amount of boronic acid, boronic acid pinacol ester (for
Suzuki-Miyaura coupling), an organic tin reagent (for
Stille coupling), or an alkene compound (for Heck
reaction) in the presence of a base in a solvent inert to
the reaction to obtain compound (F1). This compound is
preferably obtained by stirring at 60 to 120 C for 0.5 to
12 hours. The solvent used in this reaction is not
particularly limited as long as the solvent is inert to
the reaction. Examples thereof can include methanol,
ethanol, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-
dioxane, water, N,N-dimethylformamide, dimethyl sulfoxide,
benzene, toluene, xylene, and mixtures thereof. Examples
of the palladium catalyst include
tetrakis(triphenylphosphine)palladium, [1,1'-
bis(diphenylphosphino)ferrocene]dichloropalladium,
tris(dibenzylideneacetone)dipalladium, palladium acetate,
palladium acetylacetonate, and
bis(triphenylphosphine)palladium dichloride. Examples of
the nickel catalyst include [1,1'-
CA 02942883 2016-09-15
- 77 -
bis(diphenylphosphino)ferrocene]nickel dichloride and
bis(triphenylphosphine)nickel dichloride. Examples of
the base include organic bases such as triethylamine,
diisopropylethylamine, 1,8-diazabicyclo[5.4.0]-7-undecene
(DBU), and 1,5-diazabicyclo[4.3.0]-5-nonene (DBN), and
inorganic bases such as potassium bicarbonate, sodium
bicarbonate, potassium carbonate, sodium carbonate,
potassium hydroxide, sodium hydroxide, potassium
phosphate, and sodium phosphate.
[0171]
Step F-2 (deprotection):
(When R1 contains a protected amino group)
This step can be carried out in the same way as in
step A-5(1).
(When R1 contains a protected hydroxy group)
This step can be carried out in the same way as in
step A-7(1).
(When Rl contains a protected carbonyl group)
This step can be carried out in the same way as in
step A-6(1).
[0172]
Method F-(b) is a method which involves converting
the compound (F1) obtained by method F-(a) in which the
substituent R1 is a vinyl group, to an aldehyde by
oxidative cleavage (F-3), followed by step F-4 of
producing an alkene compound through Wittig-type reaction
or producing an alkyne compound by use of the Seyferth-
CA 02942883 2016-09-15
- 78 -
Gilbert method (or the Ohira-Bestmann method) or the like.
When R2 or R3 in compound (F4) contains a protected amino
group, compound F5 can be produced by the removal of the
protective group, followed by alkylation, acylation,
sulfonylation, or the like (F-5).
[Formula 12]
Method F-(b)
R5;q176 5
RS I *....NHR6
RX%Ikr1;
(If 123 and/or R3 contain(s)
0 NH 0 Wittig type reaction 0 NH 0 protected amino groups)
oxidative
Ra or Ohira-Bestmann 017 0
cleavage reaction etc. R4 1 ) deprotection R4
F1 IS
W R1 1,1
0 0 R2 2) alkylation, acylation
F-3 F-4 H);& W
H or sulfonylation
R3 R3 v
F-5 R3
F3 F4 F5
wherein R2, R3, R4, R6, R6, and V are as defined above.
[0173]
Step F-3 (oxidative cleavage reaction):
This step involves stirring compound (F1) for 0.5 to
48 hours under cooling or under heating conditions using
an oxidizing catalyst and an equal amount or an excess
amount of an oxidizing agent in a solvent inert to the
reaction to obtain compound (F3). This compound is
preferably obtained by stirring at 0 to 40 C for 0.5 to
24 hours. The solvent used in this reaction is not
particularly limited as long as the solvent is inert to
the reaction. Examples thereof can include
tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane, water,
and mixtures thereof. Examples of the oxidizing catalyst
include osmium tetroxide and microencapsulated osmium
CA 02942883 2016-09-15
- 79 -
tetroxide. Examples of the oxidizing agent include
sodium periodate and potassium periodate.
[0174]
Step F-4:
[0175]
(In the case of synthesizing alkene)
This step involves stirring compound (F3) for 0.5 to
24 hours under cooling or under heating conditions using
an equal amount or an excess amount of a corresponding
Wittig reagent, Horner-Wadsworth-Emmonds reagent, or the
like in the presence of a base in a solvent inert to the
reaction to obtain compound (F4). This compound is
preferably obtained by stirring at -78 C to room
temperature for 0.5 to 12 hours. The solvent used in
this reaction is not particularly limited as long as the
solvent is inert to the reaction. Examples thereof can
include diethyl ether, tetrahydrofuran, 1,2-
dimethoxyethane, 1,4-dioxane, and mixtures thereof.
Examples of the base include n-butyllithium, sec-
butyllithium, tert-butyllithium, lithium diisopropylamide
(LDA), lithium bis(trimethylsilyl)amide (LHMDS), sodium
hydride, potassium tert-butoxide, 1,8-
diazabicyclo[5.4.0]-7-undecene (DBU), and 1,5-
diazabicyclo[4.3.0]-5-nonene (DBN).
[0176]
(In the case of synthesizing alkyne)
CA 02942883 2016-09-15
- 80 -
This step involves stirring compound (F3) for 0.5 to
48 hours under cooling or under heating conditions using
an equal amount or an excess amount of dimethyl
diazomethylphosphonate (Seyferth-Gilbert reagent),
dimethyl (1-diazo-2-oxopropyl)phosphonate (Ohira-Bestmann
reagent), or the like in the presence of a base in a
solvent inert to the reaction to obtain compound (F4).
This compound is preferably obtained by stirring at -78 C
to room temperature for 0.5 to 24 hours. The solvent
used in this reaction is not particularly limited as long
as the solvent is inert to the reaction. Examples
thereof can include diethyl ether, tetrahydrofuran, 1,2-
dimethoxyethane, 1,4-dioxane, methanol, ethanol, and
mixtures thereof. Examples of the base include n-
butyllithium, potassium tert-butoxide, sodium carbonate,
and potassium carbonate.
Alternatively, compound (F3) may be stirred for 0.5
to 48 hours under cooling or under heating conditions
using an equal amount or an excess amount of carbon
tetrabromide and triphenylphosphine in a solvent inert to
the reaction to obtain a dibromoolefin intermediate, and
this intermediate can be treated with an excess amount of
a base to obtain compound (F4) (Corey-Fuchs method).
This compound is preferably obtained by stirring at 0 C
to room temperature for 0.5 to 24 hours. The solvent
used in this reaction is not particularly limited as long
as the solvent is inert to the reaction. Examples
CA 02942883 2016-09-15
- 81 -
thereof include dichloromethane, 1,2-dichloroethane,
chloroform, diethyl ether, tetrahydrofuran, 1,2-
dimethoxyethane, 1,4-dioxane, and mixtures thereof for
the synthesis of a dibromoolefin intermediate and include
diethyl ether, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-
dioxane, and mixtures thereof for the step of treating
the dibromoolefin intermediate with a base to obtain
compound F4. Examples of the base used in this reaction
include n-butyllithium, sec-butyllithium, and tert-
butyllithium.
[0177]
Step F-5 can be carried out in the same way as in
step A-5.
[0178]
Method G is a step which involves dehalogenating the
compound (A4), the compound (A5), the compound (A6), the
compound (A10), or the compound (F1) (when the
substituent R1 is a chlorine atom, a bromine atom, or a
C2-C6 alkenyl group) obtained by the methods mentioned
above through a hydrogenation reaction or reducing the
double bond to produce compound (G1).
[Formula 13]
CA 02942883 2016-09-15
- 82 -
Method G
0 N
0 N R6
#?(R6 ,5T1
0 N H R 0 N H R
R4 hydrogenation R4
31.
141
0 R2 R0 R2
G-1 04, =
V
R3 R3
A4, A5, A6, A10, or F1 G1
wherein R2, R3, R4, R5, R6, and V are as defined above,
and Q represents a chlorine atom, a bromine atom, or a
C2-C6 alkenyl group.
[0179]
Step G:
This step involves stirring compound (A4), compound
(A5), compound (A6), compound (A10), or compound (F1)
(when the substituent R1 is a C2-C6 alkenyl group) for 0.5
to 48 hours under a hydrogen atmosphere under cooling or
under heating conditions using a reducing catalyst in a
solvent inert to the reaction to obtain compound (G1).
This compound is preferably obtained by stirring at room
temperature to 40 C for 0.5 to 24 hours. The solvent
used in this reaction is not particularly limited as long
as the solvent is inert to the reaction. Examples
thereof can include tetrahydrofuran, 1,2-dimethoxyethane,
1,4-dioxane, water, methanol, ethanol, and mixtures
thereof. Examples of the reducing catalyst include
CA 02942883 2016-09-15
- 83 -
palladium-carbon, Raney nickel, platinum-carbon, and
platinum oxide.
[0180]
The compounds produced by these methods can each be
isolated and purified by a method known in the art, for
example, extraction, precipitation, distillation,
chromatography, fractional crystallization, or
recrystallization.
When each compound or intermediate for production
has asymmetric carbon(s), enantiomers are present. These
enantiomers can each be isolated and purified by a
routine method such as fractional crystallization (salt
resolution) by recrystallization with an appropriate salt,
or column chromatography. Examples of references for the
method for resolving a racemate to enantiomers include J.
Jacques et al. "Enantiomers, Racemates and Resolution,
John Wiley And Sons, Inc.".
Examples
[0181]
Abbreviations in the Reference Examples and Examples
are as follows: Me = methyl, tBu = tert-butyl, and TBDMS
= tert-butyldimethylsilyl.
[0182]
Reference Example 1 (step A-1)
Methyl 5-bromo-3,4-dihydroxy-2-methylbenzoate (Ala: X =
Br, R4 = Me)
CA 02942883 2016-09-15
- 84 -
Methyl 3,4-dihydroxy-2-methylbenzoate (43.1 g, 237
mmol) was dissolved in acetic acid (250 mL) and
dichloromethane (250 mL). To the solution, a solution of
bromine (37.8 g, 237 mmol) in dichloromethane (20 mL) was
added dropwise over 15 minutes under ice cooling, and the
mixture was stirred at this temperature for 4 hours.
Bromine (3.78 g, 23.7 mmol) was further added thereto,
and the mixture was stirred for 1.5 hours under ice
cooling. Then, ice water was added to the reaction
solution, followed by extraction with ethyl acetate. The
organic layer was washed with an aqueous sodium sulfite
solution and saturated saline and then concentrated under
reduced pressure. The obtained residue was washed with
dichloromethane to obtain the title compound (50.4 g, 193
mmol, 82% yield).
1H-NMR (400 MHz, CDC13) 5: 2.47 (3H, s), 3.87 (3H, s),
5.61 (1H, br s), 5.83 (1H, br s), 7.67 (1H, s).
MS (ESI) m/z: 259, 261 (M-H)-.
[0183]
Reference Example 2 (step A-1)
Methyl 5-chloro-3,4-dihydroxy-2-methylbenzoate (Alb: X =
Cl, R4 = Me)
Methyl 3,4-dihydroxy-2-methylbenzoate (12.1 g, 66.2
mmol) was dissolved in ethyl acetate (265 mL). To the
solution, N-chlorosuccinimide (13.3 g, 99.2 mmol) was
added, and the mixture was stirred at room temperature
for 1 hour. Then, p-anisole (7.15 g, 66.2 mmol) was
CA 02942883 2016-09-15
- 85 -
added thereto, and the mixture was further stirred for 15
minutes. The reaction solution was washed with water and
saturated saline, dried over magnesium sulfate, and then
concentrated under reduced pressure. The obtained
residue was washed with dichloromethane to obtain the
title compound (8.03 g, 37.1 mmol, 56% yield).
1H-NMR (400 MHz, DMSO-d6) 6: 2.34 (3H, s), 3.76 (3H, s),
7.36 (1H, s), 9.11 (1H, br s), 9.96 (1H, br s).
MS (ESI) m/z: 215 (M-H)-.
[0184]
Reference Example 3
Methyl 5-fluoro-3,4-dihydroxy-2-methylbenzoate (Alc: X =
F, R4 = Me)
[Formula 14]
cH3 c H3 TBDMS
0 0 0 0 OH TBDMS
lo
cH, ----- X 40CH3 S-3-3 CH
CH,
CH
Br OH Br Br
S-3-1 011P CH, S-3-2 S-3-4 '1,I
'IF lip 0 CH,
OH 0"CH3 0=CH3 Br 0 -, 0"CH,
0CH,
Ala S3-1 S3-2 S3-3 S3-4
c H3 CH3
OH H 0 0 0 0 0
CH3 CH, Z.:(C H3
S-3-5 F 0 Z(D H3
C H3 S-3-6 F 0
CH3 S-3-7 F 0=C H3 S-3-8 OH
0 oCH, .CH, 0.CH3 OH
W-5 S3-6 W-7 Mc
[0185]
(Step S-3-1)
Methyl 5-bromo-3,4-dimethoxy-2-methylbenzoate (S3-1)
[0186]
The compound (Ala) (3.00 g, 11.5 mmol) synthesized
in Reference Example 1 was dissolved in dimethylformamide
(10 mL). To the solution, potassium carbonate (11.1 g,
CA 02942883 2016-09-15
- 86 -
80.4 mmol) and methyl iodide (9.79 g, 68.9 mmol) were
added, and the mixture was stirred at room temperature
for 24 hours. Ethyl acetate was added to the reaction
solution, and the mixture was washed with dilute
hydrochloric acid, a saturated aqueous solution of sodium
bicarbonate, and saturated saline and then dried over
sodium sulfate. The solvent was distilled off under
reduced pressure, and the obtained residue was purified
by silica gel column chromatography (hexane:ethyl acetate
= 90:10 - 50:50) to obtain the title compound (3.29 g,
11.4 mmol, 99% yield).
[0187]
(Step S-3-2)
(5-Bromo-3,4-dimethoxy-2-methylphenyl)methanol (S3-2)
[0188]
Methyl 5-bromo-3,4-dimethoxy-2-methylbenzoate (1.00
g, 3.46 mmol) synthesized in step S-3-1 was dissolved in
toluene (20 mL). After cooling of the solution to -78 C,
a 1.0 mol/L solution of diisobutyl aluminum hydride in
hexane (6.65 mL, 6.92 mmol) was added thereto, and the
mixture was stirred at -78 C for 0.5 hours. The reaction
solution was quenched by the addition of an aqueous
Rochelle salt solution, and the temperature of the
reaction solution was raised to room temperature. Then,
the deposited solid was removed by filtration. The
filtrate was dried over sodium sulfate, and the solvent
CA 02942883 2016-09-15
- 87 -
was then distilled off under reduced pressure to obtain
the title compound (0.903 g, 3.46 mmol, 100% yield).
1H-NMR (400 MHz, CDC13) 6:1.67 (1H, t, J = 5.2 Hz), 2.21
(3H, s), 3.84 (3H, s), 3.87 (3H, s) 4.62 (2H, d, J - 5.2
Hz), 7.33 (1H, s).
[0189]
(Step S-3-3)
(5-Bromo-3,4-dimethoxy-2-methylphenyl)methoxy-tert-
butyldimethylsilane (S3-3)
[0190]
(5-Bromo-3,4-dimethoxy-2-methylphenyl)methanol
(0.903 g, 3.46 mmol) synthesized in step S-3-2 was
dissolved in dichloromethane (10 mL). To the solution,
t-butyldimethylsilyl chloride (0.626 g, 4.15 mmol),
triethylamine (1.82 g, 18.0 mmol), and 4-
dimethylaminopyridine (0.423 g, 3.46 mmol) were added at
room temperature, and the mixture was stirred for 2 hours.
Ethyl acetate was added to the reaction solution, and the
organic layer was washed with water, a saturated aqueous
solution of sodium bicarbonate, and saturated saline and
then dried over sodium sulfate. The solvent was
distilled off under reduced pressure, and the obtained
residue was purified by silica gel column chromatography
(hexane:ethyl acetate = 90:10 50:50) to obtain the
title compound (1.22 g, 3.25 mmol, 93% yield).
[0191]
(Step S-3-4)
CA 02942883 2016-09-15
- 88 -
tert-Butyl-[(5-fluoro-3,4-dimethoxy-2-
methylphenyl)methoxy]dimethylsilane (S3-4)
[0192]
A solution of (5-bromo-3,4-dimethoxy-2-
methylphenyl)methoxy-tert-butyldimethylsilane (1.22 g,
3.25 mmol) synthesized in step S-3-3 in tetrahydrofuran
(20 mL) was cooled to -78 C. A 1.6 M solution of n-
butyllithium in hexane (1.67 mL, 2.66 mmol) was added
dropwise thereto, and the mixture was then stirred at
this temperature for 5 minutes. A solution of N-
fluorobenzenesulfonimide (1.09 g, 3.46 mmol) in
tetrahydrofuran (10 mL) was added dropwise thereto, and
the mixture was stirred at -78 C for 1 hour. The
reaction solution was quenched with a saturated aqueous
solution of ammonium chloride, and the temperature of the
reaction solution was raised to room temperature,
followed by extraction by the addition of ethyl acetate.
The organic layer was washed with water, a saturated
aqueous solution of sodium bicarbonate, and saturated
saline and then dried over sodium sulfate. The solvent
was distilled off under reduced pressure, and the
obtained residue was purified by silica gel column
chromatography (hexane:ethyl acetate - 90:10 -* 50:50) to
obtain the title compound (0.738 g, 2.35 mmol, 88% yield).
[0193]
(Step S-3-5)
(5-Fluoro-3,4-dimethoxy-2-methylphenyl)methanol (S3-5)
CA 02942883 2016-09-15
- 89 -
[0194]
To tert-butyl-[(5-fluoro-3,4-dimethoxy-2-
methylphenyl)methoxy]dimethylsilane (0.738 g, 2.35 mmol)
synthesized in step S-3-4, a 1 M solution of tetrabutyl
ammonium fluoride in tetrahydrofuran (4 mL) was added,
and the mixture was stirred at room temperature for 1
hour. The reaction solution was concentrated, and the
obtained residue was purified by silica gel column
chromatography (hexane:ethyl acetate = 70:30 -* 20:80) to
obtain the title compound (0.340 g, 1.70 mmol, 70% yield).
1H-NMR (400 MHz, CDC13) 6: 1.70 (1H, br s), 2.18 (3H, s),
3.84 (3H, s), 3.94 (3H, s) 4.60-4.67 (2H, m), 6.93 (1H, d,
J = 11.6 Hz).
[0195]
(Step S-3-6)
5-Fluoro-3,4-dimethoxy-2-methylbenzaldehyde (S3-6)
[0196]
(5-Fluoro-3,4-dimethoxy-2-methylphenyl)methanol
(0.340 g, 1.70 mmol) synthesized in step S-3-5 and
triethylamine (0.137 g, 1.36 mmol) were dissolved in
dichloromethane (2 mL). To the solution, dimethyl
sulfoxide (0.4 mL) and S03-pyridine (0.162 g, 1.02 mmol)
were added under ice cooling. The mixture was stirred
for 1 hour under ice cooling and then further stirred at
room temperature for 16 hours. Water was added to the
reaction solution, followed by extraction with ethyl
acetate. The organic layer was washed with water, a
CA 02942883 2016-09-15
- 90 -
saturated aqueous solution of sodium bicarbonate, and
saturated saline and then dried over sodium sulfate. The
solvent was distilled off under reduced pressure, and the
obtained residue was purified by silica gel column
chromatography (hexane:ethyl acetate = 75:25 -* 50:50) to
obtain the title compound (0.313 g, 1.57 mmol, 93% yield).
1H-NMR (400 MHz, CDC13) 6: 2.54 (3H, s), 3.85 (3H, s),
4.07 (3H, s), 7.37 (1H, d, J = 11.6 Hz), 10.17 (1H, s).
[0197]
(Step S-3-7)
Methyl 5-fluoro-3,4-dimethoxy-2-methylbenzoate (S3-7)
[0198]
5-Fluoro-3,4-dimethoxy-2-methylbenzaldehyde (0.313 g,
1.57 mmol) synthesized in step S3-6 was dissolved in
anhydrous methanol (6 mL). To the solution, potassium
hydroxide (0.266 g, 4.73 mmol) and iodine (0.521 g, 2.05
mmol) were added under ice cooling, and the mixture was
stirred for 1.5 hours. A saturated aqueous solution of
sodium bisulfite was added thereto until the red brown
color disappeared, followed by extraction with ethyl
acetate. The organic layer was washed with water, a
saturated aqueous solution of sodium bicarbonate, and
saturated saline and then dried over sodium sulfate. The
solvent was distilled off under reduced pressure, and the
obtained residue was purified by silica gel column
chromatography (hexane:ethyl acetate = 75:25 -* 50:50) to
obtain the title compound (0.325 g, 1.42 mmol, 90% yield).
CA 02942883 2016-09-15
- 91 -
1H-NMR (400 MHz, CDC13) 6: 2.46 (3H, s), 3.82 (3H, s),
3.87 (3H, s) 4.02 (3H, s), 7.46 (1H, d, J = 11.9 Hz).
[0199]
(Step S-3-8)
Methyl 5-fluoro-3,4-dihydroxy-2-methylbenzoate (compound
(Alc): X = F, R4 = Me)
[0200]
Methyl 5-fluoro-3,4-dimethoxy-2-methylbenzoate
(0.325 g, 1.42 mmol) synthesized in step S-3-7 was
dissolved in dichloromethane (6 mL). After cooling of
the solution to 78 C, a 1 M solution of boron tribromide
in dichloromethane (3.55 mL, 3.55 mmol) was added thereto,
and the mixture was stirred at this temperature for 1
hour and then stirred at room temperature for 20 hours.
Methanol was added to the reaction solution, and the
mixture was stirred for approximately 1 hour. Then,
water was added thereto, followed by extraction with
dichloromethane. The organic layer was washed with water
and saturated saline and then dried over sodium sulfate.
The solvent was distilled off under reduced pressure to
obtain the title compound (0.265 g, 1.32 mmol, 93% yield).
1H-NMR (400 MHz, CDC13) 6: 2.48 (3H, s), 3.86 (3H, s),
7.32 (1H, d, J = 11.2 Hz).
[0201]
Reference Example 4 (step C-1)
Methyl 3,4-dihydroxy-2,5-dimethylbenzoate (Ald: X = Me,
R4 = Me)
CA 02942883 2016-09-15
- 92 -
[0202]
The compound (Ala) (3.44 g, 13.2 mmol) synthesized
in Reference Example 1 was dissolved in tetrahydrofuran
(80 mL). To the solution, bis(trimethyl aluminum)-1,4-
diazabicyclo[2.2.2]octane (5.40 g, 21.1 mmol),
tris(dibenzylideneacetone)dipalladium(0) (0.181, 0.198
mmol), and 2-dicyclohexylphosphino-2',4',6'-
triisopropylbiphenyl (0.188 g, 0.395 mmol) were added,
and the mixture was heated to reflux at 75 C for 3 hours
under the current of nitrogen. The reaction solution was
brought back to room temperature and quenched by the
addition of 1 N hydrochloric acid. After extraction with
ethyl acetate, the organic phase was washed with water
and saturated saline and dried over sodium sulfate.
After concentration under reduced pressure, the obtained
residue was purified by silica gel column chromatography
(hexane:ethyl acetate = 80:20 -* 60:40) to obtain the
title compound (2.23 g, 11.4 mmol, 86% yield).
1H-NMR (400 MHz, CDC13) 6: 2.24 (3H, s), 2.48 (3H, s),
3.85 (3H, s), 5.23 (1H, br s), 5.58 (1H, br s), 7.39 (1H,
s).
MS (ESI) m/z: 195 (M-H)-.
[0203]
Reference Example 5
Methyl 3,4-dihydroxy-5-methoxy-2-methylbenzoate (Ale: X =
OMe, R4 = Me)
[Formula 15]
CA 02942883 2016-09-15
- 93 ¨
c H3 9 H3
0 OH
0 0 0 0
H3 r C
0 0 C H,
= C H3
C H3 -a. Br 0 =
HO 0 0 op
S-5-1 0 S-5-3 0,1 1151
Bri x0H
0 H
Ala S5-1 S5-2 S5-3
9 H3
00
C H,
S-5-4 H3C.0 kip H
OH
Ale (X=0Me,124=Me)
[0204]
(Step S-5-1)
Methyl 3,4-dibenzyloxy-5-bromo-2-methylbenzoate (S5-1)
[0205]
The title compound (0.550 g, 1.24 mmol, 64% yield)
was obtained through the same reaction as in step S3-1
using the compound (Ala) (0.500 g, 1.92 mmol) synthesized
in Reference Example 1 and benzyl bromide (1.31 g, 7.66
mmol).
1H-NMR (400 MHz, CDC13) 6: 2.46 (3H, s), 3.88 (3H, s),
4.97 (2H, s), 5.10 (2H, s), 7.30-7.53 (10H, m), 7.50 (1H,
s)
[0206]
(Step S-5-2)
3,4-Dibenzyloxy-5-hydroxy-2-methylbenzoic acid (S5-2)
[0207]
Methyl 3,4-dibenzyloxy-5-bromo-2-methylbenzoate
(0.150 g, 0.340 mmol) synthesized in step S-5-1 was
dissolved in a 1,4-dioxane:water (4:1) mixed solvent. To
the solution, potassium hydroxide (0.095 g, 1.70 mmol),
CA 02942883 2016-09-15
- 94 -
tris(dibenzylideneacetone)dipalladium(0) (0.031 g, 0.034
mmol), and 2-di-tert-buty1phosphino-2',4',6'-
triisopropylbiphenyl (0.028 g, 0.068 mmol) were added,
and the mixture was stirred at 90 C for 3 hours. The
reaction solution was neutralized, followed by extraction
with ethyl acetate. The organic layer was washed with
water, a saturated aqueous solution of sodium bicarbonate,
and saturated saline and then dried over sodium sulfate.
The solvent was distilled off under reduced pressure to
obtain the title compound (0.123 g, 0.340 mmol, 100%
yield).
[0208]
(Step S-5-3)
Methyl 3,4-dibenzyloxy-5-methoxy-2-methylbenzoate (S5-3)
[0209]
The title compound (0.133 g, 0.340 mmol, 100% yield)
was obtained through the same reaction as in step S3-1
using 3,4-dibenzyloxy-5-hydroxy-2-methylbenzoic acid
(0.123 g, 0.340 mmol) synthesized in step S-5-2.
[0210]
(Step S5-4)
Methyl 3,4-dihydroxy-5-methoxy-2-methylbenzoate (compound
(Ale): X = OMe, R4 = Me)
[0211]
Ethyl 3,4-dibenzyloxy-5-methoxy-2-methylbenzoate
(0.133 g, 0.340 mmol) synthesized in step S-5-3 was
dissolved in methanol (2 mL). To the solution, 7.5%
CA 02942883 2016-09-15
- 95 -
palladium-carbon was added, and the mixture was stirred
for 1 hour under a hydrogen atmosphere. The catalyst was
filtered, and the filtrate was then concentrated to
obtain the title compound (0.077 g, 0.340 mmol, 100%
yield).
[0212]
Reference Example 6
Methyl 2,5-dichloro-3,4-dihydroxybenzoate (compound (E2))
[0213]
(Step S-6-1)
2,5-Dichloro-3,4-dihydroxybenzoic acid
[0214]
To a solution of 3,4-dihydroxybenzoic acid hydrate
(12.2 g, 70.8 mmol) in acetic acid (45 mL), sulfuryl
chloride (14.0 mL, 173 mmol) was added dropwise at 50 C
over 30 minutes, and the mixture was further stirred for
17 hours. The reaction mixture was cooled to 0 C, and
insoluble matter was then collected by filtration, washed
with hexane, and then dried under reduced pressure at
room temperature to obtain the title compound (2.68 g,
12.0 mmol, 17% yield).
1H-NMR (400 MHz, DMSO-d0 6: 7.37 (1H, s), 9.95 (1H, br
s), 10.42 (1H, br s).
MS (APCI) m/z: 221 (M-H)-.
[0215]
(Step S-6-2)
Methyl 2,5-dichloro-3,4-dihydroxybenzoate (compound (E2))
CA 02942883 2016-09-15
- 96 -
[0216]
To a solution of 2,5-dichloro-3,4-dihydroxybenzoic
acid (2.68 g, 12.0 mmol) synthesized in step S-6-1 in
methanol (30 mL), sulfuric acid (1.40 mL, 26.3 mmol) was
added, and the mixture was refluxed for 15 hours. The
reaction solution was concentrated under reduced pressure.
To the obtained residue, ethyl acetate was then added,
and the organic layer was washed with water and saturated
saline and dried over anhydrous sodium sulfate. The
solvent was concentrated under reduced pressure to obtain
the title compound (2.89 g, 11.4 mmol, 95% yield).
1H-NMR (400 MHz, DMSO-d6) 6: 3.76 (3H, s), 7.37 (1H, s).
MS (APCI) m/z: 235 (M-H)-.
[0217]
Reference Example 7
tert-Butyl N-(1-ethyny1-3-
bicyclo[1.1.1]pentanyl)carbamate (S7)
[Formula 16]
0
0 0
FiXi5LN)..01-Bu
S-7 N
H H
S7
[0218]
To a solution of tert-butyl (3-
formylbicyclo[1.1.1]pent-1-yl)carbamate (0.697 g, 3.30
mmol) in methanol (20 mL), potassium carbonate (0.957 g,
6.92 mmol) and 1-diazo-1-dimethoxyphosphoryl-propan-2-one
CA 02942883 2016-09-15
- 97 -
(0.520 mL, 3.46 mmol) were added, and the mixture was
stirred at room temperature for 1 hour. Water was added
to the reaction solution, followed by extraction with
ethyl acetate. The organic layer was washed with
saturated saline and then dried over anhydrous sodium
sulfate. The solvent was distilled off under reduced
pressure, and the obtained residue was purified by silica
gel column chromatography (hexane:ethyl acetate = 100:0
¨ 82:18) to obtain the title compound (0.564 g, 2.72
mmol, 82% yield).
1H-NMR (400 MHz, CDC13) 6: 1.44 (9H, s), 2.16 (1H, s),
2.29 (6H, s), 4.95 (1H, br s).
[0219]
Reference Example 8
tert-Butyl N-(6-ethynylspiro[3.3]heptan-2-yl)carbamate
(S8-2)
[Formula 17]
0 0
0
JL,
HN w-
0 H .t-Bu HN w-
t-Bu
<<> ,
S-8-1 H N
S-8-2
<<i>> 1>>
H 0
S8-1 S8-2
[0220]
(Step S-8-1)
CA 02942883 2016-09-15
- 98 -
tert-Butyl N-(6-formylspiro[3.3]heptan-2-yl)carbamate
(S8-1)
To a solution of tert-butyl N-[6-
(hydroxymethyl)spiro[3.3]heptan-2-yl]carbamate (3.10 g,
12.8 mmol) in dichloromethane (62 mL), a Dess-Martin
reagent (8.17 g, 19.3 mmol) was added, and the mixture
was stirred at room temperature for 1 hour. A saturated
aqueous solution of sodium thiosulfate was added to the
reaction solution, followed by extraction with ethyl
acetate. The organic layer was washed with a saturated
aqueous solution of sodium bicarbonate and saturated
saline and then dried over anhydrous sodium sulfate. The
solvent was distilled off under reduced pressure, and the
obtained residue was purified by silica gel
chromatography (hexane:ethyl acetate = 80:20) to obtain
the title compound (2.87 g, 12.0 mmol, 93% yield).
1H-NMR (400 MHz, CDC13) 6: 1.43 (9H, s), 1.73-1.90 (2H,
m), 2.01-2.15 (1H, m), 2.20-2.36 (4H, m), 2.45-2.55 (1H,
m), 3.03-3.13 (1H, m), 3.92-4.08 (1H, m), 4.59 (1H, br s),
9.69 (1H, d, J = 1.8 Hz).
[0221]
(Step S-8-2)
tert-Butyl N-(6-ethynylspiro[3.3]heptan-2-yl)carbamate
(S8-2)
The title compound (1.95 g, 8.29 mmol, 71% yield)
was obtained through the same reaction as in Reference
Example 7 using tert-butyl N-(6-formylspiro[3.3]heptan-2-
CA 02942883 2016-09-15
- 99 -
yl)carbamate (2.80 g, 11.7 mmol) synthesized in step S-8-
1.
1H-NMR (400 MHz, CDC13) 6: 1.43 (9H, s), 1.77-1.84 (2H,
m), 2.08-2.26 (4H, m), 2.34-2.50 (3H, m), 2.84-2.94 (1H,
m), 3.93-4.08 (1H, m), 4.58 (1H, br s).
[0222]
Reference Example 9
tert-Butyl 6-ethyny1-2-azaspiro[3.3]heptane-2-carboxylate
(S9-2)
[Formula 18]
t-Bu t-Bu t.-Bu
S-9-1
<IX/>>.
S-9-2
OH OH 11
S9-1 S9-2
[0223]
(Step S-9-1)
tert-Butyl 6-formy1-2-azaspiro[3.3]heptane-2-carboxylate
(S9-1)
The title compound (1.60 g, 7.10 mmol, 90% yield)
was obtained through the same reaction as in step S8-1
using tert-butyl 6-(hydroxymethyl)-2-
azaspiro[3.3]heptane-2-carboxylate (1.80 g, 7.92 mmol).
The obtained crude product was subjected to the next step
without being purified.
[0224]
CA 02942883 2016-09-15
- 100 -
(Step S-9-2)
tert-Butyl 6-ethyny1-2-azaspiro[3.3]heptane-2-carboxylate
(S9-2)
The title compound (0.95 g, 4.29 mmol, 60% yield)
was obtained through the same reaction as in step S7
using tert-butyl 6-formy1-2-azaspiro[3.3]heptane-2-
carboxylate (1.60 g, 7.11 mmol) synthesized in step S-9-1.
1H-NMR (400 MHz, CDC13) 6: 1.43 (9H, s), 2.15 (1H, d, J =
2.4 Hz), 2.23-2.33 (2H, m), 2.45-2.55 (2H, m), 2.82-2.93
(1H, m), 3.85-3.95 (4H, m).
[0225]
Reference Example 10
tert-Butyl 4-prop-2-ynylpiperidine-1-carboxylate (S10)
[Formula 19]
0't-Bu
S10
[0226]
The title compound (3.24 g, 14.5 mmol, 77% yield)
was obtained through the same reaction as in Reference
Example 7 using tert-butyl 4-(2-oxoethyl)piperidine-1-
carboxylate (4.30 g, 18.9 mmol).
1H-NMR (400 MHz, CDC13) 8: 1.12-1.31 (2H, m), 1.46 (9H,
s), 1.56-1.70 (1H, m), 1.72-1.81 (2H, m), 1.99 (1H, t, J
= 2.6 Hz), 2.15 (2H, dd, J = 6.7, 2.6 Hz), 2.61-2.78 (2H,
m), 3.98-4.27 (2H, m).
CA 029428832016-09-15
- 101 -
[0227]
Reference Example 11
tert-Butyl N-(cis-4-prop-2-ynylcyclohexyl)carbamate (S11)
[Formula 20]
0
t-Bu
N 0'
S11
[0228]
The title compound (1.20 g, 5.05 mmol, 55% yield)
was obtained through the same reaction as in Reference
Example 7 using tert-butyl N-[cis-4-(2-
oxoethyl)cyclohexyl]carbamate (2.20 g, 9.12 mmol).
1H-NMR (400 MHz, CDC13) 6: 1.23-1.35 (2H, m), 1.45 (9H,
s), 1.53-1.73 (7H, m), 1.98 (1H, t, J = 2.6 Hz), 2.14 (2H,
dd, J - 6.7, 2.6 Hz), 3.67-3.82 (1H, m), 4.64 (1H, br s).
[0229]
Reference Example 12
tert-Butyl N-(trans-4-prop-2-ynylcyclohexyl)carbamate
(S12)
[Formula 21]
.1'4'0 9
.,,N)Lcrt-Bu
S12
[0230]
The title compound (1.14 g, 4.78 mmol, 66% yield)
was obtained through the same reaction as in Reference
CA 02942883 2016-09-15
- 102 -
Example 7 using tert-butyl N-[trans-4-(2-
oxoethyl)cyclohexyl]carbamate (1.74 g, 7.22 mmol).
1H-NMR (400 MHz, CDC13) 8: 1.03-1.20 (4H, m), 1.44 (9H,
s), 1.84-1.92 (2H, m), 1.97 (1H, t, J = 2.6 Hz), 1.99-
2.05 (2H, m), 2.10 (2H, dd, J = 6.7, 2.6 Hz), 3.30-3.46
(1H, m), 4.37 (lh, br s).
[0231]
Reference Example 13
tert-Butyl N-(trans-4-ethynylcyclohexyl)carbamate (S13)
[Formula 22]
.1100
NA0t-Bu
H
S13
[0232]
The title compound (0.639 g, 2.86 mmol, 77% yield)
was obtained through the same reaction as in Reference
Example 7 using tert-butyl N-(trans-4-
formylcyclohexyl)carbamate (0.839 g, 3.69 mmol).
1H-NMR (400 MHz, CDC13) 6: 1.04-1.17 (2H, m), 1.42-1.55
(2H, m), 1.44 (9H, s), 1.94-2.05 (4H, m), 2.04 (11-1, dr J
= 2.5 Hz), 2.16-2.25 (1H, m), 3.34-3.50 (1H, m), 4.29-
4.43 (1H, br s).
[0233]
Reference Example 14
tert-Butyl N-(trans-4-ethynylcyclohexyl)-N-methyl-
carbamate (S14)
CA 02942883 2016-09-15
- 103 -
[Formula 23]
'h'I::10114,Acrtau
CH3
S14
[0234]
The title compound (2.50 g, 10.5 mmol, 69% yield)
was obtained through the same reaction as in Reference
Example 7 using tert-butyl N-(trans-4-formylcyclohexyl)-
N-methyl-carbamate (3.70 g, 15.3 mmol) synthesized
according to the method described in WO 2003053933.
1H-NMR (400 MHz, CD013) 6: 1.33-1.60 (4H, m), 1.46 (9H,
s), 1.65-1.75 (2H, m), 2.01-2.20 (3H, m), 2.05 (1H, d, J
= 2.5 Hz), 2.70 (3H, br s), 3.67-4.13 (1H, br m).
[0235]
Reference Example 15
8-Ethyny1-1,4-dioxaspiro[4.5]decane (S15)
[Formula 24]
0
S15
[0236]
The title compound (1.69 g, 10.1 mmol, 82% yield)
was obtained through the same reaction as in Reference
Example 7 using 1,4-dioxaspiro[4.5]decane-8-carbaldehyde
(2.11 g, 12.4 mmol) synthesized according to the method
described in WO 2010132247.
CA 02942883 2016-09-15
- 104 -
1H-NMR (400 MHz, CDC13) 6: 1.51-1.61 (2H, m), 1.68-1.79
(2H, m), 1.80-1.92 (4H, m), 2.04 (1H, d, J - 2.4 Hz),
2.43-2.53 (1H, m), 3.90-3.99 (4H, m).
[0237]
Reference Example 16
tert-Butyl N-[(4-ethynylcyclohexyl)methyl]carbamate (S16)
[Formula 25]
EMm.-10011VN 0
N4
H 0-t-Bu
S16
[0238]
The title compound (1.97 g, 8.30 mmol, 86% yield)
was obtained through the same reaction as in Reference
Example 7 using tert-butyl N-[(4-
formylcyclohexyl)methyl]carbamate (2.34 g, 9.70 mmol)
synthesized according to the method described in WO
2007103295.
1H-NMR (400 MHz, CDC13) 6: 0.86-0.99 (2H, m), 1.30-1.48
(3H, m), 1.44 (9H, s), 1.72-1.81 (2H, m), 1.97-2.06 (2H,
m), 2.05 (1H, d, J - 2.4 Hz), 2.13-2.23 (1H, m), 2.93-
2.99 (2H, m), 4.52-4.61 (1H, br m).
[0239]
Example 1
7-Bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-2-(tetrahydrofuran-3-y1)-1,3-
benzodioxole-5-carboxamide (1)
[Formula 26]
CA 02942883 2016-09-15
- 105 -
CH3 CH3 H3Cy..CH3
0 0 0 0 0 OH rJLNH
CH3 CH3 gal CH3 0 NH 0
Br OH Br 0 Br
2 W 0 C H3
1- 1-3
OH 1-1 0 0 1110
Br 0
Ala A2a A3a H3CP
1
[0240]
(Step 1-1)
Methyl 7-bromo-2,4-dimethy1-2-(tetrahydrofuran-3-y1)-1,3-
benzodioxole-5-carboxylate (A2a)
[0241]
To a solution of the compound (Ala) (1.00 g, 3.83
mmol) synthesized in Reference Example 1 in toluene (15
mL), triruthenium(0) dodecacarbonyl (0.122 g, 0.192 mmol)
and triphenylphosphine (0.101 g, 0.383 mmol) were added,
- and the mixture was stirred for a while at 120 C under a
nitrogen atmosphere. Then, a solution of 3-
ethynyltetrahydrofuran (1.11 g, 11.5 mmol) in toluene (5
mL) was added dropwise thereto, and the mixture was
further stirred at 120 C for 2 hours. After the
completion of the reaction, the solvent was distilled off
under reduced pressure, and the obtained residue was
purified by silica gel column chromatography
(hexane:ethyl acetate = 95:5 -* 70:30) to obtain the
title compound (1.13 g, 3.16 mmol, 83% yield).
1H-NMR (400 MHz, CDC13) 8: 1.70 (3H, s), 1.89-2.00 (1H,
m), 2.02-2.13 (1H, m), 2.38 (3H, s), 2.85-2.94 (1H, m),
CA 02942883 2016-09-15
- 106 -
3.73-3.83 (2H, m), 3.85 (3H, s), 3.87-3.96 (2H, m), 7.69
(1H, s).
MS (ESI) m/z: 357, 359 (M+H)+.
[0242]
(Step 1-2)
7-Bromo-2,4-dimethy1-2-(tetrahydrofuran-3-y1)-1,3-
benzodioxole-5-carboxylic acid (A3a)
[0243]
To the compound (A2a) (1.13 g, 3.16 mmol)
synthesized in step 1-1, tetrahydrofuran (6 mL) and
methanol (3 mL) were added, further a 2 M aqueous sodium
hydroxide solution (3.16 mL, 6.32 mmol) was added, and
the mixture was stirred at room temperature for 16 hours.
After the completion of the reaction, the reaction
solution was neutralized by the addition of 2 M
hydrochloric acid (3.16 mL, 6.32 mmol), followed by
extraction by the addition of dichloromethane. The
obtained organic layer was concentrated under reduced
pressure to obtain the title compound (1.05 g, 3.07 mmol,
97% yield).
1H-NMR (400 MHz, CDC13) 6: 1.70 (3H, s), 1.88-2.01 (1H,
m), 2.04-2.14 (1H, m), 2.44 (3H, s), 2.86-2.96 (1H, m),
3.75-3.84 (2H, m), 3.87-3.98 (2H, m), 7.84 (1H, s).
MS (ESI) m/z: 341, 343 (M-H)-.
[0244]
(Step 1-3)
CA 02942883 2016-09-15
- 107 -
7-Bromo-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-2-(tetrahydrofuran-3-y1)-1,3-
benzodioxole-5-carboxamide (1)
[0245]
To a solution of the compound (A3a) (1.05 g, 3.07
mmol) synthesized in step 1-2 in dimethylformamide (10
mL), 3-(aminomethyl)-4,6-dimethy1-1H-pyridin-2-one
hydrochloride (0.868 g, 4.60 mmol), 1-ethy1-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (0.882 g,
4.60 mmol), and 1-hydroxy-7-azabenzotriazole (0.627 g,
4.60 mmol) were added, and the mixture was stirred at
10000 for 1.5 hours under a nitrogen atmosphere. After
the completion of the reaction, water was added to the
reaction solution, and the deposited solid was collected
by filtration and dissolved again in dichloromethane.
Then, the solution was purified by silica gel column
chromatography (hexane:ethyl acetate = 2:98 0:100, and
dichloromethane:methanol = 100:0 90:10) to obtain the
title compound (0.863 g, 1.81 mmol, 59% yield).
1H-NMR (400 MHz, DMSO-d0 6: 1.63 (3H, s), 1.72-1.83 (1H,
m), 1.93-2.04 (1H, m), 2.10 (6H, s), 2.17 (3H, s), 2.88-
2.97 (1H, m), 3.55-3.68 (2H, m), 3.71-3.83 (2H, m), 4.21
(2H, d, J = 4.9 Hz), 5.86 (1H, s), 6.97 (1H, s), 8.16 (1H,
t, J = 4.9 Hz), 11.49 (1H, s).
MS (ESI) m/z: 477, 479 (M+H)+.
[0246]
Example 2
CA 02942883 2016-09-15
- 108 -
7-Bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-2-(tetrahydropyran-4-y1)-1,3-
benzodioxole-5-carboxamide (2)
[Formula 27]
H3CC H3
I NH
0 NH 0
CH3
Br 0
0
H3tC0
2
[0247]
(Step 2-1)
Methyl 7-bromo-2,4-dimethy1-2-(tetrahydropyran-4-y1)-1,3-
benzodioxole-5-carboxylate (A2b)
[0248]
The title compound (0.861 g, 2.32 mmol, 61% yield)
was obtained through the same reaction as in step 1-1
using the compound (Ala) (1.00 g, 3.83 mmol) synthesized
in Reference Example 1 and 4-ethynyltetrahydro-2H-pyran
(1.27 g, 11.5 mmol).
1H-NMR (400 MHz, CDC13) 6: 1.53-1.68 (2H, m), 1.67 (3H,
s), 1.68-1.77 (2H, m), 2.07-2.17 (1H, m), 2.39 (3H, s),
3.33-3.43 (2H, m), 3.85 (3H, s), 4.01-4.08 (2H, m), 7.68
(1H, s).
[0249]
(Step 2-2)
CA 02942883 2016-09-15
- 109 -
7-Bromo-2,4-dimethy1-2-(tetrahydropyran-4-y1)-1,3-
benzodioxole-5-carboxylic acid (A3b)
[0250]
The title compound (0.796 g, 2.23 mmol, 96% yield)
was obtained through the same reaction as in step 1-2
using the compound (A2b) (0.861 g, 2.32 mmol) synthesized
in step 2-1.
MS (ESI) m/z: 355, 357 (M-H)-.
[0251]
(Step 2-3)
7-Bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-2-(tetrahydropyran-4-y1)-1,3-
benzodioxole-5-carboxamide (2)
[0252]
The title compound (0.556 g, 1.13 mmol, 51% yield)
was obtained through the same reaction as in step 1-3
using the compound (A3b) (0.796 g, 2.23 mmol) synthesized
in step 2-2.
1H-NMR (400 MHz, DMSO-d6) 6: 1.34-1.44 (2H, m), 1.57-1.66
(2H, m), 1.62 (3H, s), 2.11 (6H, s), 2.14-2.19 (41-1, m),
3.24-3.32 (2H, m), 3.88 (2H, m), 4.21 (2H, d, J = 5.0 Hz),
5.85 (1H, s), 6.95 (1H, s), 8.14 (1H, t, J = 5.0 Hz),
11.49 (1H, s).
MS (ESI) m/z: 491, 493 (M+H) .
[0253]
Example 3
,
CA 02942883 2016-09-15
¨ 110 -
7-Bromo-2-[3-(dimethylamino)-1-bicyclo[1.1.1]pentany1]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (3)
[Formula 28]
Ç H3
c H3 0 0 0 OH
00
wai CH3 3-1 Br o Br o
0 H C H3 Al C H3
Br W 0 H W
0 0
X t-Bu ____.
3-2 WI
0 0
)1... t-Bu
H3t-15"--N 0
H3-1-----N
H H
Ala A2c A3c
H3C,C H3
H3IX7CH3 H3Crw.rC H3
I NH I NH I NH
0 NH 0 0 N H 0 0 NH 0
C H3 C H3 3-4 An C H3
3-5
Br WI 0 0 Br W 0 Br W 0
H3C N
H3-1.-15-N H2 0 C H3H3-1.-N. -
H
b H3
A4c A4c-f 3
[0254]
(Step 3-1)
Methyl 7-bromo-2-[3-(tert-butoxycarbonylamino)-1-
bicyclo[1.1.1]pentany1]-2,4-dimethyl-1,3-benzodioxole-5-
carboxylate (A2c)
[0255]
The title compound (0.495 g, 1.06 mmol, 61% yield)
was obtained through the same reaction as in step 1-1
using the compound (Ala) (0.,450 g, 1.72 mmol) synthesized
in Reference Example 1 and the compound (S7) (0.536 g,
2.59 mmol) synthesized in Reference Example 7.
CA 02942883 2016-09-15
- 111 -
1H-NMR (400 MHz, CD013) 6: 1.43 (9H, s), 1.72 (3H, s),
1.95-2.15 (6H, m), 2.37 (3H, s), 3.85 (3H, s), 4.96 (1H,
br s), 7.67 (1H, s).
[0256]
(Step 3-2)
7-Bromo-2-[3-(tert-butoxycarbonylamino)-1-
bicyclo[1.1.1]pentany1]-2,4-dimethy1-1,3-benzodioxole-5-
carboxylic acid (A3c)
[0257]
The title compound (0.467 g, 1.03 mmol, 98% yield)
was obtained through the same reaction as in step 1-2
using the compound (A2c) (0.495 g, 1.06 mmol) synthesized
in step 3-1.
[0258]
(Step 3-3)
tert-Butyl N-[1-[7-bromo-5-[(4,6-dimethy1-2-oxo-1H-
pyridin-3-yl)methylcarbamoy1]-2,4-dimethyl-1,3-
benzodioxo1-2-y1]-3-bicyclo[1.1.1]pentanyl]carbamate
(A4 c)
[0259]
The title compound (0.572 g, 0.973 mmol, 94% yield)
was obtained through the same reaction as in step 1-3
using the compound (A3c) (0.469 g, 1.03 mmol) synthesized
in step 3-2.
1H-NMR (400 MHz, CD013) 6: 1.43 (9H, s), 1.68 (3H, s),
1.98-2.10 (6H, m), 2.21 (3H, s), 2.26 (3H, s), 2.37 (3H,
CA 02942883 2016-09-15
- 112 -
s), 4.49 (2H, d, J = 6.1 Hz), 4.99 (1H, s), 5.96 (1H, s),
7.00 (1H, s), 7.20-7.25 (1H, m).
MS (APCI) m/z: 588, 590 (M+H)'.
[0260]
(Step 3-4)
2-(3-Amino-1-bicyclo[1.1.1]pentany1)-7-bromo-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (A4c-f)
[0261]
The compound (A4c) (0.572 g, 0.973 mmol) synthesized
in step 3-3 was dissolved in methanol (2 mL). To the
solution, a 4 M solution of hydrochloric acid in 1,4-
dioxane (2.07 mL, 8.23 mmol) was added, and the mixture
was stirred at room temperature for 1.5 hours. After the
completion of the reaction, the reaction solution was
neutralized by the addition of a saturated aqueous
solution of sodium bicarbonate, followed by extraction
using 20% methanol in chloroform. The organic layer was
washed with saturated saline, dried over sodium sulfate,
and then concentrated under reduced pressure to obtain
the title compound (0.404 g, 0.827 mmol, 85% yield).
[0262]
(Step 3-5)
7-Bromo-2-[3-(dimethylamino)-1-bicyclo[1.1.1]pentany1]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (3)
[0263]
CA 02942883 2016-09-15
- 113 -
The compound (A4c-f) (0.404 g, 0.827 mmol)
synthesized in step 3-4 was dissolved in methanol (7.5
mL). To the solution, a 37% aqueous formaldehyde
solution (0.141 g, 1.74 mmol) was added, and the mixture
was stirred at room temperature for 10 minutes. Then,
sodium triacetoxyborohydride (0.923 g, 4.14 mmol) was
added thereto, and the mixture was stirred at room
temperature for 18 hours. After the completion of the
reaction, the reaction solution was neutralized with a 1
M aqueous sodium hydroxide solution, followed by
extraction using 20% methanol in chloroform. The organic
layer was washed with saturated saline, dried over sodium
sulfate, and then concentrated under reduced pressure,
and the obtained residue was purified by basic silica gel
column chromatography (ethyl acetate:methanol = 100:0 -*
96:4) to obtain the title compound (0.309 g, 0.597 mmol,
72% yield).
1H-NMR (400 MHz, DMSO-d6) 6: 1.65 (6H, s), 1.67 (3H, s),
2.07 (6H, s), 2.10 (3H, s), 2.11 (3H, s), 2.17 (3H, s),
4.21 (2H, d, J = 4.9 Hz), 5.86 (1H, s), 6.94 (1H, s),
8.15 (1H, t, J = 4.9 Hz), 11.49 (1H, s).
MS (APCI) m/z: 516, 518 (M+H)+.
[0264]
Example 4
7-Bromo-2-[2-(dimethylamino)spiro[3.3]heptan-6-y1]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (4)
CA 02942883 2016-09-15
- 114 -
[0265]
(Step 4-1)
Methyl 7-bromo-2-[2-(tert-
butoxycarbonylamino)spiro[3.3]heptan-6-y1]-2,4-dimethyl-
1,3-benzodioxole-5-carboxylate (A2d)
[0266]
The title compound (0.657 g, 1.32 mmol, 86% yield)
was obtained through the same reaction as in step 1-1
using the compound (Ala) (0.400 g, 1.53 mmol) synthesized
in Reference Example 1 and the compound (S8-2) (0.541 g,
2.59 mmol) synthesized in Reference Example 8.
1H-NMR (400 MHz, CDC13) 6: 1.42 (9H, s), 1.56 (3H, s),
1.71-1.84 (2H, m), 1.95-2.09 (3H, m), 2.10-2.15 (1H, m),
2.30-2.39 (1H, m), 2.38 (3H, s), 2.42-2.51 (1H, m), 2.69-
2.78 (1H, m), 3.85 (3H, s), 3.91-4.02 (1H, m), 4.52-4.65
(1H, m), 7.66 (1H, br s).
[0267]
(Step 4-2)
7-Bromo-2-[2-(tert-butoxycarbonylamino)spiro[3.3]heptan-
6-y1]-2,4-dimethy1-1,3-benzodioxole-5-carboxylic acid
(A3d)
[0268]
The title compound (0.603 g, 1.25 mmol, 95% yield)
was obtained through the same reaction as in step 1-2
using the compound (A2d) (0.657 g, 1.32 mmol) synthesized
in step 4-1.
[0269]
CA 02942883 2016-09-15
- 115 -
(Step 4-3)
tert-Butyl N-[6-[7-bromo-5-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methylcarbamoy1]-2,4-dimethyl-1,3-
benzodioxo1-2-yl]spiro[3.3]heptan-2-yl]carbamate (A4d)
[0270]
The title compound (0.519 g, 0.842 mmol, 67% yield)
was obtained through the same reaction as in step 1-3
using the compound (A3d) (0.603 g, 1.25 mmol) synthesized
in step 4-2.
1H-NMR (400 MHz, CDC13) 6: 1.42 (9H, s), 1.53 (3H, s),
1.70-1.84 (2H, m), 1.92-2.14 (4H, m), 2.22 (3H, s), 2.26
(3H, s), 2.30-2.36 (1H, m), 2.37 (3H, s), 2.40-2.49 (1H,
m), 2.66-2.76 (1H, m), 3.89-4.05 (1H, m), 4.50 (2H, d, J
= 5.5 Hz), 4.54-4.64 (1H, m), 5.96 (1H, s), 7.00 (1H, s),
7.22 (1H, br s).
MS (APCI) m/z: 616, 618 (M+H)+.
[0271]
(Step 4-4)
2-(2-Aminospiro[3.3]heptan-6-y1)-7-bromo-N-[4,6-dimethyl-
2-oxo-1,2-dihydropyridin-3-yl)methy1]-2,4-dimethy1-1,3-
benzodioxole-5-carboxamide (A4d-f)
[0272]
The title compound (0.435 g, 0.842 mmol, 100% yield)
was obtained through the same reaction as in step 3-4
using the compound (A4d) (0.519 g, 0.842 mmol)
synthesized in step 4-3.
MS (APCI) m/z: 516, 518 (M+H)+.
CA 02942883 2016-09-15
- 116 -
[0273]
(Step 4-5)
7-Bromo-2-[2-(dimethylamino)spiro[3.3]heptan-6-y1]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (4)
[0274]
The title compound (0.353 g, 0.648 mmol, 77% yield)
was obtained through the same reaction as in step 3-5
using the compound (A4d-f) (0.435 g, 0.842 mmol)
synthesized in step 4-4.
1H-NMR (400 MHz, DMSO-d6) 6: 1.53 (3H, s), 1.58-1.78 (2H,
m), 1.79-2.01 (9H, m), 2.01-2.08 (1H, m), 2.10 (31-1, s),
2.10 (3H, s), 2.16 (3H, s), 2.30-2.44 (1H, m), 2.71-2.83
(1H, m), 4.21 (2H, d, J = 4.3 Hz), 5.85 (1H, s), 6.93 (1H,
s), 8.15 (1H, t, J = 4.3 Hz), 11.48 (1H, s).
MS (APCI) m/z: 544, 546 (M+H)+.
[0275]
Example 5
7-Bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2-(2-ethy1-2-azaspiro[3.3]heptan-6-y1)-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (5)
[0276]
(Step 5-1)
tert-Butyl 6-(7-bromo-5-methoxycarbony1-2,4-dimethy1-1,3-
benzodioxo1-2-y1)-2-azaspiro[3.3]heptane-2-carboxylate
(A2e)
[0277]
CA 02942883 2016-09-15
- 117 -
The title compound (0.727 g, 1.51 mmol, 98% yield)
was obtained through the same reaction as in step 1-1
using the compound (Ala) (0.400 g, 1.53 mmol) synthesized
in Reference Example 1 and the compound (S9-2) (0.407 g,
1.84 mmol) synthesized in Reference Example 9.
1H-NMR (400 MHz, CDC13) 6: 1.42 (9H, s), 1.58 (3H, s),
2.12-2.20 (2H, m), 2.26-2.34 (2H, m), 2.39 (3H, s), 2.67-
2.76 (1H, m), 3.86 (3H, s), 3.86-3.88 (2H, m), 3.88-3.91
(2H, m), 7.68 (1H, s).
[0278]
(Step 5-2)
7-Bromo-2-(2-tert-butoxycarbony1-2-azaspiro[3.3]heptan-6-
y1)-2,4-dimethy1-1,3-benzodioxole-5-carboxylic acid (A3e)
[0279]
The title compound (0.706 g, 1.51 mmol, 100% yield)
was obtained through the same reaction as in step 1-2
using the compound (A2e) (0.727 g, 1.51 mmol) synthesized
in step 5-1.
[0280]
(Step 5-3)
tert-Butyl 6-[7-bromo-5-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methylcarbamoy1]-2,4-dimethy1-1,3-
benzodioxo1-2-y1]-2-azaspiro[3.3]heptane-2-carboxylate
(A4e)
[0281]
The title compound (0.723 g, 1.20 mmol, 80% yield)
was obtained through the same reaction as in step 1-3
CA 02942883 2016-09-15
- 118 -
using the compound (A3e) (0.706 g, 1.51 mmol) synthesized
in step 5-2.
1H-NMR (400 MHz, CDC13) 6: 1.42 (9H, s), 1.55 (3H, s),
2.11-2.20 (2H, m), 2.23 (3H, s), 2.25-2.31 (2H, m), 2.27
(3H, s), 2.37 (3H, s), 2.64-2.73 (1H, m), 3.82-3.86 (2H,
m), 3.86-3.90 (2H, m), 4.44-4.56 (2H, m), 5.97 (1H, s),
7.01 (1H, s).
MS (APCI) m/z: 602,604 (M+H)+.
[0282]
(Step 5-4)
2-(2-Azaspiro[3.3]heptan-6-y1)-7-bromo-N-[(4,6-dimethyl-
2-oxo-1,2-dihydropyridin-3-yl)methy1]-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide (A4e-f)
[0283]
The title compound (0.603 g, 1.20 mmol, 100% yield)
was obtained through the same reaction as in step 3-4
using the compound (A4e) (0.723 g, 1.20 mmol) synthesized
in step 5-3.
MS (APCI) m/z: 502, 504 (M+H)+.
[0284]
(Step 5-5)
7-Bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2-(2-ethy1-2-azaspiro[3.3]heptan-6-y1)-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (5)
[0285]
The title compound (0.202 g, 0.380 mmol, 32% yield)
was obtained through the same reaction as in step 3-5
CA 02942883 2016-09-15
- 119 -
using the compound (A4e-f) (0.603 g, 1.20 mmol)
synthesized in step 5-4 and acetaldehyde (0.793 g, 18.0
mmol).
1H-NMR (400 MHz, DMSO-d6) 5: 1.11-1.21 (4H, m), 1.59 (3H,
s), 1.75-1.90 (5H, m), 2.02-2.09 (1H, m), 2.10 (3H, s),
2.11 (3H, s), 2.13 (6H, s), 2.16 (3H, s), 4.21 (2H, d, J
= 4.9 Hz), 5.85 (1H, s), 6.94 (1H, s), 8.14 (1H, t, J =
4.9 Hz), 11.48 (1H, s).
MS (APCI) m/z: 530, 532 (M+H)+.
[0286]
Example 6
7-Bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-2-(1-methylpyrrolidin-3-y1)-1,3-
benzodioxole-5-carboxamide (6)
[Formula 29]
0H3 0H3 0H3
0 0 00
00
CH3
CH3 CH-
ea,
6-1 j 6-3
Br II1P OH Br 0 0 6-2 Br 0
0 H?"µ
N-40..t-Bu o4,c
H3C- H3C
Ala A2f-f
AU
H3Crr;rCH3
I NH
CH3
O 6 o 0 H 0 NH 0
C H3
Br
CH3
140
's"Pj CH3 64 Br 6-5 0
Br 0
0-4,.Ø.0 H3 o30..0 H3
04.....CN-C H3
H3C H3C
H3C
Al 1 f Al 2f 6
[0287]
(Step 6-1)
CA 02942883 2016-09-15
- 120 -
tert-Butyl 3-(7-bromo-5-methoxycarbony1-2,4-dimethy1-1,3-
benzodioxol-2-yl)pyrrolidine-1-carboxylate (A2f)
[0288]
The title compound (2.11 g, 4.62 mmol, 54% yield)
was obtained through the same reaction as in step 1-1
using the compound (Ala) (2.22 g, 8.50 mmol) synthesized
in Reference Example 1 and tert-butyl 3-
ethynylpyrrolidine-1-carboxylate (2.48 g, 12.7 mmol)
synthesized according to the method described in
W02010060952.
[0289]
(Step 6-2)
Methyl 7-bromo-2,4-dimethy1-2-pyrrolidin-3-y1-1,3-
benzodioxole-5-carboxylate (A2f-f)
[0290]
The title compound (1.38 g, 3.87 mmol, 84% yield)
was obtained through the same reaction as in step 3-4
using the compound (A2f) (2.11 g, 4.62 mmol) synthesized
in step 6-1.
1H-NMR (400 MHz, CDC13) 6: 1.68 (3H, s), 1.72-1.75 (1H,
m), 1.90-1.99 (1H, m), 2.38 (3H, s), 2.68-2.76 (1H, m),
2.85-3.10 (4H, m), 3.71 (1H, s), 3.85 (3H, s), 7.68 (1H,
s).
MS (APCI) m/z: 356, 358 (M+H)'.
[0291]
(Step 6-3)
CA 02942883 2016-09-15
- 121 -
Methyl 7-bromo-2,4-dimethy1-2-(1-methylpyrrolidin-3-y1)-
1,3-benzodioxole-5-carboxylate (Allf)
[0292]
The title compound (0.250 g, 0.675 mmol, 60% yield)
was obtained through the same reaction as in step 3-5
using the compound (A2f-f) (0.400 g, 1.12 mmol)
synthesized in step 6-2.
1H-NMR (400 MHz, CDC13) 6: 1.66 (3H, s), 1.78-1.85 (1H,
m), 1.98-2.05 (1H, m), 2.33-2.40 (2H, m), 2.35 (6H, s),
2.38 (3H, s), 2.72-2.78 (1H, m), 2.84-2.91 (2H, m), 3.85
(3H, s), 7.68 (1H, s).
MS (APCI) m/z: 370, 372 (M+H)+.
[0293]
(Step 6-4)
7-Bromo-2,4-dimethy1-2-(1-methylpyrrolidin-3-y1)-1,3-
benzodioxole-5-carboxylic acid (Al2f)
The compound (Allf) (245 mg, 0.662 mmol) synthesized
in step 6-3 was dissolved in methanol (2.5 mL) and
tetrahydrofuran (5 mL). To the solution, a 1 M aqueous
sodium hydroxide solution (1.70 mL 1.70 mmol) was added
under ice cooling, and the mixture was stirred at room
temperature for 7 hours. After the completion of the
reaction, the reaction solution was neutralized with 1 M
hydrochloric acid, and the solvent was concentrated under
reduced pressure to obtain 7-bromo-2,4-dimethy1-2-(1-
methylpyrrolidin-3-y1)-1,3-benzodioxole-5-carboxylic acid
(0.197 g, 0.552 mmol, 83% yield).
CA 02942883 2016-09-15
- 122 -
1H-NMR (400 MHz, CD30D) 6: 1.68 (3H, s), 2.04-2.13 (1H,
m), 2.21-2.32 (1H, m), 2.28 (3H, s), 2.81 (3H, s), 3.35-
3.12 (4H, m), 3.41-3.48 (1H, m), 7.30 (1H, s).
MS (ESI) m/z: 356, 358 (M+H)'.
[0294]
(Step 6-5)
7-Bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-2-(1-methylpyrrolidin-3-y1)-1,3-
benzodioxole-5-carboxamide (6)
[0295]
The title compound (0.078 g, 0.159 mmol, 29% yield)
was obtained through the same reaction as in step 1-3
using the compound (Al2f) (0.196 g, 0.550 mmol)
synthesized in step 6-4.
1H-NMR (400 MHz, CD30D) 6: 1.64 (3H, s), 1.82-1.89 (1H,
m), 2.00-2.08 (1H, m), 2.16 (3H, d, J = 3.0 Hz), 2.24 (3H,
s), 2.35 (3H, s), 2.36 (3H, s), 2.40-2.51 (2H, m), 2.78-
2.85 (1H, m), 2.88-2.97 (2H, m), 4.42 (2H, s), 4.62 (1H,
s), 6.10 (1H, s), 7.01 (1H, s).
MS (ESI) m/z: 490, 492 (M+H)+.
[0296]
Example 7
(2R)-7-Bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2-(1-ethy1-4-piperidy1)-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide (7)
[Formula 30]
CA 02942883 2016-09-15
- 123 -
H3
0 0 0 OH
H3
0 0 C H3
C H3
C H3 0
0 Br W 0
0 .
Br W 0 H 7-1 H3-6--L01-f 7-2 H3-g--0....f 7-3
OH -C H3 -C H3
Ala (2R)-A2g (2R)-A3g
H3Cr.,..1.,,,C H3
I NH 1-13C1:c1...CH3 H3C:,...1zCH3
I NH NH
0 NH 0
0 NH 0 0 NH 0
C H3
C H3 C H3
Br W 0 7-4 MP 7-5 =Br 0 Br 0
0 c
H37C 0
(30 NH
H3-4C
C
C H3
(2R)-A4g-f 7
(2R)-A4g-p
[0297]
(Step 7-1)
tert-Butyl 4-[(2R)-7-bromo-5-methoxycarbony1-2,4-
dimethy1-1,3-benzodioxol-2-yl]piperidine-1-carboxylate
((2R)-A2g)
[0298]
A racemate of the title compound (4.76 g, 10.1 mmol,
35% yield) was obtained through the same reaction as in
step 1-1 using the compound (Ala) (7.50 g, 28.7 mmol)
synthesized in Reference Example 1 and tert-butyl 4-
ethynylpiperidine-1-carboxylate (9.02 g, 43.1 mmol)
synthesized according to the method described in WO
2008156739.
1H-NMR (400 MHz, 0DC13) 6: 1.34-1.49 (2H, m), 1.45 (9H,
s), 1.64 (3H, s), 1.77-1.86 (2H, m), 1.96-2.05 (1H, m),
2.38 (3H, s), 2.61-2.71 (2H, m), 3.85 (3H, s), 4.05-4.35
(2H, m), 7.67 (1H, s).
CA 02942883 2016-09-15
- 124 -
[0299]
This compound was resolved into each enantiomer
under the following conditions:
Column: Daicel CHIRALCEL OZ-H 4.6 mm ID x 250 mm L
Elution solvent: 100% acetonitrile
Flow rate: 1.00 mL/min
Temperature: 25 C
First peak: 5.7 min (specific rotation []D20 4.0 (C =
1.0, chloroform))
Second peak: 6.9 min (specific rotation []D2 = +3.6 (C =
1.0, chloroform))
[0300]
The following steps were carried out using the
compound ((2R)-A2g) of the second peak that was separated
using a preparative chiral column and identified as the R
form.
[0301]
(Step 7-2)
(2R)-7-Bromo-2-(1-tert-butoxycarbony1-4-piperidy1)-2,4-
dimethy1-1,3-benzodioxole-5-carboxylic acid ((2R)-A3g)
[0302]
The title compound (9.41 g, 20.6 mmol, 100% yield)
was obtained through the same reaction as in step 1-2
using the compound ((2R)-A2g) (9.70 g, 20.6 mmol)
synthesized in step 7-1.
[0303]
(Step 7-3)
CA 02942883 2016-09-15
- 125 -
tert-Butyl 4-[(2R)-7-bromo-5-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methylcarbamoy1]-2,4-dimethyl-1,3-
benzodioxo1-2-yl]piperidine-1-carboxylate ((2R)-A4g-p)
[0304]
The title compound (10.8 g, 18.3 mmol, 89% yield)
was obtained through the same reaction as in step 1-3
using the compound ((2R)-A3g) (9.41 g, 20.6 mmol)
synthesized in step 7-2.
1H-NMR (400 MHz, CDC13) 6: 1.30-1.45 (2H, m), 1.45 (9H,
s), 1.62 (3H, s), 1.76-1.86 (2H, m), 1.94-2.02 (1H, m),
2.22 (3H, s), 2.27 (3H, s), 2.37 (3H, s), 2.60-2.71 (2H,
m), 4.19 (2H, m), 4.50 (2H, d, J = 6.1 Hz), 5.97 (1H, s),
7.01 (1H, s), 7.23-7.27 (1H, m), 12.24 (1H, br s).
MS (APCI) m/z: 590, 592 (M+H)+.
[0305]
(Step 7-4)
(2R)-7-Bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-2-(4-piperidy1)-1,3-benzodioxole-
5-carboxamide ((2R)-A4g-f)
[0306]
The title compound (8.96 g, 18.3 mmol, 100% yield)
was obtained through the same reaction as in step 3-4
using the compound ((2R)-A4g-p) (10.8 g, 18.3 mmol)
synthesized in step 7-3.
MS (APCI) m/z: 490,492 (M+H)+.
[0307]
(Step 7-5)
CA 02942883 2016-09-15
- 126 -
(2R)-7-Bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2-(1-ethy1-4-piperidy1)-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide (7)
[0308]
The title compound (5.40 g, 10.4 mmol, 57% yield)
was obtained through the same reaction as in step 3-5
using the compound ((2R)-A4g-f) (8.96 g, 18.3 mmol)
synthesized in step 7-4 and acetaldehyde (12.1 g, 274
mmol).
1H-NMR (400 MHz, DMSO-d6) 6: 0.96 (3H, t, J = 7.3 Hz).
1.30-1.40 (2H, m), 1.61 (3H, s), 1.65-1.73 (2H, m), 1.73-
1.88 (3H, m), 2.10 (3H, s), 2.11 (3H, s), 2.16 (3H, s),
2.27 (2H, q, J = 6.7 Hz), 2.87-2.93 (2H, m), 4.21 (2H, d,
J = 4.9 Hz), 5.85 (1H, s), 6.94 (1H, s), 8.14 (1H, t, J =
4.9 Hz), 11.48 (1H, s).
MS (APCI) m/z: 518,520 (M+H)+.
[0309]
Example 8
(2R)-7-Bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-2-(1-methyl-4-piperidy1)-1,3-
benzodioxole-5-carboxamide (8)
[0310]
The title compound (0.271 g, 0.537 mmol, 88% yield)
was obtained through the same methylation reaction as in
step 3-5 using the compound ((2R)-A4g-f) (0.300 g, 0.612
mmol) synthesized in step 7-4.
CA 02942883 2016-09-15
- 127 -
1H-NMR (400 MHz, DMSO-d6) 5: 1.30-1.43 (2H, m), 1.61 (3H,
s), 1.64-1.71 (2H, m), 1.74-1.85 (3H, m), 2.10 (3H, s),
2.11 (3H, s), 2.12 (3H, s), 2.16 (3H, s), 2.76-2.83 (2H,
m), 4.21 (2H, d, J = 4.9 Hz), 5.85 (1H, s), 6.94 (1H, s),
8.14 (1H, t, J = 4.9 Hz), 11.48 (1H, s).
MS (APCI) m/z: 504, 506 (M+H)+.
[0311]
Example 9
(2R)-7-Bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-2-(1-propyl-4-piperidy1)-1,3-
benzodioxole-5-carboxamide (9)
[0312]
The title compound (0.136 g, 0.255 mmol, 42% yield)
was obtained through the same propylation reaction as in
step 3-5 using the compound ((2R)-A4g-f) (0.301 g, 0.614
mmol) synthesized in step 7-4 and propionaldehyde (0.535
g, 9.20 mmol).
1H-NMR (400 MHz, DMSO-d6) 6: 0.82 (3H, t, J = 7.6 Hz),
1.29-1.44 (4H, m), 1.61 (3H, s), 1.65-1.73 (2H, m), 1.75-
1.87 (3H, m), 2.10 (3H, s), 2.11 (3H, s), 2.16-2.21 (2H,
m), 2.17 (3H, s), 2.86-2.93 (2H, m), 4.21 (2H, d, J = 4.9
Hz), 5.85 (1H, s), 6.94 (1H, s), 8.14 (1H, t, J = 4.9 Hz),
11.48 (1H, s).
MS (APCI) m/z: 532,534 (M+H)+.
[0313]
Example 10
CA 02942883 2016-09-15
- 128 -
(2R)-7-Bromo-N-[(4,6-dimethy1-2-oxo-1H-pyridin-3-
yl)methy1]-2-[1-(2-methoxyethyl)-4-piperidy1]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (10)
[0314]
To a solution of the compound ((2R)-A4g-f) (0.300 g,
0.612 mmol) synthesized in step 7-4 in dimethylformamide
(10 mL), N,N-diisopropylethylamine (0.131 g, 1.01 mmol)
and 2-bromoethyl methyl ether (0.141 g, 1.01 mmol) were
added, and the mixture was stirred at 45 C for 8 hours.
After the completion of the reaction, the reaction
solution was concentrated, and the residue was purified
by basic silica gel column chromatography (ethyl
acetate:methanol = 100:0 -* 93:7) to obtain the title
compound (0.200 g, 0.364 mmol, 60% yield).
1H-NMR (400 MHz, DMSO-d6) 6: 1.28-1.41 (2H, m), 1.61 (3H,
s), 1.62-1.71 (2H, m), 1.78-1.93 (3H, m), 2.10 (3H, s),
2.11 (3H, s), 2.16 (3H, s), 2.41 (2H, t, J = 6.0 Hz),
2.86-2.94 (2H, m), 3.21 (3H, s), 3.39 (2H, t, J = 6.0 Hz),
4.21 (2H, d, J = 4.9 Hz), 5.85 (1H, s), 6.94 (1H, s),
8.14 (1H, t, J = 4.9 Hz), 11.48 (1H, s).
MS (APCI) m/z: 548, 550 (M+H)'.
[0315]
Example 11
(2R)-7-Bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
y1)methy1]-2-(1-ethy1su1fony1-4-piperidy1)-2,4-dimethy1-
1,3-benzodioxole-5-carboxamide (11)
[0316]
CA 02942883 2016-09-15
- 129 -
The compound ((2R)-A4g-f) (0.390 g, 0.795 mmol)
synthesized in step 7-4 was dissolved in dichloromethane
(5 mL). To the solution, triethylamine (0.131 g, 1.29
mmol) was added, then ethanesulfonyl chloride (0.123 g,
0.954 mmol) was added under ice cooling, and the mixture
was stirred at room temperature for 4 hours. After the
completion of the reaction, water was added to the
reaction solution, followed by extraction with chloroform.
The extract was concentrated. The organic layer was
washed with saturated saline, dried over sodium sulfate,
and then concentrated under reduced pressure, and the
obtained residue was purified by silica gel column
chromatography (chloroform:methanol = 100:0 -* 96:4) to
obtain the title compound (0.367 g, 0.631 mmol, 79%
yield).
1H-NMR (400 MHz, DMSO-d6) 6: 1.19 (3H, t, J = 7.3 Hz),
1.28-1.40 (2H, m), 1.63 (3H, s), 1.80-1.88 (2H, m), 2.02-
2.10 (1H, m), 2.11 (6H, s), 2.17 (3H, s), 2.73-2.82 (2H,
m), 3.02 (2H, q, J = 7.3 Hz), 3.65-3.70 (2H, m), 4.21 (2H,
d, J = 4.9 Hz), 5.86 (1H, s), 6.96 (1H, s), 8.15 (1H, t,
J = 4.9 Hz), 11.49 (1H, s).
MS (APCI) m/z: 582, 584 (M+H)'.
[0317]
Example 12
(2R)-7-Bromo-2-(1-ethy1-4-piperidy1)-2,4-dimethyl-N-[(6-
methy1-2-oxo-4-propy1-1,2-dihydropyridin-3-yl)methyl]-
1,3-benzodioxole-5-carboxamide (12)
CA 02942883 2016--15
- 130 -
[0318]
(Step 12-1)
tert-Butyl 4-[(2R)-7-bromo-2,4-dimethy1-5-[(6-methy1-2-
oxo-4-propy1-1,2-dihydropyridin-3-yl)methylcarbamoy1]-
1,3-benzodioxo1-2-yl]piperidine-1-carboxylate ((2R)-A4h)
[0319]
The title compound (1.83 g, 2.95 mmol, 67% yield)
was obtained through the same reaction as in step 1-3
using the compound ((2R)-A3g) (2.00 g, 4.38 mmol)
synthesized in step 7-2 and 3-(aminomethyl)-6-methy1-4-
propyl-1H-pyridin-2-one (0.869 g, 4.82 mmol) synthesized
according to the method described in W02011140324.
1H-NMR (400 MHz, CDC13) 6: 0.99 (3H, t, J = 7.6 Hz),
1.33-1.43 (2H, m), 1.45 (9H, s), 1.58-1.69 (5H, m), 1.76-
1.84 (2H, m), 1.93-2.02 (1H, m), 2.21 (3H, s), 2.27 (3H,
s), 2.66 (4H, m), 4.21 (2H, br s), 4.51 (2H, d, J = 5.5
Hz), 5.96 (1H, s), 7.00 (1H, s).
MS (APCI) m/z: 618, 620 (M+H)+.
[0320]
(Step 12-2)
(2R)-7-Bromo-2,4-dimethyl-N-[(6-methy1-2-oxo-4-propyl-
1,2-dihydropyridin-3-yl)methy1]-2-(4-piperidy1)-1,3-
benzodioxole-5-carboxamide ((2R)-A4h-f)
[0321]
The title compound (1.53 g, 2.95 mmol, 100% yield)
was obtained through the same reaction as in step 3-4
CA 02942883 2016-09-15
- 131 -
using the compound ((2R)-A4h) (1.83 g, 2.95 mmol)
synthesized in step 12-1.
MS (APCI) m/z: 518, 520 (M+H) .
[0322]
(Step 12-3)
(2R)-7-Bromo-2-(1-ethy1-4-piperidy1)-2,4-dimethyl-N-[(6-
methy1-2-oxo-4-propy1-1,2-dihydropyridin-3-yl)methyl]-
1,3-benzodioxole-5-carboxamide (12)
[0323]
The title compound (0.387 g, 0.707 mmol, 37% yield)
was obtained through the same reaction as in step 3-5
using the compound ((2R)-A4h-f) (1.00 g, 1.93 mmol)
synthesized in step 12-2 and acetaldehyde (1.28 g, 28.9
mmol).
1H-NMR (400 MHz, DMSO-d6) 6: 0.91 (3H, t, J = 7.6 Hz),
0.96 (3H, t, J = 7.2 Hz), 1.29-1.40 (2H, m), 1.46-1.56
(2H, m), 1.61 (3H, s), 1.65-1.73 (2H, m), 1.74-1.88 (3H,
m), 2.10 (3H, s), 2.12 (3H, s), 2.27 (2H, q, J = 7.2 Hz),
2.44-2.49 (2H, m), 2.82-2.94 (2H, m), 4.22 (2H, d, J =
4.9 Hz), 5.88 (1H, s), 6.93 (1H, s), 8.12 (1H, t, J = 4.9
Hz), 11.49 (1H, s).
MS (APCI) m/z: 546, 548 (M+H)+.
[0324]
Examples 13 and 14
[Formula 31]
CA 02942883 2016-09-15
- 132 -
9 H3 c H3
00 0 0 0 OH
an C H3 _______ al6, C H3
_______ ,i C H3
VI -
Br Wj OH 13-1 132 Br 0 Br gg' I j o
OH 0- IY
0 t-Bu 0 0
t-Bu
H3240 /N
H H
Ala
trans-A2 i trans-A3i
H3Cr;-N,C H3 H3CgtyC H3 H3CrcrC H3
I NH
I N H I N H
0 NH 0 0 NH 0 0 NH 0
C H3 --.. ., C H3 -------0
Br 0 . dk., C H3
13-3 0 13-4 WI 14
RP
Br 0 Br 0
0 0
1 t-Bu 0 0
H3-10.,V-0. CH3
11.3 II:2LO
trans-A4i 13 14 b H3
Example 13
2-(trans-4-Aminocyclohexyl)-7-bromo-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide (13)
[0325]
(Step 13-1)
Methyl 7-bromo-2-[trans-4-(tert-
butoxycarbonylamino)cyclohexyl]-2,4-dimethy1-1,3-
benzodioxole-5-carboxylate (trans-A2i)
[0326]
The title compound (38.9 g, 80.3 mmol, 89% yield)
was obtained through the same reaction as in step 1-1
using the compound (Ala) (23.5 g, 90.0 mmol) synthesized
in Reference Example 1, the compound (S-13) (9.02 g, 43.1
mmol) synthesized in Reference Example 13,
triruthenium(0) dodecacarbonyl (1.44 g, 2.25 mmol), and
5-(di-tert-butylphosphino)-1', 3', 5'-tripheny1-1'H-
[1,4']bipyrazole (3.42 g, 6.75 mmol).
CA 02942883 2016-09-15
- 133 -
1H-NMR (400 MHz, CDC13) 6: 1.04-1.15 (2H, m), 1.25-1.38
(2H, m), 1.44 (9H, s), 1.63 (3H, s), 1.79-1.87 (1H, m),
1.91-1.99 (2H, m), 2.04-2.12 (2H, m), 2.38 (3H, s), 3.31-
3.46 (1H, m), 3.84 (3H, s), 4.37 (1H, br s), 7.67 (1H, s).
[0327]
(Step 13-2)
7-Bromo-2-[trans-4-(tert-butoxycarbonylamino)cyclohexyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxylic acid (trans-
A3i)
[0328]
The title compound (22.8 g, 48.5 mmol, 100% yield)
was obtained through the same reaction as in step 1-2
using the compound (trans-A2i) (23.5 g, 48.5 mmol)
synthesized in step 13-1.
1H-NMR (400 MHz, CDC13) 6: 1.04-1.16 (2H, m), 1.25-1.38
(2H, m), 1.44 (9H, s), 1.64 (3H, s), 1.80-1.90 (1H, m),
1.92-2.00 (2H, m), 2.06-2.16 (2H, m), 2.41 (3H, s), 3.35-
3.48 (1H, m), 4.40 (1H, br s), 7.80 (1H, s).
MS (ESI) m/z: 468, 470 (M-H)-.
[0329]
(Step 13-3)
tert-Butyl N-[trans-4-[7-bromo-5-[(4,6-dimethy1-2-oxo-
1,2-dihydropyridin-3-yl)methylcarbamoy1]-2,4-dimethyl-
1,3-benzodioxo1-2-yl]cyclohexyl]carbamate (trans-A4i)
[0330]
The title compound (26.8 g, 44.3 mmol, 91% yield)
was obtained through the same reaction as in step 1-3
CA 02942883 2016-09-15
- 134 -
using the compound (trans-A3i) (22.8 g, 48.5 mmol)
synthesized in step 13-2.
1H-NMR (400 MHz, CDC13) 6: 1.02-1.15 (2H, m), 1.23-1.40
(2H, m), 1.43 (9H, s), 1.59 (3H, s), 1.75-1.84 (1H, m),
1.89-1.97 (2H, m), 2.02-2.10 (2H, m), 2.21 (3H, s), 2.26
(3H, s), 2.37 (3H, s), 3.34-3.45 (1H, m), 4.39 (1H, d, J
= 8.4 Hz), 4.49 (2H, d, J = 5.5 Hz), 5.96 (1H, s), 7.00
(1H, s), 7.21 (1H, t, J = 5.5 Hz).
MS (ESI) m/z: 604, 606 (M+H)+.
[0331]
(Step 13-4)
2-(trans-4-Aminocyclonexyl)-7-bromo-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methy1]-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide (13)
[0332]
The title compound (4.20 g, 8.33 mmol, 83% yield)
was obtained through the same reaction as in step 3-4
using the compound (trans-A4i) (6.04 g, 9.99 mmol)
synthesized in step 13-3, followed by purification by
basic silica gel chromatography (ethyl acetate:methanol =
100:0 -* 30:70).
1H-NMR (400 MHz, DMSO-d6) 6: 0.93-1.05 (2H, m), 1.08-1.23
(2H, m), 1.59 (3H, s), 1.73-1.85 (5H, m), 2.10 (3H, s),
2.11 (3H, s), 2.16 (3H, s), 2.39-2.49 (1H, m), 4.21 (2H,
d, J = 4.9 Hz), 5.85 (1H, s), 6.94 (1H, s), 8.14 (1H, t,
J = 4.9 Hz).
MS (ESI) m/z: 504, 506 (M+H)+.
CA 02942883 2016-09-15
- 135 -
[0333]
Example 14
7-Bromo-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (14)
(Step 14)
The title compound (20.0 g, 37.6 mmol, 90% yield)
was obtained through the same reaction as in step 3-5
using the compound (13) (21.0 g, 41.6 mmol) synthesized
in step 13-4.
1H-NMR (400 MHz, DMSO-d6) 6: 1.08-1.23 (4H, m), 1.59 (3H,
s), 1.75-1.90 (5H, m), 2.02-2.09 (1H, m), 2.10 (3H, s),
2.11 (3H, s), 2.13 (6H, s), 2.16 (3H, s), 4.21 (2H, d, J
= 4.9 Hz), 5.85 (1H, s), 6.94 (1H, s), 8.14 (1H, t, J =
4.9 Hz), 11.48 (1H, s).
MS (APCI) m/z: 532, 534 (M+H)+.
[0334]
This compound was resolved into each enantiomer
under the following conditions:
Column: Daicel CHIRALCEL OZ-3 4.6 mm ID x 150 mm L
Elution solvent: n-hexane:ethanol:diethylamine --
60:40:0.04 (V/V)
Flow rate: 1.00 mL/min
Temperature: 35 C
First peak: 4.4 min (specific rotation [a]r)20 = -7.2 (C --
1.0, chloroform))
CA 02942883 2016-09-15
- 136 -
Second peak: 6.6 min (specific rotation [a]D2 = +9.0 (C =
1.0, chloroform))
[0335]
Example 15
(2R)-7-Bromo-2-[trans-4-(dimethylamino)cyclohexyl]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (15)
[Formula 32]
oH3 9 H3
0 0 Optical 0 0 0 OH
resolution
C H3
C H3 C H,
At --...111. 110 %, --.-..I. 15-3
".-1.1 SI . 141)
Br W 0 Br 0 15-2 Br 0 0
0 0
0 0 oL
t-Bu H3-tOwdLoot-Bu
H3640,N, -0-
t-Bu
H3--CAOwN U
H H H
trans-A2i trans-(2R)-A2i trans-(2R)-A3i
)
H3C1:;c1,CH3 H3C1:;Qtr,CH3 H3C ,C H3
I
I N H I NH ryNH
0 NH 0
0 N H 0 0 NH 0
al C H3 --, aim C H3 --ow Ari C H3
15-4 15-5 Br W 0
Br W 0 Br W 0 0
0t00'
0
fi t-Bu 0 C H3
H3 "
113-C-40"'N H2 H3-C:LO'"N
r...0
H,.= .. 3
trans-(2R)-A4i trans-(2R)-A4i-f 15
[0336]
(Step 15-1)
(2R)-Methyl 7-bromo-2-[trans-4-(tert-
butoxycarbonylamino)cyclohexyl]-2,4-dimethy1-1,3-
benzodioxole-5-carboxylate (trans-(2R)-A2i)
[0337]
The compound (trans-A2i) synthesized in step 13-1
was resolved into each enantiomer under the following
conditions:
CA 02942883 2016-09-15
- 137 -
Column: Daicel CHIRALCEL OZ-H 4.6 mm ID x 250 mm L
Elution solvent: n-hexane:ethanol = 98:2 (V/V)
Flow rate: 1.00 mL/min
Temperature: 25 C
First peak: 11.2 min (specific rotation [a] = 6.5 (C =
1.0, chloroform))
Second peak: 12.3 min (specific rotation [a]02 = +6.3 (C
= 1.0, chloroform))
[0338]
The following steps were carried out using the
compound ((2R)-A2i) of the second peak that was separated
using a preparative chiral column and identified as the R
form.
[0339]
(Step 15-2)
(2R)-7-Bromo-2-[trans-4-(tert-
butoxycarbonylamino)cyclohexyl]-2,4-dimethy1-1,3-
benzodioxole-5-carboxylic acid (trans-(2R)-A3i)
[0340]
The title compound (0.903 g, 1.92 mmol, 97% yield)
was obtained through the same reaction as in step 1-2
using the compound ((2R)-A2i) (second peak, 0.956 g, 1.97
mmol) separated in step 15-1.
[0341]
(Step 15-3)
tert-Butyl N-[trans-4-[(2R)-7-bromo-5-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methylcarbamoyl]-2,4-
CA 02942883 2016-09-15
- 138 -
dimethy1-1,3-benzodioxo1-2-yl]cyclohexyl]carbamate
(trans-(2R)-A4i)
[0342]
The title compound (0.801 g, 1.32 mmol, 69% yield)
was obtained through the same reaction as in step 1-3
using the compound (trans-(2R)-A3i) (0.903 g, 1.92 mmol)
synthesized in step 15-2.
1H-NMR (400 MHz, 0DC13) 6: 1.03-1.15 (2H, m), 1.21-1.38
(2H, m), 1.44 (9H, s), 1.59 (3H, s), 1.75-1.84 (IH, m),
1.89-1.97 (2H, m), 2.02-2.10 (2H, m), 2.21 (3H, s), 2.26
(3H, s), 2.37 (3H, s), 3.34-3.45 (1H, m), 4.41-4.45 (1H,
m), 4.49 (2H, d, J = 6.0 Hz), 5.95 (1H, s), 7.00 (1H, s),
7.18 (1H, t, J = 6.0 Hz).
MS (APCI) m/z: 604, 606 (M+H)'.
[0343]
(Step 15-4)
(2R)-2-(trans-4-Aminocyclohexyl)-7-bromo-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (trans-(2R)-A4i-
f)
[0344]
The title compound (0.668 g, 1.32 mmol, 100% yield)
was obtained through the same reaction as in step 3-4
using the compound (trans-(2R)-A4i) (0.801 g, 1.32 mmol)
synthesized in step 15-3.
1H-NMR (400 MHz, DMSO-d6) 6: 0.93-1.05 (2H, m), 1.08-1.23
(2H, m), 1.59 (3H, s), 1.73-1.85 (5H, m), 2.10 (3H, s),
CA 02942883 2016-09-15
- 139 -
2.11 (3H, s), 2.16 (3H, s), 2.39-2.49 (1H, m), 4.21 (2H,
d, J = 4.9 Hz), 5.85 (1H, s), 6.94 (1H, s), 8.14 (1H, t,
J = 4.9 Hz).
MS (ESI) m/z: 504, 506 (M+H)+.
[0345]
(Step 15-5)
(2R)-7-Bromo-2-[trans-4-(dimethylamino)cyclohexyl]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (15)
[0346]
The title compound (0.616 g, 1.16 mmol, 87% yield)
was obtained through the same reaction as in step 3-5
using the compound (trans-(2R)-A4i-f) (0.668 g, 1.32
mmol) synthesized in step 15-4.
1H-NMR (400 MHz, DMSO-d6) 6: 1.08-1.20 (4H, m), 1.59 (3H,
s), 1.75-1.90 (5H, m), 2.02-2.12 (1H, m), 2.09 (3H, s),
2.11 (3H, s), 2.13 (6H, s), 2.16 (3H, s), 4.21 (2H, d, J
= 4.9 Hz), 5.85 (1H, s), 6.93 (1H, s), 8.12 (1H, t, J =
4.9 Hz), 11.47 (1H, s).
MS (APCI) m/z: 532, 534 (M+H)+.
Specific rotation []D2 = -7.2 (C = 1.0, chloroform)
This compound agreed with the compound of the first
peak obtained under the resolution conditions using a
chiral column described in Example 14.
[0347]
Example 16
CA 02942883 2016-09-15
- 140 -
7-Bromo-2-[trans-4-(dimethylamino)cyclohexyli-N-[(4-
methoxy-6-methy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide (16)
[0348]
(Step 16-1)
tert-Butyl N-[trans-4-[7-bromo-5-[(4-methoxy-6-methy1-2-
oxo-1H-pyridin-3-yl)methylcarbamoyl]-2,4-dimethyl-1,3-
benzodioxo1-2-yl]cyclohexyl]carbamate
[0349]
The title compound (0.237 g, 0.382 mmol, 74% yield)
was obtained through the same reaction as in step 1-3
using 7-bromo-2-[trans-4-(tert-
butoxycarbonylamino)cyclohexyl]-2,4-dimethy1-1,3-
benzodioxole-5-carboxylic acid (0.243 g, 0.517 mmol)
synthesized in step 13-2 and 3-(aminomethyl)-4-methoxy-6-
methy1-1H-pyridin-2-one hydrochloride (0.116 g, 0.568
mmol) synthesized according to the method described in
W020131201042.
1H-NMR (400 MHz, DMSO-d6) 6: 1.06-1.21 (4H, m), 1.35 (9H,
s), 1.59 (3H, s), 1.73-1.85 (5H, m), 2.10 (3H, s), 2.18
(3H, s), 3.07-3.20 (1H, m), 3.78 (3H, s), 4.14 (2H, d, J
= 4.4 Hz), 6.09 (1H, s), 6.74 (1H, d, J = 8.0 Hz), 6.93
(1H, s), 7.95 (1H, t, J = 4.4 Hz), 11.45 (1H, s).
MS (APCI) m/z: 620, 622 (M+H)+.
[0350]
(Step 16-2)
CA 02942883 2016-09-15
- 141 -
2-(trans-4-Aminocyclohexyl)-7-bromo-N-[(4-methoxy-6-
methy1-2-oxo-1H-pyridin-3-yl)methyl]-2,4-dimethy1-1,3-
benzodioxole-5-carboxamide
[0351]
The title compound (0.187 g, 0.359 mmol, 94% yield)
was obtained through the same reaction as in step 3-4
using tert-butyl N-[trans-4-[7-bromo-5-[(4-methoxy-6-
methy1-2-oxo-1H-pyridin-3-yl)methylcarbamoyl]-2,4-
dimethy1-1,3-benzodioxo1-2-yl]cyclohexyl]carbamate (0.237
g, 0.382 mmol) synthesized in step 16-1.
1H-NMR (400 MHz, DMSO-d6) 6: 0.89-1.04 (2H, m), 1.06-1.23
(2H, m), 1.57 (3H, s), 1.71-1.83 (5H, m), 2.09 (3H, s),
2.17 (3H, s), 2.37-2.50 (1H, m), 3.55 (3H, s), 3.78 (3H,
s), 4.15 (2H, d, J = 4.8 Hz), 6.09 (1H, s), 6.92 (1H, s),
7.93 (1H, t, J = 4.8 Hz).
MS (APCI) m/z: 520, 522 (M+H)+.
[0352]
(Step 16-3)
7-Bromo-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4-
methoxy-6-methy1-2-oxo-1H-pyridin-3-yl)methy1]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide
[0353]
The title compound (0.126 g, 0.229 mmol, 64% yield)
was obtained through the same reaction as in step 3-5
using 2-(trans-4-aminocyclohexyl)-7-bromo-N-[(4-methoxy-
6-methy1-2-oxo-1H-pyridin-3-yl)methy1]-2,4-dimethyl-1,3-
CA 02942883 2016-09-15
- 142 -
benzodioxole-5-carboxamide (0.187 g, 0.359 mmol)
synthesized in step 16-2.
1H-NMR (400 MHz, DMSO-d6) 6: 1.06-1.22 (4H, m), 1.58 (3H,
s), 1.72-1.90 (5H, m), 2.00-2.21 (1H, m), 2.09 (3H, s),
2.12 (6H, s), 2.16 (3H, s), 3.78 (3H, s), 4.15 (2H, d, J
= 4.4 Hz), 6.08 (1H, s), 6.91 (1H, s), 7.93 (1H, t, J =
4.4 Hz), 11.4 (1H, br s).
MS (APCI) m/z: 548, 550 (M+H)'.
[0354]
Example 17
7-Bromo-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4-
ethy1-6-methy1-2-oxo-1,2-dihydropyridin-3-y1)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (17)
[Formula 33]
cH3 cH3
91-13
0 0 0 0
00
C H3 C H3
C H3
4111 17-1 0 --== Br glPj 0
17-2 17-3
Br 0
H 3-14-0",N H2 0
0 0
t-Bu
H3-24.04NC H, 3
H3-1Ø,N4'
a H3
trans-A2 trans-H1a trans-H2a
C
H3CX1---
I NH
0 0 H
0 NH 0
C H3
Br 0 17-4 C H3
0 Br 0
0
H3¨Ckcea, NC H= 3 C H3
F137140wW
CH3
C H3
trans-H3a 17
[0355]
(Step 17-1)
CA 02942883 2016-09-15
- 143 -
Methyl 2-(trans-4-aminocyclohexyl)-7-bromo-2,4-dimethyl-
1,3-benzodioxole-5-carboxylate (trans-Hla)
[0356]
The title compound (0.160 g, 0.417 mmol, 100% yield)
was obtained through the same reaction as in step 3-4
using the compound (trans-A2i) (0.200 g, 0.413 mmol)
synthesized in step 13-1.
1H-NMR (400 MHz, CDC13) 6: 1.05-1.15 (2H, m), 1.24-1.33
(2H, m), 1.63 (3H, s), 1.80-1.88 (1H, m), 1.89-1.97 (4H,
m), 2.38 (3H, s), 2.60-2.68 (1H, m), 3.85 (3H, d, J = 1.2
Hz), 7.67 (1H, s).
MS (ESI) m/z: 384, 386 (M+H)+.
[0357]
(Step 17-2)
Methyl 7-bromo-2-[trans-4-(dimethylamino)cyclohexyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxylate (trans-H2a)
[0358]
The title compound (0.124 g, 0.417 mmol, 93% yield)
was obtained through the same reaction as in step 3-5
using the compound (trans-Hla) (0.124 g, 0.413 mmol)
synthesized in step 17-1.
1H-NMR (400 MHz, CDC13) 6: 1.16-1.31 (4H, m), 1.63 (3H,
s), 1.78-1.86 (1H, m), 1.90-2.05 (4H, m), 2.10-2.20 (1H,
m), 2.27 (6H, s), 2.38 (3H, s), 3.84 (3H, s), 7.66 (1H,
s).
MS (ESI) m/z: 412, 414 (M+H)+.
[0359]
CA 02942883 2016-09-15
- 144 -
(Step 17-3)
7-Bromo-2-[trans-4-(dimethylamino)cyclohexy1]-2,4-
dimethy1-1,3-benzodioxole-5-carboxylic acid (trans-H3a)
[0360]
The title compound (0.597 g, 0.505 mmol, 47% yield)
was obtained through the same reaction as in step 6-4
using the compound (trans-H2a) (0.523 g, 1.27 mmol)
synthesized in step 17-2.
MS (ESI) m/z: 398, 400 (M+H)+.
[0361]
(Step 17-4)
7-Bromo-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4-
ethy1-6-methy1-2-oxo-1,2-dihydropyridin-3-y1)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (17)
[0362]
The title compound (0.245 g, 0.448 mmol, 75% yield)
was obtained through the same reaction as in step 1-3
using the compound (trans-H3a) (0.238 g, 0.597 mmol)
synthesized in step 17-3 and 3-(aminomethyl)-4-ethy1-6-
methyl-1H-pyridin-2-one (0.119 g, 0.717 mmol) synthesized
according to the method described in W02011140324.
1H-NMR (400 MHz, CDC13) 8.: 1.20 (3H, t, J = 7.7 Hz),
1.21-1.30 (4H, m), 1.60 (3H, s), 1.75-1.90 (1H, m), 1.92-
2.02 (2H, m), 2.22 (3H, s), 2.27 (6H, s), 2.28 (3H, s),
2.71 (2H, q, J = 7.7 Hz), 4.52 (2H, d, J = 5.5 Hz), 5.99
(1H, s), 6.99 (1H, s), 7.26 (1H, t, J = 5.5 Hz).
MS (ESI) m/z: 546, 548 (M+H)+.
CA 02942883 2016-09-15
- 145 -
[0363]
Example 18
7-Bromo-2-[trans-4-(dimethylamino)cyclohexyl]-2,4-
dimethyl-N-[(6-methy1-2-oxo-4-propy1-1,2-dihydropyridin-
3-yl)methy1]-1,3-benzodioxole-5-carboxamide (18)
[0364]
The title compound (0.314 g, 0.560 mmol, 75% yield)
was obtained through the same reaction as in step 1-3
using the compound (trans-H3a) (0.297 g, 0.745 mmol)
synthesized in step 17-3 and 3-(aminomethyl)-6-methy1-4-
propyl-1H-pyridin-2-one (0.161 g, 0.894 mmol) synthesized
according to the method described in W02011140324.
1H-NMR (400 MHz, CDC13) 6: 0.99 (3H, t, J = 7.3 Hz),
1.19-1.28 (4H, m), 1.60 (3H, s), 1.76-1.84 (1H, m), 1.92-
1.98 (4H, m), 2.09-2.17 (1H, m), 2.21 (3H, s), 2.27 (9H,
s), 2.62-2.68 (2H, m), 4.51 (2H, d, J = 5.0 Hz), 5.96 (1H,
s), 6.99 (1H, s), 7.25 (1H, t, J = 5.0 Hz).
MS (ESI) m/z: 560, 562 (M+H)+.
[0365]
Example 19
7-Bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2-[trans-4-(ethylamino)cyclohexy1]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (19)
[0366]
The title compound (0.360 g, 0.676 mmol, 68% yield)
was obtained through the same reaction as in step 3-5
CA 02942883 2016-09-15
- 146 -
using the compound (13) (0.500 g, 0.992 mmol) synthesized
in step 13-4 and acetaldehyde (0.440 g, 9.99 mmol).
1H-NMR (400 MHz, DMSO-d0 6: 0.90-1.02 (2H, m), 0.97 (3H,
t, J = 7.2 Hz), 1.08-1.22 (2H, m), 1.59 (3H, s), 1.75-
1.85 (3H, m), 1.85-1.94 (2H, m), 2.10 (3H, s), 2.11 (3H,
s), 2.16 (3H, s), 2.23-2.33 (1H, m), 2.52 (2H, q, J = 7.2
Hz), 4.21 (2H, d, J = 4.9 Hz), 5.85 (1H, s), 6.93 (1H, s),
8.12 (1H, t, J = 4.9 Hz).
MS (ESI) m/z: 532, 534 (M+H)+.
[0367]
Example 20
7-Bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2-[trans-4-[N-ethyl(N-
methyl)amino]cyclohexy11-2,4-dimethy1-1,3-benzodioxole-5-
carboxamide (20)
[0368]
The title compound (0.065 g, 0.119 mmol, 63% yield)
was obtained through the same reaction as in step 3-5
using the compound (19) (0.100 g, 0.188 mmol) synthesized
in Example 19.
1H-NMR (400 MHz, DMSO-d6) 6: 0.94 (3H, t, J = 7.2 Hz),
1.08-1.27 (2H, m), 1.59 (3H, s), 1.72-1.90 (5H, m), 2.10
(3H, s), 2.11 (6H, s), 2.16 (3H, s), 2.24-2.343 (1H, m),
2.41 (2H, q, J = 7.2 Hz), 4.21 (2H, d, J = 4.9 Hz), 5.86
(1H, s), 6.94 (1H, s), 8.13 (1H, t, J = 4.9 Hz), 11.48
(1H, br s).
MS (ESI) m/z: 546, 548 (M+H)+.
CA 02942883 2016-09-15
- 147 -
[0369]
Example 21
7-Bromo-2-[trans-4-(diethylamino)cyclohexyl]-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (21)
The title compound (0.065 g, 0.116 mmol, 39% yield)
was obtained through the same reaction as in step 3-5
using the compound (19) (0.160 g, 0.300 mmol) synthesized
in Example 19 and acetaldehyde (0.132 g, 3.00 mmol).
1H-NMR (400 MHz, DMSO-d6) 6: 0.93 (6H, t, J = 7.2 Hz),
1.08-1.27 (4H, m), 1.59 (3H, s), 1.72-1.90 (5H, m), 2.10
(3H, s), 2.11 (3H, s), 2.17 (3H, s), 2.44 (4H, q, J = 7.2
Hz), 4.21 (2H, d, J = 4.9 Hz), 5.86 (1H, s), 6.94 (1H, s),
8.14 (1H, t, J = 4.9 Hz), 11.49 (1H, br s).
MS (ESI) m/z: 560, 562 (M+H)+.
[0370]
Example 22
7-Bromo-2-[(2S,5R)-5-(dimethylamino)tetrahydropyran-2-
y1]-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-1,3-benzodioxole-5-carboxamide
(22)
[0371]
(Step 22-1)
Methyl 7-bromo-2-[(2S,5R)-5-(tert-
butoxycarbonylamino)tetrahydropyran-2-y1]-2,4-dimethyl-
1,3-benzodioxole-5-carboxylate
[0372]
CA 02942883 2016-09-15
- 148 -
The title compound (0.443 g, 0.911 mmol, 59% yield)
was obtained through the same reaction as in step 13-1
using the compound (Ala) (0.400 g, 1.53 mmol) synthesized
in Reference Example 1 and tert-butyl N-[(3R,6S)-6-
ethynyltetrahydropyran-3-yl]carbamate (0.414 g, 1.84
mmol) synthesized according to the method described in WO
2007105154.
1H-NMR (400 MHz, CDC13) 6: 1.22-1.34 (1H, m), 1.45 (9H,
s), 1.52-1.63 (1H, m), 1.67-1.76 (3H, m), 1.80-1.90 (1H,
m), 2.10-2.19 (1H, m), 2.39 (3H, s), 2.99-3.07 (1H, m),
3.45-3.51 (1H, m), 3.55-3.70 (1H, m), 3.85 (3H, s), 4.10-
4.19 (1H, m), 4.21-4.41 (1H, m), 7.68 (1H, s).
[0373]
(Step 22-2)
7-Bromo-2-[(2S,5R)-5-(tert-
butoxycarbonylamino)tetrahydropyran-2-y1]-2,4-dimethyl-
1,3-benzodioxole-5-carboxylic acid
[0374]
The title compound (0.423 g, 0.895 mmol, 98% yield)
was obtained through the same reaction as in step 1-2
using methyl 7-bromo-2-[(2S,5R)-5-(tert-
butoxycarbonylamino)tetrahydropyran-2-y1]-2,4-dimethyl-
1,3-benzodioxole-5-carboxylate (0.443 g, 0.911 mmol)
synthesized in step 22-1.
[0375]
(Step 22-3)
CA 02942883 2016-09-15
- 149 -
tert-Butyl N-[(3R,6S)-6-[7-bromo-5-[(4,6-dimethy1-2-oxo-
1,2-dihydropyridin-3-yl)methylcarbamoy1]-2,4-dimethyl-
1,3-benzodioxo1-2-ylltetrahydropyran-3-yl]carbamate
[0376]
The title compound (0.212 g, 0.349 mmol, 39% yield)
was obtained through the same reaction as in step 1-3
using 7-bromo-2-[(2S,5R)-5-(tert-
butoxycarbonylamino)tetrahydropyran-2-y1]-2,4-dimethyl-
1,3-benzodioxole-5-carboxylic acid (0.423 g, 0.895 mmol)
synthesized in step 22-2.
1H-NMR (400 MHz, CDC13) 6: 1.21-1.34 (1H, m), 1.43 (9H,
s), 1.50-1.62 (1H, m), 1.67 (3H, s), 1.75-1.87 (1H, m),
2.05-2.17 (1H, m), 2.23 (3H, s), 2.26 (3H, s), 2.36 (3H,
s), 2.97-3.06 (1H, m), 3.41-3.48 (1H, m), 3.52-3.74 (1H,
m), 4.09-4.19 (1H, m), 4.21-4.32 (1H, m), 4.49 (2H, d, J
= 5.5 Hz), 5.97 (1H, s), 7.01 (1H, s), 12.35 (1H, br s).
MS (APCI) m/z: 606, 608 (M+H)+.
[0377]
(Step 22-4)
2-[(2S,5R)-5-Aminotetrahydropyran-2-y1]-7-bromo-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide
The title compound (0.177 g, 0.350 mmol, 100% yield)
was obtained through the same reaction as in step 3-4
using tert-butyl N-[(3R,6S)-6-[7-bromo-5-[(4,6-dimethyl-
2-oxo-1,2-dihydropyridin-3-yl)methylcarbamoy1]-2,4-
dimethy1-1,3-benzodioxo1-2-ylltetrahydropyran-3-
CA 02942883 2016-09-15
- 150 -
yl]carbamate (0.212 g, 0.349 mmol) synthesized in step
22-3.
MS (APCI) m/z: 506, 508 (M+H)+.
[0378]
(Step 22-5)
7-Bromo-2-[(2S,5R)-5-(dimethylamino)tetrahydropyran-2-
y1]-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-1,3-benzodioxole-5-carboxamide
(22)
The title compound (0.169 g, 0.316 mmol, 90% yield)
was obtained through the same reaction as in step 3-5
using 2-[(2S,5R)-5-aminotetrahydropyran-2-y1]-7-bromo-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (0.177 g, 0.350
mmol) synthesized in step 22-4.
1H-NMR (400 MHz, DMSO-d6) 6: 1.29-1.47 (2H, m), 1.61 (3H,
s), 1.73-1.80 (1H, m), 1.93-2.05 (1H, m), 2.09 (3H, s),
2.11 (3H, s), 2.15 (6H, s), 2.16 (3H, s), 2.16-2.23 (1H,
m), 3.12-3.20 (1H, m), 3.49-3.56 (1H, m), 3.99-4.05 (1H,
m), 4.21 (2H, d, J = 5.5 Hz), 5.86 (1H, s), 6.94 (1H, s),
8.15 (1H, t, J = 5.5 Hz), 11.49 (1H, s).
MS (APCI) m/z: 534, 536 (M+H)+.
[0379]
Example 23
2-[trans-4-(Dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methy1]-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide (23)
CA 02942883 2016-09-15
- 151 -
[0380]
The compound (14) (200 mg, 0.376 mmol) synthesized
in Example 14 was dissolved in methanol (5 mL). To the
solution, 4 M hydrochloric acid in 1,4-dioxane (0.094 mL,
0.376 mmol) and a 10% palladium-carbon catalyst (0.200 g)
were added, and the mixture was stirred at room
temperature for 6 hours under a hydrogen atmosphere.
After purging with nitrogen, the catalyst was filtered
off through celite, and the solvent was distilled off
under reduced pressure. The obtained residue was
neutralized by the addition of a 1 M aqueous sodium
hydroxide solution, followed by extraction with 20%
methanol in dichloromethane. The organic layer was
washed with saturated saline and then dried over
anhydrous sodium sulfate to obtain the title compound
(0.098 g, 0.215 mmol, 57% yield) in a debrominated form.
1H-NMR (400 MHz, DMSO-d6) 6: 1.19-1.32 (4H, m), 1.54 (3H,
s), 1.75-1.85 (1H, m), 1.93-2.05 (4H, m), 2.19 (3H, s),
2.19-2.29 (1H, m), 2.24 (3H, s), 2.29 (6H, s), 2.35 (3H,
s), 4.42 (2H, s), 6.10 (1H, s), 6.54 (1H, d, J = 7.9 Hz),
6.84 (1H, d, J = 7.9 Hz).
MS (ESI) m/z: 454 (M+H) .
[0381]
Example 24
7-Bromo-2-[trans-4-[(dimethylamino)methyl]cyclohexyl]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (24)
CA 02942883 2016-09-15
- 152 -
[0382]
(Step 24-1)
Methyl 7-bromo-2-[trans-4-[(tert-
butoxycarbonylamino)methyl]cyclohexyl]-2,4-dimethy1-1,3-
benzodioxole-5-carboxylate
[0383]
The title compound (1.28 g, 2.57 mmol, 84% yield)
was obtained through the same reaction as in step 13-1
using the compound (Ala) (0.800 g, 3.06 mmol) synthesized
in Reference Example 1 and the compound (S-16) (1.09 g,
4.60 mmol) synthesized in Reference Example 16.
1H-NMR (400 MHz, CDC13) 6: 0.88-1.00 (2H, m), 1.16-1.27
(2H, m), 1.44 (9H, s), 1.63 (3H, s), 1.78-1.88 (3H, m),
1.90-1.98 (2H, m), 2.38 (3H, s), 2.97 (2H, t, J = 6.4 Hz),
3.85 (3H, s), 4.59 (1H, br s), 7.66 (1H, s).
[0384]
(Step 24-2)
7-Bromo-2-[trans-4-[(tert-
butoxycarbonylamino)methyl]cyclohexyl]-2,4-dimethy1-1,3-
benzodioxole-5-carboxylic acid
[0385]
The title compound (1.24 g, 2.57 mmol, 100% yield)
was obtained through the same reaction as in step 1-2
using methyl 7-bromo-2-[trans-4-[(tert-
butoxycarbonylamino)methyl]cyclohexyl]-2,4-dimethy1-1,3-
benzodioxole-5-carboxylate (1.28 g, 2.57 mmol)
synthesized in step 24-1.
CA 02942883 2016-09-15
- 153 -
[0386]
(Step 24-3)
tert-Butyl N-Htrans-4-[7-bromo-5-[(4,6-dimethy1-2-oxo-
1,2-dihydropyridin-3-yl)methylcarbamoyl]-2,4-dimethyl-
1,3-benzodioxo1-2-yl]cyclohexyl]methyl]carbamate
[0387]
The title compound (1.26 g, 2.04 mmol, 80% yield)
was obtained through the same reaction as in step 1-3
using 7-bromo-2-[trans-4-[(tert-
butoxycarbonylamino)methyl]cyclohexyl]-2,4-dimethy1-1,3-
benzodioxole-5-carboxylic acid (1.24 g, 2.57 mmol)
synthesized in step 24-2.
1H-NMR (400 MHz, CDC13) 6: 0.88-1.00 (2H, m), 1.15-1.27
(2H, m), 1.43 (9H, s), 1.60 (3H, s), 1.77-1.86 (3H, m),
1.90-1.94 (2H, m), 2.21 (3H, s), 2.26 (3H, s), 2.37 (3H,
s), 2.96 (2H, t, J = 6.4 Hz), 4.49 (2H, d, J = 5.5 Hz),
4.59 (1H, br s), 5.95 (1H, s), 6.99 (1H, s), 7.20 (1H, t,
J = 5.5 Hz), 11.55 (1H, br s).
MS (ESI) m/z: 618, 620 (M+)
[0388]
(Step 24-4)
2-[trans-4-(Aminomethyl)cyclohexyl]-7-bromo-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide
[0389]
The title compound (0.923 g, 1.78 mmol, 87% yield)
was obtained in an amino form through the same reaction
CA 02942883 2016-09-15
- 154 -
as in step 3-4 using tert-butyl N-Htrans-4-[7-bromo-5-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methylcarbamoy1]-2,4-dimethy1-1,3-benzodioxol-2-
yl]cyclohexyl]methyl]carbamate (1.26 g, 2.04 mmol)
synthesized in step 24-3.
MS (ESI) m/z: 518, 520 (M+H)+.
[0390]
(Step 24-5)
7-Bromo-2-[trans-4-[(dimethylamino)methyl]cyclohexyl]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-y1)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (24)
[0391]
The title compound (0.116 g, 0.213 mmol, 55% yield)
was obtained through the same reaction as in step 3-5
using 2-[trans-4-(aminomethyl)cyclohexyl]-7-bromo-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-y1)methyll-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (0.200 g, 0.386
mmol) synthesized in step 24-4.
1H-NMR (400 MHz, CD30D) 6: 0.89-1.00 (2H, m), 1.19-1.30
(2H, m), 1.43-1.53 (1H, m), 1.60 (3H, s), 1.81-1.96 (5H,
m), 2.14-2.18 (2H, m), 2.17 (3H, s), 2.21 (6H, s), 2.24
(3H, s), 2.35 (3H, s), 4.41 (2H, s), 6.10 (1H, s), 6.98
(1H, s).
MS (ESI) m/z: 546, 548 (M+H)+.
[0392]
Example 25
CA 02942883 2016-09-15
- 155 -
7-Bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-2-[(1-methyl-4-piperidyl)methyl]-
1,3-benzodioxole-5-carboxamide (25)
[0393]
(Step 25-1)
tert-Butyl 4-[(7-bromo-5-methoxycarbony1-2,4-dimethy1-
1,3-benzodioxol-2-yl)methyl]piperidine-1-carboxylate
[0394]
The title compound (0.280 g, 0.578 mmol, 76% yield)
was obtained through the same reaction as in step 1-1
using the compound (Ala) (0.200 g, 0.766 mmol)
synthesized in Reference Example 1 and the compound (S-
10) (0.257 g, 1.15 mmol) synthesized in Reference Example
10.
1H-NMR (400 MHz, CDC13) 6: 1.13-1.29 (2H, m), 1.45 (9H,
s), 1.70 (3H, s), 1.71-1.80 (3H, m), 1.94 (2H, d, J = 6.1
Hz), 2.38 (3H, s), 2.64-2.73 (2H, m), 3.85 (3H, s), 3.95-
4.15 (2H, m), 7.69 (1H, s).
[0395]
(Step 25-2)
7-Bromo-2-[(1-tert-butoxycarbony1-4-piperidyl)methy1]-
2,4-dimethy1-1,3-benzodioxole-5-carboxylic acid
[0396]
The title compound (0.258 g, 0.548 mmol, 95% yield)
was obtained through the same reaction as in step 1-2
using tert-butyl 4-[(7-bromo-5-methoxycarbony1-2,4-
dimethy1-1,3-benzodioxol-2-yl)methyl]piperidine-1-
CA 02942883 2016-09-15
- 156 -
carboxylate (0.280 g, 0.578 mmol) synthesized in step 25-
1.
[0397]
(Step 25-3)
tert-Butyl 4-[[7-bromo-5-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methylcarbamoy1]-2,4-dimethy1-1,3-
benzodioxo1-2-yl]methyl]piperidine-l-carboxylate
[0398]
The title compound (0.327 g, 0.564 mmol, 100% yield)
was obtained through the same reaction as in step 1-3
using 7-bromo-2-[(1-tert-butoxycarbony1-4-
piperidyl)methy1]-2,4-dimethyl-1,3-benzodioxole-5-
carboxylic acid (0.258 g, 0.548 mmol) synthesized in step
25-2.
1H-NMR (400 MHz, CDC13) .3: 1.10-1.27 (2H, m), 1.44 (9H,
s), 1.55-1.65 (1H, m), 1.66 (3H, s), 1.69-1.79 (3H, m),
1.91 (2H, d, J = 5.5 Hz), 2.22 (3H, s), 2.27 (3H, s),
2.37 (3H, s), 2.63-2.74 (2H, m), 3.90-4.15 (2H, m), 4.50
(2H, d, J = 5.6 Hz), 5.96 (1H, s), 7.02 (1H, s), 7.25 (1H,
br s).
MS (APCI) m/z: 604, 606 (M+H)+.
[0399]
(Step 25-4)
7-Bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-2-(4-piperidylmethyl)-1,3-
benzodioxole-5-carboxamide
[0400]
CA 02942883 2016-09-15
- 157 -
The title compound (0.235 g, 0.466 mmol, 83% yield)
was obtained through the same reaction as in step 3-4
using tert-butyl 4-[[7-bromo-5-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methylcarbamoy1]-2,4-dimethyl-1,3-
benzodioxo1-2-yl]methyl]piperidine-1-carboxylate (0.327 g,
0.564 mmol) synthesized in (Step 25-3.
MS (APCI) m/z: 504, 506 (M+H)+.
[0401]
(Step 25-5)
7-Bromo-N-[(4,6-dimethy1-2-oxo-1H-pyridin-3-yl)methyl]-
2,4-dimethy1-2-[(1-methy1-4-piperidyl)methyl]-1,3-
benzodioxole-5-carboxamide (25)
[0402]
The title compound (0.198 g, 0.382 mmol, 82% yield)
was obtained through the same reaction as in step 3-5
using 7-bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-
3-yl)methyl]-2,4-dimethyl-2-(4-piperidylmethyl)-1,3-
benzodioxole-5-carboxamide (0.235 g, 0.466 mmol)
synthesized in step 25-4.
1H-NMR (400 MHz, DMSO-d6) 5: 1.12-1.29 (2H, m), 1.40-1.51
(1H, m), 1.64-1.71 (2H, m), 1.65 (3H, s), 1.72-1.82 (2H,
m), 1.89 (2H, d, J = 6.7 Hz), 2.08 (3H, s), 2.09 (3H, s),
2.11 (3H, s), 2.17 (3H, s), 2.62-2.68 (2H, m), 4.21 (2H,
d, J = 4.9 Hz), 5.85 (1H, s), 6.95 (1H, s), 8.16 (1H, t,
J = 4.9 Hz), 11.48 (1H, s).
MS (APCI) m/z: 518, 520 (M+H)+.
[0403]
CA 02942883 2016-09-15
- 158 -
Example 26
7-Bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2-[(1-ethy1-4-piperidyl)methyl]-2,4-dimethyl-
1,3-benzodioxole-5-carboxamide (26)
[0404]
The title compound (0.632 g, 1.19 mmol, 60% yield)
was obtained through the same reaction as in step 3-5
using 7-bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-
3-yl)methyl]-2,4-dimethyl-2-(4-piperidylmethyl)-1,3-
benzodioxole-5-carboxamide (1.00 g, 1.98 mmol)
synthesized in step 25-4 and acetaldehyde (0.873 g, 19.8
mmol).
1H-NMR (400 MHz, DMSO-d6) 6: 0.94 (3H, t, J = 7.0 Hz),
1.12-1.26 (2H, m), 1.38-1.55 (1H, m), 1.65 (3H, s), 1.65-
1.72 (2H, m), 1.72-1.82 (2H, m), 1.89 (2H, d, J = 6.1 Hz),
2.09 (3H, s), 2.11 (3H, s), 2.17 (3H, s), 2.23 (2H, q, J
= 7.0 Hz), 2.73-2.80 (2H, m), 4.21 (2H, d, J = 4.9 Hz),
5.86 (1H, s), 6.96 (1H, s), 8.17 (1H, t, J = 4.9 Hz),
11.50 (1H, s).
MS (APCI) m/z: 532, 534 (M+H)+.
[0405]
Example 27
7-Bromo-2-Hcis-4-(dimethylamino)cyclohexyl]methyl]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (27)
[0406]
(Step 27-1)
CA 02942883 2016-09-15
- 159 -
Methyl 7-bromo-2-[[cis-4-(tert-
butoxycarbonylamino)cyclohexyl]methy1]-2,4-dimethy1-1,3-
benzodioxole-5-carboxylate
[0407]
The title compound (1.47 g, 2.96 mmol, 96.4% yield)
was obtained through the same reaction as in step 13-1
using the compound (Ala) (0.800 g, 0.3.06 mmol)
synthesized in Reference Example 1 and the compound (S-
11) (1.09 g, 4.60 mmol) synthesized in Reference Example
11.
1H-NMR (400 MHz, CDC13) .5: 1.28-1.37 =(2H, m), 1.44 (9H,
s), 1.56-1.75 (5H, m), 1.69 (3H, s), 1.94 (2H, d, J = 6.7
Hz), 2.37 (3H, s), 3.49 (2H, d, J = 4.9 Hz), 3.66-3.74
(1H, m), 3.85 (3H, s), 4.58 (1H, br s), 7.68 (1H, s).
[0408]
(Step 27-2)
7-Bromo-2-[[cis-4-(tert-
butoxycarbonylamino)cyclohexyl]methy1]-2,4-dimethy1-1,3-
benzodioxole-5-carboxylic acid
[0409]
The title compound (1.43 g, 2.96 mmol, 100% yield)
was obtained through the same reaction as in step 1-2
using methyl 7-bromo-2-Hcis-4-(tert-
butoxycarbonylamino)cyclohexyl]methy1]-2,4-dimethy1-1,3-
benzodioxole-5-carboxylate (1.47 g, 2.96 mmol)
synthesized in step 27-1.
MS (ESI) m/z: 506, 508 (M+Na)'.
CA 02942883 2016-09-15
- 160 -
[0410]
(Step 27-3)
tert-Butyl N-[cis-4-[[7-bromo-5-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methylcarbamoy1]-2,4-dimethyl-1,3-
benzodioxo1-2-yl]methyl]cyclohexyl]carbamate
[0411]
The title compound (1.68 g, 2.71 mmol, 92% yield)
was obtained through the same reaction as in step 1-3
using 7-bromo-2-Hcis-4-(tert-
butoxycarbonylamino)cyclohexyl]methy1]-2,4-dimethy1-1,3-
benzodioxole-5-carboxylic acid (1.43 g, 2.99 mmol)
synthesized in step 27-2.
1H-NMR (400 MHz, DMSO-d6) .3: 1.36 (9H, s), 1.40-1.49 (8H,
m), 1.66 (3H, s), 1.66-1.75 (1H, m), 1.90 (2H, d, J = 6.1
Hz), 2.09 (3H, s), 2.11 (3H, s), 2.17 (3H, s), 3.28-3.37
(1H, m), 4.21 (2H, d, J = 5.1 Hz), 5.85 (1H, s), 6.67 (1H,
d, J = 7.3 Hz), 6.96 (1H, s), 8.14 (1H, t, J = 5.1 Hz),
11.48 (1H, br s).
MS (ESI) m/z: 618, 620 (M+H) .
[0412]
(Step 27-4)
2-[(cis-4-Aminocyclohexyl)methy1]-7-bromo-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide
[0413]
The title compound (0.961 g, 1.85 mmol, 68% yield)
was obtained through the same reaction as in step 3-4
CA 02942883 2016-09-15
- 161 -
using tert-butyl N-[cis-4-[[7-bromo-5-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methylcarbamoy1]-2,4-
dimethy1-1,3-benzodioxo1-2-yl]methyl]cyclohexyl]carbamate
(1.68 g, 2.71 mmol) synthesized in step 27-3.
MS (ESI) m/z: 518, 520 (M+H) .
[0414]
(Step 27-5)
7-Bromo-2-Hcis-4-(dimethylamino)cyclohexyl]methyl]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (27)
[0415]
The title compound (0.112 g, 0.205 mmol, 53% yield)
was obtained through the same reaction as in step 3-5
using 2-[(cis-4-aminocyclohexyl)methy1]-7-bromo-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (0.200 g, 0.386
mmol) synthesized in step 27-4.
1H-NMR (400 MHz, CD30D) 6: 1.43-1.56 (4H, m), 1.60-1.73
(4H, m), 1.67 (3H, s), 1.92-1.98 (1H, m), 2.02 (2H, d, J
= 6.1 Hz), 2.13-2.20 (1H, m), 2.15 (3H, s), 2.24 (3H, s),
2.26 (6H, s), 2.35 (3H, s), 4.41 (2H, s), 6.10 (1H, s),
6.99 (1H, s).
MS (ESI) m/z: 546, 548 (M+H)+.
[0416]
Example 28
CA 02942883 2016-09-15
- 162 -
7-Bromo-2-[[trans-4-(dimethylamino)cyclohexyl]methy1]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (28)
[0417]
(Step 28-1)
Methyl 7-bromo-2-[[trans-4-(tert-
butoxycarbonylamino)cyclohexyl]methy1]-2,4-dimethy1-1,3-
benzodioxole-5-carboxylate
[0418]
The title compound (1.17 g, 2.96 mmol, 96% yield)
was obtained through the same reaction as in step 13-1
using the compound (Ala) (0.800 g, 0.3.06 mmol)
synthesized in Reference Example 1 and the compound (S-
12) (1.09 g, 4.60 mmol) synthesized in Reference Example
12.
1H-NMR (400 MHz, CDC13) 6: 1.01-1.17 (4H, m), 1.43 (9H,
s), 1.43-1.60 (1H, m), 1.68 (3H, s), 1.82-1.92 (4H, m),
1.98 (2H, d, J = 9.7 Hz), 2.37 (3H, s), 3.26-3.40 (1H, m),
3.85 (3H, s), 4.34 (1H, br s), 7.68 (1H, s).
[0419]
(Step 28-2)
7-Bromo-2-[[trans-4-(tert-
butoxycarbonylamino)cyclohexyl]methy1]-2,4-dimethy1-1,3-
benzodioxole-5-carboxylic acid
[0420]
The title compound (1.14 g, 2.36 mmol, 100% yield)
was obtained through the same reaction as in step 1-2
CA 02942883 2016-09-15
- 163 -
using methyl 7-bromo-2-[[trans-4-(tert-
butoxycarbonylamino)cyclohexyl]methy1]-2,4-dimethyl-1,3-
benzodioxole-5-carboxylate (1.17 g, 2.36 mmol)
synthesized in step 28-1.
MS (ESI) m/z: 482, 484 (M-H)-.
[0421]
(Step 28-3)
tert-Butyl N-[trans-4-[[7-bromo-5-[(4,6-dimethy1-2-oxo-
1H-pyridin-3-yl)methylcarbamoyl]-2,4-dimethyl-1,3-
benzodioxo1-2-yl]methyllcyclohexyl]carbamate
[0422]
The title compound (1.39 g, 2.24 mmol, 95% yield)
was obtained through the same reaction as in step 1-3
using 7-bromo-2-[[trans-4-(tert-
butoxycarbonylamino)cyclohexyl]methy1]-2,4-dimethyl-1,3-
benzodioxole-5-carboxylic acid (1.14 g, 2.36 mmol)
synthesized in step 28-2.
1H-NMR (400 MHz, DMSO-d6) 6: 0.96-1.13 (4H, m), 1.30-1.46
(1H, m), 1.36 (9H, s), 1.64 (3H, s), 1.68-1.81 (4H, m),
1.85 (2H, d, J = 6.1 Hz), 2.09 (3H, s), 2.11 (3H, s),
2.17 (3H, s), 3.06-3.15 (1H, m), 4.21 (2H, d, J = 4.9 Hz),
5.86 (1H, s), 6.64 (1H, d, J = 7.9 Hz), 6.95 (1H, s),
8.15 (1H, t, J = 4.9 Hz), 11.48 (1H, br s).
MS (ESI) m/z: 618, 620 (M+H)+.
[0423]
(Step 28-4)
CA 02942883 2016-09-15
- 164 -
2-[(trans-4-Aminocyclohexyl)methy1]-7-bromo-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide
[0424]
The title compound (0.830 g, 1.60 mmol, 71% yield)
was obtained through the same reaction as in step 3-4
using tert-butyl N-[trans-4-[[7-bromo-5-[(4,6-dimethy1-2-
.
oxo-1,2-dihydropyridin-3-yl)methylcarbamoy1]-2,4-
dimethy1-1,3-benzodioxo1-2-yl]methyl]cyclohexyl]carbamate
(1.39 g, 2.24 mmol) synthesized in step 28-3.
MS (ESI) m/z: 518, 520 (M+H)+.
[0425]
(Step 28-5)
7-Bromo-2-[[trans-4-(dimethylamino)cyclohexyl]methy1]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (28)
[0426]
The title compound (0.137 g, 0.251 mmol, 65% yield)
was obtained through the same reaction as in step 3-5
using 2-[(trans-4-aminocyclohexyl)methy1]-7-bromo-N-
[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-y1)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (0.200 g, 0.386
mmol) synthesized in step 28-4.
1H-NMR (400 MHz, CD30D) 6: 1.00-1.26 (4H, m), 1.46-1.58
(1H, m), 1.65 (3H, s), 1.85-1.99 (4H, m), 1.88 (2H, d, J
= 6.1 Hz), 2.14 (3H, d, J - 2.4 Hz), 2.16-2.22 (1H, m),
CA 02942883 2016-09-15
- 165 -
2.24 (3H, s), 2.26 (6H, s), 2.35 (3H, s), 4.41 (2H, s),
6.10 (1H, s), 6.99 (1H, s).
MS (ESI) m/z: 546, 548 (M+H)+.
[0427]
Example 29
(2R)-7-Bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-2-[[(3S)-1-methylpyrrolidin-3-
yl]oxymethy1]-1,3-benzodioxole-5-carboxamide (29)
[0428]
(Step 29-1)
tert-Butyl (3S)-3-[[(2R)-7-bromo-5-methoxycarbony1-2,4-
dimethy1-1,3-benzodioxol-2-yl]methoxy]pyrrolidine-1-
carboxylate
[0429]
A racemate of the title compound (1.98 g, 4.07 mmol,
50% yield) was obtained through the same reaction as in
step 1-1 using the compound (Ala) (2.15 g, 8.24 mmol)
synthesized in Reference Example 1 and tert-butyl (3S)-3-
prop-2-ynoxypyrrolidine-1-carboxylate (2.78 g, 12.4 mmol)
synthesized according to the method described in J. Am.
Chem. Soc., 2010, 132 (8), pp 2570-2572.
1H-NMR (400 MHz, CDC13) 8: 1.45 (9H, s), 1.74 (3H, s),
1.84-1.93 (2H, m), 2.39 (3H, s), 3.25-3.47 (4H, m), 3.63-
3.71 (2H, m), 3.85 (3H, s), 4.13-4.18 (1H, m), 7.69 (1H,
s).
[0430]
CA 02942883 2016-09-15
- 166 -
This compound was resolved into each diastereomer
under the following conditions:
Column: Daicel CHIRALCEL AY-H 4.6 mm ID x 250 mm L
Elution solvent: n-hexane:2-propanol = 90:10 (V/V)
Flow rate: 1.00 mL/min
Temperature: 40 C
First peak: 8.4 min
Second peak: 10.3 min
[0431]
The following steps were carried out using the
second peak separated using a preparative chiral column.
[0432]
(Step 29-2)
(2R)-7-Bromo-2-[[(3S)-1-tert-butoxycarbonylpyrrolidin-3-
y1]oxymethy1]-2,4-dimethy1-1,3-benzodioxole-5-carboxylic
acid
[0433]
The title compound (1.17 g, 2.47 mmol, 100% yield)
was obtained through the same reaction as in step 1-2
using tert-butyl (3S)-3-[[(2R)-7-bromo-5-methoxycarbony1-
2,4-dimethy1-1,3-benzodioxol-2-yl]methoxy]pyrrolidine-1-
carboxylate (second peak, 1.20 g, 2.47 mmol) synthesized
in step 29-1.
MS (APCI) m/z: 470, 472 (M-H)-.
[0434]
(Step 29-3)
CA 02942883 2016-09-15
- 167 -
tert-Butyl (3S)-3-[[(2R)-7-bromo-5-[(4,6-dimethy1-2-oxo-
1,2-dihydropyridin-3-yl)methylcarbamoy1]-2,4-dimethyl-
1,3-benzodioxo1-2-yl]methoxy]pyrrolidine-1-carboxylate
[0435]
The title compound (1.32 g, 2.18 mmol, 89% yield)
was obtained through the same reaction as in step 1-3
using (2R)-7-bromo-2-[[(3S)-1-tert-
butoxycarbonylpyrrolidin-3-yl]oxymethy1]-2,4-dimethyl-
1,3-benzodioxole-5-carboxylic acid (1.17 g, 2.47 mmol)
synthesized in step 29-2.
1H-NMR (400 MHz, CDC13) 6: 1.44 (9H, s), 1.71 (3H, br s),
1.82-1.98 (2H, m), 2.23 (3H, s), 2.27 (3H, s), 2.37 (3H,
s), 3.29-3.47 (4H, m), 3.64 (2H, s), 4.12-4.17 (1H, m),
4.50 (2H, d, J = 6.1 Hz), 5.97 (1H, s), 7.03 (1H, s),
7.29 (1H, br s).
MS (APCI) m/z: 606,608 (M+H)+.
[0436]
(Step 29-4)
(2R)-7-Bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-2-[[(3S)-pyrrolidin-3-
y1]oxymethy1]-1,3-benzodioxole-5-carboxamide
[0437]
The title compound (1.01 g, 1.99 mmol, 93% yield)
was obtained through the same reaction as in step 3-4
using tert-butyl (3S)-3-[[(2R)-7-bromo-5-[(4,6-dimethyl-
2-oxo-1,2-dihydropyridin-3-yl)methylcarbamoy1]-2,4-
CA 02942883 2016-09-15
- 168 -
dimethy1-1,3-benzodioxo1-2-y1]methoxy]pyrrolidine-1-
carboxylate (1.30 g, 2.14 mmol) synthesized in step 29-3.
MS (APCI) m/z: 506,508 (M+H)+.
[0438]
(Step 29-5)
(2R)-7-Bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-2-[[(3S)-1-methylpyrrolidin-3-
yl]oxymethy1]-1,3-benzodioxole-5-carboxamide (29)
[0439]
The title compound (0.442 g, 0.849 mmol, 86% yield)
was obtained through the same reaction as in step 3-5
using (2R)-7-bromo-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methy1]-2,4-dimethyl-2-[[(3S)-
pyrrolidin-3-yl]oxymethy1]-1,3-benzodioxole-5-carboxamide
(0.500 g, 0.987 mmol) synthesized in step 29-4.
1H-NMR (400 MHz, DMSO-dd 6: 1.52-1.61 (1H, m), 1.64 (3H,
s), 1.90-2.01 (1H, m), 2.10 (3H, s), 2.11 (3H, s), 2.17
(6H, s), 2.18-2.27 (2H, m), 2.32-2.37 (1H, m), 2.37-2.48
(1H, m), 3.63 (2H, d, J = 12.0 Hz), 3.66 (1H, d, J = 12.0
Hz), 4.06-4.12 (1H, m), 4.21 (2H, d, J = 4.9 Hz), 5.86
(1H, s), 6.96 (1H, s), 8.17 (1H, t, J = 4.9 Hz), 11.50
(1H, s).
MS (APCI) m/z: 520,522 (M+H) .
[0440]
Example 30
CA 02942883 2016--15
- 169 -
7-Chloro-2-[2-(dimethylamino)spiro[3.3]heptan-6-y1]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-y1)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (30)
[0441]
(Step 30-1)
Methyl 2-[2-(tert-butoxycarbonylamino)spiro[3.3]heptan-6-
y1]-7-chloro-2,4-dimethyl-1,3-benzodioxole-5-carboxylate
[0442]
The title compound (0.555 g, 1.23 mmol, 89% yield)
was obtained through the same reaction as in step 13-1
using the compound (Alb) (0.300 g, 1.38 mmol) synthesized
in Reference Example 2 and the compound (S8-2) (0.489 g,
2.08 mmol) synthesized in Reference Example 8.
1H-NMR (400 MHz, CDC13) 6: 1.41 (9H, s), 1.55 (3H, s),
1.70-1.85 (2H, m), 1.92-2.16 (4H, m), 2.27-2.40 (1H, m),
2.39 (3H, s), 2.40-2.52 (1H, m), 2.67-2.77 (1H, m), 3.84
(3H, s), 3.89-4.02 (1H, m), 4.54-4.68 (1H, m), 7.52 (1H,
s).
[0443]
(Step 30-2)
2-[2-(tert-Butoxycarbonylamino)spiro[3.3]heptan-6-y1]-7-
chloro-2,4-dimethy1-1,3-benzodioxole-5-carboxylic acid
[0444]
The title compound (0.538 g, 1.23 mmol, 100% yield)
was obtained through the same reaction as in step 1-2
using methyl 2-[2-(tert-
butoxycarbonylamino)spiro[3.3]heptan-6-y1]-7-chloro-2,4-
CA 02942883 2016-09-15
- 170 -
dimethy1-1,3-benzodioxole-5-carboxylate (0.555 g, 1.23
mmol) synthesized in step 30-1.
MS (APCI) m/z: 436 (M-H)-.
[0445]
(Step 30-3)
tert-Butyl N-[6-[7-chloro-5-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methylcarbamoy1]-2,4-dimethyl-1,3-
benzodioxo1-2-yl]spiro[3.3]heptan-2-yl]carbamate
[0446]
The title compound (0.683 g, 1.20 mmol, 97% yield)
was obtained through the same reaction as in step 1-3
using 2-[2-(tert-butoxycarbonylamino)spiro[3.3]heptan-6-
y1]-7-chloro-2,4-dimethy1-1,3-benzodioxole-5-carboxylic
acid (0.538 g, 1.23 mmol) synthesized in step 30-2.
1H-NMR (400 MHz, CDC13) 6: 1.41 (9H, s), 1.53 (3H, s),
1.68-1.84 (2H, m), 1.88-1.98 (2H, m), 2.00-2.15 (2H, m),
2.24 (3H, s), 2.25 (3H, s), 2.28-2.40 (1H, m), 2.36 (3H,
s), 2.40-2.50 (1H, m), 2.64-2.76 (1H, m), 3.90-4.02 (1H,
m), 4.49 (2H, d, J = 6.0 Hz), 4.54-4.64 (1H, m), 5.95 (1H,
s), 6.87 (1H, s), 7.24 (1H, t, J = 6.0 Hz), 11.7 (1H, br
s).
MS (APCI) m/z: 572 (M+H)+.
[0447]
(Step 30-4)
2-(2-Aminospiro[3.3]heptan-6-y1)-7-chloro-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide
CA 02942883 2016-09-15
- 171 -
[0448]
The title compound (0.564 g, 1.20 mmol, 100% yield)
was obtained through the same reaction as in step 3-4
using tert-butyl N-[6-[7-chloro-5-[(4,6-dimethy1-2-oxo-
1,2-dihydropyridin-3-yl)methylcarbamoy1]-2,4-dimethyl-
1,3-benzodioxo1-2-yl]spiro[3.3]heptan-2-yl]carbamate
(0.683 g, 1.20 mmol) synthesized in step 30-3.
MS (APCI) m/z: 472 (M+H)+.
[0449]
(Step 30-5)
7-Chloro-2-[2-(dimethylamino)spiro[3.3]heptan-6-y1]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (30)
[0450]
The title compound (0.057 g, 0.115 mmol, 21% yield)
was obtained through the same reaction as in step 3-5
using 2-(2-aminospiro[3.3]heptan-6-y1)-7-chloro-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (0.257 g, 0.543
mmol) synthesized in step 30-4.
1H-NMR (400 MHz, DMSO-d6) 6: 1.52 (3H, s), 1.59-1.66 (1H,
m), 1.67-1.74 (1H, m), 1.78-1.98 (4H, m), 1.94 (6H, s),
2.00-2.13 (2H, m), 2.11 (3H, s), 2.12 (3H, s), 2.17 (3H,
s), 2.30-2.42 (1H, m), 2.70-2.82 (1H, m), 4.21 (2H, d, J
= 4.8 Hz), 5.85 (1H, s), 6.84 (1H, s), 8.14 (1H, t, J =
4.8 Hz), 11.47 (1H, br s).
MS (APCI) m/z: 500 (M+H)+.
CA 02942883 2016-09-15
- 172 -
[0451]
Example 31
(2R)-7-Chloro-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-
3-yl)methy1]-2-(1-ethyl-4-piperidy1)-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide (31)
[0452]
(Step 31-1)
tert-Butyl 4-[(2R)-7-chloro-5-methoxycarbony1-2,4-
dimethy1-1,3-benzodioxol-2-yl]piperidine-1-carboxylate
[0453]
A racemate of the title compound (8.47 g, 19.9 mmol,
50.7% yield) was obtained through the same reaction as in
step 1-1 using the compound (Alb) (8.50 g, 39.2 mmol)
synthesized in Reference Example 2 and tert-butyl 4-
ethynylpiperidine-1-carboxylate (12.3 g, 58.9 mmol)
synthesized according to the method described in WO
2008156739.
1H-NMR (400 MHz, CDC13) 6: 1.30-1.45 (2H, m), 1.46 (9H,
s), 1.67 (3H, s), 1.78-1.87 (2H, m), 1.96-2.05 (1H, m),
2.39 (3H, s), 2.58-2.73 (2H, m), 3.85 (3H, s), 4.10 (2H,
m), 7.55 (1H, s).
[0454]
This compound was resolved into each diastereomer
under the following conditions:
Column: Daicel CHIRALCEL OZ-H 4.6 mm ID x 250 mm L
Elution solvent: n-hexane:2-propanol:methanol = 97:1:2
(V/V)
CA 02942883 2016-09-15
- 173 -
Flow rate: 1.00 mL/min
Temperature: 40 C
First peak: 7.1 min (specific rotation Eodan = _18.4 (C =
1.0, chloroform))
Second peak: 7.9 min (specific rotation [a]02 = +17.7 (C
= 1.0, chloroform))
[0455]
The following steps were carried out using the
second peak separated using a preparative chiral column.
[04561
(Step 31-2)
(2R)-2-(1-tert-Butoxycarbony1-4-piperidy1)-7-chloro-2,4-
dimethy1-1,3-benzodioxole-5-carboxylic acid
[0457]
The title compound (0.827 g, 2.01 mmol, 85% yield)
was obtained through the same reaction as in step 1-2
using tert-butyl 4-[(2R)-7-chloro-5-methoxycarbony1-2,4-
dimethyl-1,3-benzodioxol-2-yl]piperidine-1-carboxylate
(second peak, 1.01 g, 2.37 mmol) synthesized in step 31-1.
[0458]
(Step 31-3)
tert-Butyl 4-[(2R)-7-chloro-5-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methylcarbamoy1]-2,4-dimethyl-1,3-
benzodioxo1-2-yllpiperidine-1-carboxylate
[0459]
The title compound (0.986 g, 1.81 mmol, 90% yield)
was obtained through the same reaction as in step 1-3
CA 02942883 2016-09-15
- 174 -
using (2R)-2-(1-tert-butoxycarbony1-4-piperidy1)-7-
chloro-2,4-dimethyl-1,3-benzodioxole-5-carboxylic acid
(0.827 g, 2.01 mmol) synthesized in step 31-2.
'H-NMR (400 MHz, CDC13) S: 1.31-1.43 (2H, m), 1.45 (9H,
s), 1.61 (3H, s), 1.75-1.86 (2H, m), 1.93-2.01 (1H, m).
2.23 (3H, s), 2.26 (3H, s), 2.37 (3H, s), 2.60-2.72 (2H,
m), 4.13-4.28 (2H, m), 4.49 (2H, d, J = 5.5 Hz), 5.95 (1H,
s), 6.88 (1H, s), 7.21 (1H, br s).
MS (APCI) m/z: 546 (M+H) .
[0460]
(Step 31-4)
(2R)-7-Chloro-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-
3-yl)methy1]-2,4-dimethyl-2-(4-piperidy1)-1,3-
benzodioxole-5-carboxamide
[0461]
The title compound (0.805 g, 1.81 mmol, 100% yield)
was obtained through the same reaction as in step 3-4
using tert-butyl 4-[(2R)-7-chloro-5-[(4,6-dimethy1-2-oxo-
1,2-dihydropyridin-3-yl)methylcarbamoy1]-2,4-dimethyl-
1,3-benzodioxo1-2-yllpiperidine-1-carboxylate (0.986 g,
1.81 mmol) synthesized in step 31-3.
MS (APCI) m/z: 446 (M+H)+.
[0462]
(Step 31-5)
(2R)-7-Chloro-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-
3-yl)methy1]-2-(1-ethy1-4-piperidy1)-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide (31)
CA 02942883 2016-09-15
- 175 -
[0463]
The title compound (0.508 g, 1.07 mmol, 59% yield)
was obtained through the same reaction as in step 3-5
using (2R)-7-chloro-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methy1]-2,4-dimethyl-2-(4-piperidy1)-
1,3-benzodioxole-5-carboxamide (0.805 g, 1.81 mmol)
synthesized in step 31-4 and acetaldehyde (1.19 g, 27.1
mmol).
1H-NMR (400 MHz, DMSO-d6) 6: 0.96 (3H, t, J = 7.3 Hz),
1.29-1.42 (2H, m), 1.61 (3H, s), 1.66-1.89 (5H, m), 2.10
(3H, s), 2.11 (3H, s), 2.17 (3H, s), 2.27 (2H, q, J = 7.3
Hz), 2.87-2.88 (2H, m), 4.21 (2H, d, J = 4.9 Hz), 5.85
(1H, s), 6.84 (1H, s), 8.14 (1H, t, J = 4.9 Hz), 11.48
(1H, s).
MS (APCI) m/z: 474 (M+H)+.
[0464]
Example 32
7-Chloro-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-2-[trans-4-
(methylamino)cyclohexy1]-1,3-benzodioxole-5-carboxamide
(32)
[0465]
(Step 32-1)
Methyl 2-[tarns-4-[tert-
butoxycarbonyl(methyl)amino]cyclohexyl]-7-chloro-2,4-
dimethy1-1,3-benzodioxole-5-carboxylate
[0466]
CA 02942883 2016-09-15
- 176 -
The title compound (0.475 g, 1.05 mmol, 76% yield)
was obtained through the same reaction as in step 13-1
using the compound (Alb) (0.300 g, 1.38 mmol) synthesized
in Reference Example 2 and the compound (S-14) (0.493 g,
2.08 mmol) synthesized in Reference Example 14.
1H-NMR (400 MHz, CDC13) 6: 1.24-1.52 (4H, m), 1.46 (9H,
s), 1.63 (3H, s), 1.72-1.86 (3H, m), 1.94-2.05 (2H, m),
2.38 (3H, s), 2.71 (3H, br s), 3.60-4.06 (1H, m), 3.85
(3H, s), 7.53 (1H, s).
[0467]
(Step 32-2)
2-[trans-4-[tert-Butoxycarbonyl(methyl)amino]cyclohexyl]-
7-chloro-2,4-dimethy1-1,3-benzodioxole-5-carboxylic acid
[0468]
The title compound (0.460 g, 1.05 mmol, 100% yield)
was obtained through the same reaction as in step 1-2
using methyl 2-[trans-4-[tert-
butoxycarbonyl(methyl)amino]cyclohexy11-7-chloro-2,4-
dimethy1-1,3-benzodioxole-5-carboxylate (0.475 g, 1.05
mmol) synthesized in step 32-1.
1H-NMR (CDC13) 6: 1.30-1.52 (4H, m), 1.47 (9H, s), 1.65
(3H, s), 1.72-1.86 (3H, m), 1.94-2.05 (2H, m), 2.38 (3H,
s), 2.71 (3H, br s), 7.77 (1H, s).
MS (APCI) m/z: 438 (M-H)-.
[0469]
(Step 32-3)
CA 02942883 2016-09-15
- 177 -
tert-Butyl N-[trans-4-[7-chloro-5-[(4,6-dimethy1-2-oxo-
1,2-dihydropyridin-3-yl)methylcarbamoy1]-2,4-dimethyl-
1,3-benzodioxo1-2-yl]cyclohexyl]-N-methyl-carbamate
[0470]
The title compound (0.559 g, 0.973 mmol, 93% yield)
was obtained through the same reaction as in step 1-3
using 2-[trans-4-[tert-
butoxycarbonyl(methyl)amino]cyclohexy11-7-chloro-2,4-
dimethy1-1,3-benzodioxole-5-carboxylic acid (0.460 g,
1.05 mmol) synthesized in step 32-2.
1H-NMR (400 MHz, 0DC13) 6: 1.24-1.50 (4H, m), 1.45 (9H,
s), 1.59 (3H, s), 1.71-1.81 (3H, m), 1.92-2.02 (2H, m),
2.22 (3H, s), 2.26 (3H, s), 2.36 (3H, s), 2.70 (3H, br s),
3.58-4.06 (1H, br m), 4.49 (2H, d, J = 5.2 Hz), 5.96 (1H,
s), 6.87 (1H, s), 7.27 (1H, t, J = 5.2 Hz), 12.2 (1H, br
s).
MS (APCI) m/z: 574 (M+H)+.
[0471]
(Step 32-4)
7-Chloro-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-2-[trans-4-
(methylamino)cyclohexy1]-1,3-benzodioxole-5-carboxamide
(32)
[0472]
The title compound (0.297 g, 0.626 mmol, 64% yield)
was obtained through the same reaction as in step 3-4
using tert-butyl N-[trans-4-[7-chloro-5-[(4,6-dimethy1-2-
CA 02942883 2016-09-15
- 178 -
oxo-1,2-dihydropyridin-3-yl)methylcarbamoy1]-2,4-
dimethy1-1,3-benzodioxo1-2-yl]cyclohexyl]-N-methyl-
carbamate (0.559 g, 0.973 mmol) synthesized in step 32-3.
1H-NMR (400 MHz, DMSO-d6) 6: 0.87-0.99 (2H, m), 1.08-1.21
(2H, m), 1.58 (3H, s), 1.74-1.87 (3H, m), 1.87-1.95 (2H,
m), 2.05-2.18 (1H, m), 2.10 (6H, s), 2.15 (3H, s), 2.22
(3H, s), 4.20 (2H, d, J = 4.8 Hz), 5.84 (1H, s), 6.82 (1H,
s), 8.12 (1H, t, J = 4.8 Hz).
MS (APCI) m/z: 474 (M+H)+.
[0473]
Example 33
7-Chloro-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2-[trans-4-[formyl(methyl)amino]cyclohexyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide (33)
[0474]
The compound (32) (0.100 g, 0.211 mmol) synthesized
in step 32-4 was dissolved in toluene (4 mL) and formic
acid (2 mL). To the solution, acetic anhydride (0.001 g,
0.011 mmol) was added, and the mixture was refluxed for 8
hours. The reaction solution was concentrated under
reduced pressure, followed by extraction by the addition
of ethyl acetate and water. The organic layer was washed
with water and saturated saline and dried over sodium
sulfate. After concentration under reduced pressure, the
obtained residue was purified by silica gel column
chromatography (ethyl acetate:methanol = 100:0 -* 60:40)
CA 02942883 2016-09-15
- 179 -
to obtain the title compound (0.034 g, 0.069 mmol, 33%
yield) in a formyl form.
1H-NMR (400 MHz, CD30D) 6: 1.37-1.47 (2H, m), 1.63 (3H,
s), 1.63-1.81 (4H, m), 1.88-1.96 (1H, m), 2.00-2.06 (2H,
m), 2.17 (3H, s), 2.24 (3H, s), 2.35 (3H, s), 2.78 (3H,
s), 3.45-3.50 (1H, m), 4.41 (2H, s), 6.10 (1H, s), 6.87
(1H, s), 8.12 (1H, s).
MS (ESI) m/z: 502 (M+H)'.
[0475]
Example 34
7-Chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (34)
[Formula 34]
cH3
C H3 0 0 0 0 H
Oó
tok
c H3
c H3
C H3 34.1 Cl 0
34-2 Cl IP so 34-3
Cl WI OH 0 0 0 0 t-Bu
,t-Bu
OH 1-132LOwN
A1 b trans-A23 trans-A3j
H C C H3 H3CrrC H3 H3CC H3
1..
3 r*:%,1,=
I N H N H I N H
0 NH 0 0 N H 0 0 N H 0
C H3 C H3 C H3
----3;47=C WO a 0 3" Cl
H034,0c 0 0
C
NH2 H32LO,N H,,
sC H3
trans-A4j-f
trans-A4j 34
[0476]
(Step 34-1)
CA 02942883 2016-09-15
- 180 -
Methyl 2-[trans-4-(tert-butoxycarbonylamino)cyclohexyl]-
7-chloro-2,4-dimethy1-1,3-benzodioxole-5-carboxylate
(trans-A2j)
[0477]
The title compound (1.00 g, 2.28 mmol, 49% yield)
was obtained through the same reaction as in step 13-1
using the compound (Alb) (1.00 g, 4.62 mmol) synthesized
in Reference Example 2 and the compound (S-13) (1.55 g,
6.93 mmol) synthesized in Reference Example 13.
1H-NMR (400 MHz, CDC13) 8: 1.02-1.16 (2H, m), 1.24-1.40
(2H, m), 1.44 (9H, s), 1.62 (3H, s), 1.78-1.88 (1H, m),
1.91-2.00 (2H, m), 2.04-2.12 (2H, m), 2.38 (3H, s), 3.33-
3.46 (1H, m), 3.85 (3H, s), 4.37 (1H, br s), 7.53 (1H, s).
[0478]
(Step 34-2)
2-[trans-4-(tert-Butoxycarbonylamino)cyclohexyl]-7-
chloro-2,4-dimethy1-1,3-benzodioxole-5-carboxylic acid
(trans-A3j)
[0479]
The title compound (0.972 g, 2.28 mmol, 100% yield)
was obtained through the same reaction as in step 1-2
using the compound (trans-A2j) (1.00 g, 2.28 mmol)
synthesized in step 34-1.
1H-NMR (400 MHz, CDC13) 6: 1.04-1.16 (2H, m), 1.24-1.40
(2H, m), 1.44 (9H, s), 1.64 (3H, s), 1.80-1.88 (1H, m),
1.92-2.02 (2H, m), 2.04-2.14 (2H, m), 2.42 (3H, s), 3.35-
3.45 (1H, m), 4.39 (1H, br s), 7.68 (1H, s).
CA 02942883 2016-09-15
- 181 -
MS (APCI) m/z: 424 (M-H)-.
[0480]
(Step 34-3)
tert-Butyl N-[trans-4-[7-chloro-5-[(4,6-dimethy1-2-oxo-
1,2-dihydropyridin-3-yl)methylcarbamoyl]-2,4-dimethyl-
1,3-benzodioxo1-2-yllcyclohexyl]carbamate (trans-A4j)
[0481]
The title compound (0.676 g, 1.21 mmol, 52.9% yield)
was obtained through the same reaction as in step 1-3
using the compound (trans-A3j) (0.972 g, 2.28 mmol)
synthesized in step 34-2.
1H-NMR (400 MHz, CDC13) 6: 1.02-1.16 (2H, m), 1.23-1.38
(2H, m), 1.44 (9H, s), 1.60 (3H, s), 1.76-1.84 (1H, m),
1.90-1.98 (2H, m), 2.03-2.10 (2H, m), 2.23 (3H, s), 2.26
(3H, s), 2.37 (3H, s), 3.30-3.46 (1H, m), 4.40 (1H, d, J
= 8.5 Hz), 4.50 (2H, d, J = 6.1 Hz), 5.97 (1H, s), 6.88
(1H, s), 7.28 (1H, t, J = 6.1 Hz).
MS (APCI) m/z: 560 (M+H)+.
[0482]
(Step 34-4)
2-(trans-4-Aminocyclohexyl)-7-chloro-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methy1]-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide (trans-A4j-f)
[0483]
The title compound (0.555 g, 1.21 mmol, 100% yield)
was obtained through the same reaction as in step 3-4
CA 02942883 2016-09-15
- 182 -
using the compound (trans-A4j) (0.676 g, 1.21 mmol)
synthesized in step 34-3.
MS (APCI) m/z: 460 (M+H)+.
[0484]
(Step 34-5)
7-Chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (34)
[0485]
The title compound (0.425 g, 0.872 mmol, 72% yield)
was obtained through the same reaction as in step 3-5
using the compound (trans-A4j-f) (0.555 g, 1.21 mmol)
synthesized in step 34-4.
1H-NMR (400 MHz, DMSO-d6) 6: 1.04-1.21 (4H, m), 1.60 (3H,
s), 1.73-1.90 (5H, m), 2.03-2.10 (1H, m), 2.11 (6H, s),
2.14 (6H, s), 2.16 (3H, s), 4.21 (2H, d, J = 4.9 Hz),
5.85 (1H, s), 6.84 (1H, s), 8.12 (1H, t, J = 4.9 Hz),
11.47 (1H, s).
MS (APCI) m/z: 488 (M+H)+.
[0486]
This compound was resolved into each enantiomer
under the following conditions:
Column: Daicel CHIRALCEL OZ-H 4.6 mm ID x 250 mm L
Elution solvent: n-hexane:ethanol:diethylamine =
60:40:0.04 (V/V)
Flow rate: 1.00 mL/min
Temperature: 35 C
CA 02942883 2016-09-15
- 183 -
First peak: 6.5 min (specific rotation [u]02 ,___ +1.0 (C -=
1.0, chloroform))
Second peak: 9.6 min (specific rotation [ct]D2o = -0.9 (C =
1.0, chloroform))
[0487]
Example 35
(2R)-7-Chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (35)
[Formula 35]
cH3 cH,
0 0 0 6 0 OH
C H3 ZIC H3 C H3
--... ----. di
35-2 35-3
Cl 411 0 35-1 Cl Cl 0
0 0
t-Bu 0 0
H3
)1. ,t-Bu 0 0 21ØNX0. H3-1.0aN 0 H3t0
X0,t-Bu
H H H
trans-A2j trans-(2R)-A2j trans-(2R)-A3j
H3CrrC H3 H3Cr-4,4trC H3 H3CreC H3
NH NH H
0 NH 0 0 _64NH 0 , 01 _NH 0
-.. ---..
C H3 35-4 ain C H3
H30,,N H2
35-5 C H3
CI 41 0 CI 11411 0 MAIP
0 0
F13-6-41D"WCI-13
/13-1.1aN 0
H a H3
trans-(2R)-A4j trans-(2R)-A4j-f 35
[0488]
(Step 35-1)
Methyl (2R)-2-[trans-4-(tert-
butoxycarbonylamino)cyclohexyl]-7-chloro-2,4-dimethyl-
1,3-benzodioxole-5-carboxylate (trans-(2R)-A2j)
[0489]
CA 02942883 2016-09-15
- 184 -
The compound (trans-A2j) synthesized in step 34-1
was resolved into each enantiomer under the following
conditions:
Column: Daicel CHIRALCEL OZ-H 4.6 mm ID x 250 mm L
Elution solvent: n-hexane:ethanol = 98:2 (V/V)
Flow rate: 1.00 mL/min
Temperature: 25 C
First peak: 10.7 min ( [a] = 18.3 (C = 0.92,
chloroform))
Second peak: 11.7 min Hal02 - +18.3 (C = 0.96,
chloroform))
[0490]
The following steps were carried out using the
second peak separated using a preparative chiral column.
[0491]
(Step 35-2)
(2R)-2-[trans-4-(tert-Butoxycarbonylamino)cyclohexyl]-7-
chloro-2,4-dimethy1-1,3-benzodioxole-5-carboxylic acid
(trans-(2R)-A3j)
[0492]
The title compound (0.227 g, 0.532 mmol, 100% yield)
was obtained through the same reaction as in step 1-2
using the compound (trans-(2R)-A2j) (second peak, 0.234 g,
0.532 mmol) separated in step 35-1.
[0493]
(Step 35-3)
CA 02942883 2016-09-15
- 185 -
tert-Butyl N-[trans-4-[(2R)-7-chloro-5-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methylcarbamoy1]-2,4-
dimethy1-1,3-benzodioxo1-2-ylicyclohexyl]carbamate
(trans-(2R)-A4j)
[0494]
The title compound (0.298 g, 0.532 mmol, 100% yield)
was obtained through the same reaction as in step 1-3
using the compound (trans-(2R)-A3j) (0.227 g, 0.532 mmol)
synthesized in step 35-2.
1H-NMR (400 MHz, CDC13) 6: 1.01-1.16 (2H, m), 1.23-1.38
(2H, m), 1.44 (9H, s), 1.59 (3H, s), 1.76-1.84 (1H, m),
1.88-1.95 (2H, m), 2.02-2.11 (2H, m), 2.22 (3H, s), 2.25
(3H, s), 2.37 (3H, s), 3.30-3.46 (1H, m), 4.35-4.41 (1H,
m), 4.49 (2H, d, J = 6.1 Hz), 5.96 (1H, s), 6.87 (1H, s),
7.23 (1H, t, J - 6.1 Hz).
MS (APCI) m/z: 560 (M+H) .
[0495]
(Step 35-4)
(2R)-2-(trans-4-Aminocyclohexyl)-7-chloro-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (trans-(2R)-A4j-
f)
[0496]
The title compound (0.241 g, 0.524 mmol, 98% yield)
was obtained through the same reaction as in step 3-4
using the compound (trans-(2R)-A4j) (0.298 g, 0.532 mmol)
synthesized in step 35-3.
CA 02942883 2016-09-15
- 186 -
MS (APCI) m/z: 460 (M+H)+.
[0497]
(Step 35-5)
(2R)-7-Chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (35)
[0498]
The title compound (0.187 g, 0.383 mmol, 73% yield)
was obtained through the same reaction as in step 3-5
using the compound (trans-(2R)-A4j-f) (0.241 g, 0.524
mmol) synthesized in step 35-4.
1H-NMR (400 MHz, DMSO-d6) 6: 1.08-1.21 (4H, m), 1.59 (3H,
s), 1.77-1.90 (5H, m), 2.03-2.09 (1H, m), 2.11 (6H, s),
2.13 (6H, s), 2.16 (3H, s), 4.21 (2H, d, J = 4.9 Hz),
5.85 (1H, s), 6.84 (1H, s), 8.13 (1H, t, J = 4.9 Hz),
11.48 (1H, s).
MS (APCI) m/z: 488 (M+H)+.
Specific rotation [a] 02 0 = +1.0 (C = 1.0, chloroform)
This compound agreed with the compound of the first
peak obtained under the resolution conditions using a
chiral column described in Example 34.
[0499]
Example 36
7-Chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4-
methoxy-6-methy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide (36)
[0500]
CA 02942883 2016-09-15
- 187 -
The compound of Example 36 was obtained in the same
way as in steps 13-3, 13-4, and 13-5.
[0501]
(Step 36-1)
tert-Butyl N-[trans-4-[7-chloro-5-[(4-methoxy-6-methy1-2-
oxo-1,2-dihydropyridin-3-yl)methylcarbamoy1]-2,4-
dimethy1-1,3-benzodioxo1-2-yl]cyclohexyl]carbamate
[0502]
The title compound (0.263 g, 0.456 mmol, 80% yield)
was obtained through the same reaction as in step 1-3
using the compound (trans-A3j) (0.242 g, 0.568 mmol)
synthesized in step 34-2 and 3-(aminomethyl)-4-methoxy-6-
methy1-1H-pyridin-2-one hydrochloride (0.128 g, 0.625
mmol) synthesized according to the method described in
W020131201042.
1H-NMR (400 MHz, DMSO-d6) 5: 1.05-1.22 (4H, m), 1.35 (9H,
s), 1.58 (3H, s), 1.73-1.87(5H, m), 2.11 (3H, s), 2.17
(3H, s), 3.05-3.22 (1H, m), 3.79 (3H, s), 4.15 (2H, d, J
= 4.8 Hz), 6.08 (1H, s), 6.73 (1H, d, J = 8.0 Hz), 6.81
(1H, s), 7.93 (1H, t, J = 4.8 Hz), 11.4 (1H, br s).
MS (APCI) m/z: 576 (M+H) .
[0503]
(Step 36-2)
2-(trans-4-Aminocyclohexyl)-7-chloro-N-[(4-methoxy-6-
methy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide
[0504]
CA 02942883 2016-09-15
- 188 -
The title compound (0.206 g, 0.434 mmol, 95% yield)
was obtained through the same reaction as in step 3-4
using tert-butyl N-[trans-4-[7-chloro-5-[(4-methoxy-6-
methy1-2-oxo-1,2-dihydropyridin-3-yl)methylcarbamoyl]-
2,4-dimethy1-1,3-benzodioxo1-2-yl]cyclohexyl]carbamate
(0.263 g, 0.456 mmol) synthesized in step 36-1.
1H-NMR (400 MHz, DMSO-d6) 6: 0.91-1.04 (2H, m), 1.08-1.22
(2H, m), 1.58 (3H, s), 1.71-1.82 (5H, m), 2.10 (3H, s),
2.17 (3H, s), 2.38-2.47 (1H, m), 3.56 (2H, s), 3.78 (3H,
s), 4.15 (2H, d, J = 4.3 Hz), 6.08 (1H, s), 6.81 (1H, s),
7.93 (1H, t, J - 4.3 Hz).
MS (APCI) m/z: 476 (M+H)+.
[0505]
(Step 36-3)
7-Chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4-
methoxy-6-methy1-2-oxo-1,2-dihydropyridin-3-y1)methyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide (36)
[0506]
The title compound (0.157 g, 0.311 mmol, 72% yield)
was obtained through the same reaction as in step 3-5
using tert-butyl N-[trans-4-[7-chloro-5-[(4-methoxy-6-
methy1-2-oxo-1,2-dihydropyridin-3-yl)methylcarbamoyl]-
2,4-dimethy1-1,3-benzodioxo1-2-yllcyclohexyl]carbamate
(0.206 g, 0.434 mmol) synthesized in step 36-2.
1H-NMR (400 MHz, DMSO-d6) 6: 1.06-1.22 (4H, m), 1.58 (3H,
s), 1.72-1.90 (5H, m), 2.00-2.19 (1H, m), 2.10 (3H, s),
2.12 (6H, s), 2.17 (3H, s), 3.78 (3H, s), 4.15 (2H, d, J
CA 02942883 2016-09-15
- 189 -
= 4.4 Hz), 6.08 (1H, s), 6.81 (1H, s), 7.93 (1H, t, J =
4.4 Hz), 11.4 (1H, brs).
MS (APCI) m/z: 504 (M+H)+.
[0507]
Example 37
7-Chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4-
ethy1-6-methy1-2-oxo-1,2-dihydropyridin-3-y1)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (37)
[0508]
(Step 37-1)
tert-Butyl N-[trans-4-[7-chloro-5-[(4-ethy1-6-methy1-2-
oxo-1,2-dihydropyridin-3-yl)methylcarbamoy1]-2,4-
dimethy1-1,3-benzodioxo1-2-yl]cyclohexyl]carbamate
[0509]
The title compound (0.528 g, 0.920 mmol, 65% yield)
was obtained through the same reaction as in step 1-3
using the compound (trans-A3j) (0.602 g, 1.41 mmol)
synthesized in step 34-2 and 3-(aminomethyl)-4-ethy1-6-
methyl-1H-pyridin-2-one (0.259 g, 1.56 mmol) synthesized
according to the method described in W02011140324.
1H-NMR (400 MHz, CDC13) 6: 1.02-1.15 (2H, m), 1.20 (3H, t,
J = 7.5 Hz), 1.25-1.37 (2H, m), 1.43 (9H, s), 1.59 (3H,
s), 1.72-1.85 (1H, m), 1.89-1.97 (2H, m), 2.03-2.11 (2H,
m), 2.22 (3H, s), 2.27 (3H, s), 2.71 (2H, q, J = 7.5 Hz),
3.32-3.45 (1H, m), 4.39 (1H, br s), 4.51 (2H, d, J = 5.5
Hz), 5.98 (1H, s), 6.87 (1H, s), 7.22-7.31 (1H, m).
MS (APCI) m/z: 574 (M+H)+.
CA 02942883 2016-09-15
- 190 -
[0510]
(Step 37-2)
2-(trans-4-Aminocyclohexyl)-7-chloro-N-[(4-ethy1-6-
methy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide
[0511]
The title compound (0.436 g, 0.920 mmol, 100% yield)
was obtained through the same reaction as in step 3-4
using tert-butyl N-[trans-4-[7-chloro-5-[(4-ethy1-6-
methy1-2-oxo-1,2-dihydropyridin-3-yl)methylcarbamoyl]-
2,4-dimethy1-1,3-benzodioxo1-2-yllcyclohexyl]carbamate
(0.528 g, 0.920 mmol) synthesized in step 37-1.
MS (APCI) m/z: 474 (M+H)+.
[0512]
(Step 37-3)
7-Chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4-
ethy1-6-methy1-2-oxo-1,2-dihydropyridin-3-y1)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (37)
[0513]
The title compound (0.399 g, 0.794 mmol, 86% yield)
was obtained through the same reaction as in step 3-5
using 2-(trans-4-aminocyclohexyl)-7-chloro-N-[(4-ethy1-6-
methy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (0.436 g, 0.920
mmol) synthesized in step 37-2.
1H-NMR (400 MHz, DMSO-d6) 6: 1.10 (3H, t, J = 7.6 Hz),
1.12-1.19 (4H, m), 1.60 (3H, s), 1.77-1.89 (5H, m), 2.03-
CA 02942883 2016-09-15
- 191 -
2.10 (1H, m), 2.11 (3H, s), 2.12 (3H, s), 2.13 (6H, s),
2.51 (2H, q, J = 7.6 Hz), 4.23 (2H, d, J = 4.9 Hz), 5.90
(1H, s), 6.84 (1H, s), 8.14 (1H, t, J = 4.9 Hz), 11.50
(1H, s).
MS (APCI) m/z: 502 (M+H)+.
[0514]
Example 38
7-Chloro-2-[(2S,5R)-5-(dimethylamino)tetrahydropyran-2-
y1]-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-1,3-benzodioxole-5-carboxamide
(38)
[0515]
(Step 38-1)
Methyl 2-[(2S,5R)-5-(tert-
butoxycarbonylamino)tetrahydropyran-2-y1]-7-chloro-2,4-
dimethy1-1,3-benzodioxole-5-carboxylate
[0516]
The title compound (0.379 g, 0.857 mmol, 74% yield)
was obtained through the same reaction as in step 13-1
using the compound (Alb) (0.250 g, 1.15 mmol) synthesized
in Reference Example 2 and tert-butyl N-[(3R,6S)-6-
ethynyltetrahydropyran-3-yl]carbamate (0.390 g, 1.73
mmol) synthesized according to the method described in
W02007105154.
1H-NMR (400 MHz, CDC13) 6:1.21-1.35 (1H, m), 1.43 (9H, s),
1.52-1.63 (1H, m), 1.70, 1.71 (3H, s x2), 1.81-1.90 (1H,
m), 2.10-2.20 (1H, m), 2.40 (3H, s), 2.99-3.07 (1H, m),
CA 02942883 2016-09-15
- 192 -
3.45-3.51 (1H, m), 3.55-3.70 (1H, m), 3.85 (3H, s), 4.12-
4.30 (2H, m), 7.55 (1H, s).
[0517]
(Step 38-2)
2-[(2S,5R)-5-(tert-Butoxycarbonylamino)tetrahydropyran-2-
y1]-7-chloro-2,4-dimethy1-1,3-benzodioxole-5-carboxylic
acid
[0518]
The title compound (0.346 g, 0.833 mmol, 97% yield)
was obtained through the same reaction as in step 1-2
using methyl 2-[(2S,5R)-5-(tert-
butoxycarbonylamino)tetrahydropyran-2-y1]-7-chloro-2,4-
dimethy1-1,3-benzodioxole-5-carboxylate (0.379 g, 0.858
mmol) synthesized in step 38-1.
MS (APCI) m/z: 426 (M-H)-.
[0519]
(Step 38-3)
tert-Butyl N-[(3R,6S)-6-[7-chloro-5-[(4,6-dimethy1-2-oxo-
1,2-dihydropyridin-3-yl)methylcarbamoy1]-2,4-dimethyl-
1,3-benzodioxo1-2-yl]tetrahydropyran-3-yl]carbamate
[0520]
The title compound (0.457 g, 0.813 mmol, 100% yield)
was obtained through the same reaction as in step 1-3
using 2-[(2S,5R)-5-(tert-
butoxycarbonylamino)tetrahydropyran-2-y1]-7-chloro-2,4-
dimethy1-1,3-benzodioxole-5-carboxylic acid (0.348 g,
0.814 mmol) synthesized in step 38-2.
CA 02942883 2016-09-15
- 193 -
1H-NMR (400 MHz, CDC13) 6: 1.21-1.33 (1H, m), 1.43 (9H,
s), 1.50-1.72 (1H, m), 1.67, 1.68 (3H, s x2), 1.77-1.88
(1H, m), 2.08-2.17 (1H, m), 2.23 (3H, s), 2.25 (3H, s),
2.36 (3H, s), 2.98-3.06 (1H, m), 3.42-3.48 (1H, m), 3.52-
3.74 (1H, m), 4.10-4.20 (1H, m), 4.21-4.32 (1H, m), 4.49
(2H, d, J = 5.6 Hz), 5.96 (1H, s), 6.89 (1H, s), 7.24 (1H,
t, J = 5.6 Hz), 11.73 (1H, br s).
MS (APCI) m/z: 562 (M+H)+.
[0521]
(Step 38-4)
2-[(2S,5R)-5-Aminotetrahydropyran-2-y1]-7-chloro-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-y1)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide
[0522]
The title compound (0.343 g, 0.742 mmol, 91% yield)
was obtained through the same reaction as in step 3-4
using tert-butyl N-[(3R,6S)-6-[7-chloro-5-[(4,6-dimethy1-
2-oxo-1,2-dihydropyridin-3-y1)methylcarbamoyl]-2,4-
dimethy1-1,3-benzodioxo1-2-yl]tetrahydropyran-3-
yl]carbamate (0.457 g, 0.813 mmol) synthesized in step
38-3.
1H-NMR (400 MHz, DMSO-d6) 6: 1.09-1.22 (1H, m), 1.29-1.44
(1H, m), 1.58 (3H, s), 1.62-1.71 (1H, m), 1.84-1.93 (1H,
m), 2.07 (3H, s), 2.09 (3H, s), 2.15 (3H, s), 2.42-2.58
(1H, m), 2.85-2.93 (1H, m), 3.42-3.48 (1H, m), 4.19 (2H,
d, J = 5.6 Hz), 5.88 (1H, s), 6.81 (1H, s), 8.14 (1H, t,
J = 5.6 Hz).
CA 02942883 2016-09-15
- 194 -
MS (APCI) m/z: 462 (M+H)+.
[0523]
(Step 38-5)
7-Chloro-2-[(2S,5R)-5-(dimethylamino)tetrahydropyran-2-
y1]-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-1,3-benzodioxole-5-carboxamide
(38)
[0524]
The title compound (0.132 g, 0.269 mmol, 37% yield)
was obtained through the same reaction as in step 3-5
using 2-[(2S,5R)-5-aminotetrahydropyran-2-y1]-7-chloro-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (0.337 g, 0.730
mmol) synthesized in step 38-4.
1H-NMR (400 MHz, DMSO-d6) 6: 1.30-1.46 (2H, m), 1.60 (3H,
s), 1.72-1.80 (1H, m), 1.92-2.01 (1H, m), 2.07-2.19(1H,
m), 2.11 (6H, s), 2.14 (6H, s), 2.16 (3H, s), 3.12-3.20
(1H, m), 3.48-3.54 (1H, m), 3.96-4.05 (1H, m), 4.20 (2H,
d, J = 4.8 Hz), 5.84 (1H, s), 6.83 (1H, s), 8.14 (1H, t,
J = 4.8 Hz), 11.47 (1H, br s).
MS (APCI) m/z: 490 (M+H)+.
[0525]
Example 39
7-Chloro-2-[(2S,5R)-5-(dimethylamino)tetrahydropyran-2-
y1]-N-[(4-methoxy-6-methy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-1,3-benzodioxole-5-carboxamide
(39)
CA 02942883 2016-09-15
- 195 -
[0526]
(Step 39-1)
tert-Butyl N-[(3R,6S)-6-[7-chloro-5-[(4-methoxy-6-methy1-
2-oxo-1,2-dihydropyridin-3-yl)methylcarbamoyl]-2,4-
dimethy1-1,3-benzodioxo1-2-yl]tetrahydropyran-3-
yl]carbamate
[0527]
The title compound (0.191 g, 0.331 mmol, 86% yield)
was obtained through the same reaction as in step 1-3
using 2-[(2S,5R)-5-(tert-
butoxycarbonylamino)tetrahydropyran-2-y1]-7-chloro-2,4-
dimethy1-1,3-benzodioxole-5-carboxylic acid (0.165 g,
0.386 mmol) synthesized in step 38-2 and 3-(aminomethyl)-
4-methoxy-6-methy1-1,2-dihydropyridin-2-one hydrochloride
(0.087 g, 0.424 mmol) synthesized according to the method
described in WO 20131201042.
1H-NMR (400 MHz, DMSO-d6) 6: 1.28-1.51 (2H, m), 1.35 (9H,
s), 1.61 (3H, s), 1.69-1.78 (1H, m), 1.83-1.92 (1H, m).
2.11 (3H, s), 2.17 (3H, s), 2.94-3.04 (1H, m), 3.25-3.36
(1H, m), 3.46-3.53 (1H, m), 3.76-3.86 (1H, m), 3.78 (3H,
s), 4.15 (2H, d, J = 4.8 Hz), 6.08 (1H, s), 6.78-6.85 (2H,
m), 7.95 (1H, t, J = 4.8 Hz), 11.44 (1H, br s). MS APCI)
m/z: 578 (M+H)+.
[0528]
(Step 39-2)
CA 02942883 2016-09-15
- 196 -
2-[(2S,5R)-5-Aminotetrahydropyran-2-y1]-7-chloro-N-[(4-
methoxy-6-methy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide
[0529]
The title compound (0.152 g, 0.318 mmol, 97% yield)
was obtained through the same reaction as in step 3-4
using tert-butyl N-[(3R,6S)-6-[7-chloro-5-[(4-methoxy-6-
methy1-2-oxo-1,2-dihydropyridin-3-yl)methylcarbamoyl]-
2,4-dimethy1-1,3-benzodioxo1-2-y1ltetrahydropyran-3-
yl]carbamate (0.189 g, 0.327 mmol) synthesized in step
39-1.
1H-NMR (400 MHz, DMSO-d6) 6: 1.08-1.23 (1H, m), 1.30-1.47
(1H, m), 1.57-1.73 (1H, m), 1.60 (3H, s), 1.84-1.93 (1H,
m), 2.10 (3H, s), 2.16 (3H, s), 2.45-2.59 (1H, m), 2.84-
2.92 (1H, m), 3.27-3.37 (1H, m), 3.43-3.49 (1H, m), 3.55
(2H, s), 3.75-3.83 (1H, m), 3.78 (3H, s), 4.15 (1H, d, J
= 4.4 Hz), 6.08 (1H, s), 6.82 (1H, s), 7.94 (1H, t, J =
4.4 Hz).
MS (APCI) m/z: 478 (M+H)+.
[0530]
(Step 39-3)
7-Chloro-2-[(2S,5R)-5-(dimethylamino)tetrahydropyran-2-
y1]-N-[(4-methoxy-6-methy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-1,3-benzodioxole-5-carboxamide
(39)
[0531]
CA 02942883 2016-09-15
- 197 -
The title compound (0.119 g, 0.234 mmol, 97% yield)
was obtained through the same reaction as in step 3-5
using 2-[(2S,5R)-5-aminotetrahydropyran-2-y1]-7-chloro-N-
[(4-methoxy-6-methy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-1,3-benzodioxole-5-carboxamide
(0.150 g, 0.314 mmol) synthesized in step 39-2.
1H-NMR (400 MHz, DMSO-d6) 6: 1.28-1.48 (2H, m), 1.61 (3H,
s), 1.72-1.80 (1H, m), 1.90-2.02 (1H, m), 2.09-2.20 (1H,
m), 2.10 (3H, s), 2.13 (6H, s), 2.17 (3H, s), 3.12-3.20
(1H, m), 3.48-3.54 (1H, m), 3.78 (3H, s), 3.96-4.06 (1H,
m), 4.16 (2H, d, J - 4.9 Hz), 6.08 (1H, s), 6.83 (1H, s),
7.95 (1H, t, J = 4.9 H), 11.4 (1H, s).
MS (APCI) m/z: 506 (M+H)+.
[0532]
Example 40
7-Chloro-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-2-[(1-methyl-4-piperidyl)methyl]-
1,3-benzodioxole-5-carboxamide (40)
[0533]
(Step 40-1)
tert-butyl 4-[(7-Chloro-5-methoxycarbony1-2,4-dimethy1-
1,3-benzodioxol-2-yl)methyl]piperidine-1-carboxylate
[0534]
The title compound (1.45 g, 3.30 mmol, 65% yield)
was obtained through the same reaction as in step 1-1
using the compound (Alb) (1.10 g, 5.08 mmol) synthesized
CA 02942883 2016-09-15
- 198 -
in Reference Example 2 and the compound (S-10) (1.70 g,
7.62 mmol) synthesized in Reference Example 10.
1H-NMR (400 MHz, CDC13) 6: 1.14-1.30 (2H, m), 1.45 (9H,
s), 1.70 (3H, s), 1.72-1.80 (3H, m), 1.94 (2H, d, J = 5.5
Hz), 2.39 (3H, s), 2.60-2.80 (2H, m), 3.86 (3H, s), 3.92-
4.15 (2H, m), 7.56 (1H, s).
[0535]
(Step 40-2)
2-[(1-tert-Butoxycarbony1-4-piperidyl)methy1]-7-ch10r0-
2,4-dimethy1-1,3-benzodioxole-5-carboxylic acid
[0536]
The title compound (1.27 g, 2.99 mmol, 91% yield)
was obtained through the same reaction as in step 1-2
using tert-butyl 4-[(7-chloro-5-methoxycarbony1-2,4-
dimethy1-1,3-benzodioxol-2-yl)methyl]piperidine-1-
carboxylate (1.45 g, 3.30 mmol) synthesized in step 40-1.
[0537]
(Step 40-3)
tert-Butyl 4-[[7-chloro-5-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methylcarbamoy1]-2,4-dimethyl-1,3-
benzodioxo1-2-yl]methyl]piperidine-l-carboxylate
[0538]
The title compound (1.67 g, 2.98 mmol, 100% yield)
was obtained through the same reaction as in step 1-3
using 2-[(1-tert-butoxycarbony1-4-piperidyl)methy1]-7-
chloro-2,4-dimethyl-1,3-benzodioxole-5-carboxylic acid
(1.27 g, 2.99 mmol) synthesized in step 40-2.
CA 02942883 2016-09-15
- 199 -
1H-NMR (400 MHz, CDC13) 6: 1.11-1.25 (2H, m), 1.44 (9H,
s), 1.66 (3H, s), 1.69-1.79 (3H, m), 1.92 (2H, d, J = 5.5
Hz), 2.23 (3H, s), 2.26 (3H, s), 2.37 (3H, s), 2.62-2.75
(2H, m), 3.92-4.12 (2H, m), 4.50 (2H, d, J = 6.1 Hz),
5.97 (1H, s), 6.90 (1H, s), 7.26 (1H, t, J = 6.1 Hz),
12.15 (1H, s).
MS (APCI) m/z: 560 (M+H)+.
[0539]
(Step 40-4)
7-Chloro-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-2-(4-piperidylmethyl)-1,3-
benzodioxole-5-carboxamide
[0540]
The title compound (0.619 g, 1.34 mmol, 45% yield)
was obtained through the same reaction as in step 3-4
using tert-butyl 4-[[7-chloro-5-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methylcarbamoy1]-2,4-dimethyl-1,3-
benzodioxo1-2-yl]methyl]piperidine-l-carboxylate (1.67 g,
2.98 mmol) synthesized in step 40-3.
MS (APCI) m/z: 460 (M+H) .
[0541]
(Step 40-5)
7-Chloro-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-2-[(1-methyl-4-piperidyl)methyl]-
1,3-benzodioxole-5-carboxamide (40)
[0542]
CA 02942883 2016-09-15
- 200 -
The title compound (0.612 g, 1.29 mmol, 96% yield)
was obtained through the same reaction as in step 3-5
using 7-chloro-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-
3-yl)methyl]-2,4-dimethyl-2-(4-piperidylmethyl)-1,3-
benzodioxole-5-carboxamide (0.619 g, 2.98 mmol)
synthesized in step 40-4.
1H-NMR (400 MHz, DMSO-d6) 6: 1.15-1.30 (2H, m), 1.41-1.51
(1H, m), 1.65 (3H, s), 1.66-1.71 (2H, m), 1.72-1.82 (2H,
m), 1.90 (2H, d, J = 6.1 Hz), 2.08 (3H, s), 2.11 (6H, s),
2.17 (3H, s), 2.63-2.69 (2H, m), 4.22 (2H, d, J = 4.9 Hz),
5.86 (1H, s), 6.86 (1H, s), 8.16 (1H, t, J = 4.9 Hz),
11.49 (1H, s).
MS (APCI) m/z: 474 (M+H) .
[0543]
Example 41
7-Bromo-2-[cis-4-(dimethylamino)cyclohexyl]-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (41)
[0544]
(Step 41-1)
Methyl 7-bromo-2-(1,4-dioxaspiro[4.5]decan-8-y1)-2,4-
dimethy1-1,3-benzodioxole-5-carboxylate
[0545]
The title compound (0.923 g, 2.16 mmol, 32% yield)
was obtained through the same reaction as in step 1-1
using the compound (Ala) (1.75 g, 6.70 mmol) synthesized
CA 02942883 2016-09-15
- 201 -
in Reference Example 1 and the compound (S-15) (1.67 g,
10.1 mmol) synthesized in Reference Example 15.
1H-NMR (400 MHz, CDC13) 6: 1.51-1.60 (4H, m), 1.64 (3H,
s), 1.76-1.99 (5H, m), 2.39 (3H, s), 3.85 (3H, s), 3.95
(4H, s), 7.67 (1H, s).
MS (APCI) m/z: 427,429 (M+H)+.
[0546]
(Step 41-2)
7-Bromo-2-(1,4-dioxaspiro[4.5]decan-8-y1)-2,4-dimethyl-
1,3-benzodioxole-5-carboxylic acid
[0547]
The title compound (0.817 g, 1.98 mmol, 95% yield)
was obtained through the same reaction as in step 1-2
using methyl 7-bromo-2-(1,4-dioxaspiro[4.5]decan-8-y1)-
2,4-dimethy1-1,3-benzodioxole-5-carboxylate (0.893 g,
2.09 mmol) synthesized in step 41-1.
[0548]
(Step 41-3)
7-Bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2-(1,4-dioxaspiro[4.5]decan-8-y1)-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide
[0549]
The title compound (1.02 g, 1.87 mmol, 95% yield)
was obtained through the same reaction as in step 1-3
using 7-bromo-2-(1,4-dioxaspiro[4.5]decan-8-y1)-2,4-
dimethy1-1,3-benzodioxole-5-carboxylic acid (0.817 g,
1.98 mmol) synthesized in step 41-2.
CA 02942883 2016-09-15
- 202 -
1H-NMR (400 MHz, DMSO-d0 6: 1.30-1.53 (4H, m), 1.60 (3H,
s), 1.66-1.73 (2H, m), 1.73-1.81 (2H, m), 1.84-1.99 (1H,
m), 2.10 (3H, s), 2.11 (3H, s), 2.16 (3H, s), 3.84 (4H,
s), 4.21 (2H, d, J = 4.9 Hz), 5.85 (1H, s), 6.94 (1H, s),
8.14 (1H, t, J = 4.9 Hz), 11.48 (1H, s).
MS (APCI) m/z: 547, 549 (M+H)+.
[0550]
(Step 41-4)
7-Bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-2-(4-oxocyclohexyl)-1,3-
benzodioxole-5-carboxamide
[0551]
7-Bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2-(1,4-dioxaspiro[4.5]decan-8-y1)-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (0.817 g, 1.98
mmol) synthesized in step 41-3 was dissolved in aqueous
tetrahydrofuran (2.4 mL). To the solution, 4 M
hydrochloric acid in 1,4-dioxane (0.819 mL, 3.28 mmol)
was added, and the mixture was stirred at room
temperature for 16 hours. The reaction solution was
neutralized by the addition of a saturated aqueous
solution of sodium bicarbonate, followed by extraction
with chloroform. The organic layer was dried over sodium
sulfate. After concentration under reduced pressure, the
obtained residue was purified by silica gel column
chromatography (methanol:chloroform = 100:0 - 95:5) to
CA 02942883 2016-09-15
- 203 -
obtain the title compound (0.292 g, 0.580 mmol, 35%
yield).
MS (APCI) m/z: 503,505 (M+H)'.
[0552]
(Step 41-5)
7-Bromo-2-[cis-4-(dimethylamino)cyclohexyl]-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-y1)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (41)
[0553]
The title compound (0.089 g, 0.167 mmol, 29% yield)
was obtained through the same reaction as in step 3-5
using 7-bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-
3-yl)methyl]-2,4-dimethyl-2-(4-oxocyclohexyl)-1,3-
benzodioxole-5-carboxamide (0.292 g, 0.580 mmol)
synthesized in step 41-4 and a 2.0 M solution of
dimethylamine in tetrahydrofuran (2.90 mL, 5.79 mmol).
1H-NMR (400 MHz, DMSO-d6) 6: 1.25-1.39 (2H, m), 1.45-1.54
(4H, m), 1.58 (3H, s), 1.88-1.98 (4H, m), 2.10 (3H, s),
2.11 (3H, s), 2.12 (6H, s), 2.16 (3H, s), 4.21 (2H, d, J
= 4.9 Hz), 5.85 (1H, s), 6.93 (1H, s), 8.13 (1H, t, J =
4.9 Hz), 11.47 (1H, s).
MS (APCI) m/z: 532, 534 (M+H)'.
[0554]
Example 42
7-Bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-2-(piperazin-1-ylmethyl)-1,3-
benzodioxole-5-carboxamide (42)
CA 02942883 2016-09-15
- 204 -
[Formula 36]
H3 ÇH3 ÇH3
9113 0 0 0 0 0 0
00
C H 3 .1
C H3 C H3 C H3 0
= * )1.0 t-Bu
Br 9" OH 42-1 Br 0 0 424 = Br 0 H 42-3 Br 0 (-
1.41
14--/
0 H
H3C H3C H3C
Ala A2k A2k-f A21
H3CcyCH3 H3CrcrCH3
0 OH r NH (A NH
C H3 3 t-Bu 0 NH 0 0 NH 0 1.
Br =("-N C H3 t-Bu cH3
H
424 0 N 42-6 42-6
Br 1µ (-N
Br IW
H3C 04L,N-)
H3C H3C
A31 A41 42
[0555]
(Step 42-1)
Methyl 7-bromo-2,4-dimethy1-2-(tetrahydropyran-2-
yloxymethyl)-1,3-benzodioxole-5-carboxylate (A2k)
[0556]
The title compound (23.5 g, 58.5 mmol, 80% yield)
was obtained through the same reaction as in step 1-1
using the compound (Ala) (19.0 g, 72.8 mmol) synthesized
in Reference Example 1 and 2-(2-
propynyloxy)tetrahydropyran (20.4 g, 146 mmol).
1H-NMR (400 MHz, CDC13) 6: 1.40-1.66 (6H, m), 1.77 (3H,
s), 2.39 (3H, s), 3.48-3.55 (1H, m), 3.66-3.73 (1H, m),
3.80-3.90 (1H, m), 3.85 (3H, s), 3.88-3.94 (1H, m), 4.70-
4.75 (1H, m), 7.68 (1H, s).
[0557]
(Step 42-2)
Methyl 7-bromo-2-(hydroxymethyl)-2,4-dimethy1-1,3-
benzodioxole-5-carboxylate (A2k-f)
CA 02942883 2016-09-15
- 205 -
[0558]
To a solution of the compound (A2k) (21.0 g, 52.3
mmol) synthesized in step 42-1 in methanol (156 mL), p-
toluenesulfonic acid hydrate (0.498 g, 2.62 mmol) was
added, and the mixture was stirred at room temperature
for 5 hours. The solvent in the reaction solution was
distilled off, and the obtained residue was diluted with
ethyl acetate, washed with a saturated aqueous solution
of sodium bicarbonate and saturated saline, and then
dried over sodium sulfate. The organic layer was
filtered through celite, and the solvent was distilled
off under reduced pressure. The obtained residue was
purified by silica gel column chromatography
(hexane:ethyl acetate = 100:0 -* 80:20) to obtain the
title compound (11.7 g, 37.0 mmol, 71% yield).
1H-NMR (400 MHz, CDC13) 6: 1.76 (3H, s), 2.02 (1H, br s),
2.43 (3H, s), 3.87 (2H, d, J = 7.2 Hz), 3.88 (3H, s),
3.85 (3H, s), 3.88-3.94 (1H, m), 4.70-4.75 (1H, m), 7.73
(1H, s).
MS (APCI) m/z: 317, 319 (M+H)+.
[0559]
(Step 42-3)
tert-Butyl 4-[(7-bromo-5-methoxycarbony1-2,4-dimethyl-
1,3-benzodioxo1-2-yl)methyl]piperazine-1-carboxylate
(A2I)
[0560]
CA 02942883 2016-09-15
- 206 -
The compound (A2k-f) (0.250 g, 0.788 mmol)
synthesized in step 42-2 was suspended in acetonitrile (8
mL). To the suspension, triethylamine (0.239 g, 2.36
mmol) and trifluoromethanesulfonic anhydride (0.278 g,
0.985 mmol) were added under ice cooling, and the mixture
was then stirred for 1 hour. 1-(tert-
Butoxycarbonyl)piperazine (0.220 g, 1.18 mmol) was added
to the reaction solution at 0 C, and the mixture was
stirred at 60 C for 15 hours. The reaction solution was
diluted with ethyl acetate, washed with a saturated
aqueous solution of sodium bicarbonate and saturated
saline, and dried over sodium sulfate. After filtration
through celite, the solvent was distilled off under
reduced pressure, and the obtained residue was purified
by silica gel column chromatography (hexane:ethyl acetate
= 100:0 -* 86:14) to obtain the title compound (0.269 g,
0.554 mmol, 70% yield).
1H-NMR (400 MHz, CDC13) 6: 1.43 (9H, s), 1.75 (3H, s),
2.37 (3H, s), 2.48-2.60 (4H, m), 2.75 (2H, s), 3.17-3.27
(4H, m), 3.86 (3H, s), 7.68 (1H, s).
MS (APCI) m/z: 485, 487 (M+H)+.
[0561]
(Step 42-4)
7-Bromo-2-[(4-tert-butoxycarbonylpiperazin-1-yl)methy1]-
2,4-dimethy1-1,3-benzodioxole-5-carboxylic acid (A3I)
[0562]
CA 02942883 2016-09-15
- 207 -
The title compound (0.261 g, 0.554 mmol, 100% yield)
was obtained through the same reaction as in step 1-2
using the compound (A2I) (0.269 g, 0.554 mmol)
synthesized in step 42-3.
MS (APCI) m/z: 469, 471 (M+H)+.
[0563]
(Step 42-5)
tert-Butyl 4-[[7-bromo-5-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methylcarbamoyl]-2,4-dimethy1-1,3-
benzodioxo1-2-yl]methyl]piperazine-1-carboxylate (A4I)
[0564]
The title compound (0.233 g, 0.385 mmol, 70% yield)
was obtained through the same reaction as in step 1-3
using the compound (A3I) (0.261 g, 0.554 mmol)
synthesized in step 42-4.
1H-NMR (400 MHz, CDC13) 5: 1.44 (9H, s), 1.72 (3H, s),
2.21 (3H, s), 2.25 (3H, s), 2.37 (3H, s), 2.40-2.70 (4H,
m), 2.72 (2H, s), 3.23-3.33 (4H, m), 4.45-4.50 (2H, m),
5.93 (1H, s), 7.00 (1H, s), 7.13-7.18 (1H, m).
MS (APCI) m/z: 605, 607 (M+H)+.
[0565]
(Step 42-6)
7-Bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-2-(piperazin-1-ylmethyl)-1,3-
benzodioxole-5-carboxamide
[0566]
CA 02942883 2016-09-15
- 208 -
The title compound (0.170 g, 0.336 mmol, 87% yield)
was obtained through the same reaction as in step 3-4
using the compound (A4I) (0.233 g, 0.385 mmol)
synthesized in step 42-5.
1H-NMR (400 MHz, CDC13) 6: 1.72 (3H, s), 2.21 (3H, s),
2.26 (3H, s), 2.37 (3H, s), 2.50-2.65 (4H, m), 2.69 (2H,
s), 2.71-2.77 (4H, m), 4.48 (2H, d, J = 6.1 Hz), 5.94 (1H,
s), 7.00 (1H, s), 7.19 (1H, t, J = 6.1 Hz).
MS (APCI) m/z: 505, 507 (M+H)+.
[0567]
Example 43
7-Bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-2-[(4-methylpiperazin-1-
yl)methy1]-1,3-benzodioxole-5-carboxamide (43)
[Formula 37]
9113 H3 H3Cr;''..Y:i 113
0 0 0 0 0 OH 0 N H 0
CH3 Br C H3 C H3 H3 c
Br W 0 41 (-Nt.0 H3 gr (le H2-'
0-4,0 H 43-1 040õ../N..../ 43-2 - 43-3 Br 04 H3)
H3C H3C H3C H3C
A2k-f A2m A3m 43
[0568]
(Step 43-1)
Methyl 7-bromo-2,4-dimethy1-2-[(4-methylpiperazin-1-
yl)methy1]-1,3-benzodioxole-5-carboxylate (A2m)
[0569]
The title compound (0.138 g, 0.346 mmol, 44% yield)
was obtained through the same reaction as in step 42-3
using the compound (A2k-f) (0.250 g, 0.788 mmol)
CA 02942883 2016-09-15
- 209 -
synthesized in step 42-2 and 1-methylpiperazine (0.158 g,
1.58 mmol).
1H-NMR (400 MHz, CDC13) 6: 1.74 (3H, s), 2.11-2.45 (4H,
m), 2.22 (3H, s), 2.37 (3H, s), 2.55-2.80 (4H, m), 2.75
(2H, s), 3.85 (3H, s), 7.68 (1H, s).
MS (APCI) m/z: 399, 401 (M+H)+.
[0570]
(Step 43-2)
7-Bromo-2,4-dimethy1-2-[(4-methylpiperazin-1-y1)methyl]-
1,3-benzodioxole-5-carboxylic acid (A3m)
[0571]
The title compound (0.133 g, 0.346 mmol, 100% yield)
was obtained through the same reaction as in step 1-2
using the compound (A2m) (0.138 g, 0.346 mmol)
synthesized in step 43-1.
MS (APCI) m/z: 385, 387 (M+H)+.
[0572]
(Step 43-3)
7-Bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-2-[(4-methylpiperazin-1-
yl)methy1]-1,3-benzodioxole-5-carboxamide (43)
[0573]
The title compound (0.096 g, 0.184 mmol, 53% yield)
was obtained through the same reaction as in step 1-3
using the compound (A3m) (0.133 g, 0.346 mmol)
synthesized in step 43-2.
CA 02942883 2016-09-15
- 210 -
1H-NMR (400 MHz, CDC13) 6: 1.72 (3H, s), 2.15-2.45 (4H,
m), 2.22 (6H, s), 2.27 (3H, s), 2.37 (3H, s), 2.55-2.75
(4H, m), 2.72 (2H, s), 4.50 (2H, d, J = 5.5 Hz), 5.96 (1H,
s), 7.01 (2H, s), 7.20-7.28 (1H, m), 11.85 (1H, br s).
MS (APCI) m/z: 519, 521 (M+H)+.
[0574]
Example 44
7-Bromo-2-[[4-(dimethy1amino)-1-piperidyl]methy1]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (44)
[Formula 38]
H3 ÇH3 H3CC H3
0 0 0 0 0 OH I NH
CH3
C H3 CH3 C H3 C, 0 NH 0
Br J(40 44-1 Br -C H 44-2 Br 11.111111 co (3N
C H3 CH3
041,0 N-CH, 44-3 g N-C H3
H3C H3C H3C Br 0 g
A2k-f A2n A3n 44
[0575]
(Step 44-1)
Methy1-7-bromo-2-[[4-(dimethylamino)-1-piperidyl]methy1]-
2,4-dimethy1-1,3-benzodioxole-5-carboxylate (A2n)
[0576]
The title compound (0.808 g, 1.89 mmol, 100% yield)
was obtained through the same reaction as in step 42-3
using the compound (A2k-f) (0.250 g, 0.788 mmol)
synthesized in step 42-2 and 4-dimethylaminopiperidine
(0.600 g, 1.89 mmol).
1H-NMR (400 MHz, CDC13) 6:1.22-1.38 (2H, m), 1.68-1.74
(2H, m), 1.73 (3H, s), 2.00-2.28 (3H, m), 2.30 (6H, s),
CA 02942883 2016-09-15
- 211 -
2.38 (3H, s), 2.73 (2H, s), 2.95-3.05 (2H, m), 3.84 (3H,
s), 7.66 (1H, s).
[0577]
(Step 44-2)
7-Bromo-2-[[4-(dimethylamino)-1-piperidyl]methy1]-2,4-
dimethy1-1,3-benzodioxole-5-carboxylic acid (A3n)
[0578]
The title compound (0.135 g, 0.328 mmol, 100% yield)
was obtained through the same reaction as in step 1-2
using the compound (A2n) (0.140 g, 0.328 mmol)
synthesized in step 44-1.
[0579]
(Step 44-3)
7-Bromo-2-[[4-(dimethylamino)-1-piperidyl]methy1]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (44)
[0580]
The title compound (0.048 g, 0.088 mmol, 27% yield)
was obtained through the same reaction as in step 1-3
using the compound (A3n) (0.135 g, 0.328 mmol)
synthesized in step 44-2.
1H-NMR (400 MHz, DMSO-d6) 6: 1.10-1.23 (2H, m), 1.51-1.63
(2H, m), 1.67 (3H, s), 1.88-1.94 (1H, m), 2.07 (6H, s),
2.10 (3H, s), 2.11 (3H, s), 2.16 (3H, s), 2.12-2.20 (2H,
m), 2.70 (2H, s), 2.85-2.92 (2H, m), 4.21 (2H, d, J = 4.9
Hz), 5.86 (1H, s), 6.95 (1H, s), 8.11 (1H, d, J = 4.9 Hz),
11.50 (1H, br s).
CA 02942883 2016-09-15
- 212 -
MS (APCI) m/z: 547, 549 (M+H) .
[0581]
Example 45
(2R)-7-Bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-2-(morpholinomethyl)-1,3-
benzodioxole-5-carboxamide (45)
[Formula 39]
cH, CH, cH,
00 00 00
CH, cH, cHõ
45-1 Br 45-2 Br 0 r 1
Br 0 0 45-3
H3C H3C- H3C
A2k-f (2R)-A2k-f (2R)-A2p
CH3rcrC H3
I N H
0 OH
0 N H 0
CH3
= 45-4 C H3
Br I./1
Br 0 (1
H3C
H3d
(2R)-A2p 45
[0582]
(Step 45-1)
Methyl (2R)-7-bromo-2,4-dimethy1-2-(hydroxymetny1)-1,3-
benzodioxole-5-carboxylate ((2R)-A2k-f)
[0583]
The compound (A2k-f) synthesized in step 42-2 was
resolved into each enantiomer under the following
conditions:
Column: Daicel CHIRALCEL OZ-H 4.6 mm ID x 250 mm L
Elution solvent: n-hexane:2-propanol - 90:10 (V/V)
CA 02942883 2016-09-15
- 213 -
Flow rate: 1.00 mL/min
Temperature: 25 C
First peak: 6.6 min (specific rotation []D20 = +7.1 (C =
1.0, chloroform))
Second peak: 7.8 min (specific rotation []D20 = 6.7 (C =
1.0, chloroform))
[0584]
The following steps were carried out using the first
peak separated using a preparative chiral column.
[0585]
(Step 45-2)
Methyl (2R)-7-bromo-2,4-dimethy1-2-(morpholinomethyl)-
1,3-benzodioxole-5-carboxylate ((2R)-A2p)
[0586]
The title compound (12.2 g, 31.6 mmol, 100% yield)
was obtained through the same reaction as in step 42-3
using the compound ((2R)-A2k-f) (first peak, 10.0 g, 31.5
mmol) synthesized in step 45-1.
1H-NMR (400 MHz, CDC13) 6: 1.76 (3H, s), 2.37 (3H, s),
2.57-2.62 (4H, m), 2.73 (2H, s), 3.51-3.56 (4H, m), 3.86
(3H, s), 7.68 (1H, s).
MS (ESI) m/z: 386, 388 (M+H)+.
[0587]
(Step 45-3)
(2R)-7-Bromo-2,4-dimethy1-2-(morpholinomethyl)-1,3-
benzodioxole-5-carboxylic acid ((2R)-A3p)
CA 02942883 2016-09-15
- 214 -
The title compound (11.7 g, 31.5 mmol, 100% yield)
was obtained through the same reaction as in step 1-2
using the compound ((2R)-A2p) (12.2 g, 31.5 mmol)
synthesized in step 45-2.
1H-NMR (400 MHz, 0DC13) 6: 1.77 (3H, s), 2.40 (3H, s),
2.55-2.68 (4H, m), 2.75 (2H, s), 3.50-3.61 (4H, m), 7.82
(1H, s).
MS (ESI) m/z: 370, 372 (M-H)-.
[0588]
(Step 45-4)
(2R)-7-Bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2,4-dimethy1-2-(morpholinomethyl)-1,3-
benzodioxole-5-carboxamide (45)
[0589]
The title compound (14.1 g, 27.9 mmol, 88% yield)
was obtained through the same reaction as in step 1-3
using the compound ((2R)-A3p) (11.7 g, 31.5 mmol)
synthesized in step 45-3.
1H-NMR (400 MHz, CDC13) 6: 1.73 (3H, s), 2.21 (3H, s),
2.27 (3H, s), 2.37 (3H, s), 2.54-2.64 (4H, m), 2.71 (2H,
s), 3.55-3.61 (4H, m), 4.50 (2H, d, J = 5.5 Hz), 5.96 (1H,
s), 7.01 (1H, s), 7.23 (1H, t, J = 5.5 Hz), 11.77 (1H, br
s).
MS (ESI) m/z: 506, 508 (M+H)+.
[0590]
Example 46
CA 02942883 2016-09-15
- 215 -
2-[trans-4-(Dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methy1]-7-fluoro-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (46)
[0591]
(Step 46-1)
Methyl 2-[trans-4-(tert-butoxycarbonylamino)cyclohexy1]-
7-fluoro-2,4-dimethyl-1,3-benzodioxole-5-carboxylate
[0592]
The title compound (0.563 g, 1.49 mmol, 100% yield)
was obtained through the same reaction as in step 13-1
using the compound (Alc) (0.265 g, 1.32 mmol) synthesized
in Reference Example 3 and the compound (S-13) (0.444 g,
1.99 mmol) synthesized in Reference Example 13.
1H-NMR (400 MHz, CDC13) 6: 1.05-1.15 (2H, m), 1.30-1.39
(2H, m), 1.44 (9H, s), 1.61 (3H, s), 1.77-1.90 (1H, m),
1.95-2.01 (2H, m), 2.06-2.13 (2H, m), 2.38 (3H, s), 3.30-
3.46 (1H, m), 3.85 (3H, s), 4.38 (1H, br s), 7.36 (1H, d,
LT = 11.0 Hz).
[0593]
(Step 46-2)
2-[trans-4-(tert-Butoxycarbonylamino)cyclohexyl]-7-
fluoro-2,4-dimethy1-1,3-benzodioxole-5-carboxylic acid
[0594]
The title compound (0.188 g, 0.459 mmol, 93% yield)
was obtained through the same reaction as in step 1-2
using methyl 2-[trans-4-(tert-
butoxycarbonylamino)cyclohexyl]-7-fluoro-2,4-dimethyl-
CA 02942883 2016-09-15
- 216 -
1,3-benzodioxole-5-carboxylate (0.210 g,Ø495 mmol)
synthesized in step 46-1.
[0595]
(Step 46-3)
tert-Butyl N-[trans-4-[5-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methylcarbamoyl]-7-fluoro-2,4-
dimethy1-1,3-benzodioxo1-2-yl]cyclohexyl]carbamate
[0596]
The title compound (0.208 g, 0.383 mmol, 83% yield)
was obtained through the same reaction as in step 1-3
using 2-[trans-4-(tert-butoxycarbonylamino)cyclohexyl]-7-
fluoro-2,4-dimethy1-1,3-benzodioxole-5-carboxylic acid
(0.188 g, 0.459 mmol) synthesized in step 46-2.
1H-NMR (400 MHz, CDC13) 8: 1.04-1.13 (2H, m), 1.22-1.36
(2H, m), 1.44 (9H, s), 1.58 (3H, s), 1.73-1.86 (1H, m),
1.89-1.98 (2H, m), 2.03-2.11 (2H, m), 2.22 (3H, s), 2.25
(3H, s), 2.37 (3H, s), 3.32-3.45 (1H, m), 4.36 (1H, br s),
4.49 (2H, d, J = 5.6 Hz), 5.95 (1H, s), 6.73 (1H, d, J =
10.0 Hz), 7.23 (1H, t, J - 5.8 Hz), 11.30 (1H, br s).
MS (APCI) m/z: 544 (M+H)+.
[0597]
(Step 46-4)
2-(trans-4-Aminocyclohexyl)-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methy1]-7-fluoro-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide
[0598]
CA 02942883 2016-09-15
- 217 -
The title compound (0.064 g, 0.144 mmol, 98% yield)
was obtained through the same reaction as in step 3-4
using tert-butyl N-[trans-4-[5-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methylcarbamoy1]-7-fluoro-2,4-
dimethy1-1,3-benzodioxo1-2-yl]cyclohexyl]carbamate (0.080
g, 0.147 mmol) synthesized in step 46-3.
[0599]
(Step 46-5)
2-[trans-4-(Dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-y1)methy1]-7-fluoro-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (46)
[0600]
The title compound (0.038 g, 0.081 mmol, 56% yield)
was obtained through the same reaction as in step 3-5
using 2-(trans-4-aminocyclohexyl)-N-[(4,6-dimethy1-2-oxo-
1,2-dihydropyridin-3-y1)methyl]-7-fluoro-2,4-dimethyl-
1,3-benzodioxole-5-carboxamide (0.064 g, 0.144 mmol)
synthesized in step 46-4.
1H-NMR (400 MHz, CDC13) 6: 1.19-1.31 (4H, m), 1.59 (3H,
s), 1.77-1.85 (1H, m), 1.96-2.01 (4H, m), 2.21-2.24 (1H,
m), 2.23 (3H, s), 2.25 (3H, s), 2.27 (6H, s), 2.37 (3H,
s), 4.49 (2H, d, J = 5.6 Hz), 5.95 (1H, s), 6.73 (1H, d,
J = 10.4 Hz), 7.24 (1H, t, J = 5.6 Hz), 11.61 (1H, br s).
MS (APCI) m/z: 472 (M+H) .
[0601]
Example 47
CA 02942883 2016-09-15
- 218 -
2-[trans-4-(Dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methy1]-2,4,7-trimethyl-1,3-
benzodioxole-5-carboxamide (47)
[0602]
(Step 47-1)
Methyl 2-[trans-4-(tert-butoxycarbonylamino)cyclohexyl]-
2,4,7-trimethy1-1,3-benzodioxole-5-carboxylate
[0603]
The title compound (7.99 g, 19.0 mmol, 95% yield)
was obtained through the same reaction as in step 13-1
using the compound (Ald) (3.92 g, 20.0 mmol) synthesized
in Reference Example 4 and the compound (S-13) (6.70 g,
30.0 mmol synthesized in Reference Example 13.
1H-NMR (400 MHz, CDC13) 6: 1.02-1.15 (2H, m), 1.26-1.37
(2H, m), 1.44 (9H, s), 1.57 (3H, s), 1.75-1.82 (1H, m),
1.90-1.98 (2H, m), 2.03-2.11 (2H, m), 2.16 (3H, s), 2.38
(3H, s), 3.30-3.47 (1H, m), 3.84 (3H, s), 4.37 (1H, br s),
7.36 (1H, s).
MS (ESI) m/z: 442 (M+Na)+.
[0604]
(Step 47-2)
2-[trans-4-(tert-Butoxycarbonylamino)cyclohexyl]-2,4,7-
trimethy1-1,3-benzodioxole-5-carboxylic acid
[0605]
The title compound (5.79 g, 14.3 mmol, 75% yield)
was obtained through the same reaction as in step 1-2
using methyl 2-[trans-4-(tert-
CA 02942883 2016-09-15
- 219 -
butoxycarbonylamino)cyclohexyl]-2,4,7-trimethy1-1,3-
benzodioxole-5-carboxylate (7.99 g, 19.0 mmol)
synthesized in step 47-1.
1H-NMR (400 MHz, CDC13) 6: 1.04-1.16 (2H, m), 1.27-1.37
(2H, m), 1.44 (9H, s), 1.58 (3H, s), 1.76-1.84 (1H, m),
1.92-1.98 (2H, m), 2.03-2.12 (2H, m), 2.18 (3H, s), 2.42
(3H, s), 3.35-3.47 (1H, m), 4.40 (1H, br s), 7.51 (1H, s).
MS (ESI) m/z: 428 (M+Na)+.
[0606]
(Step 47-3)
tert-Butyl N-[trans-4-[5-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methylcarbamoy1]-2,4,7-trimethyl-1,3-
benzodioxo1-2-yl]cyclohexyl]carbamate
[0607]
The title compound (6.09 g, 11.3 mmol, 79% yield)
was obtained through the same reaction as in step 1-3
using 2-[trans-4-(tert-butoxycarbonylamino)cyclohexyl]-
2,4,7-trimethy1-1,3-benzodioxole-5-carboxylic acid (5.79
g, 14.3 mmol) synthesized in step 47-2.
1H-NMR (400 MHz, DMSO-d6) 6: 1.05-1.23 (4H, m), 1.36 (9H,
s), 1.53 (3H, s), 1.68-1.74 (1H, m), 1.74-1.88 (4H, m),
2.07 (3H, s), 2.09 (3H, s), 2.10 (3H, s), 2.17 (3H, s),
3.08-3.20 (1H, m), 4.22 (2H, d, J = 4.9 Hz), 5.85 (1H, s),
6.66 (1H, s), 6.73 (1H, d, J = 7.9 Hz), 7.88 (1H, t, J =
4.9 Hz), 11.47 (1H, s).
MS (ESI) m/z: 540 (M+H)+.
[0608]
CA 02942883 2016-09-15
- 220 -
(Step 47-4)
2-(trans-4-Aminocyclohexyl)-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methy1]-2,4,7-trimethyl-1,3-
benzodioxole-5-carboxamide
[0609]
The title compound (6.25 g, 14.2 mmol, 100% yield)
was obtained through the same reaction as in step 3-4
using tert-butyl N-[trans-4-[5-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methylcarbamoy1]-2,4,7-trimethyl-1,3-
benzodioxo1-2-yl]cyclohexyl]carbamate (7.68 g, 14.2 mmol)
synthesized in step 47-3.
1H-NMR (400 MHz, DMSO-d6) 6: 0.90-1.05 (2H, m), 1.18-1.22
(2H, m), 1.52 (3H, s), 1.67-1.82 (5H, m), 2.07 (3H, s),
2.09 (3H, s), 2.10 (3H, s), 2.17 (3H, s), 2.38-2.48 (1H,
m), 4.22 (2H, d, J = 4.9 Hz), 5.85 (1H, s), 6.65 (1H, s),
7.87 (1H, t, J = 4.9 Hz), 8.23 (1H, s).
MS (ESI) m/z: 440 (M+H)+.
[0610]
(Step 47-5)
2-[trans-4-(Dimethylamino)cyclohexy1]-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methy1]-2,4,7-trimethyl-1,3-
benzodioxole-5-carboxamide (47)
[0611]
The title compound (5.16 g, 11.0 mmol, 78% yield)
was obtained through the same reaction as in step 3-5
using 2-(trans-4-aminocyclohexyl)-N-[(4,6-dimethy1-2-oxo-
1,2-dihydropyridin-3-y1)methyl]-2,4,7-trimethyl-1,3-
CA 02942883 2016-09-15
- 221 -
benzodioxole-5-carboxamide (6.25 g, 14.2 mmol)
synthesized in step 47-4.
'H-NR (400 MHz, CD30D) 6: 1.32-1.46 (2H, m), 1.48-1.61
(2H, m), 1.57 (3H, s), 1.88-1.97 (1H, m), 2.07-2.20 (4H,
m), 2.11 (4H, s), 2.15 (3H, s), 2.24 (3H, s), 2.36 (3H,
s), 2.82 (6H, s), 3.10-3.23 (1H, m), 4.42 (2H, s), 6.11
(1H, s), 6.71 (1H, s).
MS (ESI) raiz: 468 (M+H)'.
[0612]
This compound was resolved into each enantiomer
under the following conditions:
Column: Daicel CHIRALCEL OZ-3 4.6 mm ID x 150 mm L
Elution solvent: n-hexane:ethanol:diethylamine =
60:40:0.04 (V/V)
Flow rate: 1.00 mL/min
Temperature: 35 C
First peak: 4.5 min (specific rotation []D2 = +15.6 (C =
1.0, chloroform))
Second peak: 6.2 min (specific rotation []D20 15.6 (C
= 1.0, chloroform))
[0613]
Example 48
(2S)-2-[trans-4-(Dimethylamino)cyclohexyl]-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4,7-
trimethy1-1,3-benzodioxole-5-carboxamide (48)
[Formula 40]
CA 02942883 2016-09-15
- 222 -
H3C
OirC H3
0
0 OH oo 0 OH
= C H3 C H3H03-t, 48-2 c C H3
48_1 H3
H3C 0 H3C 0 H3C 0 48-3
0 0
t-Bu 0 0
tCL0.t-Bu H03-t-O.N5.Øt-Bu
H3-CAN-0.,,C0 H3V-
trans-A3q trans-(2S)-A5 trans-(2S)-A3q
HaCrcrC H3 H3Cr.r. C H3 H3CrcrC Ha
I N H I N H N H
0 N H 0 0 N H 0 0 N H 0
,C H3= C Ha
48-4 C H3
48-5
H3C 0 H3C 0 I-13C40
0 0
H03-g-0.4j.o.t-Bu H3-64-0 C H3
I-1364'0"N H2
C H3
trans-(2S)-A4q trans-(2S)-A4q-f a
[0614]
(Step 48-1)
[(3aR,5R,5aS,8aS,8bR)-2,2,7,7-Tetramethy1-5,5a,8a,8b-
tetrahydro-3aH-di[1,3]dioxolo[4,5-a:5',4'-d]pyran-5-
yl]methyl (2S)-2-[trans-4-(tert-
butoxycarbonylamino)cyclohexyl]-2,4,7-trimethy1-1,3-
benzodioxole-5-carboxylate (trans-(2S)-A5)
[0615]
The title compound (61.5 g, 94.9 mmol, 80% yield)
was obtained by esterification under the same conditions
as in step 1-3 using the compound (trans-A3q) (48.0 g,
118 mmol) synthesized in step 47-2 and 1,2:3,4-di-0-
isopropylidene-a-D-galactopyranose (46.2 g, 178 mmol).
1H-NMR (400 MHz, CDC13) 6: 1.02-1.15 (2H, m), 1.25-1.37
(2H, m), 1.33 (3H, s), 1.35 (3H, s), 1.44 (9H, s), 1.48
(3H, s), 1.52 (3H, s), 1.56 (3H, s), 1.73-1.83 (1H, m),
1.90-1.98 (2H, m), 2.03-2.10 (2H, m), 2.16 (3H, s), 2.38
CA 02942883 2016-09-15
- 223 -
(3H, s), 3.32-3.47 (1H, m), 4.14-4.19 (1H, m), 4.29-4.41
(4H, m), 4.42-4.48 (1H, m), 4.62-4.67 (1H, m), 5.56 (1H,
J = 5.1 Hz), 7.39 (1H, s).
[0616]
This compound was resolved into each diastereomer
under the following conditions:
Column: Daicel CHIRALPAK ID 4.6 mm ID x 250 mm L
Elution solvent: n-hexane:2-propanol = 70:30 (V/V)
Flow rate: 1.00 mL/min
Temperature: 40 C
First peak: 7.1 min (specific rotation []D20 = -63.1 (C =
1.0, chloroform))
Second peak: 9.0 min (specific rotation []D2 = 10.6 (C
= 1.0, chloroform))
[0617]
The following steps were carried out using the
second peak separated using a preparative chiral column.
[0618]
(Step 48-2)
(2S)-2-[trans-4-(tert-Butoxycarbonylamino)cyclohexyl]-
2,4,7-trimethy1-1,3-benzodioxole-5-carboxylic acid
(trans-(2S)-A3q)
[0619]
The title compound (3.86 g, 9.51 mmol, 100% yield)
was obtained through the same reaction as in step 1-2
using the compound (trans-(25)-A5) (second peak, 6.16 g,
9.51 mmol) synthesized in step 48-1.
CA 02942883 2016-09-15
- 224 -
[0620]
(Step 48-3)
tert-Butyl N-[trans-4-[(2S)-5-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methylcarbamoy1]-2,4,7-trimethyl-1,3-
benzodioxo1-2-yl]cyclohexyl]carbamate (trans-(2S)-A4q)
[0621]
The title compound (4.73 g, 8.76 mmol, 92% yield)
was obtained through the same reaction as in step 1-3
using the compound (trans-(2S)-A3q) (3.86 g, 9.51 mmol)
synthesized in step 48-2.
1H-NMR (400 MHz, CDC13) 6: 1.01-1.13 (2H, m), 1.20-1.35
(2H, m), 1.44 (9H, s), 1.54 (3H, s), 1.70-1.80 (1H, m),
1.86-1.95 (2H, m), 2.02-2.10 (2H, m), 2.10 (3H, s), 2.23
(6H, s), 2.37 (3H, s), 3.30-3.45 (1H, m), 4.37 (1H, d, J
= 7.9), 4.50 (2H, d, J = 6.1 Hz), 5.94 (1H, s), 6.71 (1H,
s), 7.08 (1H, t, J = 6.1 Hz), 11.86 (1H, br s).
MS (ESI) m/z: 540 (M+H) .
[0622]
(Step 48-4)
(2S)-2-(trans-4-Aminocyclohexyl)-N-[(4,6-dimethy1-2-oxo-
1,2-dihydropyridin-3-yl)methy1]-2,4,7-trimethyl-1,3-
benzodioxole-5-carboxamide (trans-(2S)-A4q-f)
[0623]
The title compound (4.09 g, 8.76 mmol, 100% yield)
was obtained through the same reaction as in step 3-4
using the compound (trans-(2S)-A4q) (4.73 g, 8.76 mmol)
synthesized in step 48-3.
CA 02942883 2016-09-15
- 225 -
1H-NMR (400 MHz, CDC13) 6: 1.01-1.15 (2H, m), 1.18-1.31
(2H, m), 1.54 (3H, s), 1.71-1.81 (1H, m), 1.85-1.94 (4H,
m), 2.10 (3H, s), 2.24 (6H, s), 2.37 (3H, s), 2.57-2.66
(1H, m), 3.71 (2H, s), 4.51 (2H, d, J = 6.1 Hz), 5.94 (1H,
s), 6.71 (1H, s), 7.08-7.14 (1H, m).
MS (ESI) m/z: 440 (M+H)+.
[0624]
(Step 48-5)
(2S)-2-[trans-4-(Dimethylamino)cyclohexyl]-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4,7-
trimethy1-1,3-benzodioxole-5-carboxamide (48)
[0625]
The title compound (3.03 g, 6.48 mmol, 74% yield)
was obtained through the same reaction as in step 3-5
using the compound (trans-(2S)-A4q-f) (4.11 g, 8.82 mmol)
synthesized in step 48-4.
1H-NMR (400 MHz, DMSO-d6) 6: 1.05-1.22 (4H, m), 1.53 (3H,
s), 1.70-1.90 (5H, m), 2.02-2.10 (1H, m), 2.07 (3H, s),
2.10 (3H, s), 2.11 (3H, s), 2.13 (6H, s), 2.17 (3H, s),
4.22 (2H, d, J = 5.5 Hz), 5.85 (1H, s), 6.66 (1H, s),
7.88 (1H, t, J = 5.5 Hz), 11.48 (1H, br s).
MS (ESI) m/z: 468 (M+H)+.
Specific rotation []D20 = +15.6 (C = 1.0, chloroform)
This compound agreed with the compound of the first
peak obtained under the resolution conditions using a
chiral column described in Example 47.
[0626]
,
CA 02942883 2016-09-15
- 226 -
Example 49
2-[(2S,5R)-5-(Dimethylamino)tetrahydropyran-2-y1]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4,7-trimethy1-1,3-benzodioxole-5-carboxamide (49)
[0627]
(Step 49-1)
Methyl 2-[(2S,5R)-5-(tert-
butoxycarbonylamino)tetrahydropyran-2-y1]-2,4,7-
trimethy1-1,3-benzodioxole-5-carboxylate
[0628]
The title compound (0.154 g, 0.365 mmol, 37% yield)
was obtained through the same reaction as in step 13-1
using the compound (Ald) (0.196 g, 1.00 mmol) synthesized
in Reference Example 4 and tert-butyl N-[(3R,6S)-6-
ethynyltetrahydropyran-3-yl]carbamate (0.338 g, 1.50
mmol) synthesized according to the method described in WO
2007105154.
1H-NMR (400 MHz, CDC13) 43: 1.21-1.34 (1H, m), 1.44 (9H,
s), 1.51-1.62 (1H, m), 1.66 (3H, s), 1.80-1.90 (1H, m),
2.09-2.18 (1H, m), 2.19 (3H, s), 2.39 (3H, s), 2.99-3.08
(1H, m), 3.41-3.49 (1H, m), 3.52-3.70 (1H, m), 3.84 (3H,
s), 4.14-4.28 (1H, m), 7.38 (1H, s).
[0629]
(Step 49-2)
2-[(2S,5R)-5-(tert-Butoxycarbonylamino)tetrahydropyran-2-
y1]-2,4,7-trimethy1-1,3-benzodioxole-5-carboxylic acid
[0630]
CA 02942883 2016-09-15
- 227 -
The title compound (0.147 g, 0.365 mmol, 100% yield)
was obtained through the same reaction as in step 1-2
using methyl 2-[(2S,5R)-5-(tert-
butoxycarbonylamino)tetrahydropyran-2-y1]-2,4,7-
trimethy1-1,3-benzodioxole-5-carboxylate (0.154 g, 0.365
mmol) synthesized in step 49-1.
1H-NMR (400 MHz, CDC13) 6: 1.24-1.35 (1H, m), 1.45 (9H,
s), 1.51-1.63 (1H, m), 1.67 (3H, s), 1.80-1.90 (1H, m),
2.09-2.18 (2H, m), 2.20 (3H, s), 2.42 (3H, s), 2.99-3.09
(1H, m), 3.42-3.50 (1H, m), 3.51-3.76 (1H, m), 4.13-4.30
(1H, m), 7.52 (1H, s).
MS (APCI) miz: 406 (M-H)-.
[0631]
(Step 49-3)
tert-Butyl N-[(3R,6S)-6-[5-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methylcarbamoy1]-2,4,7-trimethy1-1,3-
benzodioxo1-2-yl]tetrahydropyran-3-yllcarbamate
[0632]
The title compound (0.190 g, 0.351 mmol, 96% yield)
was obtained through the same reaction as in step 1-3
using 2-[(2S,5R)-5-(tert-
butoxycarbonylamino)tetrahydropyran-2-y1]-2,4,7-
trimethy1-1,3-benzodioxole-5-carboxylic acid (0.147 g,
0.365 mmol) synthesized in step 49-2.
1H-NMR (400 MHz, CDC13) 6: 1.20-1.32 (1H, m), 1.44 (9H,
s), 1.49-1.61 (1H, m), 1.63 (3H, s), 1.77-1.87 (1H, m),
2.08-2.16 (1H, m), 2.12 (3H, s), 2.24 (6H, s), 2.38 (3H,
CA 02942883 2016-09-15
- 228 -
s), 2.98-3.07 (1H, m), 3.39-3.46 (1H, m), 3.53-3.70 (1H,
m), 4.13-4.21 (1H, m), 4.22-4.30 (1H, m), 4.50 (2H, d, J
= 5.5 Hz), 5.94 (1H, s), 6.73 (1H, s), 7.07 (1H, t, J =
5.5 Hz), 11.49 (1H, br s).
MS (APCI) m/z: 542 (M+H)+.
[0633]
(Step 49-4)
2-[(2S,5R)-5-Aminotetrahydropyran-2-y1]-N-[(4,6-dimethyl-
2-oxo-1,2-dihydropyridin-3-yl)methy1]-2,4,7-trimethyl-
1,3-benzodioxole-5-carboxamide
[0634]
The title compound (0.143 g, 0.324 mmol, 92% yield)
was obtained through the same reaction as in step 3-4
using tert-butyl N-[(3R,6S)-6-[5-[(4,6-dimethy1-2-oxo-
1,2-dihydropyridin-3-yl)methylcarbamoy1]-2,4,7-trimethyl-
1,3-benzodioxo1-2-yl]tetrahydropyran-3-yl]carbamate
(0.190 g, 0.351 mmol) synthesized in step 49-3.
1H-NMR (400 MHz, CDC13) 6: 1.14-1.28 (1H, m), 1.43-1.58
(1H, m), 1.64 (3H, s), 1.74-1.83 (1H, m), 2.01-2.10 (1H,
m), 2.12 (3H, s), 2.23 (3H, s), 2.24 (3H, s), 2.37 (3H,
s), 2.78-2.90 (1H, m), 2.94-3.07 (1H, m), 3.39-3.46 (1H,
m), 4.00-4.08 (1H, m), 4.50 (2H, d, J = 5.5 Hz), 5.94 (1H,
s), 6.73 (1H, s), 7.07 (1H, t, J = 5.5 Hz), 11.80 (1H, br
s).
MS (APCI) m/z: 442 (M+H)+.
[0635]
(Step 49-5)
CA 02942883 2016-09-15
- 229 -
2-[(2S,5R)-5-(Dimethylamino)tetrahydropyran-2-y1]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4,7-trimethy1-1,3-benzodioxole-5-carboxamide (49)
[0636]
The title compound (0.128 g, 0.273 mmol, 84% yield)
was obtained through the same reaction as In step 3-5
using 2-[(2S,5R)-5-aminotetrahydropyran-2-y1]-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4,7-
trimethy1-1,3-benzodioxole-5-carboxamide (0.143 g, 0.324
mmol) synthesized in step 49-4.
1H-NMR (400 MHz, DMSO-d6) 6: 1.26-1.46 (2H, m), 1.56 (3H,
s), 1.68-1.80 (1H, m), 1.90-2.01 (1H, m), 2.07 (3H, s),
2.09 (3H, s), 2.10 (3H, s), 2.14 (6H, s), 2.17 (3H, s),
3.16 (1H, t, J = 10.3 Hz), 3.44 (1H, d, J = 10.3 Hz),
3.99-4.08 (1H, m), 4.22 (2H, d, J = 4.9 Hz), 5.85 (1H, s),
6.67 (1H, s), 7.89 (1H, t, J = 4.9 Hz), 11.7 (1H, br s).
MS (APCI) m/z: 470 (M+H)+.
[0637]
Example 50
2-[trans-4-(Dimethylamino)cyclohexy1]-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methy1]-7-methoxy-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (50)
[0638]
(Step 50-1)
Methyl 2-[trans-4-(tert-butoxycarbonylamino)cyclohexyl]-
7-methoxy-2,4-dimethy1-1,3-benzodioxole-5-carboxylate
CA 02942883 2016-09-15
- 230 -
The title compound (0.043 g, 0.098 mmol, 27% yield)
was obtained through the same reaction as in step 13-1
using the compound (Ale) (0.077 g, 0.364 mmol)
synthesized in Reference Example 5 and tert-butyl N-
(trans-4-ethynylcyclohexyl)carbamate (0.122 g, 0.547 mmol
synthesized in Reference Example 13.
1H-NMR (400 MHz, CDC13) 6: 1.04-1.13 (2H, m), 1.30-1.39
(2H, m), 1.44 (9H, s), 1.60 (3H, s), 1.79-1.89 (1H, m),
1.95-1.98 (2H, m), 2.01-2.09 (2H, m), 2.37 (3H, s), 3.30-
3.45 (1H, m), 3.86 (3H, s), 3.89 (3H, s), 4.37 (1H, br s),
7.21 (1H, s).
[0639]
(Step 50-2)
2-[trans-4-(tert-Butoxycarbonylamino)cyclohexyl]-7-
methoxy-2,4-dimethy1-1,3-benzodioxole-5-carboxylic acid
[0640]
The title compound (0.042 g, 0.098 mmol, 100% yield)
was obtained through the same reaction as in step 1-2
using methyl 2-[trans-4-(tert-
butoxycarbonylamino)cyclohexyl]-7-methoxy-2,4-dimethyl-
1,3-benzodioxole-5-carboxylate (0.043 g, 0.098 mmol)
synthesized in step 50-1.
[0641]
(Step 50-3)
tert-Butyl N-[trans-4-[5-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methylcarbamoy1]-7-methoxy-2,4-
dimethy1-1,3-benzodioxo1-2-yl]cyclohexylicarbamate
CA 02942883 2016-09-15
- 231 -
[0642]
The title compound (0.044 g, 0.079 mmol, 80% yield)
was obtained through the same reaction as in step 1-3
using 2-[trans-4-(tert-butoxycarbonylamino)cyclohexyl]-7-
methoxy-2,4-dimethy1-1,3-benzodioxole-5-carboxylic acid
(0.042 g, 0.098 mmol) synthesized in step 50-2.
1H-NMR (400 MHz, CDC13) 6: 1.03-1.18 (2H, m), 1.28-1.37
(2H, m), 1.43 (9H, s), 1.56 (3H, s), 1.72-1.82 (1H, m),
1.90-1.97 (2H, m), 2.01-2.09 (2H, m), 2.20 (3H, s), 2.23
(3H, s), 2.38 (3H, s), 3.30-3.45 (1H, m), 3.82 (3H, s),
4.39 (1H, d, J = 8.0 Hz), 4.52 (2H, d, J = 6.1 Hz), 5.96
(1H, s), 6.63 (1H, s), 7.16 (1H, t, J = 6.1 Hz), 12.36
(1H, br s).
MS (APCI) m/z: 556 (M+H)+.
[0643]
(Step 50-4)
2-(trans-4-Aminocyclohexyl)-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methy1]-7-methoxy-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide
[0644]
The title compound (0.033 g, 0.072 mmol, 86% yield)
was obtained through the same reaction as in step 3-4
using tert-butyl N-[trans-4-[5-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methylcarbamoy1]-7-methoxy-2,4-
dimethy1-1,3-benzodioxo1-2-yl]cyclohexyl]carbamate (0.044
g, 0.079 mmol) synthesized in step 50-3.
[0645]
CA 02942883 2016-09-15
- 232 -
(Step 50-5)
2-[trans-4-(Dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methy1]-7-methoxy-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (50)
[0646]
The title compound (0.018 g, 0.037 mmol, 51% yield)
was obtained through the same reaction as in step 3-5
using 2-(trans-4-aminocyclohexyl)-N-[(4,6-dimethy1-2-oxo-
1,2-dihydropyridin-3-y1)methyl]-7-methoxy-2,4-dimethyl-
1,3-benzodioxole-5-carboxamide (0.033 g, 0.072 mmol)
synthesized in step 50-4.
1H-NMR (400 MHz, CDC13) 6: 1.18-1.31 (4H, m),1.57 (3H, s),
1.76-1.82 (1H, m), 1.92-2.01 (4H, m), 2.11-2.16 (1H, m),
2.21 (3H, s), 2.23 (3H, s), 2.27 (6H, s), 2.38 (3H, s),
3.83 (3H, s), 4.51 (2H, d, J = 6.0 Hz), 5.94 (1H, s),
6.62 (1H, s), 7.11 (1H, t, J = 6.1 Hz), 11.47 (1H, br s).
MS (APCI) m/z: 484 (M+H)+.
[0647]
Example 51
4,7-Dichloro-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2-methy1-2-(1-methyl-4-piperidy1)-1,3-
benzodioxole-5-carboxamide (51)
[0648]
(Step 51-1)
tert-Butyl 4-(4,7-dichloro-5-methoxycarbony1-2-methy1-
1,3-benzodioxol-2-yl)piperidine-1-carboxylate
[0649]
CA 02942883 2016-09-15
- 233 -
The title compound (2.81 g, 6.30 mmol, 83% yield)
was obtained through the same reaction as in step 1-1
using the compound (E2) (1.80 g, 7.59 mmol) synthesized
in Reference Example 6 and tert-butyl 4-
ethynylpiperidine-1-carboxylate (2.38 g, 11.4 mmol)
synthesized according to the method described in WO
2008156739.
1H-NMR (400 MHz, CDC13) 6: 1.36-1.44 (2H, m), 1.46 (9H,
s), 1.71 (3H, s), 1.81-1.87 (2H, m), 2.00-2.10 (1H, m),
2.62-2.73 (2H, m), 3.90 (3H, s), 4.15-4.30 (2H, m), 7.52
(1H, s).
[0650]
(Step 51-2)
2-(1-tert-Butoxycarbony1-4-piperidy1)-4,7-dich10r0-2-
methy1-1,3-benzodioxole-5-carboxylic acid
[0651]
The title compound (2.72 g, 6.29 mmol, 100% yield)
was obtained through the same reaction as in step 1-2
using tert-butyl 4-(4,7-dichloro-5-methoxycarbony1-2-
methy1-1,3-benzodioxol-2-yl)piperidine-1-carboxylate
(2.81 g, 6.30 mmol) synthesized in step 51-1.
[0652]
(Step 51-3)
tert-Butyl 4-[4,7-dichloro-5-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methylcarbamoy1]-2-methy1-1,3-
benzodioxo1-2-yl]piperidine-l-carboxylate
[0653]
CA 02942883 2016-09-15
- 234 -
The title compound (2.78 g, 4.91 mmol, 78% yield)
was obtained through the same reaction as in step 1-3
using 2-(1-tert-butoxycarbony1-4-piperidy1)-4,7-dichloro-
2-methyl-1,3-benzodioxole-5-carboxylic acid (2.72 g, 6.29
mmol) synthesized in step 51-2.
1H-NMR (400 MHz, CDC13) 6: 1.33-1.45 (2H, m), 1.45 (9H,
s), 1.67 (3H, s), 1.78-1.85 (2H, m), 1.97-2.06 (1H, m),
2.26 (3H, s), 2.37 (3H, s), 2.59-2.71 (2H, m), 4.09-4.35
(2H, m), 4.53 (2H, d, J - 5.5 Hz), 5.96 (1H, s), 7.19 (1H,
s), 7.53-7.61 (1H, m).
MS (APCI) m/z: 566 (M+H)+.
[0654]
(Step 51-4)
4,7-Dichloro-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2-methy1-2-(4-piperidy1)-1,3-benzodioxole-5-
carboxamide
[0655]
The title compound (2.13 g, 4.57 mmol, 93% yield)
was obtained through the same reaction as in step 3-4
using tert-butyl 4-(4,7-dichloro-5-methoxycarbony1-2-
methy1-1,3-benzodioxol-2-yl)piperidine-1-carboxylate
(2.78 g, 4.91 mmol) synthesized in step 51-3.
MS (APCI) m/z: 466 (M+H)+.
[0656]
(Step 51-5)
CA 02942883 2016-09-15
- 235 -
4,7-Dichloro-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2-methy1-2-(1-methyl-4-piperidy1)-1,3-
benzodioxole-5-carboxamide (51)
[0657]
The title compound (1.04 g, 2.17 mmol, 96% yield)
was obtained through the same reaction as in step 3-5
using 4,7-dichloro-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methy1]-2-methyl-2-(4-piperidy1)-1,3-
benzodioxole-5-carboxamide (1.05 g, 2.25 mmol)
synthesized in step 51-4.
1H-NMR (400 MHz, DMSO-d6) 6: 1.30-1.43 (2H, m), 1.66-1.72
(2H, m), 1.68 (3H, s), 1.75-1.83 (2H, m), 1.84-1.93 (1H,
m), 2.11 (3H, s), 2.12 (3H, s), 2.17 (3H, s), 2.76-2.84
(2H, m), 4.23 (2H, d, J = 4.9 Hz), 5.86 (1H, s), 6.95 (1H,
s), 8.32 (1H, t, J = 4.9 Hz), 11.50 (1H, s).
MS (APCI) m/z: 480 (M+H)+.
[0658]
Example 52
4,7-Dichloro-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2-(1-ethy1-4-piperidy1)-2-methyl-1,3-
benzodioxole-5-carboxamide (52)
[0659]
The title compound (0.757 g, 1.53 mmol, 68% yield)
was obtained in an ethyl form through the same reaction
as in step 3-5 using 4,7-dichloro-N-[(4,6-dimethy1-2-oxo-
1,2-dihydropyridin-3-yl)methy1]-2-methyl-2-(4-piperidy1)-
1,3-benzodioxole-5-carboxamide (1.05 g, 2.25 mmol)
CA 02942883 2016-09-15
- 236 -
synthesized in step 51-4 and acetaldehyde (1.48 g, 33.8
mmol).
1H-NMR (400 MHz, DMSO-d6) 6: 0.97 (3H, t, J = 7.0 Hz),
1.28-1.42 (2H, m), 1.68 (3H, s), 1.68-1.74 (2H, m), 1.73-
1.86 (2H, m), 1.87-1.96 (1H, m), 2.11 (3H, s), 2.17 (3H,
s), 2.22-2.32 (2H, m), 2.88-2.96 (2H, m), 4.23 (2H, d, J
= 5.5 Hz), 5.86 (1H, s), 6.95 (1H, s), 8.32 (1H, t, J =
5.5 Hz), 11.50 (1H, s).
MS (APCI) m/z: 494 (M+H)+.
[0660]
Example 53
4,7-Dichloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2-
methy1-1,3-benzodioxole-5-carboxamide (53)
[0661]
(Step 53-1)
Methyl 2-[trans-4-(tert-butoxycarbonylamino)cyclohexyl]-
4,7-dichloro-2-methy1-1,3-benzodioxole-5-carboxylate
[0662]
The title compound (0.918 g, 1.92 mmol, 68% yield)
was obtained through the same reaction as in step 13-1
using the compound (E2) (0.721 g, 2.83 mmol) synthesized
in Reference Example 6 and tert-butyl N-(trans-4-
ethynylcyclohexyl)carbamate (0.950 g, 4.25 mmol
synthesized in Reference Example 13.
1H-NMR (400 MHz, CDC13) 6: 1.04-1.18 (2H, m), 1.27-1.40
(2H, m), 1.43 (9H, s), 1.68 (3H, s), 1.82-2.02 (3H, m),
CA 02942883 2016-09-15
- 237 -
2.03-2.14 (2H, m), 3.32-3.48 (1H, m), 3.89 (3H, s), 4.37
(1H, br s), 7.51 (1H, s).
[0663]
(Step 53-2)
2-[trans-4-(tert-Butoxycarbonylamino)cyclohexyl]-4,7-
dichloro-2-methy1-1,3-benzodioxole-5-carboxylic acid
[0664]
The title compound (0.194 g, 0.413 mmol, 92% yield)
was obtained through the same reaction as in step 1-2
using methyl 2-[trans-4-(tert-
butoxycarbonylamino)cyclohexy1]-4,7-dichloro-2-methyl-
1,3-benzodioxole-5-carboxylate (0.215 g, 0.450 mmol)
synthesized in step 53-1.
1H-NMR (400 MHz, CDC13) 6: 1.06-1.20 (2H, m), 1.28-1.43
(2H, m), 1.44 (9H, s), 1.70 (3H, s), 1.84-2.02 (3H, m),
2.05-2.15 (2H, m), 3.34-3.50 (1H, m), 4.40 (1H, br s),
7.67 (1H, s).
MS (APCI) m/z: 444 (M-H)-.
[0665]
(Step 53-3)
tert-Butyl N-[trans-4-[4,7-dichloro-5-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methylcarbamoy1]-2-methyl-
1,3-benzodioxo1-2-yl]cyclohexyl]carbamate
[0666]
The title compound (0.225 g, 0.384 mmol, 95% yield)
was obtained through the same reaction as in step 1-3
using 2-[trans-4-(tert-butoxycarbonylamino)cyclohexyl]-
CA 02942883 2016-09-15
- 238 -
4,7-dichloro-2-methy1-1,3-benzodioxole-5-carboxylic acid
(0.190 g, 0.405 mmol) synthesized in step 53-2.
1H-NMR (400 MHz, CDC13) 6: 1.02-1.16 (2H, m), 1.24-1.38
(2H, m), 1.43 (9H, s), 1.65 (3H, s), 1.79-1.98 (3H, m),
2.03-2.12 (2H, m), 2.26 (3H, s), 2.37 (3H, s), 3.32-3.46
(1H, m), 4.38 (1H, d, J = 7.9 Hz), 4.52 (2H, d, J = 6.0
Hz), 5.95 (1H, s), 7.18 (1H, s), 7.55 (1H, d, J = 6.0 Hz),
11.7 (1H, br s).
MS(APCI) m/z: 580 (M+H)+.
[0667]
(Step 53-4)
2-(trans-4-Aminocyclohexyl)-4,7-dichloro-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2-methyl-
1,3-benzodioxole-5-carboxamide
[0668]
The title compound (0.182 g, 0.378 mmol, 100% yield)
was obtained through the same reaction as in step 3-4
using tert-butyl N-[trans-4-[4,7-dichloro-5-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methylcarbamoyl]-
2-methy1-1,3-benzodioxo1-2-yl]cyclohexyl]carbamate (0.221
g, 0.378 mmol) synthesized in step 53-3.
1H-NMR (400 MHz, CDC13) 6: 1.03-1.18 (2H, m), 1.21-1.36
(2H, m), 1.66 (3H, s), 1.80-1.98 (5H, m), 2.26 (3H, s),
2.38 (3H, s), 2.59-2.70 (1H, m), 3.71 (2H,$), 4.52 (2H, d,
J = 6.1 Hz), 5.94 (1H, s), 7.18 (1H, s), 7.54 (1H, t, J =-
6.1 Hz).
MS(APCI) m/z: 480 (M+H)+.
CA 02942883 2016-09-15
- 239 -
[0669]
(Step 53-5)
4,7-Dichloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2-
methy1-1,3-benzodioxole-5-carboxamide (53)
[0670]
The title compound (0.088 g, 0.173 mmol, 46% yield)
was obtained through the same reaction as in step 3-5
using 2-(trans-4-aminocyclohexyl)-4,7-dichloro-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2-methyl-
1,3-benzodioxole-5-carboxamide (0.182 g, 0.378 mmol)
synthesized in step 53-4.
1H-NMR (400 MHz, CDC13) 6: 1.15-1.33 (4H, m), 1.66 (3H,
s), 1.79-1.89 (1H, m), 1.91-2.04 (4H, m), 2.09-2.20 (1H,
m), 2.26 (3H, s), 2.27 (6H, s), 2.37 (3H, s), 4.53 (2H, d,
J = 5.6 Hz), 5.95 (1H, s), 7.17-7.19 (1H, m), 7.55 (1H, t,
J = 5.6 Hz), 11.87 (1H, br s).
MS(APCI) m/z: 508 (M+H)+.
[0671]
Example 54
4,7-Dichloro-2-[(2S,5R)-5-(dimethylamino)tetrahydropyran-
2-yll-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2-methy1-1,3-benzodioxole-5-carboxamide (54)
[0672]
(Step 54-1)
CA 02942883 2016-09-15
- 240 -
Methyl 2-[(2S,5R)-5-(tert-
butoxycarbonylamino)tetrahydropyran-2-y1]-4,7-dichloro-2-
methy1-1,3-benzodioxole-5-carboxylate
[0673]
The title compound (0.496 g, 1.07 mmol, 70% yield)
was obtained through the same reaction as in step 13-1
using the compound (E2) (0.500 g, 1.54 mmol) synthesized
in Reference Example 6 and tert-butyl N-[(3R,6S)-6-
ethynyltetrahydropyran-3-yl]carbamate (0.520 g, 2.31
mmol) synthesized according to the method described in WO
2007105154.
1H-NMR (400 MHz, CDC13) 6: 1.22-1.36 (2H, m), 1.43 (9H,
s), 1.64-1.75 (1H, m), 1.75 (3H, s), 1.82-1.95 (1H, m),
2.10-2.22 (1H, m), 2.99-3.08 (1H, m), 3.48-3.55 (1H, m),
3.56-3.74 (1H, m), 3.90 (3H, s), 4.10-4.17 (1H, m), 4.25
(1H, br s), 7.52 (1H, s).
[0674]
(Step 54-2)
2-[(2S,5R)-5-(tert-Butoxycarbonylamino)tetrahydropyran-2-
y1]-4,7-dichloro-2-methy1-1,3-benzodioxole-5-carboxylic
acid
[0675]
The title compound (0.481 g, 1.07 mmol, 100% yield)
was obtained through the same reaction as in step 1-2
using methyl 2-[(2S,5R)-5-(tert-
butoxycarbonylamino)tetrahydropyran-2-y1]-4,7-dichloro-2-
CA 02942883 2016-09-15
- 241 -
methyl-1,3-benzodioxole-5-carboxylate (0.496 g, 1.07
mmol) synthesized in step 54-1.
MS (ESI) m/z: 446 (M-H)-.
[0676]
(Step 54-3)
tert-Butyl N-[(3R,6S)-6-[4,7-dichloro-5-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methylcarbamoy1]-2-methyl-
1,3-benzodioxo1-2-ylltetrahydropyran-3-yl]carbamate
[0677]
The title compound (0.336 g, 0.569 mmol, 53% yield)
was obtained through the same reaction as in step 1-3
using 2-[(2S,5R)-5-(tert-
butoxycarbonylamino)tetrahydropyran-2-y1]-4,7-dichloro-2-
methy1-1,3-benzodioxole-5-carboxylic acid (0.481 g, 1.07
mmol) synthesized in step 54-2.
MS (ESI) m/z: 582 (M+H)+.
[0678]
(Step 54-4)
2-[(2S,5R)-5-Aminotetrahydropyran-2-y1]-4,7-dichloro-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2-
methy1-1,3-benzodioxole-5-carboxamide
[0679]
The title compound (0.176 g, 0.364 mmol, 64% yield)
was obtained through the same reaction as in step 3-4
using tert-butyl N-[(3R,6S)-6-[4,7-dichloro-5-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methylcarbamoyl]-
2-methy1-1,3-benzodioxo1-2-ylltetrahydropyran-3-
CA 02942883 2016-09-15
- 242 -
yl]carbamate (0.332 g, 0.569 mmol) synthesized in (Step
54-3.
MS (ESI) m/z: 482 (M+H)+.
[0680]
(Step 54-5)
4,7-Dichloro-2-[(2S,5R)-5-(dimethylamino)tetrahydropyran-
2-y1]-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2-methy1-1,3-benzodioxole-5-carboxamide (54)
[0681]
The title compound (0.036 g, 0.070 mmol, 19% yield)
was obtained through the same reaction as in step 3-5
using 2-[(2S,5R)-5-aminotetrahydropyran-2-y1]-4,7-
dichloro-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2-methy1-1,3-benzodioxole-5-carboxamide (0.176
g, 0.345 mmol) synthesized in step 54-4.
1H-NMR (400 MHz, CD30D) 6: 1.70 (3H, s), 2.24 (3H, s),
2.29 (3H, s), 2.35 (3H, s), 4.43 (2H, s), 6.10 (1H, s),
6.61 (1H, s), 6.98 (1H, s).
MS (ESI) m/z: 510 (M+H)+.
[0682]
Example 55
N-[(4,6-Dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2-
ethy1-7-[6-(4-ethylpiperazin-1-y1)-3-pyridy1]-4-methyl-2-
(tetrahydropyran-4-y1)-1,3-benzodioxole-5-carboxamide
(55)
[Formula 41]
CA 02942883 2016-09-15
- 243 -
H3
H3
OH
0 0 C H3
= C H3
CH3
Br
Br
554 ofs,c1 55-2 0 55-3
Br OH
OH
H3C 0 01.,C0
H3C
Ala A2r A3r
H3CrcrCH3
H3C(117CH3 NH
I NH
0 N H 0
0 NH 0
C H3
C H3
Br 'WI 0 r-N N 13-1121
0
H3C
0 C
0 H3C H3C
[0683]
(Step 55-1)
Methyl 7-bromo-2-ethy1-4-methy1-2-(tetrahydropyran-4-y1)-
1,3-benzodioxole-5-carboxylate (A2r)
[0684]
The compound (Ala) (2.50 g, 9.58 mmol) synthesized
in Reference Example 1 was dissolved in toluene (100 mL)
under a nitrogen atmosphere. To the solution, 1-
tetrahydropyran-4-ylpropan-1-one (2.15 g, 14.4 mmol) and
montmorillonite K10, powder (5.00 g) were added, and the
mixture was refluxed for 12 hours while removing water
using a Dean-Stark apparatus. Insoluble matter was
removed by filtration, and the filtrate was then
concentrated under reduced pressure. The obtained
residue was purified by silica gel column chromatography
(hexane:ethyl acetate = 90:10) to obtain the title
compound (0.179 mg, 0.463 mmol, 4.8% yield).
CA 02942883 2016-09-15
- 244 -
1H-NMR (400 MHz, CDC13) 6: 0.98 (3H, t, J = 7.3 Hz),
1.59-1.69 (4H, m), 1.98 (2H, q, J = 7.3 Hz), 2.08-2.19
(1H, m), 2.39 (3H, s), 3.33-3.35 (2H, m), 3.85 (3H, s),
4.00-4.06 (2H, m), 7.66 (1H, s).
[0685]
(Step 55-2)
7-Bromo-2-ethy1-4-methy1-2-(tetrahydropyran-4-y1)-1,3-
benzodioxole-5-carboxylic acid (A3r)
[0686]
The title compound (0.122 g, 0.330 mmol, 75% yield)
was obtained through the same reaction as in step 1-2
using the compound (A2r) (170 mg, 0.441 mmol) synthesized
in step 55-1.
1H-NMR (400 MHz, 0DC13) 6: 0.99 (3H, t, J = 7.3 Hz),
1.61-1.76 (4H, m), 2.00 (2H, q, J = 7.3 Hz), 2.09-2.20
(1H, m), 2.43 (3H, s), 3.32-3.43 (2H, m), 4.01-4.06 (2H,
m), 7.81 (1H, s).
MS (ESI) m/z: 369, 371 (M-H)-.
[0687]
(Step 55-3)
7-Bromo-N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-2-ethy1-4-methyl-2-(tetrahydropyran-4-y1)-1,3-
benzodioxole-5-carboxamide (55p)
[0688]
The title compound (0.120 g, 0.238 mmol, 72% yield)
was obtained through the same reaction as in step 1-3
CA 02942883 2016-09-15
- 245 -
using the compound (A3r) (0.122 g, 0.330 mmol)
synthesized in step 55-2.
1H-NMR (400 MHz, CDC13) 8: 0.95 (3H, t, J = 7.3 Hz),
1.57-1.65 (4H, m), 1.60 (3H, s), 1.95 (2H, q, J = 7.3 Hz),
2.05-2.14 (1H, m), 2.22 (3H, s), 2.25 (3H, s), 2.37 (3H,
s), 3.30-3.43 (2H, m), 3.98-4.07 (2H, m), 4.49 (2H, d, J
= 6.1 Hz), 5.95 (1H, s), 6.99 (1H, s), 7.18 (1H, s).
MS (ESI) m/z: 505, 507 (M+H)+.
[0689]
(Step 55-4)
N-[(4,6-Dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2-
ethy1-7-[6-(4-ethylpiperazin-l-y1)-3-pyridyl]-4-methyl-2-
(tetrahydropyran-4-y1)-1,3-benzodioxole-5-carboxamide
(55)
[0690]
The compound (55p) (0.110 g, 0.218 mmol) synthesized
in step 55-3 was dissolved in 1,4-dioxane (4.4 mL) and
water (1.1 mL). To the solution, 6-(4-ethyl-piperazin-1-
yl)pyridine-3-boronic acid pinacol ester (0.083 g, 0.261
mmol), potassium phosphate (0.139 g, 0.653 mmol), and a
[1,1'-bis(dipheny1phosphino)ferrocene]pa11adium(II)
dichloride-dichloromethane complex (1:1) (0.027 g, 0.033
mmol) were added, and the mixture was stirred at 80 C for
4 hours under a nitrogen atmosphere. After the
completion of the reaction, the reaction solution was
filtered through celite, and ethyl acetate was added to
the filtrate. The organic layer was washed with a
CA 02942883 2016-09-15
- 246 -
saturated aqueous solution of sodium bicarbonate and
saturated saline and then dried over sodium sulfate. The
solvent was distilled off under reduced pressure, and the
obtained residue was purified by silica gel column
chromatography (hexane:methanol = 100:0 -* 95:5) to
obtain the title compound (0.040 g, 0.064 mmol, 30%
yield).
1H-NMR (400 MHz, CD30D) 6: 0.97 (3H, t, J = 7.3 Hz), 1.17
(3H, t, J = 7.3 Hz), 1.52-1.62 (2H, m), 1.68-1.71 (2H, m),
2.00 (2H, q, J = 7.3 Hz), 2.17-2.22 (1H, m), 2.24 (6H, s),
2.37 (3H, s), 2.52-2.60 (2H, m), 2.63-2.71 (4H, m), 3.35-
3.42 (2H, m), 3.60 (2H, q, J = 7.3 Hz), 3.60-3.75 (2H, m),
3.92-3.98 (2H, m), 4.45 (2H, s), 6.11 (1H, s), 6.90 (1H,
d, J = 8.5 Hz), 7.08 (1H, s), 7.92 (1H, dd, J - 8.5, 2.7
Hz), 8.51 (1H, d, J = 2.7 Hz).
MS (ESI) m/z: 616 (M+H) .
[0691]
Example 56
N-[(4,6-Dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-
[6-(4-ethylpiperazin-1-y1)-3-pyridy1]-2,4-dimethy1-2-
(tetrahydropyran-4-y1)-1,3-benzodioxole-5-carboxamide
(56)
[0692]
The title compound (0.154 g, 0.256 mmol, 84% yield)
was obtained through the same reaction as in step 55-4
using the compound (2) (0.150 g, 0.305 mmol) synthesized
in step 2-3.
CA 02942883 2016-09-15
- 247 -
1H-NMR (400 MHz, DMSO-dd 6: 1.04 (3H, t, J = 7.0 Hz),
1.60 (3H, s), 1.62-1.70 (2H, m), 2.11 (3H, s), 2.15-2.20
(6H, m), 2.36 (2H, q, J = 7.0), 2.41-2.48 (4H, m), 3.24-
3.33 (2H, m), 3.48-3.55 (4H, m), 3.85-3.93 (2H, m), 4.26
(2H, d, J - 4.9 Hz), 5.86 (1H, s), 6.92 (1H, d, J = 8.5
Hz), 7.04 (1H, s), 7.85 (1H, d, J = 8.5 Hz), 8.11 (1H, t,
J = 4.9 Hz), 8.48 (1H, s), 11.48 (1H, s).
MS (ESI) m/z: 602 (M+H)+.
[0693]
Example 57
N-[(4,6-Dimethy1-2-oxo-1,2-dihydropyridin-3-y1)methyl]-7-
[6-(4-ethylpiperazin-1-y1)-3-pyridy1]-2,4-dimethyl-2-
(tetrahydrofuran-3-y1)-1,3-benzodioxole-5-carboxamide
(57)
[0694]
The title compound (0.130 g, 0.256 mmol, 82% yield)
was obtained through the same reaction as in step 55-4
using the compound (1) (0.150 g, 0.314 mmol) synthesized
in step 1-3.
1H-NMR (400 MHz, DMSO-d6) 6: 1.04 (3H, t, J = 7.3 Hz),
1.62 (3H, s), 1.76-1.87 (1H, m), 1.94-2.05 (1H, m), 2.10
(3H, s), 2.15-2.20 (6H, m), 2.31-2.40 (2H, m), 2.40-2.48
(4H, m), 2.88-2.98 (1H, m), 3.46-3.56 (4H, m), 3.59-3.68
(2H, m), 3.71-3.84 (2H, m), 4.26 (2H, d, J = 4.9 Hz),
5.86 (1H, s), 6.91 (1H, d, J = 8.5 Hz), 7.05 (1H, s),
7.84 (1H, dd, J - 8.5, 2.4 Hz), 8.13 (1H, t, J = 4.9 Hz),
8.47 (1H, d, J - 2.4 Hz), 11.48 (1H, s).
CA 02942883 2016-09-15
- 248 -
MS (ESI) m/z: 588 (M+H)+.
[0695]
Example 58
7-(Cyclopenten-1-y1)-2-[trans-4-
(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-y1)methy1]-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide (58)
[0696]
The title compound (0.156 g, 0.300 mmol, 64% yield)
was obtained through the same reaction as in step 55-4
using the compound (14) (0.250 g, 0.470 mmol) synthesized
in Example 14 and cyclopenten-l-ylboronic acid pinacol
ester (0.137 g, 0.704 mmol).
1H-NMR (400 MHz, CD30D) 6: 1.20-1.34 (4H, m), 1.58 (3H,
s), 1.79-1.87 (1H, m), 1.92-2.03 (6H, m), 2.18 (3H, s),
2.22-2.31 (1H, m), 2.24 (3H, s), 2.29 (6H, s), 2.36 (3H,
s), 2.47-2.61 (2H, m), 2.66-2.70 (2H, m), 4.43 (2H, s),
6.10 (1H, s), 6.34 (1H, m), 6.83 (1H, s).
MS (ESI) m/z: 520 (M+H) .
[0697]
Example 59
2-[trans-4-(Dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-y1)methy1]-2,4-dimethyl-7-
pheny1-1,3-benzodioxole-5-carboxamide (59)
[0698]
The title compound (0.059 g, 0.112 mmol, 29.7%
yield) was obtained through the same reaction as in step
CA 02942883 2016-09-15
- 249 -
55-4 using the compound (61) (0.200 g, 0.376 mmol)
synthesized in Example 14 and phenylboronic acid (0.069 g,
0.563 mmol).
1H-NMR (400 MHz, DMSO-d6) 6: 1.22-1.36 (4H, m), 1.61 (3H,
s), 1.82-1.92 (1H, m), 1.95-2.07 (4H, m), 2.22-2.31 (1H,
m), 2.23 (6H, s), 2.29 (6H, s), 2.37 (3H, s), 4.45 (2H,
s), 6.11 (1H, s), 7.12 (1H, s), 7.27-7.31 (1H, m), 7.36-
7.43 (2H, m), 7.65-7.70 (2H, m).
MS (ESI) m/z: 530 (M+H)+.
[0699]
Example 60
7-(Cyclohexen-1-y1)-2-[trans-4-
(dimethylamino)cyclohexyli-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methy1]-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide (60)
[0700]
The title compound (0.116 g, 0.218 mmol, 46% yield)
was obtained through the same reaction as in step 55-4
using the compound (14) (0.250 g, 0.470 mmol) synthesized
in Example 14 and cyclohexene-l-boronic acid pinacol
ester (0.147 g, 0.704 mmol).
1H-NMR (400 MHz, CD30D) 8: 1.21-1.32 (4H, m), 1.56 (3H,
s), 1.61-1.68 (2H, m), 1.71-1.77 (2H, m), 1.79-1.85 (1H,
m), 1.99 (4H, m), 2.17 (3H, s), 2.17-2.20 (2H, m), 2.24
(3H, s), 2.24-2.27 (1H, m), 2.29 (6H, s), 2.34-2.39 (1H,
m), 2.36 (3H, s), 4.43 (2H, s), 6.10 (1H, s), 6.22-6.26
(1H, m), 6.82 (1H, s).
CA 02942883 2016-09-15
- 250 -
MS (ESI) m/z: 534 (M+H) .
[0701]
Example 61
2-[trans-4-(Dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methy1]-7-[6-(4-
ethylpiperazin-1-y1)-3-pyridy1]-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide (61)
[0702]
The title compound (0.195 g, 0.303 mmol, 22% yield)
was obtained through the same reaction as in step 55-4
using the compound (14) (0.750 g, 1.41 mmol) synthesized
in Example 14.
1H-NMR (400 MHz, DMSO-d0 6: 1.04 (3H, t, J = 7.3 Hz),
1.11-1.28 (5H, m), 1.58 (3H, s), 1.76-1.93 (4H, m), 2.04-
2.09 (1H, m), 2.10 (3H, s), 2.13 (6H, s), 2.17 (3H, s),
2.18 (3H, s), 2.36 (2H, q, J = 7.3 Hz), 2.42-2.46 (4H, m),
3.49-3.55 (4H, m), 4.25 (2H, d, J = 4.9 Hz), 5.86 (1H, s),
6.92 (1H, d, J - 9.1 Hz), 7.03 (1H, s), 7.84 (1H, dd, J =
9.1, 2.4 Hz), 8.10 (1H, t, J = 4.9 Hz), 8.47 (1H, d, J =
2.4 Hz), 11.48 (1H, s).
MS (APCI) m/z: 643 (M+H) .
[0703]
Example 62
7-(3,6-Dihydro-2H-pyran-4-y1)-2-[trans-4-
(dimethylamino)cyclohexy1]-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methy1]-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide (62)
CA 02942883 2016-09-15
- 251 -
[0704]
The title compound (0.106 g, 0.198 mmol, 42% yield)
was obtained through the same reaction as in step 55-4
using the compound (14) (0.250 g, 0.470 mmol) synthesized .
in Example 14 and 3,6-dihydro-2H-pyran-4-boronic acid
pinacol ester (0.148 g, 0.704 mmol).
1H-NMR (400 MHz, CD30D) 6: 1.20-1.33 (4H, m), 1.58 (3H,
s), 1.78-1.88 (1H, m), 1.94-2.05 (4H, m), 2.19 (3H, s),
2.24 (3H, s), 2.24 (1H, br s), 2.29 (6H, s), 2.36 (3H, s),
2.45-2.51 (2H, m), 3.88 (2H, t, J = 5.5 Hz), 4.28-4.26
(2H, m), 4.43 (2H, s), 6.10 (1H, s), 6.34-6.38 (1H, m),
6.87 (1H, s).
MS (ESI) m/z: 536 (M+H)+.
[0705]
Example 63
2-[trans-4-(Dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methy1]-2,4-dimethyl-7-[6-
(morpholinomethyl)-3-pyridy1]-1,3-benzodioxole-5-
carboxamide (63)
[0706]
The title compound (0.024 g, 0.039 mmol, 2.7% yield)
was obtained through the same reaction as in step 55-4
using the compound (14) (0.750 g, 1.41 mmol) synthesized
in Example 14 and [6-(morpholinomethyl)-3-pyridyl]boronic
acid (0.375 g, 1.69 mmol).
1H-NMR (400 MHz, DMSO-d6) 6: 1.11-1.24 (4H, m), 1.60 (3H,
s), 1.77-1.97 (5H, m), 2.05-2.20 (1H, m), 2.11 (3H, s),
CA 02942883 2016-09-15
- 252 -
2.14 (6H, s), 2.18 (3H, s), 2.19 (3H, s), 2.40-2.46 (4H,
m), 3.57-3.66 (6H, m), 4.26 (2H, d, J = 4.9 Hz), 5.86 (1H,
s), 7.12 (1H, s), 7.53 (1H, d, J - 8.5 Hz), 8.06 (1H, dd,
J = 8.5, 2.4 Hz), 8.15 (1H, t, J = 4.9 Hz), 8.83 (1H, d,
J = 2.4 Hz), 11.48 (1H, s).
MS (APCI) m/z: 630 (M+H)+.
[0707]
Example 64
2-[trans-4-(Dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methy1]-2,4-dimethyl-7-(3-
pyridy1)-1,3-benzodioxole-5-carboxamide (64)
[0708]
The title compound (0.014 g, 0.026 mmol, 9.9% yield)
was obtained through the same reaction as in step 55-4
using the compound (14) (0.140 g, 0.263 mmol) synthesized
in Example 14 and pyridine-3-boronic acid (0.048 g, 0.394
mmol).
1H-NMR (400 MHz, CD30D) 6: 1.23-1.38 (4H, m), 1.64 (3H,
s), 1.86-1.95 (1H, m), 1.97-2.09 (4H, m), 2.24 (3H, s),
2.26 (3H, s), 2.33 (6H, s), 2.33-2.36 (1H, m), 2.37 (3H,
s), 4.46 (2H, s), 6.11 (1H, s), 6.61 (1H, s), 7.19 (1H,
s), 7.48-7.52 (1H, m), 8.14-8.18 (1H, m), 8.45-8.47 (1H,
m), 8.89-8.91 (1H, m).
MS (ESI) m/z: 531 (M+H)+.
[0709]
Example 65
CA 02942883 2016-09-15
- 253 -
2-[trans-4-(Dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-y1)methy1]-2,4-dimethyl-7-(1-
methylpyrazol-4-y1)-1,3-benzodioxole-5-carboxamide
hydrochloride (65)
[0710]
The title compound (0.107 g, 0.187 mmol, 50% yield)
was obtained as a solid (monohydrochloride) through the
same reaction as in step 55-4 using the compound (14)
(0.200 g, 0.376 mmol) synthesized in Example 14 and 1-
methy1-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-1H
pyrazole (0.156 g, 0.751 mmol), followed by conversion to
the hydrochloride with 4 M hydrochloric acid in ethyl
acetate.
1H-NMR (400 MHz, CD30D) 6: 1.37-1.59 (4H, m), 1.66 (3H,
s), 1.97-2.04 (1H, m), 2.09-2.20 (4H, m), 2.20 (3H, s),
2.27 (3H, s), 2.40 (3H, s), 2.83 (6H, s), 3.16-3.27 (1H,
m), 3.92 (3H, s), 4.46 (2H, s), 6.20 (1H, s), 7.17 (1H,
s), 7.86 (1H, s), 7.98 (1H, s).
MS (ESI) m/z: 534 (M+H)+.
[0711]
Example 66
2-[trans-4-(Dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methy1]-2,4-dimethyl-7-vinyl-
1,3-benzodioxole-5-carboxamide (66)
[0712]
The title compound (0.171 g, 0.357 mmol, 95% yield)
was obtained through the same reaction as in step 55-4
CA 02942883 2016-09-15
- 254 -
using the compound (14) (0.200 g, 0.376 mmol) synthesized
in Example 14 and 4,4,5,5-tetramethy1-2-viny1-1,3,2-
dioxaborolane (0.087 g, 0.563 mmol).
1H-NMR (400 MHz, CD30D) 6: 1.21-1.35 (4H, m), 1.59 (3H,
s), 1.80-1.90 (1H, m), 1.95-2.04 (4H, m), 2.18 (3H, s),
2.24 (3H, s), 2.22-2.28 (1H, m), 2.29 (6H, s), 2.36 (3H,
s), 4.43 (2H, s), 5.30 (1H, d, J = 12.1 Hz), 5.85 (1H, d,
J = 17.6 Hz), 6.11 (1H, s), 6.58 (1H, dd, J = 17.6, 12.1
Hz), 6.90 (1H, s).
MS (ESI) m/z: 480 (M-FH) .
[0713]
Example 67
2-[trans-4-(Dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-
oxo-1,2-dihydropyridin-3-yl)methy1]-7-ethyny1-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (67)
[Formula 42]
ii,crzky. C H3 H3Crr,C H3 H3Cr IrC H3
I I N H NH NH
0 NH 0 0 NH 0 0 N H 0
C H3 --... ---...
li
67-1 o U4 C H3 674
ElriX0 WI o
0 0
L .t-Bu 0
H3-240',N)L 1-au
0
H H 0 0 0
14324-0, N., 0 J-Bu
H3-C/s0,,N,L0
H
trans-A4i trans-A4s trans-A4t
H3CC H3I N H
C H3Cfc.i.,C H3
I_JH3Crc.r. H3
I
I NH NH
0 NH 0 0 NH 0 0 NH 0
..,, C H3 -----1. C H3 C H3
V o 67-4
Vi o 67-5 - VI o
0 0
x .t-Bu 0 0
1130"NH
C H32
H C H3
trans-A4u trans-A4u-f 67
[0714]
(Step 67-1)
CA 02942883 2016-09-15
- 255 -
tert-Butyl N-[trans-4-[5-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methylcarbamoy1]-2,4-dimethyl-7-
viny1-1,3-benzodioxo1-2-yl]cyclohexyl]carbamate (trans-
A4s)
[0715]
The title compound (0.352 g, 0.638 mmol, 97% yield)
was obtained through the same reaction as in Example 66
using the compound (trans-A4i) (0.400 g, 0.662 mmol)
synthesized in step 13-3.
MS (ESI) m/z: 552 (M+H)+.
[0716]
(Step 67-2)
tert-Butyl N-[trans-4-[5-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methylcarbamoy1]-7-formy1-2,4-
dimethy1-1,3-benzodioxo1-2-yl]cyclohexyl]carbamate
(trans-A4t)
[0717]
The compound (trans-A4s) (0.352 g, 0.638 mmol)
synthesized in step 67-1 was dissolved in tetrahydrofuran
(6.0 mL) and water (3.0 mL. To the solution,
microencapsulated osmium oxide (content: approximately
10%) (0.008 g, 0.032 mmol) and sodium periodate (0.273 g,
1.28 mmol) were added, and the mixture was stirred at
room temperature for 17 hours. After the completion of
the reaction, insoluble matter was removed by filtration,
and a saturated aqueous solution of sodium nitrite was
added to the filtrate, followed by extraction with ethyl
CA 02942883 2016-09-15
- 256 -
acetate. The organic layer was washed with water and
saturated saline and dried over anhydrous sodium sulfate.
Then, the solvent was distilled off under reduced
pressure, and the obtained residue was purified by silica
gel column chromatography (hexane:ethyl acetate = 100:0
-* 77:23) to obtain the title compound (0.205 g, 0.369
mmol, 58% yield).
1H-NMR (400 MHz, CDC13) 6: 1.04-1.15 (2H, m), 1.27-1.37
(2H, m), 1.44 (9H, s), 1.63 (3H, s), 1.79-1.89 (1H, m),
1.90-1.98 (2H, m), 2.04-2.12 (2H, m), 2.24 (3H, s), 2.31
(3H, s), 2.37 (3H, s), 3.32-3.44 (1H, m), 4.40 (1H, d, J
= 7.9 Hz), 4.51 (2H, d, J = 6.1 Hz), 5.96 (1H, s), 7.27-
7.30 (1H, t, J = 6.1 Hz), 7.31 (1H, s), 10.02 (1H, s),
11.87 (1H, br s).
MS (ESI) m/z: 554 (M+H)+.
[0718]
(Step 67-3)
tert-Butyl N-[trans-4-[5-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methylcarbamoy1]-7-ethyny1-2,4-
dimethy1-1,3-benzodioxo1-2-yl]cyclohexyl]carbamate
(trans-A4u)
[0719]
The compound (trans-A4s) (0.200 g, 0.361 mmol)
synthesized in step 67-2 was dissolved in methanol (6 mL).
To the solution, potassium carbonate (0.100 g, 0.379
mmol) was added, and a solution of dimethyl (1-diazo-2-
oxopropyl)phosphonate (0.073 g, 0.379 mmol) in methanol
CA 02942883 2016-09-15
- 257 -
(6 mL) was gradually added dropwise under ice cooling.
The reaction solution was stirred at room temperature for
17 hours and concentrated under reduced pressure. To the
obtained residue, ethyl acetate was added, and the
organic layer was washed with water and saturated saline
and dried over anhydrous sodium sulfate. The solvent was
distilled off under reduced pressure to obtain the title
compound (0.154 g, 0.279 mmol, 77% yield).
1H-NMR (400 MHz, CDC13) 6: 1.01-1.15 (2H, m), 1.24-1.37
(2H, m), 1.43 (9H, s), 1.59 (3H, s), 1.73-1.85 (1H, m),
1.89-1.98 (2H, m), 2.00-2.10 (2H, m), 2.26 (6H, s), 2.37
(3H, s), 3.17 (1H, s), 3.32-3.45 (1H, m), 4.38 (1H, d, J
= 7.9 Hz), 4.49 (2H, d, J = 6.1 Hz), 5.96 (1H, s), 6.97
(1H, s), 7.25 (1H, t, J = 6.1 Hz), 11.90 (1H, br s).
MS (ESI) m/z: 550 (M+H) .
[0720]
(Step 67-4)
2-(trans-4-Aminocyclohexyl)-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methy1]-7-ethynyl-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide (trans-(2S)-A4u-f)
[0721]
The title compound (0.123 g, 0.273 mmol, 98% yield)
was obtained through the same reaction as in step 3-4
using the compound (trans-A4u) (0.154 g, 0.279 mmol)
synthesized in step 67-3.
MS (ESI) m/z: 450 (M+H)+.
[0722]
CA 02942883 2016-09-15
- 258 -
(Step 67-5)
2-[trans-4-(Dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methy1]-7-ethyny1-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (67)
[0723]
The title compound (0.053 g, 0.111 mmol, 41% yield)
was obtained through the same reaction as in step 3-5
using the compound (trans-A4u-f) (0.123 g, 0.273 mmol)
synthesized in step 67-4.
1H-NMR (400 MHz, CD30D) 6: 1.22-1.38 (4H, m), 1.60 (3H,
s), 1.80-1.90 (1H, m), 1.88-2.12 (4H, m), 2.18 (3H, s),
2.24 (3H, s), 2.24-2.29 (1H, m), 2.30 (6H, s), 2.35 (3H,
s), 3.62 (1H, s), 4.41 (2H, s), 6.10 (1H, s), 6.90 (1H,
s).
MS (ESI) m/z: 478 (M+H)+.
[0724]
Example 68
7-Cyclopropy1-2-[trans-4-(dimethylamino)cyclohexyl]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide (68)
[0725]
The title compound (0.007 g, 0.014 mmol, 3.7% yield)
was obtained through the same reaction as in step 55-4
using the compound (14) (0.200 g, 0.376 mmol) synthesized
in Example 14 and cyclopropylboronic acid (0.048 g, 0.563
mmol).
CA 02942883 2016-09-15
- 259 -
1H-NMR (400 MHz, CD30D) 6: 0.73-0.77 (2H, m), 0.84-0.89
(2H, m), 1.24-1.32 (4H, m), 1.55 (3H, s), 1.77-1.84 (2H,
m), 1.95-2.05 (4H, m), 2.14 (3H, s), 2.24 (3H, s), 2.32-
2.35 (1H, m), 2.33 (6H, s), 2.35 (3H, s), 4.41 (2H, s),
6.10 (1H, s), 6.51 (1H, s).
MS (ESI) m/z: 494 (M+H) .
[0726]
Example 69
2-[trans-4-(Dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methy1]-2,4-dimethyl-7-[2-(4-
methylpiperazin-1-y1)-4-pyridy1]-1,3-benzodioxole-5-
carboxamide (69)
[0727]
The title compound (0.256 g, 0.408 mmol, 29% yield)
was obtained through the same reaction as in step 55-4
using the compound (14) (0.750 g, 1.41 mmol) synthesized
in Example 14 and 1-methy1-4-[4-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-y1)-2-pyridyl]piperazine (0.513 g,
1.69 mmol).
1H-NMR (400 MHz, DMSO-d5) 6: 1.10-1.25 (4H, m), 1.59 (3H,
s), 1.78-1.95 (5H, m), 2.01-2.09 (1H, m), 2.10 (3H, s),
2.14 (6H, s), 2.18 (3H, s), 2.19 (3H, s), 2.22 (3H, s),
2.35-2.45 (4H, m), 3.48-3.54 (4H, m), 4.26 (2H, d, J =
4.9 Hz), 5.86 (1H, s), 6.97 (1H, d, J - 5.5 Hz), 7.05 (1H,
s), 7.15 (1H, s), 8.14 (1H, t, J = 4.9 Hz), 8.16 (1H, d,
J = 5.5 Hz), 11.47 (1H, s).
MS (APCI) m/z: 629 (M+H)+.
CA 02942883 2016-09-15
- 260 -
[0728]
Example 70
2-[trans-4-(Dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methy1]-2,4-dimethyl-7-
thiazol-5-y1-1,3-benzodioxole-5-carboxamide hydrochloride
(70)
[0729]
The title compound (0.015 g, 0.027 mmol, 9.4% yield)
was obtained through the same reaction as in step 55-4
using the compound (14) (0.150 g, 0.282 mmol) synthesized
in Example 14 and thiazole-5-boronic acid pinacol ester
(0.089 g, 0.423 mmol).
1H-NMR (400 MHz, CD30D) 6: 1.35-1.52 (2H, m), 1.52-1.65
(2H, m), 1.73 (3H, s), 2.05-2.25 (5H, m), 2.30 (3H, s),
2.51 (3H, s), 2.62 (3H, s), 2.83 (6H, s), 3.18-3.30 (1H,
m), 4.59 (2H, s), 6.99 (1H, s), 7.56 (1H, s), 8.67 (1H,
s), 9.73 (1H, s).
MS (ESI) m/z: 537 (M+H)+.
[0730]
Example 71
2-[trans-4-(Dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methy1]-2,4-dimethyl-7-(1-
methy1-3,6-dihydro-2H-pyridin-4-y1)-1,3-benzodioxole-5-
carboxamide (71)
[0731]
The title compound (0.144 g, 0.263 mmol, 70% yield)
was obtained through the same reaction as in step 55-4
CA 02942883 2016-09-15
- 261 -
using the compound (14) (0.200 g, 0.376 mmol) synthesized
in Example 14 and 1-methy1-4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-y1)-3,6-dihydro-2H-pyridine (0.126 g,
0.563 mmol).
1H-NMR (400 MHz, CD30D) 6: 1.19-1.33 (4H, m), 1.57 (3H,
s), 1.79-1.86 (1H, m), 1.94-2.05 (4H, m), 2.18 (3H, s),
2.20-2.30 (1H, m), 2.24 (3H, s), 2.29 (6H, s), 2.35 (3H,
s), 2.37 (3H, s), 2.57-2.61 (2H, m), 2.67-2.71 (2H, m),
3.11-3.14 (2H, m), 4.43 (2H, s), 6.29-6.32 (1H, m), 6.60
(1H, s), 6.87 (1H, s).
MS (ESI) m/z: 549 (M+H)+.
[0732]
Example 72
7-Acety1-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide hydrochloride
(72)
[Formula 43]
H3Cr.c,, C H3 H3CrC H3
I NH I NH I NH
0 NH 0 0 NH 0 0 NH 0
CH3 CH _____
1,1 r0 72-2 CH3
Br 0 72-1 0 WI
0 0
0 CO
CH H31 H3 0
CH41a3
30 CH CH30
CH -C-i*OgN- 3 H3-3.N= 3
aH 3
CH3 CH3
14 72p 72
[0733]
(Step 72-1)
CA 02942883 2016-09-15
- 262 -
2-Ltrans-4-(Dimethylamino)cyclohexyll-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methy1]-2,4-dimethyl-7-(2-
methy1-1,3-dioxolan-2-y1)-1,3-benzodioxole-5-carboxamide
(72p)
[0734]
To a solution of the compound (14) (500 mg, 0.939
mmol) synthesized in Example 14 in ethylene glycol (4 mL),
palladium acetate (0.011 g, 0.047 mmol), 1,3-
bis(diphenylphosphino)propane (0.039 g, 0.094 mmol),
ethylene glycol monovinyl ether (0.165 g, 1.88 mmol), and
triethylamine (0.143 g, 1.41 mmol) were added, and the
mixture was reacted at 110 C for 3 hours in a microwave
reaction apparatus. After the completion of the reaction,
ethyl acetate was added thereto, and the organic layer
was washed with water and saturated saline and dried over
anhydrous sodium sulfate. The solvent was distilled off
under reduced pressure, and the obtained residue was
purified by basic silica gel column chromatography (ethyl
acetate:methanol = 100:0 -4 81:19) to obtain the title
compound (0.104 g, 0.192 mmol, 21% yield).
MS (ESI) m/z: 540 (M+H)+.
[0735]
(Step 72-2)
7-Acety1-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide hydrochloride
(72)
CA 02942883 2016-09-15
- 263 -
[0736]
The compound (72p) (0.104 g, 0.192 mmol) synthesized
in step 72-1 was dissolved in tetrahydrofuran (4 mL). To
the solution, 1 M hydrochloric acid (0.404 mL, 0.404
mmol) was added, and the mixture was stirred at room
temperature for 8 hours. After the completion of the
reaction, the reaction solution was neutralized and
rendered weakly alkaline with a 1 M aqueous sodium
hydroxide solution. Ethyl acetate was added to the
reaction solution, and the organic layer was washed with
water and saturated saline and dried over anhydrous
sodium sulfate. The solvent was distilled off under
reduced pressure, and the obtained residue was then
dissolved in ethyl acetate. To the solution, a 4 M
solution of hydrochloric acid in 1,4-dioxane (0.050 mL)
was added, and the deposited solid was filtered to obtain
the title compound (0.085 g, 0.160 mmol, 83% yield) as a
monohydrochloride.
1H-NMR (400 MHz, CD30D) 6: 1.37-1.57 (4H, m), 1.69 (3H,
s), 2.00-2.07 (1H, m), 2.10-2.19 (4H, m), 2.25 (3H, s),
2.30 (3H, s), 2.41 (3H, s), 2.55 (3H, s), 2.84 (6H, s),
3.18-3.28 (1H, m), 4.47 (2H, s), 6.32 (1H, s), 7.41 (1H,
s).
MS (ESI) m/z: 496 (M+H)+.
[0737]
Example 73
CA 02942883 2016-09-15
- 264 -
2-[trans-4-(Dimethylamino)cyclohexyl]-N-[(4-ethy1-6-
methy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[6-(4-
ethylpiperazin-1-y1)-3-pyridy1]-2,4-dimethy1-1,3-
benzodioxole-5-carboxamide hydrochloride (73)
[0738]
The title compound (0.062 g, 0.086 mmol, 32% yield)
was obtained as a dihydrochloride through the same
reaction as in step 55-4 using the compound (17) (0.145 g,
0.265 mmol) synthesized in Example 17, followed by
conversion to the hydrochloride by the addition of 4 M
hydrochloric acid in ethyl acetate (0.060 mL).
1H-NMR (400 MHz, CD30D) 6: 1.17 (3H, t, J = 7.3 Hz), 1.22
(3H, t, J - 7.3 Hz), 1.34-1.51 (4H, m), 1.63 (3H, s).
1.90-1.99 (1H, m), 2.05-2.15 (4H, m), 2.23 (3H, s), 2.25
(3H, s), 2.54 (2H, q, J = 7.3 Hz), 2.62-2.68 (4H, m),
2.66 (6H, s), 2.73 (2H, q, J = 7.3 Hz), 2.89-2.95 (1H, m),
3.56-3.63 (4H, m), 4.48 (2H, s), 6.13 (1H, s), 6.62 (IH,
s), 6.86 (1H, d, J - 9.1 Hz), 7.09 (1H, s), 7.89 (1H, dd,
J = 9.1, 2.4 Hz), 8.50 (1H, d, J = 2.4 Hz).
MS (ESI) m/z: 657 (M+H)+.
[0739]
Example 74
2-[trans-4-(Dimethylamino)cyclohexyl]-7-[6-(4-
ethylpiperazin-1-y1)-3-pyridy1]-2,4-dimethyl-N-[(6-
methy1-2-oxo-4-propy1-1,2-dihydropyridin-3-y1)methyl]-
1,3-benzodioxole-5-carboxamide (74)
[0740]
CA 02942883 2016-09-15
- 265 -
The title compound (0.090 g, 0.134 mmol, 37% yield)
was obtained through the same reaction as in step 55-4
using the compound (18) (0.205 g, 0.366 mmol) synthesized
in Example 18.
1H-NMR (400 MHz, CD30D) 5: 1.02 (3H, t, J = 7.3 Hz), 1.15
(3H, t, J = 7.0 Hz), 1.24-1.34 (4H, m), 1.60-1.68 (2H, m),
1.62 (3H, s), 1.83-1.91 (1H, m), 1.97-2.07 (4H, m), 2.20-
2.28 (1H, m), 2.23 (3H, s), 2.25 (3H, s), 2.28 (6H, s),
2.50 (2H, q, J = 7.3 Hz), 2.57-2.63 (4H, m), 2.67-2.72
(2H, m), 3.57-3.62 (4H, m), 4.48 (2H, s), 6.11 (1H, s),
6.52 (1H, s), 6.87 (1H, d, J = 9.1 Hz), 7.07 (1H, s),
7.89 (1H, dd, J = 9.1, 2.4 Hz), 8.49 (1H, d, J = 2.4 Hz).
MS (ESI) m/z: 671 (M+H)'.
[0741]
Example 75
2-[trans-4-(Dimethylamino)cyclohexyl]-N-[(4-ethyl-6-
methy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-7-(1-methylpyrazol-4-y1)-1,3-benzodioxole-5-
carboxamide hydrochloride (75)
[0742]
The title compound (0.052 g, 0.090 mmol, 25% yield)
was obtained as a monohydrochloride through the same
reaction as in step 55-4 using the compound (17) (0.200 g,
0.366 mmol) synthesized in Example 17 and 1-methy1-4-
(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-1H pyrazole
(0.089 g, 0.423 mmol), followed by conversion to the
CA 02942883 2016-09-15
- 266 -
hydrochloride by the addition of 4 M hydrochloric acid in
ethyl acetate (0.041 mL).
1H-NMR (400 MHz, CD310D) 6: 1.23 (3H, t, J = 7.6 Hz),
1.37-1.59 (4H, m), 1.66 (3H, s), 1.97-2.04 (1H, m), 2.10-
2.18 (4H, m), 2.20 (3H, s), 2.27 (3H, s), 2.74 (2H, q, J
= 7.6 Hz), 2.83 (6H, s), 3.15-3.25 (1H, m), 3.92 (3H, s),
4.46 (2H, s), 6.18 (1H, s), 7.16 (1H, s), 7.85 (1H, s),
7.97 (1H, s).
MS (ESI) m/z: 548 (M+H)+.
[0743]
Example 76
2-[trans-4-(Dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methy1]-7-ethyl-2,4-dimethyl-
1,3-benzodioxole-5-carboxamide (76)
[0744]
The title compound (0.054 g, 0.111 mmol, 36% yield)
was obtained through the same hydrogenation reaction as
in Example 23 using the compound (66) (150 mg, 0.313
mmol) synthesized in Example 66.
1H-NMR (400 MHz, CD310D) 6: 1.16 (3H, t, J = 7.6 Hz),
1.20-1.35 (4H, m), 1.55 (3H, s), 1.75-1.85 (1H, m), 1.94-
2.06 (4H, m), 2.16 (3H, s), 2.24 (3H, s), 2.27-2.32 (1H,
m), 2.31 (6H, s), 2.36 (3H, s), 2.51 (2H, m), 4.42 (2H,
s), 6.10 (1H, s), 6.71 (1H, s).
MS (ESI) m/z: 482 (M+H)+.
[0745]
Example 77
CA 02942883 2016-09-15
- 267 -
(2R)-N-[(4,6-Dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methy1]-7-[6-(4-ethylpiperazin-1-y1)-3-pyridyl]-2,4-
dimethy1-2-(morpholinomethyl)-1,3-benzodioxole-5-
carboxamide (77)
[0746]
The title compound (11.2 g, 18.1 mmol, 70% yield)
was obtained through the same reaction as in step 55-4
using the compound (45) (13.2 g, 26.0 mmol) synthesized
in step 45-4.
1H-NMR (400 MHz, DMSO-d6) 6: 1.03 (3H, t, J = 7.3 Hz),
1.68 (3H, s), 2.11 (3H, s), 2.16 (3H, s), 2.18 (3H, s),
5.67 (2H, q, J = 7.3 Hz), 2.41-2.47 (4H, m), 2.49-2.55
(4H, m), 2.75 (2H, s), 3.43-3.48 (4H, m), 3.48-3.54 (4H,
m), 4.26 (2H, d, J = 4.9 Hz), 5.86 (1H, s), 6.90 (1H, d,
J = 9.2 Hz), 7.05 (1H, s), 7.82 (1H, dd, J = 9.2, 2.4 Hz),
8.12 (1H, t, J = 4.9 Hz), 8.46 (1H, d, J = 2.4 Hz), 11.48
(1H, br s).
MS (ESI) m/z: 617 (M+H) .
Specific rotation []o20 = -38.9 (C = 1.0, chloroform)
[0747]
Example 78
(2R)-7-Chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methy1]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide hydrochloride
(78)
[0748]
CA 02942883 2016-09-15
- 268 -
To the compound (35) (0.205 g, 0.420 mmol)
synthesized in Example 35, acetone (8.12 mL) and a 5.88
mol/L aqueous hydrochloric acid solution (0.071 mL, 0.420
mmol) were added at room temperature. Then, the mixture
was stirred at 40 C for approximately 20 hours and
further stirred at room temperature for approximately 0.5
hours, and the deposited solid was then collected by
filtration. Then, the solid was dried overnight at room
temperature to obtain the title compound (0.218 g, rate
of recovery: 99%).
1H-NMR (400 MHz, DMSO-d6) 6: 1.16-1.31 (2H, m), 1.38-1.53
(2H, m), 1.62 (3H, s), 1.87-1.99 (3H, m), 2.02-2.11 (2H,
m), 2.11 (3H, s), 2.12 (3H, s), 2.17 (3H, s), 2.65 (3H,
s), 2.66 (3H, s), 3.08-3.19 (1H, m), 4.22 (2H, d, J - 4.8
Hz), 5.86 (1H, s), 6.86 (1H, s), 8.14 (1H, t, J = 4.8 Hz),
10.31 (1H, br s), 11.48 (1H, s).
Elemental analysis Anal. Calcd for C26H34C1N304=HC1 C,
59.54; H, 6.73; N, 8.01; Cl, 13.52. Found: C, 55.73; H,
7.01; N, 7.52; Cl, 12.36.
[0749]
Example 79
(2R)-7-Chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-y1)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide methanesulfonic
acid (79)
[0750]
CA 02942883 2016-09-15
- 269 -
To the compound (35) (0.205 g, 0.420 mmol)
synthesized in Example 35, acetone (8.14 ml) and a 5.93
mol/L aqueous methanesulfonic acid solution (0.071 mL,
0.420 mmol) were added at room temperature. Then, the
mixture was stirred at 40 C for approximately 20 hours
and further stirred at room temperature for approximately
0.5 hours, and the deposited solid was then collected by
filtration. Then, the solid was dried overnight at room
temperature to obtain the title compound (0.240 g, rate
of recovery: 99%).
1H-NMR (DMSO-d6) 6: 1.17-1.31 (2H, m), 1.37-1.52 (2H, m),
1.62 (3H, s), 1.88-2.07 (5H, m), 2.09-2.14 (1H, m), 2.11
(3H, s), 2.12 (3H, s), 2.17 (3H, s), 2.31 (3H, s), 2.70
(3H, s), 2.72 (3H, s), 3.41 (1H, s), 4.22 (2H, d, J = 5.4
Hz), 5.84-5.87 (1H, m), 6.87 (1H, br s), 8.14 (1H, t, J =
5.4 Hz), 9.36 (1H, br s), 11.48 (1H, s).
Elemental analysis Anal. Calcd for C26H34C1N304=CH403S: C,
55.52; H, 6.56; N, 7.19; Cl, 6.07; S, 5.49. Found: C,
54.11; H, 6.65; N, 7.00; Cl, 5.86; S, 5.40.
[0751]
Example 80
(2R)-7-Chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide p-
toluenesulfonate (80)
[0752]
CA 02942883 2016-09-15
- 270 -
To the compound (35) (0.202 g, 0.414 mmol)
synthesized in Example 35, acetone (7.97 mL) and a 4.00
mol/L aqueous p-toluenesulfonic acid solution (0.103 mL,
0.414 mmol) were added at room temperature. Then, the
mixture was stirred at 4000 for approximately 20 hours
and further stirred at room temperature for approximately
0.5 hours, and the deposited solid was then collected by
filtration. Then, the solid was dried overnight at room
temperature to obtain the title compound (0.256 g, rate
of recovery: 99%).
1H-NMR (DMSO-d6) 6: 1.15-1.32 (2H, m), 1.36-1.50 (2H, m),
1.62 (3H, s), 1.88-2.06 (5H, m), 2.11 (3H, s), 2.12 (3H,
s), 2.17 (3H, s), 2.29 (3H, s), 2.70 (3H, s), 2.71 (3H,
s), 3.10-3.22 (1H, m), 4.22 (2H, d, J = 5.0 Hz), 5.86 (1H,
s), 6.87 (1H, s), 7.11 (2H, d, J = 8.2 Hz), 7.48 (2H, d,
J = 8.2 Hz), 8.14 (1H, t, J = 5.0 Hz), 9.31 (1H, br s),
11.48 (1H, s).
Elemental analysis Anal. Calcd for C26H34C1N304.C7H803S: C,
60.03; H, 6.41; N, 6.36; 01, 5.37; S, 4.86. Found: C,
58.81; H, 6.48; N, 6.21; Cl, 5.32; S, 4.85.
[0753]
Example 81
(2R)-7-Chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide hemifumarate (81)
[0754]
CA 02942883 2016-09-15
- 271 -
To the compound (35) (0.200 g, 0.411 mmol)
synthesized in Example 35, fumaric acid (0.024 g, 0.205
mmol) and ethyl acetate (8.01 mL) were added at room
temperature. Then, the mixture was stirred at 400C for
approximately 20 hours and further stirred at room
temperature for approximately 0.5 hours, and the
deposited solid was then collected by filtration. Then,
the solid was dried overnight at room temperature to
obtain the title compound (0.222 g, rate of recovery:
(CO
1H-NMR (DMSO-dd 6: 1.10-1.34 (4H, m), 1.60 (3H, s),
1.80-1.96 (5H, m), 2.11 (3H, s), 2.12 (3H, s), 2.17 (3H,
s), 2.33 (6H, s), 2.41-2.50 (2H, m), 4.22 (2H, d, J - 5.1
Hz), 5.85 (1H, s), 6.45 (1H, s), 6.85 (1H, s), 8.13 (1H,
t, J - 5.1 Hz), 11.48 (1H, s).
Elemental analysis Anal. Calcd for C26H34C1N304-1/2C4H404: C,
61.59; H, 6.64; N, 7.70; Cl, 6.49. Found: C, 59.64; H,
6.75; N, 7.46; Cl, 6.24.
[0755]
Example 82
(2R)-7-Chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide hemi-L-tartrate
(82)
[0756]
To the compound (35) (0.202 g, 0.414 mmol)
synthesized in Example 35, L-tartaric acid (0.031 g,
CA 02942883 2016-09-15
- 272 -
0.208 mmol) and acetone (8.09 mL) were added at room
temperature. Then, the mixture was stirred at 40 C for
approximately 20 hours and further stirred at room
temperature for approximately 0.5 hours, and the
deposited solid was then collected by filtration. Then,
the solid was dried overnight at room temperature to
obtain the title compound (0.233 mg, rate of recovery:
99%).
1H-NMR (DMSO-d0 6: 1.10-1.37 (4H, m), 1.61 (3H, s).
1.81-1.98 (5H, m), 2.11 (3H, s), 2.12 (3H, s), 2.17 (3H,
s), 2.39 (6H, s), 2.52-2.63 (1H, m), 3.86 (1H, s), 4.22
(2H, d, J = 4.8 Hz), 5.85 (1H, s), 6.85 (1H, s), 8.13 (1H,
t, J = 4.8 Hz), 11.48 (1H, br s).
Elemental analysis Anal. Calcd for C26H3401N304=1/2C4H606: Cf
59.73; H, 6.62; N, 7.46; 01, 6.30. Found: C, 57.71; H,
6.77; N, 7.14; 01, 6.06.
[0757]
Example 83
(2R)-7-Chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-
[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-
dimethy1-1,3-benzodioxole-5-carboxamide phosphate (83)
[0758]
To the compound (35) (0.205 g, 0.421 mmol)
synthesized in Example 35, acetone (8.11 mL) and a 4.01
mol/L aqueous phosphoric acid solution (0.105 mL, 0.421
mmol) were added at room temperature. Then, the mixture
was stirred at 40 C for approximately 20 hours and
CA 02942883 2016-09-15
- 273 -
further stirred at room temperature for approximately 0.5
hours, and the deposited solid was then collected by
filtration. Then, the solid was dried overnight at room
temperature to obtain the title compound (0.244 g, rate
of recovery: 99%).
1H-NMR (DMSO-d6) 6: 1.11-1.38 (4H, m), 1.61 (3H, s),
1.81-2.00 (5H, m), 2.11 (3H, s), 2.12 (3H, s), 2.17 (3H,
s), 2.39 (6H, s), 2.53-2.65 (1H, m), 4.21 (2H, d, J = 4.8
Hz), 5.86 (1H, s), 6.85 (1H, s), 8.13 (1H, t, J - 4.8 Hz).
Elemental analysis Anal. Calcd for C26H34C1N304=H3PO4: C,
53.29; H, 6.36; N, 7.17; 01, 6.05; P, 5.29. Found: C,
51.10; H, 6.45; N, 7.04; 01, 5.90; P, 5.15.
[0759]
Example 84
(2S)-2-[trans-4-(Dimethylamino)cyclohexyl]-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4,7-
trimethy1-1,3-benzodioxole-5-carboxamide sulfate (84)
[0760]
To the compound (48) (0.200 g, 0.428 mmol)
synthesized in Example 48, 1-propanol (2.00 mL) and a
5.79 mol/L aqueous sulfuric acid solution (0.078 mL,
0.449 mmol) were added at room temperature. Then, the
mixture was stirred at 40 C for approximately 20 hours
and further stirred at room temperature for approximately
0.5 hours, and the deposited solid was then collected by
filtration. Then, the solid was dried overnight at room
CA 02942883 2016-09-15
- 274 -
temperature to obtain the title compound (0.182 g, rate
of recovery: 75%).
1H-NMR (DMSO-dÃ) 6: 1.15-1.30 (2H, m), 1.33-1.48 (2H, m),
1.55 (3H, s), 1.80-1.90 (1H, m), 1.90-2.04 (4H, m), 2.08
(3H, s), 2.11 (6H, s), 2.17 (3H, s), 2.67 (6H, s), 3.00-
3.14 (1H, m), 4.22 (2H, d, J = 5.0 Hz), 5.86 (1H, s),
6.68 (1H, s), 7.87 (1H, t, J = 5.0 Hz), 9.51 (1H, br s).
Elemental analysis Anal. Calcd for C27H37N304=H2SO4: C,
57.32; H, 6.95; N, 7.43; S, 5.67. Found: C, 55.75; H,
7.17; N, 7.10; S, 5.05.
[0761]
Example 85
(2S)-2-[trans-4-(Dimethylamino)cyclohexyl]-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4,7-
trimethy1-1,3-benzodioxole-5-carboxamide methanesulfonate
(85)
[0762]
To the compound (48) (0.202 g, 0.431 mmol)
synthesized in Example 48, acetone (2.02 mL) and a 5.93
mol/L aqueous methanesulfonic acid solution (0.076 mL,
0.451 mmol) were added at room temperature. Then, the
mixture was stirred at 40 C for approximately 20 hours
and further stirred at room temperature for approximately
0.5 hours, and the deposited solid was then collected by
filtration. Then, the solid was dried overnight at room
temperature to obtain the title compound (0.216 g, rate
of recovery: 89%).
CA 02942883 2016-09-15
- 275 -
1H-NMR (DMSO-d6) 6: 1.16-1.30 (2H, m), 1.35-1.50 (2H, m),
1.56 (3H, s), 1.80-1.91 (1H, m), 1.91-2.05 (4H, m), 2.08
(3H, s), 2.11 (6H, s), 2.17 (3H, s), 2.32 (3H, s), 2.70
(3H, s), 2.71 (3H, s), 3.09-3.21 (1H, m), 4.22 (2H, d, J
= 5.1 Hz), 5.86 (1H, s), 6.68 (1H, s), 7.88 (1H, t, J =
5.1 Hz), 9.37 (1H, br s), 11.48 (1H, s).
Elemental analysis Anal. Calcd for C27H37N304=CH403S: C,
59.65; H, 7.33; N, 7.45; S, 5.69. Found: C, 58.05, H,
7.32; N, 7.19; S, 5.54.
[0763]
Example 86
(2S)-2-[trans-4-(Dimethylamino)cyclohexyl]-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4,7-
trimethy1-1,3-benzodioxole-5-carboxamide hemifumarate
(86)
[0764]
To the compound (48) (0.202 g, 0.431 mmol)
synthesized in Example 48, fumaric acid (0.027 mg, 0.233
mmol) and ethyl acetate (2.02 mL) were added at room
temperature. Then, the mixture was stirred at 40 C for
approximately 20 hours and further stirred at room
temperature for approximately 0.5 hours, and the
deposited solid was then collected by filtration. Then,
the solid was dried overnight at room temperature to
obtain the title compound (0.219 g, rate of recovery:
97%).
CA 02942883 2016-09-15
- 276 -
1H-NMR (DMSO-d6) 6: 1.11-1.33 (4H, m), 1.54 (3H, s),
1.73-1.84 (1H, m), 1.85-1.96 (4H, m), 2.08 (3H, s), 2.10
(3H, s), 2.11 (3H, s), 2.17 (3H, s), 2.34 (6H, s), 2.43-
2.50 (1H, m), 4.22 (2H, d, J = 5.2 Hz), 5.85 (1H, s),
6.46 (1H, s), 6.67 (1H, s), 7.86 (1H, t, J = 5.2 Hz),
11.46 (1H, s).
Elemental analysis Anal. Calcd for C2 H m n /9r r-T n r
7-37-3-4'-, - -4-4-4
66.26; H, 7.48; N, 7.99. Found: C, 63.02, H, 7.62; N,
7.51.
[0765]
Example 87
(2S)-2-[trans-4-(Dimethylamino)cyclohexyl]-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4,7-
trimethy1-1,3-benzodioxole-5-carboxamide maleate (87)
[0766]
To the compound (48) (0.201 g, 0.430 mmol)
synthesized in Example 48, maleic acid (0.053 g, 0.457
mmol) and ethyl acetate (2.01 mL) were added at room
temperature. Then, the mixture was stirred at 40 C for
approximately 20 hours and further stirred at room
temperature for approximately 0.5 hours, and the
deposited solid was then collected by filtration. Then,
the solid was dried overnight at room temperature to
obtain the title compound (0.210 g, rate of recovery:
84%).
1H-NMR (DMSO-d6) 6: 1.15-1.31 (2H, m), 1.35-1.50 (2H, m),
1.56 (3H, s), 1.81-1.91 (1H, m), 1.91-2.05 (4H, m), 2.08
CA 02942883 2016-09-15
- 277 -
(3H, s), 2.11 (6H, s), 2.17 (3H, s), 2.71 (6H, s), 3.09-
3.21 (1H, m), 4.22 (2H, d, J = 5.0 Hz), 5.86 (1H, s),
6.03 (2H, s), 6.69 (1H, s), 7.87 (1H, t, J - 5.0 Hz),
9.33 (1H, br s), 11.47 (1H, br s).
Elemental analysis Anal. Calcd for C27H37N304-C4H404: Cf
63.79; H, 7.08; N, 7.20. Found: C, 62.09, H, 7.13; N,
6.99
[0767]
Example 88
(2S)-2-[trans-4-(Dimethylamino)cyclohexyl]-N-[(4,6-
dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4,7-
trimethy1-1,3-benzodioxole-5-carboxamide hemisuccinate
(88)
[0768] ,
To the compound (48) (0.201 g, 0.431 mmol)
synthesized in Example 48, succinic acid (0.027 g, 0.229
mmol) and ethyl acetate (2.01 mL) were added at room
temperature. Then, the mixture was stirred at 40 C for
approximately 20 hours and further stirred at room
temperature for approximately 0.5 hours, and the
deposited solid was then collected by filtration. Then,
the solid was dried overnight at room temperature to
obtain the title compound (0.214 g, rate of recovery:
94%).
1H-NMR (DMSO-d6) 6: 1.06-1.31 (4H, m), 1.54 (3H, s),
1.72-1.83 (1H, m), 1.83-1.94 (4H, m), 2.07 (3H, s), 2.10
(3H, s), 2.11 (3H, s), 2.17 (3H, s), 2.29 (6H, s), 2.32
CA 02942883 2016-09-15
- 278 -
(2H, s), 2.34-2.41 (1H, m), 4.22 (2H, d, J = 4.8 Hz),
5.85 (1H, s), 6.67 (1H, s), 7.86 (1H, t, J = 4.8 Hz),
11.47 (1H, br s).
Elemental analysis Anal. Calcd for C27H37N304-1/2C4H604: C,
66.13; H, 7.65; N, 7.98. Found: C, 63.03, H, 7.78; N,
7.51.
[0769]
[Test Example 1]
EZH1 methyltransferase inhibitory activity evaluation
25 L each of reaction solutions containing varying
concentrations of the compounds of Examples 1 to 77 (50
mM Tris (pH 8.8), 5 mM MgC12, 4 mM dithiothreitol, 0.005%
bovine serum albumin, 0.75 M biotin-H3 peptide, 8 ng/ L
PRC2-EZH1, 1 M S-adenosyl-L-methionine, 0.2 M adenosyl-
L-methionine, S-[methyl-3H]- (PerkinElmer, Inc.,
#NET155H), 1% dimethyl sulfoxide, and 25-0.0061 M
compounds) was added to each well of Streptavidin
FlashPlate HTS PLUS, 384-well (PerkinElmer, Inc.,
#SMP410A001PK) and incubated at room temperature for 2
hours. Then, each well was washed with 50 mL of a
washing buffer (50 mM Tris (pH 7.6) and 150 mM NaC1))
twice. Then, the residual radioactivity was measured
using TopCount NXT HTS (PerkinElmer, Inc., model C384V01).
On the basis of the measured residual radioactivity, the
extent of enzyme inhibition by the compounds of Examples
1 to 77 was measured at each concentration, and the
obtained data was analyzed with medical statistical
CA 02942883 2016-09-15
- 279 -
analysis software GraphPad Prism (GraphPad Software,
Inc.) to calculate IC50 values. The PRC2-EZH1 complex
was purchased from Reaction Biology Corp. (#HMT-25-115).
The biotin-H3 peptide was prepared by the synthesis of a
sequence from the 12- to 40-positions of human histone H3
protein (GGKAPRKQLATKAARKSAPATGGVKKPHR), followed by N-
terminal biotinylation.
[0770]
[Test Example 2]
EZH2 methyltransferase inhibitory activity evaluation
25 L each of reaction solutions containing varying
concentrations of the compounds of Examples 1 to 77 (50
mM Tris (pH 8.8), 5 mM MgC12, 4 mM dithiothreitol, 0.005%
bovine serum albumin, 0.75 M biotin-H3 peptide, 8 ng/mL
PRC2-EZH2, 1 M S-adenosyl-L-methionine, 0.1 M adenosyl-
L-methionine, S-[methyl-31-11- (PerkinElmer, Inc.,
#NET155H), 1% dimethyl sulfoxide, and 25-0.0061 M
compounds) was added to each well of Streptavidin
FlashPlate HTS PLUS, 384-well (PerkinElmer, Inc.,
#SMP410A001PK) and incubated at room temperature for 2
hours. Then, each well was washed with 50 L of a
washing buffer (50 mM Tris (pH 7.6) and 150 mM NaC1))
twice. Then, the residual radioactivity was measured
using TopCount NXT HTS (PerkinElmer, Inc., model C384V01).
On the basis of the measured residual radioactivity, the
extent of enzyme inhibition by the compounds of Examples
1 to 77 was measured at each concentration, and the
CA 02942883 2016-09-15
- 280 -
obtained data was analyzed with medical statistical
analysis software GraphPad Prism to calculate IC50 values.
The PRC2-EZH2 complex was prepared according to the
method of Cao R. et al. (Mol. Cell, 15, 57-67 (2004)).
[0771]
[Test Example 3]
Intracellular H3K27me3 inhibitory activity evaluation
HCT116 cells were inoculated at 1500 cells/90
L/well to a 96-well plate (IWAKI, #3860-096) and
cultured overnight at 37 C. The HCT116 cells were
purchased from American Type Culture Collection (ATCC).
Then, 10 L each of solutions containing the compounds of
Examples 1 to 77 was added to each well, and the cells
were cultured at 37 C for 3 days. Intracellular H3K27me3
was quantified using AlphaLISA H3K27me3 Cellular
Detection Kit (PerkinElmer, Inc., #AL722F). The cells
thus cultured in each well were washed with 100 mL of PBS.
Cell-Histone Lysis buffer diluted 6-fold with PBS was
added thereto at 80 L/well, and the plate was then
incubated at room temperature for 15 minutes while shaken.
Then, Cell-Histone Extraction buffer was added thereto at
40 L/well, and the plate was incubated at room
temperature for 10 minutes while shaken. 10 L of the
reaction solution was transferred from each well to each
well of a 384-well plate (PerkinElmer, Inc., #6008350).
An AlphaLISA anti-H3K27me3 Acceptor beads/Biotinylated
Antibody anti-Histone H3 (C-ter) mixed solution was added
CA 02942883 2016-09-15
- 281 -
thereto at 3.3 mL/well, and the plate was incubated at
room temperature for 60 minutes. Then, Streptavidin
(SA)-coated Donor beads were added thereto at 3.3 mL/well,
and the plate was incubated at room temperature for 30
minutes with the plate shielded from light. Signals were
measured using EnVision 2104 Multilabel Reader
(PerkinElmer, Inc.). The extent of H3K27me3 inhibition
by the compounds of Examples 1 to 77 was measured at each
concentration, and the obtained data was analyzed with
medical statistical analysis software GraphPad Prism to
calculate IC50 values.
[0772]
The results of Test Examples 1 to 3 are shown in
Tables 1-1 and 1-2.
[0773]
[Table 1-1]
CA 02942883 2016-09-15
- 282 -
Example Test Test Test Example Test Test Test
Example 1 Example 2 Example 3 Example 1 Example 2 Example 3
ICso (1-LM)
WT EZH1 WT EZH2 H3K27me3
1050 GIM) WT EZH1 WT EZH2 H3K27me3
inhibition 1050 (1-1M) 1050 (L.tM) inhibition
(HCT116) (HCT116)
1050 (PM) IC50 (t./M)
_
1 0.14 0.024 0.029 2 0.052 0.022 0.009
_
3 0.66 0.03 0.026 4 0.13 0.025 0.0083 -
0.25 0.015 0.051 6 0.51 0.039 0.045
._ .
8 0.097 0.016 0.006 7 0.038 0.0036 0.0084
9 0.066 0.011 0.013 10_ 0.13 0.011 0.018
_
11 0.068 0.0091 0.0037 12 0.2 0.028 0.14
13 0.021 0.016 0.0059 14 0.021 0.024 0.00055
_
0.0074 0.01 0.00047 16 0.0094 0.012 0.0014
17 0.017 0.023 0.0012 18 0.019 0.023 0.0058
19 0.028 0.025 0.011 20 0.023 0.017 0.0028
_
21 0.06 0.018 0.01 22 0.088 0.014 0.0016
_
23 0.0041 0.0056 0.0028 24 0.14 0.012 0.019
0.11 0.012 0.045 26 0.19 0.023 0.037
_
27 0.023 0.022 0.0038 28 0.078 0.020 0.014
29 0.068 0.0094 0.016 _30 0.18 0.021 0.016
31 0.11 0.018 0.009 32 0.03 0.017 0.0048
33 0.26 0.028 0.014 34 0.023 0.016 0.00062
0.0084 0.0025 0.00044 36 _0.013 0.013 0.0016
37 0.028 0.019 0.0016 38 0.057 0.012 0.0028
39 0.04 0.014 0.0022 40 0.21 0.011 0.032
41 0.059 0.014 0.011 42 0.19 0.027 0.067
_
43 0.38 0.041 0.044 44 0.077 0.0079 0.014
0.11 0.0096 0.013 46 0.072 0.0067 0.0034
[0774]
[Table 1-2]
CA 02942883 2016-09-15
- 283 -
Example Test Test Test Example Test Test Test
Example 1 Example 2 Example 3 Example 1 Example 2 Example 3
WT EZHI WT EZH2 H3K27me3 WT EZH1 WT EZH2 H3K27me3
1050 GINO IC50 (11M) inhibition 1050 (11M) Icso GIM) inhibition
(HCT116) (HCT116)
1C50 (PM) IC50(1.tM)
_
47 0.022 0.010 0.0014 48 0.0089 0.0080 0.00048
49 0.092 0.018 0.0026 50 0.053 0.020 0.0071
51 0.39 0.035 0.042 52 0.37 0.029 0.037
_
53 0.026 0.013 0.00063 54 0.21 0.027 0.0038
55 0.053 0.028 0.011 56 0.068 0.023 0.0064
57 0.11 0.036 0.012 _ 58 0.0044 0.01 0.0029
_
59 0.0057 0.0087 0.0018 60 0.0073 0.014 0.0037
61 0.008 0.021 0.01 62 0.011 0.0066 0.0055
63 0.017 0.022 0.013 64 0.022 0.014 0.0068
65 0.023 0.018 0.013 66 0.027 0.022 0.0017
67 0.017 0.019 0.0010 68 0.029 0.018 0.0016
-
69 0.032 0.024 0.029 70 0.038 0.026 0.0043
-
71 0.043 0.019 0.099 72 0.076 0.017 0.013
_ -
73 0.012 0.022 0.0061 74 0.013 0.029 0.023
75 0.021 0.026 0.011 76 _0.02 0.012 0.00088
_
77 0.091 0.011 0.024
[0775]
[Test Example 4]
Cell growth inhibitory activity evaluation
Cells were purchased from ATCC (G401 (human kidney-
derived rhabdoid tumor), HepG2, LNCaP, LS180, MV4 ; 1 1,
NCI-H1563, NCI-H1703, NCI-H520, NCI-H522, NCI-N87, RS4;11,
and THP-1), Deutsche Sammlung von Mikroorganismen und
Zellkulturen GmbH (DSMZ) (KARPAS-422 (EZH2 Y641C mutant
human diffuse large B-cell lymphoma) and KOPN8), and
Health Science Research Resource Bank (OVMANA). The
media for the culture of each cell line used were an EMEM
medium supplemented with 10% FBS (LS180 and HepG2), a
CA 02942883 2016-09-15
- 284 -
McCoy's 5A medium supplemented with 10% FBS (G401
(rhabdoid tumor cell line deficient in SNF5, a subunit of
the SWI/SNF complex)), an RPMI1640 medium supplemented
with 10% FBS (KOPN8, RS4;11, MV4;11, NCI-H1703, NCI-N87,
NCI-H522, THP-1, LNCaP, OVMANA, NCI-H520, and NCI-H1563),
and an RPMI1640 medium supplemented with 20% FBS (KARPAS-
422). During the test period, DMSO (final concentration:
0.1%) or a solution of the compound of Example 14 in DMSO
(final concentration: 1 uM (final concentration of DMSO:
0.1%) was added to the medium, and the cells of each line
were cultured at 37 C under 5% CO2. The cultured cells of
each line were inoculated to a 6-well culture plate for
cell culture and subcultured for a total of 10 days to 11
days while passage or medium replacement was carried out
at 3-day to 4-day intervals. Then, the cells were
inoculated to a 96-well assay plate. On the day of
inoculation to the 96-well assay plate (inoculation date)
and 4 days or 5 days thereafter (effect determination
date), reaction was carried out using CellTiter-Glo
Luminescent Cell Viability Assay reagent (Promega Corp.,
#G7573) or ATPlite lstep Luminescence Assay System
(PerkinElmer, Inc., #6016739) according to the attached
manual. Then, the luminescence intensity of each well
was measured using a plate reader (EnVision, PerkinElmer,
Inc.). The extent of cell growth inhibition was
calculated from the luminescence intensity of a sample-
supplemented group (Ts) and a DMSO-supplemented group
CA 02942883 2016-09-15
- 285 -
(Cs) measured on the inoculation date and a sample-
supplemented group (T) and a DMSO-supplemented group (C)
measured on the effect determination date according to
the following expression:
Extent of cell growth inhibition (%) = {1 - (T - Ts) / (C
- Cs) 1 x 100
When the number of cells in the sample-supplemented
group is decreased on the determination date compared
with the inoculation date (T ( Ts) , a cytocidal effect
was calculated according to the following expression:
Cytocidal rate (%) = (T - Ts) / Ts x (- 100)
The results are shown in Table 2.
[0776]
[Table 2]
Extent of cell
Cancer type Cell line Cytocidal rate
growth inhibition
Lymphoma KARPAS-422 >100% 100%
Rhabdoid tumor G401 >100% 100%
Leukemia KOPN8 >100% 99%
Leukemia RS4;11 >100% 94%
Leukemia MV4;11 >100% 88%
Lung cancer NCI-H1703 >100% 49%
Stomach cancer NCI-N87 >100% 15%
Lung cancer NCI-H522 >100% 13%
Leukemia THP-1 >100% 7%
Prostate cancer LNCaP >100% 6%
Colorectal
LS180 >100% 6%
cancer
Ovarian cancer OVMANA 95% -
CA 02942883 2016-09-15
,
- 286 -
Lung cancer NCI-H520 80%
Liver cancer HepG2 78%
Lung cancer NCI-H1563 56%
[0777]
[Test Example 5]
Evaluation of antitumor activity against EZH2 Y641C
mutant human diffuse large B-cell lymphoma KARPAS-422-
subcutaneously transplanted model
EZH2 Y641C mutant human diffuse large B-cell
lymphoma KARPAS-422 cells were subcutaneously
transplanted in an amount of 2 x 107 cells/head to the
right abdomens of female SCID mice. After 30 days, the
mice were grouped on the basis of their presumed tumor
volumes (major axis x minor axis x minor axis / 2) and
body weights. The KARPAS-422 cells were purchased from
DSMZ. The female SCID mice were purchased from Charles
River Laboratories Japan Inc. From the day following
grouping, the compound of Example 14 or the compound of
Example 34 was orally administered at a,dose set to 5, 25,
or 200 mg/kg/day once a day for 14 consecutive days (QD x
14) as the dosing schedule. The tumor volume of each
individual was measured from the grouping date to 45 days
thereafter (test completion date).
[0778]
[Test Example 6]
CA 02942883 2016-09-15
- 287 -
Evaluation of antitumor activity against SNF5 deletion
mutant human kidney-derived rhabdoid tumor G401-
subcutaneously transplanted model
SNF5 deletion mutant human kidney-derived rhabdoid
tumor G401 cells were subcutaneously transplanted in an
amount of 1 x 107 cells/head to the right abdomens of
female BALB/c-nu/nu mice. After 23 days, the mice were
grouped on the basis of their presumed tumor volumes and
body weights. The G401 cells were purchased from ATCC.
The female BALB/c-nu/nu mice were purchased from Charles
River Laboratories Japan Inc. From the day following
grouping, the compound of Example 14 or the compound of
Example 34 was orally administered at a dose set to 50 or
200 mg/kg/day once a day for 12 consecutive days (QD x
12) as the dosing schedule. The tumor volume of each
individual was measured from the grouping date to 36 days
thereafter (test completion date).
[0779]
The antitumor activity against the EZH2 Y641C mutant
human diffuse large B-cell lymphoma KARPAS-422-
subcutaneously transplanted models in Test Example 5, and
the antitumor activity against the human kidney-derived
rhabdoid tumor G401-subcutaneously transplanted models in
Test Example 6 were calculated on their respective test
completion dates according to the following expression:
Extent of tumor growth inhibition (%) = (1 - TVCt / TVCc)
x 100
CA 02942883 2016-09-15
- 288 -
TVC = (Tumor volume of each individual on the test
completion date) - (Tumor volume of each individual on
the grouping date)
TVCt: Average TVC of the drug administration group
TVCc: Average TVC of the non-administration group
As for a group whose extent of tumor growth
inhibition exceeded 100% (indicated by > 100%), the
extent of tumor regression was calculated according to
the following expression:
Extent of tumor regression (%) = Average value of (1 -
(Tumor volume of each individual on the test completion
date / Tumor volume of each individual on the grouping
date) x 100
[0780]
[Test Example 7]
Evaluation of antitumor activity against human colorectal
cancer LS180-subcutaneously transplanted model
Human colorectal cancer LS180 cells were
subcutaneously transplanted in an amount of 5 x 106
cells/head to the right abdomens of female SCID mice.
After 3 days, the mice were grouped on the basis of their
presumed tumor volumes and body weights. The LS180 cells
were purchased from ATCC. The female SCID mice were
purchased from Charles River Laboratories Japan Inc.
From the day following grouping, the compound of Example
34 was orally administered at a dose set to 50 or 200
mg/kg/day twice a day for 13 consecutive days (BID x 13)
CA 02942883 2016-09-15
- 289 -
as the dosing schedule. The tumor volume of each
individual was measured from the grouping date to 17 days
thereafter (test completion date).
[0781]
[Test Example 8]
Evaluation of antitumor activity against human stomach
cancer NCI-N87-subcutaneously transplanted model
Human stomach cancer NCI-N87 cells were
subcutaneously transplanted in an amount of 8 x 106
cells/head to the right abdomens of female BALB/c-nu/nu
mice. After 12 days, the mice were grouped on the basis
of their presumed tumor volumes and body weights. The
NCI-N87 cells were purchased from ATCC. The female
BALB/c-nu/nu mice were purchased from Charles River
Laboratories Japan Inc. From the day following grouping,
the compound of Example 34 was orally administered at a
dose set to 50 or 200 mg/kg/day once a day for 28
consecutive days (Q x 28) as the dosing schedule. The
tumor volume of each individual was measured from the
grouping date to 82 days thereafter (test completion
date).
[0782]
The antitumor activity against the human colorectal
cancer LS180-subcutaneously transplanted models in Test
Example 7, and the antitumor activity against the human
stomach cancer NCI-N87-subcutaneously transplanted models
in Test Example 8 were calculated on their respective
CA 02942883 2016-09-15
- 290 -
test completion dates according to the following
expression:
Extent of tumor growth inhibition (%) = (1 - TVCt / TVCc)
x 100
TVC = (Tumor volume of each individual on the test
completion date) - (Tumor volume of each individual on
the grouping date)
TVCt: Average TVC of the drug administration group
TVCc: Average TVC of the non-administration group
The results of Test Examples 5 to 8 are shown in
Table 3.
[0783]
[Table 3]
¨ 291 ¨
Cancer type Cell line Dose Dosing Compound of
Compound of Example Compound of Example Compound of Example
(mg/kg) schedule Example 14 34 15
35
Extent of Extent of Extent of Extent of
Extent of Extent of Extent of Extent of
tumor tumor tumor tumor tumor
tumor tumor tumor
growth regression growth regression growth
regression growth regression
inhibition inhibition
inhibition inhibition
Test Example KARPAS- 5 QDx14 26% - 44% - 54% -
52% -
422
lymphoma 25 QDx14 80% - 76% - >100%
27% >100% 14%
P
200 QDx14 >100% 50% >100% 52% - -
- -
.3
.3
Test Example G401 50 QDx12 >100% 19% >100% 22% - -
- -
,
6
.
,
rhabdoid
200 QDx12 >100% 29% >100% 17% _
_ _ _ .
,
,
tumor
-
Test Example LS I 80 50 B1Dx13 - - 8% - -
- - -
7
colorectal 200 BIDx13 - - 73% _ _
_ _ _
cancer
-
Test Example NCI-N87 50 QDx28 - - 80% - - -
- -
8
stomach 200 QDx28 - - 87% _ - -
- -
cancer
CA 02942883 2016-09-15
- 292 -
Industrial Applicability
[0784]
The compound represented by the general formula (I)
of the present invention or the pharmacologically
acceptable salt thereof has an excellent inhibitory
effect on EZH1 and/or EZH2 activity and as such, is
useful as a therapeutic drug for tumors.
